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1.1 Background  
 
α,β-Unsaturated aldehydes are ubiquitously present in our surroundings, and human exposure 
occurs from endogenous sources as well as from exogenous sources including the diet. Various 
aldehydes are present in fruits, vegetables and beverages as natural constituents [1], and many of 
them are intentionally added as food flavouring agents because of their aromatic features. The 
structure of α,β-unsaturated aldehydes is characterized by the presence of a polarized 
carbon-oxygen double bond, and a double bond between carbons 2 and 3 (α and β) (Figure 1.1). 
Due to the electrophilic nature of the α,β-unsaturated aldehyde moiety, α,β-unsaturated aldehydes 
readily react with DNA via Michael addition [2]. This reactive nature of α,β-unsaturated 
aldehydes raises a food safety concern for genotoxicity. α,β-Unsaturated aldehydes have been 
shown to be positive in in vitro genotoxicity tests using bacteria or mammalian cell lines [3-5]. In 
vivo, DNA adduct formation in the liver has been detected when rats were orally exposed to high 
doses of trans-2-hexenal for a single time but not at doses lower than 50 mg/kg bw [6, 7]. 
Considering that DNA adduct formation was observed only at exposure levels that were four 
orders of magnitude higher than the estimated daily intake (EDI) of trans-2-hexenal when used as 
an added flavouring (1 μg/kg bw/day), the relevance of DNA adduct formation observed in the 
rodent studies at high dose levels for the human situation remains to be established.  
 
Figure 1.1 Michael addition of guanine to an α,β-unsaturated aldehyde [8] 
 
The JECFA (Joint FAO/WHO Expert Committee on Food Additives) [9-11] and the 
Expert Panel of the FEMA (Flavor and Extract Manufacturers Association) [12, 13] considered 
that the use of α,β-unsaturated aldehydes as flavouring agents does not pose a significant risk 
because of low levels of use as added flavouring agents and possible rapid detoxification in vivo. 
For these reasons the FEMA Exert Panel affirmed that the α,β-unsaturated aldehydes are GRAS 
 
 
(Generally Recognized as Safe). In contrast, EFSA (European Food Safety Authority) considered 
the α,β-unsaturated aldehyde moiety to be an alert for genotoxicity and the safety cannot be 
established unless in vivo data become available to overrule concerns raised by positive in vitro 
genotoxicity data [14]. As a result the use of more than 70 α,β-unsaturated aldehydes and related 
compounds that are metabolized to α,β-unsaturated aldehyde as food flavouring agents is 
suspended in the EU since 2013. Data on their genotoxicity, especially in vivo, have been 
requested by EFSA. It can be questioned, however, whether low exposure levels, as a result of 
their use as flavourings, would lead to a safety concern. A significant adverse effect may not 
occur at low doses due to protection mechanisms such as detoxification of the genotoxic 
substance in vivo. For the safety evaluation of the α,β-unsaturated aldehydes insight in 
genotoxicity at low dietary doses needs to be obtained taking dose-dependent detoxification into 
account. However, measuring such adverse effects in vivo at low dose levels for large amount of 
compounds is practically not feasible. Therefore the objective of the research described in this 
PhD thesis was to quantitatively integrate detoxification kinetics, and define dose-dependent in 
vivo DNA adduct formation for a group of structurally related α,β-unsaturated aldehydes used as 
food flavourings by developing physiologically based in silico models. This should provide 
insight in the DNA adduct formation at low exposure levels relevant to realistic human dietary 
exposure, and generate data on in vivo DNA adduct formation that cannot be obtained by animal 
experiments. 
 
1.2 Structures of α,β-unsaturated aldehydes and exposure 
 
Many α,β-unsaturated aldehydes are produced by plants as natural fungicides. For this reason 
these aldehydes are present in many foods and beverages of plant origin as natural constituents 
[1]. α,β-Unsaturated aldehydes are often volatile and give distinguished odours resembling 
different fruits, vegetables and herbs. For instance, trans-2-hexenal gives a fresh apple-like smell 
and is called “leaf aldehyde” (see Table 1.1 for the structure). trans-2-cis-6-Nonadienal gives a 
cucumber-like smell and trans-2-decenal gives an odour that is characteristic of coriander. 
Cinnamaldehyde gives the unique odor of cinnamon. Due to their aromatic features, many 
α,β-unsaturated aldehydes are intentionally added to a broad type of foods as flavouring agents. 
Some examples of α,β-unsaturated aldehydes that may be used as food flavouring agents are 
presented in Table 1.1. The examples are listed in accordance with the classification made by 
EFSA based on the structural similarity [14]. The highest dietary α,β-unsaturated aldehyde intake 
is reported to result from cinnamaldehyde: 59,000 μg/day/capita in the US and 2,500 
μg/day/capita in Europe [9]. Among the aliphatic substances, the majority of the production has 
been attributed to 2-hexenal and its corresponding alcohol and acetate ester [10].  The estimated 
daily intakes of 2-hexenal as an added flavouring agent in Europe and the US are 791 and 409 
μg/day/capita, respectively [9]. 
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 Exposure to α,β-unsaturated aldehydes also comes from other sources than the diet. 
2-Propenal (acrolein) and 2-butenal (crotonaldehyde) for example are produced during 
combustion of organic materials and therefore found in all types of smoke including cigarette 
smoke and exhaust from engines [2, 10]. 2-Propenal is present at 25 – 140 μg/cigarette in the gas 
phase of the smoke [2]. α,β-Unsaturated aldehydes are furthermore formed endogenously by lipid 
peroxidation of polyunsaturated fatty acids (PUFAs) [2, 15]. Lipid peroxidation, initiated by a 
free-radical chain reaction mechanism, yields lipid hydroperoxides as major initial reaction 
products. Subsequent decomposition of lipid hydroperoxides generates a number of degradation 
products including 2-propenal, 4-hydroxy-2-alkenals, and malondialdehyde [16].   
 
Table 1.1 Examples of food-borne α,β-unsaturated aldehydes listed in accordance with the 
categories made by EFSA based on the structural similarity [14] 
Description of the category Name Structure Sources 
Alphatic 
With or without 
additional 
non-conjugated 
double-bonds 
 
2-propenal (acrolein) 
 
red wine [1], 
tabacco smoke 
[2] 
2-butenal 
(crotonaldehyde)  
red wine [1], 
tabacco smoke 
[2] 
trans-2-hexenal 
 
banana [1], fig 
[17]  
trans-2-octenal  
grape, orange 
[1] 
trans-2-cis-6-nonadie
nal  
cucumber [18] 
2-alkylated aldehydes 
with or without 
additional double 
-bonds 
2-methylcrotonaldehy
de  
 
trans-2-methyl-2-pete
nal  
black tea [19] 
3-alkylated aldehydes 
with or without 
additional 
double-bonds 
citral (mixture of 
neral and geranial) 
 
 
lime [1] 
Two or more 
conjugated 
double-bonds with or 
without additional 
non-conjugated 
double-bonds 
trans-2-trans-4-hexad
ienal  
fig [17], 
blueberry [20] 
trans-2-trans-4-octad
ienal  
 
  
 
 
Alicyclic 
  
α,β-unsaturation in 
side chain 
p-mentha-1,8(10)-die
n-9-al 
 
 
α,β-unsaturation in 
ring/side chain 
p-mentha-1,8-dien-7-
al 
 
 
more complex 
2,6,6-trimethylcycloh
exa-1,3-diene-1- 
carbaldehyde 
 
 
Cinnamyl 
derivatives 
and other 
aromatic alkyl 
substituted 
aldehydes   
Cinnamyl aldehyde 
trans-cinnamaldehyd
e 
 
cassia (bark 
oil) [1] 
2-phenyl-2-alkenals 
5-methyl-2-phenylhe
x-2-enal 
 
 
Heterocyclic  
Furfural derivatives Furfural 
 
cacao, coffee, 
meat products 
[21] 
Furans with 
conjugation in side 
chain 
Furfurylidene-2-buta
nal 
 
 
Others 
Other sulphur 
containing substances 
2-(Methylthiomethyl)
-3-phenylpropenal 
 
 
 
1.3 ADME (absorption, distribution, metabolism and excretion) 
 
α,β-Unsaturated aldehydes are rapidly absorbed, distributed, metabolized and excreted in urine, 
faeces and expired air. When male Wistar rats were exposed to 100 mg/kg bw of 14C labelled 
trans-2-nonenal or trans-2-pentenal by gavage [22], both aldehydes entered the systemic 
circulation from the gastrointestinal (GI) tract, and were metabolized to yield C-3 mercapturic 
acids within 24 hours. Only trace amount of trans-2-nonenal or trans-2-pentenal were found in 
faeces [22]. In another study, male and female Sprague-Dawley rats were exposed to 2.5 or 15 
mg/kg bw 14C labelled 2-propenal by gavage [23]. Urine was the major excretion route 
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(40.6-63.4%) in all groups. Excretion in faeces increased from 14.8% to 28.4% in male and from 
12.8% to 30.6% in female rats when the dose levels increased from 2.5 to 15 mg/kg bw, 
suggesting that at the higher dose level a higher proportion of 2-propenal reacted with food 
components already in the GI tract, ending up in faeces. More than 80% of 2-propenal was 
excreted via urine, faeces or expired air within 24 hours at both exposure doses. Sapienza et al. 
administered 5, 50 or 500 mg/kg bw 14C-labelled cinnamaldehyde to male F344 rats by gavage 
[24]. More than 81% of the cinnamaldehyde was excreted in urine and 3.2-5.1% was excreted in 
faeces within 24 hours in all animal groups. In another study, male Fischer 344 (F344) rats were 
exposed to 5, 50 and 500 mg/kg bw of [14C] citral via oral administration [25]. In all exposure 
groups, the majority of citral (76.7-93.7%) was excreted within 24 hours in the urine 
(47.9-63.4%), faeces (12.0-15.6%) or as CO2 (10.4-16.6%). Altogether these in vivo studies 
indicate that α,β-unsaturated aldehydes are swiftly absorbed and excreted within 24 hours and that 
the principle route of excretion is via urine. The studies also indicate that the administered 
aldehydes may react with food residues in the GI tract resulting in excretion via faeces and a 
reduction in bioavailability. 
As Figure 1.2 illustrates, α,β-unsaturated aldehydes are detoxified via three pathways: 
oxidation, conjugation with glutathione (GSH), and reduction. 
 
Oxidation 
α,β-Unsaturated aldehydes are oxidized by NAD+-dependent aldehyde dehydrogenases (ALDHs) 
to α,β-unsaturated carboxylic acids. In humans, ALDHs are present throughout the body including 
liver, lungs, kidneys, GI tract, heart, and in the brain [26]. Sixteen ALDH genes and three 
pseudogenes have been identified in the human genome [27], and this diversity enables oxidation 
of a wide variety of substrates with varying specificity of the aldehydes towards each ALDH 
isoenzyme [28]. Among the isoenzymes, ALDH I and ALDH II, which are mostly present in 
cytosol and mitochondrial matrix respectively, play a predominant role in the metabolism of linear 
aldehydes in the digestive tract [26, 29, 30]. The α,β-unsaturated carboxylic acids formed are 
further metabolized via β oxidation and the tricarboxylic acid (TCA) cycle to acetyl-CoA or 
propionyl-CoA, and are eventually excreted from the body as CO2 or water [12].  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Metabolism of α,β-unsaturated 
aldehydes taking trans-2-hexenal as an example. 
 
 
Conjugation with GSH 
α,β-Unsaturated aldehydes react with GSH to form GSH conjugates via Michael addition. The 
carbon double bond between the α and β carbons connected to an electron-withdrawing aldehyde 
group results in a positively polarized β-carbon, which becomes a preferred site for an attack by 
soft nucleophiles such as GSH [31]. The reaction occurs spontaneously, but the reaction rate 
increases remarkably in the presence of a family of phase II enzymes, glutathione S-transferases 
(GSTs) [4]. GSTs are present in mitochondria and microsomes, but cytosolic GSTs represent the 
largest family of this group of enzymes [32]. Among different isoenzymes GST A4-4, a cytosolic 
GST, is recognized as one of the predominant enzymes responsible for the metabolism of 
2-alkenals [33, 34]. The presence of GSH in cells is a prerequisite for the reaction, and depletion 
of GSH at high exposure levels hampers this pathway regardless of the GST kinetics. Following 
the conjugation with GSH, the aldehyde functional group is oxidized or reduced, and the 
metabolites are ultimately excreted in urine as corresponding mercapturic acids [35-37]. 
 
Reduction 
The reduction of α,β-unsaturated aldehydes to α,β-unsaturated alcohols is catalysed by aldose 
reductases (ARs) such as AKR1B1, or closely related aldo-keto reductases such as AKR1B10 and 
AKR1C1 [38-40]. These enzymes are present in a variety of human tissues (e.g. intestine, liver, 
heart, kidney) and have broadly overlapping substrate specificity. The enzymes play an important 
role not only in the detoxification of exogenous compounds but also in cytokine-mediating 
signalling processes. For the latter reason many literature studies have focused on the features of 
ARs as a possible therapeutic target for different diseases such as diabetes and inflammatory 
diseases. Little is known about AR isoenzymes [41].  
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[24]. More than 81% of the cinnamaldehyde was excreted in urine and 3.2-5.1% was excreted in 
faeces within 24 hours in all animal groups. In another study, male Fischer 344 (F344) rats were 
exposed to 5, 50 and 500 mg/kg bw of [14C] citral via oral administration [25]. In all exposure 
groups, the majority of citral (76.7-93.7%) was excreted within 24 hours in the urine 
(47.9-63.4%), faeces (12.0-15.6%) or as CO2 (10.4-16.6%). Altogether these in vivo studies 
indicate that α,β-unsaturated aldehydes are swiftly absorbed and excreted within 24 hours and that 
the principle route of excretion is via urine. The studies also indicate that the administered 
aldehydes may react with food residues in the GI tract resulting in excretion via faeces and a 
reduction in bioavailability. 
As Figure 1.2 illustrates, α,β-unsaturated aldehydes are detoxified via three pathways: 
oxidation, conjugation with glutathione (GSH), and reduction. 
 
Oxidation 
α,β-Unsaturated aldehydes are oxidized by NAD+-dependent aldehyde dehydrogenases (ALDHs) 
to α,β-unsaturated carboxylic acids. In humans, ALDHs are present throughout the body including 
liver, lungs, kidneys, GI tract, heart, and in the brain [26]. Sixteen ALDH genes and three 
pseudogenes have been identified in the human genome [27], and this diversity enables oxidation 
of a wide variety of substrates with varying specificity of the aldehydes towards each ALDH 
isoenzyme [28]. Among the isoenzymes, ALDH I and ALDH II, which are mostly present in 
cytosol and mitochondrial matrix respectively, play a predominant role in the metabolism of linear 
aldehydes in the digestive tract [26, 29, 30]. The α,β-unsaturated carboxylic acids formed are 
further metabolized via β oxidation and the tricarboxylic acid (TCA) cycle to acetyl-CoA or 
propionyl-CoA, and are eventually excreted from the body as CO2 or water [12].  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Metabolism of α,β-unsaturated 
aldehydes taking trans-2-hexenal as an example. 
 
 
Conjugation with GSH 
α,β-Unsaturated aldehydes react with GSH to form GSH conjugates via Michael addition. The 
carbon double bond between the α and β carbons connected to an electron-withdrawing aldehyde 
group results in a positively polarized β-carbon, which becomes a preferred site for an attack by 
soft nucleophiles such as GSH [31]. The reaction occurs spontaneously, but the reaction rate 
increases remarkably in the presence of a family of phase II enzymes, glutathione S-transferases 
(GSTs) [4]. GSTs are present in mitochondria and microsomes, but cytosolic GSTs represent the 
largest family of this group of enzymes [32]. Among different isoenzymes GST A4-4, a cytosolic 
GST, is recognized as one of the predominant enzymes responsible for the metabolism of 
2-alkenals [33, 34]. The presence of GSH in cells is a prerequisite for the reaction, and depletion 
of GSH at high exposure levels hampers this pathway regardless of the GST kinetics. Following 
the conjugation with GSH, the aldehyde functional group is oxidized or reduced, and the 
metabolites are ultimately excreted in urine as corresponding mercapturic acids [35-37]. 
 
Reduction 
The reduction of α,β-unsaturated aldehydes to α,β-unsaturated alcohols is catalysed by aldose 
reductases (ARs) such as AKR1B1, or closely related aldo-keto reductases such as AKR1B10 and 
AKR1C1 [38-40]. These enzymes are present in a variety of human tissues (e.g. intestine, liver, 
heart, kidney) and have broadly overlapping substrate specificity. The enzymes play an important 
role not only in the detoxification of exogenous compounds but also in cytokine-mediating 
signalling processes. For the latter reason many literature studies have focused on the features of 
ARs as a possible therapeutic target for different diseases such as diabetes and inflammatory 
diseases. Little is known about AR isoenzymes [41].  
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1.4 Genotoxicity and carcinogenicity of α,β-unsaturated aldehydes  
 
The structure of α,β-unsaturated aldehydes is characterized by the presence of a polarized 
carbon-oxygen double bond, and a double bond between carbons 2 and 3 (α and β). Because of 
the difference in electronegativity between the oxygen and the carbon atom in the aldehyde group, 
the β-carbon becomes positively polarized and is the preferred site of nucleophilic attack [1, 42]. 
This electrophilic nature of the aldehydes enables them to interact with electron-rich 
macromolecules including DNA. The major DNA adducts formed by α,β-unsaturated aldehydes 
are 1,N2-hydroxypropano adducts of deoxyguanosine (Figure 1.1) [8]. Stereocenters are generated 
in the course of reaction leading to diastereomeric adducts.  
 
 Genotoxicity 
In vitro 
In vitro results indicate genotoxicity and mutagenicity of α,β-unsaturated aldehydes. 
trans-2-Hexenal and crotonaldehyde react directly with calf thymus DNA resulting in the 
formation of 1,N2-propanodeoxyguanosine adducts. The formation of these DNA adducts was 
also observed in cells from the human lymphoblastoid Namalva cell line and in primary rat colon 
mucosa cells [3]. The aldehydes are mutagenic in bacteria [42-44] and in mammalian cells [45].  
2-Alkenals (2-pentenal, 2-hexenal, 2-heptenal, 2-octenal and 2-nonenal) were shown to be 
mutagenic in V79 Chinese hamster cells and the mutagenic potencies increased with increasing 
carbon chain length [46]. The aldehydes induce DNA single-strand breaks in vitro [4, 43]. 
2-Propenal, 2-butenal and trans-2-hexenal induce DNA single strand breaks in human Namalva 
cells as well as in rat primary hepatocytes [4].  In addition, 2-butenal, trans-2-hexenal and 
trans-2-cis-6-nonadienal were reported to cause chromosomal aberrations, micronuclei and sister 
chromatid exchanges in human blood lymphocytes and Namalva cells [5]. Altogether these results 
support that α,β-unsaturated aldehydes are genotoxic as well as mutagenic in in vitro assays. 
 
In vivo 
In contrast to in vitro experiments, in vivo data on genotoxicity of α,β-unsaturated aldehydes are 
limited. The formation of DNA adducts in vivo has been reported for trans-2-hexenal and 
2-butenal (crotonaldehyde) upon single oral administration of extremely high doses of the 
aldehydes [6, 7, 47] (Table 1.2). Schuler and Eder [6] reported the formation of DNA adducts, 
namely exocyclic 1,N2-propanodeoxyguanosine adducts, formed upon exposure to 
trans-2-hexenal in male F344 rats and detected using 32P-labeling. The DNA adducts were 
quantifiable in the liver and the tissues that had a direct contact with the compound (e.g. 
forestomach, glandular stomach, oesophagus) as well as in tissues that the aldehyde could reach 
only after absorption into the systemic circulation (e.g. kidney) at 200 or 500 mg/kg bw. At 50 
mg/kg bw, however, a quantifiable amount of DNA adducts was found only in the oesophagus. In 
2008, Stout et al. [7] investigated DNA adduct formation using the same exposure conditions as 
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1.4 Genotoxicity and carcinogenicity of α,β-unsaturated aldehydes  
 
The structure of α,β-unsaturated aldehydes is characterized by the presence of a polarized 
carbon-oxygen double bond, and a double bond between carbons 2 and 3 (α and β). Because of 
the difference in electronegativity between the oxygen and the carbon atom in the aldehyde group, 
the β-carbon becomes positively polarized and is the preferred site of nucleophilic attack [1, 42]. 
This electrophilic nature of the aldehydes enables them to interact with electron-rich 
macromolecules including DNA. The major DNA adducts formed by α,β-unsaturated aldehydes 
are 1,N2-hydroxypropano adducts of deoxyguanosine (Figure 1.1) [8]. Stereocenters are generated 
in the course of reaction leading to diastereomeric adducts.  
 
 Genotoxicity 
In vitro 
In vitro results indicate genotoxicity and mutagenicity of α,β-unsaturated aldehydes. 
trans-2-Hexenal and crotonaldehyde react directly with calf thymus DNA resulting in the 
formation of 1,N2-propanodeoxyguanosine adducts. The formation of these DNA adducts was 
also observed in cells from the human lymphoblastoid Namalva cell line and in primary rat colon 
mucosa cells [3]. The aldehydes are mutagenic in bacteria [42-44] and in mammalian cells [45].  
2-Alkenals (2-pentenal, 2-hexenal, 2-heptenal, 2-octenal and 2-nonenal) were shown to be 
mutagenic in V79 Chinese hamster cells and the mutagenic potencies increased with increasing 
carbon chain length [46]. The aldehydes induce DNA single-strand breaks in vitro [4, 43]. 
2-Propenal, 2-butenal and trans-2-hexenal induce DNA single strand breaks in human Namalva 
cells as well as in rat primary hepatocytes [4].  In addition, 2-butenal, trans-2-hexenal and 
trans-2-cis-6-nonadienal were reported to cause chromosomal aberrations, micronuclei and sister 
chromatid exchanges in human blood lymphocytes and Namalva cells [5]. Altogether these results 
support that α,β-unsaturated aldehydes are genotoxic as well as mutagenic in in vitro assays. 
 
In vivo 
In contrast to in vitro experiments, in vivo data on genotoxicity of α,β-unsaturated aldehydes are 
limited. The formation of DNA adducts in vivo has been reported for trans-2-hexenal and 
2-butenal (crotonaldehyde) upon single oral administration of extremely high doses of the 
aldehydes [6, 7, 47] (Table 1.2). Schuler and Eder [6] reported the formation of DNA adducts, 
namely exocyclic 1,N2-propanodeoxyguanosine adducts, formed upon exposure to 
trans-2-hexenal in male F344 rats and detected using 32P-labeling. The DNA adducts were 
quantifiable in the liver and the tissues that had a direct contact with the compound (e.g. 
forestomach, glandular stomach, oesophagus) as well as in tissues that the aldehyde could reach 
only after absorption into the systemic circulation (e.g. kidney) at 200 or 500 mg/kg bw. At 50 
mg/kg bw, however, a quantifiable amount of DNA adducts was found only in the oesophagus. In 
2008, Stout et al. [7] investigated DNA adduct formation using the same exposure conditions as 
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used by Schuler and Eder [6]. Using LC/MS/MS, the DNA adducts were detected at 200 and 500 
mg trans-2-hexenal/kg bw in the forestomach, glandular stomach and liver but not at 50 mg/kg 
bw. The adduct levels reported by Stout et al. in the liver were up to 1,000 times lower than the 
levels reported by Schuler and Eder. Stout et al., discussed that this striking gap may be attributed 
to the differences in purity of trans-2-hexenal (98% vs 99%), in the specificity of quantification 
methods (LC/MS/MS vs 32P-labeling), and in the animal fasting status (non-fasted vs not 
described) between the two studies. Budiawan and Eder [47] reported DNA adduct formation in 
female F344 rats that were exposed to 200 or 300 mg 2-butenal/kg bw by gavage. The amount of 
DNA adducts in the liver, lung, kidney and large intestine was quantified using 32P-labeling. The 
maximum level of DNA adducts in the liver after single exposure of 200 mg 2-butenal/kg bw was 
2.9 adducts/108 nucleotides (nt) at 20 hrs after the exposure.  
Negative in vivo genotoxicity has been reported for 2,4-hexadienal and cinnamaldehyde upon oral 
exposure [52, 55]. Male and female mice were exposed daily to 7.5 to 120 mg/kg bw 
2,4-hexadienal for 14 weeks, or  4,100 to 33,000 ppm cinnamaldehyde in the feed (equivalent 
650 and 5,475 mg/kg bw/day) for 3 months. Peripheral blood samples were obtained from the 
mice to determine the frequency of micronuclei in normochromatic erythrocytes. In both studies 
there was no increase in the frequency of micronucleated normochromatic erythrocytes compared 
to the control groups.     
 
 Carcinogenicity 
There are several chronic studies and sub-chronic in vivo studies available where carcinogenicity 
of α,β-unsaturated aldehydes has been examined [49, 52, 54, 55]. Interestingly, as summarized 
below and in Table 1.2, these studies reported mixed results depending on the compound.  
 
Cinnamaldehyde  
Male and female F344 rats and B6C3F1 mice were exposed to trans-cinnamaldehyde for two 
years [55]. The compound was encapsulated in starch microcapsules for the stabilisation and 
placed in the feed. The doses given were between 1,000 and 4,100 ppm, corresponding to 50-200 
mg/kg bw/day for rats and 125-550 mg/kg bw/day for mice.  Tissues from more than 40 sites 
were examined for every animal, and there was no development of neoplasms observed due to the 
exposure to cinnamaldehyde in rats or mice.  
 
Citral  
In vivo carcinogenicity of citral was examined in a rodent study [54]. Male and female F344 rats 
and B6C3F1 mice were exposed to citral for two years. The compound was encapsulated in starch 
microcapsules for the stabilization and placed in the feed. The doses given were between 1,000 
and 4,000 ppm, corresponding to 50-210 mg/kg bw/day for rats and 60-260 mg/kg bw/day for 
mice. There were no neoplasms or nonneoplastic lesions observed upon exposure to citral in rats 
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and male mice. An increase in malignant lymphomas was observed for female mice at the highest 
exposure group, which was attributed to the consumption of citral.  
 
2-propenal (acrolein) 
Two in vivo studies examined the carcinogenicity of 2-propenal. In the study of Parent et al., male 
and female Sprague-Dawley rats were treated daily with 0-2.5 mg/kg bw/day 2-propenal in water 
by gavage [49]. After two years, there was no significant increase in the development of 
neoplasms in the treated animals compared to the control group. In a 14-week study conducted by 
NTP [51], however, incidences of squamous hyperplasia of the forestomach epithelium showed a 
dose-dependent increase. In another study [57] F344 rats and B6C3F1 mice were administered 0–
10 mg and 0-20 mg 2-propenal/kg bw/day by gavage, respectively. The frequency of the 
incidences of neoplasms in the forestomach was significantly increased at 5 and 10 mg/kg bw/day 
in male rats, at 2.5 mg/kg bw/day or greater in female rats, and at 2.5, 5, or 10 mg/kg bw/day in 
male and female mice (Table 1.3). 2-Propenal was also shown to significantly increase mortality 
in both species, and the reduced number of neoplasms in the highest exposure group  (i.e. 20 
mg/kg bw/day) in mice was attributed to the increased mortality observed at this level of 
exposure, which amounted to 100% in male and female.  
 
Table 1.3 Number (and percentage) of animals with neoplasm in forestomach per number of 
animals necropsied upon exposure to 2-propenal (derived from NTP [51]) 
F344 rats 
 Control 0.75 
mg/kg bw/day 
 
1.25 
mg/kg bw/day 
2.5 
mg/kg bw/day 
5 
mg/kg bw/day 
10 
mg/kg bw/day 
Male    0/10 (0%)   0/10 (0%)   0/10 (0%) 3/10 (30%) 8/10 (80%)   9/10 (90%) 
Female    0/10 (0%)   0/10 (0%)   3/10 (30%) 5/10 (50%) 8/10 (80%) 10/10 (100%) 
B6C3F1 mice 
 Control 1.25 
mg/kg bw/day 
 
2.5 
mg/kg bw/day 
5 
mg/kg bw/day 
10 
mg/kg bw/day 
20 
mg/kg bw/day 
Male   0/10 (0%)   2/10 (20%)   6/10 (60%) 7/10 (70%) 10/10 (100%) 0/10 (0%) 
Female   0/10 (0%)   0/10 (0%)   4/10 (40%) 7/10 (70%)   8/10 (80%) 2/10 (20%) 
 
2,4-hexadienal  
Carcinogenicity of 2,4-hexadienal was examined in a two-year rodent study [52]. Male and 
female F344 rats and B6C3F1 mice were exposed daily to 2,4-hexadienal by gavage. The 
compound was dissolved in corn oil and was deposited directly in the forestomach through a tube. 
After two years, animals receiving 2,4-hexadienal showed significantly greater occurrences of 
neoplasms in the forestomach, including papillomas and malignant carcinomas in both species. 
The occurrence increased dose-dependently (see Table 1.4).  
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Table 1.4 Number (and percentage) of animals with neoplasm per number of animals necropsied 
upon exposure to 2,4-hexadienal (derived from NTP [52]) 
F344 rats 
 Control 22.5 
mg/kg bw/day 
 
45 
mg/kg bw/day 
90 
mg/kg bw/day 
Male  0/50 (0%) 3/50 (6%) 10/50 (20%) 29/50 (58%) 
Female  0/50 (0%) 1/50(2%)   5/50 (10%) 17/50 (34%) 
B6C3F1 mice 
 Control 30 
mg/kg bw/day 
 
60 
mg/kg bw/day 
120 
mg/kg bw/day 
Male 2/50 (4%) 4/50 (8%)   5/50 (10%) 10/50 (20%) 
Female 2/50 (4%) 2/49 (4%) 11/50 (22%) 18/50 (36%) 
 
The Joint FAO/WHO Expert Committee on Food Additives (JECFA) mentioned that a 
development of neoplasia is a common finding in bioassays in which a high concentration of an 
irritating material is delivered by gavage into the forestomach every day for two years, and the 
genotoxicity of the compound is not believed to be the basis for its effects in the rodent 
forestomach but rather, the injury to the forestomach epithelium attributable to exposure is 
believed to be the primary cause [11]. It was furthermore considered that the conditions of 
exposure during oral administration are unusual in that physical effects may cause high local 
concentrations of test substances in the forestomach and prolonged exposure of the epithelium. 
Also, the forestomach was the only site of increased neoplasia in treated animals. Based on these 
reasons JECFA concluded that the appearance of forestomach tumours by 2,4-hexadienal in 
rodents observed in the study by NTP [52] is of no relevance to humans [11].  
 
1.5 Safety evaluation and regulatory status of α,β-unsaturated aldehydes  
 
The Joint FAO/WHO Expert Committee on Food Additives (JECFA) evaluated the safety of 
2-alkenals, 2,4-dienals, and cinnamaldehyde and their related carboxylic acids, alcohols and esters 
as added food flavourings [9-11]. All the substances evaluated were categorized as Cramer Class I 
in their evaluation scheme, which includes “flavouring agents that have simple chemical 
structures and efficient modes of metabolism which would suggest a low order of toxicity by the 
oral route”. For 2-alkenals and 2,4-dienals the human daily exposure levels to these aldehydes 
were estimated to be below the threshold of toxicological concern (TTC) for Cramer Class I 
(1,800 μg/day) both in Europe and in the US [9-11]. Therefore JECFA concluded that these 
substances would not be of safety concern at their currently estimated levels of intake as 
flavouring agents. The daily intake of cinnamaldehyde was estimated to be 2,500 and 59,000 
μg/day/capita in Europe and in the US respectively, which exceeds the TTC of 1,800 μg/day [9]. 
The Committee proceeded to the next step where the intake levels were compared with the no 
observed adverse effect level (NOAEL). The NOAEL of cinnamaldehyde was determined to be 
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substances would not be of safety concern at their currently estimated levels of intake as 
flavouring agents. The daily intake of cinnamaldehyde was estimated to be 2,500 and 59,000 
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620 mg/kg bw/day (i.e. 37,200 mg/day/capita for a person of 60 kg) in a 13-week toxicity study in 
rat, and the margin of safety of > 600 times compared to the estimated intake level in the US was 
considered sufficient to conclude that the use of cinnamaldehyde as a flavouring agent is not of 
concern [9].  
In the US, the Expert Panel of the Flavor and Extract Manufacturers Association (FEMA) 
conducted a safety evaluation on the use of aliphatic, linear α,β-unsaturated aldehydes and related 
compounds [12], and of cinnamaldehyde and their related compounds [13] as flavouring 
ingredients. The conclusions were comparable to those of JECFA. The Panel affirmed the GRAS 
(generally recognized as safe) status of the substances based on their rapid absorption, metabolic 
detoxification, and excretion in humans and other animals, their low level of flavour use, the wide 
margins of safety between the conservative estimates of intake and the NOAELs determined from 
subchronic and chronic studies, and the lack of significant genotoxic and mutagenic potential 
when tested at non-cytotoxic concentrations. For cinnamaldehyde the Panel additionally 
mentioned that this evidence of safety is supported by the fact that the intake of cinnamyl 
derivatives as natural components of traditional foods is much greater than their intake as 
intentionally added flavoring substances [13]. With this GRAS status, the use of α,β-unsaturated 
aldehydes as intentionally added food additives is allowed in the US under the Federal Food, 
Drug, and Cosmetic Act. 
EFSA took a different approach for the safety assessment as compared to JECFA or 
FEMA. The EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
evaluated the use of 347 flavouring substances in the EU Register that are α,β-unsaturated 
aldehydes or related compounds which may give rise to such aldehydes via hydrolysis or 
oxidation [14]. The flavouring substances were divided into 28 subgroups depending on the 
structural similarity. For most of the subgroups, the Panel considered that the α,β-unsaturated 
aldehyde and ketone structures are alerts for genotoxicity and concluded that there is a need for 
additional information before conclusions can be reached. It was furthermore mentioned that the 
required data include data on mode of action and metabolism, genotoxicity data especially in vivo 
or data on carcinogenicity. Based on this opinion of EFSA, the use of most of the aldehydes and 
related substances has been suspended in the EU under the Regulation (EC) No. 1334/2008 and 
under the new regulation that came into force in 2013 (Regulation (EU) No. 872/2012). 
 
1.6 Uncertainties in effects of genotoxic agents at low exposure levels 
 
The discrepancy in the conclusions by JECFA and FEMA on one side and the conclusion by the 
EFSA on the other, clearly illustrates the lack of consensus within authorities and scientists related 
to safety evaluations of genotoxic agents at low exposure levels. In general it is considered that 
when DNA is damaged by a xenobiotic genotoxic agent, the damage may result in a mutation 
during the following DNA synthesis if it is not repaired in time. This mutation may contribute to 
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tumour development for example by inducing the proliferation of the cell, resulting in the 
formation of an identifiable focal lesion and accumulation of genetic damage. The so-called 
one-hit theory assumes that a single DNA damaging event in a cell is able to induce a single point 
mutation that may lead to increased proliferation of the cell, which may result in a tumour 
formation. Although current scientific insights rather assume that tumour formation is a multistep 
process [58], in conventional toxicological risk assessment it is still assumed that tumour 
formation by genotoxic carcinogens can be a one hit event so that there is no threshold that 
defines a safe level of exposure.  
Because of the absence of a safe level of exposure, genotoxic carcinogenic compounds are 
not allowed to be intentionally added to foods in the EU. This implies that compounds for which 
positive in vitro genotoxicity data exist require follow up in vivo studies to exclude the concern 
over genotoxicity and carcinogenicity. With the implementation of the new EU regulation for 
food flavouring agents (Regulation (EU) No. 872/2012), this approach now also applies to 
flavouring agents. Questions can be raised, however, whether the low exposure levels resulting 
from their use as flavourings, would lead to a significant risk. The effects of the genotoxic agents 
at low exposure levels may not be significant compared to the effects of endogenous and 
unavoidable exogenous genotoxic compounds, because of  cytoprotective mechanisms including 
metabolism that swiftly converts DNA damaging agents to non-reactive metabolites to prevent 
formation of DNA damage, and efficient DNA repair that eliminates DNA damages. Oesche et al. 
[59] for instance presented that DNA strand breaks caused by styrene oxide caused in V79 
Chinese hamster cells were not observed at lower concentrations than 100 μM when the cells 
were genetically engineered to express human microsomal epoxide hydrolase. The results suggest 
that the detoxification enzymes may play an important role in the protection against the DNA 
damaging agent. The importance of DNA repair to prevent genotoxic adverse effects is for 
example supported by a study by Doak et al. [60]. The alkylating agents methyl 
methanesulphonate or ethyl methanesulphonate  have been known to show non-linear 
concentration-response curves for gross chromosomal damage and mutagenicity with no-observed 
effect levels (NOELs) in vitro. Doak et al. investigated gene expression levels involved in DNA 
repair and found  that expression of O6-methylguanine DNA methyltransferase is up-regulated at 
low exposure concentrations within the NOEL, reflecting sub-linear DNA adduct formation and 
protection against the DNA damage at low exposure concentrations. 
It has important implications in the safety evaluation of DNA reactive agents to determine 
genotoxic effects at low exposure levels relevant to realistic exposure in vivo.  However, 
determination of genotoxic effects at such low exposure levels in vivo is generally problematic. 
Very sensitive tests are required, and moreover, the experiments may require thousands of 
animals per dose to quantify an increase in the responses above background levels in a statistically 
robust manner [61]. In addition, in case of α,β-unsaturated aldehydes, providing in vivo data on 
all the aldehydes listed as food flavourings would not be realistic considering the large number of 
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metabolism that swiftly converts DNA damaging agents to non-reactive metabolites to prevent 
formation of DNA damage, and efficient DNA repair that eliminates DNA damages. Oesche et al. 
[59] for instance presented that DNA strand breaks caused by styrene oxide caused in V79 
Chinese hamster cells were not observed at lower concentrations than 100 μM when the cells 
were genetically engineered to express human microsomal epoxide hydrolase. The results suggest 
that the detoxification enzymes may play an important role in the protection against the DNA 
damaging agent. The importance of DNA repair to prevent genotoxic adverse effects is for 
example supported by a study by Doak et al. [60]. The alkylating agents methyl 
methanesulphonate or ethyl methanesulphonate  have been known to show non-linear 
concentration-response curves for gross chromosomal damage and mutagenicity with no-observed 
effect levels (NOELs) in vitro. Doak et al. investigated gene expression levels involved in DNA 
repair and found  that expression of O6-methylguanine DNA methyltransferase is up-regulated at 
low exposure concentrations within the NOEL, reflecting sub-linear DNA adduct formation and 
protection against the DNA damage at low exposure concentrations. 
It has important implications in the safety evaluation of DNA reactive agents to determine 
genotoxic effects at low exposure levels relevant to realistic exposure in vivo.  However, 
determination of genotoxic effects at such low exposure levels in vivo is generally problematic. 
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the compounds in the group [14]. Alternative methods to investigate concerns over genotoxicity 
of α,β-unsaturated aldehyde food flavouring agents at low dose exposure are of high interest. This 
thesis therefore aims to develop physiologically based in silico models for examination of low 
dose DNA adduct formation of food-borne α,β-unsaturated aldehydes to facilitate safety 
evaluation of their use a flavouring agents.  
 
1.7 PBK/D modeling for genotoxic compounds 
 
In order to obtain insights in the kinetic and dynamic behaviour of a chemical at low dose 
exposure including the possible saturation in metabolism, physiologically based in silico models 
have proven to be a powerful tool [62-64]. A PBK/D (physiologically based kinetic/dynamic) 
model is a set of mathematical descriptions simulating a relationship between external exposure 
levels and chemical concentrations in biological matrices (kinetics) and their effect on the 
organism (dynamics) over time. In a PBK/D model a body is divided into different compartments. 
The choice of compartments for the model is a crucial step that has a significant influence on the 
model outcomes. In general target tissues and tissues that metabolize the substance of interest are 
represented as individual compartments and non-target tissues are lumped together into “slowly 
perfused tissues” (e.g. muscle and skin) or “richly perfused tissues” (e.g. brain and spleen) 
compartments depending on relative perfusion rates [65].  
Development of PBK/D models consists of four steps: model representation, 
parameterization, simulation and evaluation [66]. Model Representation involves the development 
of conceptual and mathematical descriptions of the relevant compartments of the animal as well as 
the identification of the exposure and metabolic pathways of the chemical. Model 
Parameterization is the step where independent measures of the mechanistic determinants are 
obtained. The parameters are usually classified as either physiological (e.g. body weight, cardiac 
output), physico-chemical (e.g. logKow, tissue: blood partition coefficients) or biochemical (e.g. 
Vmax and Km of metabolism). Physiological parameters can usually be collected from literature, 
while physico-chemical and biochemical parameters are chemical specific and therefore usually 
need to be defined for each compound by using in silico modelling or by performing experiments. 
The step of Model Simulation involves the prediction of ADME and further dynamics of a 
chemical for a defined exposure scenarios, using a numerical integration algorithm. The last step 
Model Evaluation or Model Validation involves the comparison of predicted values of the model 
with experimentally obtained in vivo data. Depending on how well the prediction matches with in 
vivo data, the model will be refused, refined, or accepted for further use [66]. Once a PBK/D 
model is developed, it can be used to obtain mechanistic insights in the extrapolation of high 
exposure doses used in animal studies to the exposure levels relevant for realistic human exposure 
that are usually orders of magnitude lower. Furthermore, by replacing all parameters in a model 
specific for rats with the corresponding physiological and kinetic parameters for humans, a 
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PBK/D models for human can be defined. If parameters in a model are replaced from one 
individual to another the interindividual (intraspecies) variation can be investigated, which allows 
examination of the influence of for example polymorphisms in detoxification and/or bioactivation 
efficiencies [62]. Furthermore, PBK/D models can be used to facilitate read-across from one 
compound to another structurally related compound that exerts toxicity via a similar mode of 
action by replacing chemical specific parameters including biochemical and physicochemical 
parameters [67]. 
A number of toxicological research papers about physiologically based in silico models 
have been published for, for instance, drugs, cosmetic products or food constituents. Yet, the 
majority of the publications aim at simulating ADME of the compounds of interest administered 
through different exposure routes, and examples of models for genotoxic compounds allowing 
prediction of DNA damage are limited. In 2007 Young et al. published a PBK/D model 
simulating DNA adduct formation of glycidamide, a metabolite of acrylamide [68] in rats, mice 
and humans. In this study, toxicokinetic data as well as DNA binding kinetics in rats and mice 
were collected by exposing animals to acrylamide in drinking water for 1 week. The PBK/D 
models developed for rats and mice were subsequently extended to human, by fitting the 
predictions for acrylamide excretion in urine to observed human data. PBK/D models may be 
developed based on in vivo data, as shown by Young et al., however, it requires use of animals, 
and moreover, it may not be feasible for all compounds to obtain kinetic and dynamic data in 
vivo, especially when a model for DNA adduct formation upon human exposure to an avoidable 
genotoxic compound needs to be developed. In 2008, Paini et al. developed a model where DNA 
adduct formation by estragole, one of the alkenylbenzenes present in the diet, is described [64].  
The parameters to address metabolism of estragole and DNA adduct formation of 
1ʹ-sulfooxyestragole, the ultimate carcinogen of estragole, were obtained by in vitro assays by 
incubating estragole or its metabolites with relevant tissue fractions or primary cells. 
 
1.8 Objectives and outline of the thesis 
 
The main objective of the present thesis was to develop physiologically based in silico models for 
examination of DNA adduct formation of food-borne α,β-unsaturated aldehydes at low doses to 
facilitate safety evaluation of their use a flavouring agents. PBK/D models were developed based 
on kinetic parameters derived from in vitro incubations using relevant tissue fractions. In order to 
facilitate the extension of PBK/D models from one α,β-unsaturated aldehyde to other structurally 
related substances that exert toxicity via a similar mode of action, a QSAR (quantitative  
structure-activity relationship) approach was applied to accelerate the determination of the kinetic 
parameters. The PBK/D model outcomes were used to provide mechanistic insights in dose- and 
species- dependent detoxification and DNA adduct formation by different α,β-unsaturated 
aldehydes present in the diet. 
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Chapter 1, the current chapter, introduces occurrence, metabolism, genotoxicity and 
carcinogenicity, and regulatory status of dietary α,β-unsaturated aldehydes as the basic 
background information of the compounds. Also, the uncertainty in the evaluation of genotoxicity 
at low exposure doses, a challenge for the safety evaluation of these flavouring compounds, the 
use of PBK/D models, and finally the aim and overall objectives of the thesis are introduced.  
Chapter 2 presents the development of a PBK/D model for trans-2-hexenal in rats. 
trans-2-Hexenal was selected as a model dietary α,β-unsaturated aldehyde for the development of 
this first PBK/D model enabling prediction of DNA adduct formation at low dose levels. The 
kinetic parameters are collected by performing in vitro incubations using relevant pooled rat tissue 
fractions. In order to address the influence of the depletion of GSH, GSH pool kinetics are also 
described in the model. The model performance is evaluated, and the dose-dependent 
detoxification and DNA adduct formation are simulated to obtain insights in the significance of 
the DNA adduct level increase at low doses relevant for human dietary exposure.  
Chapter 3 describes the development of a PBK/D model for trans-2-hexenal in humans. 
The structure of the model is based on the rat model developed in Chapter 2. The kinetic 
parameters are collected by performing in vitro incubations using pooled human tissue fractions. 
In order to determine the influence of polymorphisms in the detoxification efficiencies on DNA 
adduct formation, the kinetic parameters are defined also for 11 individuals using individual 
human tissue fractions. By performing Monte-Carlo simulations, the distribution of formation of 
DNA adduct levels in the population upon exposure to trans-2-hexenal is determined. Based on 
the outcomes, it is discussed if the increase in DNA adduct levels in the liver due to dietary 
exposure to trans-2-hexenal in the human population is significant compared to reported 
background levels of DNA adducts.  
trans-2-Hexenal is only one of many dietary α,β-unsaturated aldehydes of interest. 
Chapter 4 extends the rat PBK/D model developed for trans-2-hexenal to 18 other structurally 
related food-borne α,β-unsaturated aldehydes using a QSAR approach for definition of the PBK/D 
parameters. The kinetic parameters are first experimentally determined for a training set of 6 
acyclic α,β-unsaturated aldehyde to define QSAR models. Based on the QSAR models, kinetic 
parameters of the other 12 aldehydes are predicted and integrated into PBK/D models. Based on 
the outcomes, the significance of DNA adduct formation at dietary exposure levels as well as a 
compound that represents the worst case within the group will be defined. 
For most of the aldehydes, in vivo data on genotoxicity and carcinogenicity that can 
overcome the concerns raised by in vitro genotoxicity data, are lacking. In contrast, 
cinnamaldehyde has been shown to be not genotoxic or carcinogenic in a rodent study and has 
been approved as flavouring agent despite its α,β-unsaturated aldehyde moiety. Chapter 5 
therefore investigates DNA adduct formation by cinnamaldehyde at doses where no genotoxicity 
or carcinogenicity has been observed in vivo, using PBK/D modelling, and compares these DNA 
adduct levels to those predicted for the 18 aldehydes in Chapter 4. Rat and human PBK/D models 
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for cinnamaldehyde are built based on biochemical parameters collected by performing in vitro 
incubations. Based on the PBK/D models outcomes, possibilities to apply read-across from the 
negative genotoxicity and carcinogenicity results obtained for cinnamaldehyde in vivo to any of 
the 18 aldehydes will be discussed.  
Finally Chapter 6 presents the overall discussion including the performance of the 
PBK/D models developed in this thesis and implication of the PBK/D model outcomes for the 
safety evaluation of food-borne α,β-unsaturated aldehydes used as flood flavourings, as well as 
suggestions for future work.  
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ABSTRACT  
 
trans-2-Hexenal is an α,β-unsaturated aldehyde that occurs naturally in a wide range of fruits, 
vegetables, and spices. trans-2-Hexenal as well as other α,β-unsaturated aldehydes that are natural 
food constituents or flavoring agents may raise a concern for genotoxicity due to the ability of the 
α,β-unsaturated aldehyde moiety to react with DNA. Controversy remains, however, on whether 
α,β-unsaturated aldehydes result in significant DNA adduct formation in vivo at realistic dietary 
exposure. In this study, a rat physiologically based in silico model was developed for 
trans-2-hexenal as a model compound to examine the time- and dose-dependent detoxification 
and DNA adduct formation of this selected α,β-unsaturated aldehyde. The model was developed 
based on in vitro and literature-derived parameters, and its adequacy was evaluated by comparing 
predicted DNA adduct formation in the liver of rats exposed to trans-2-hexenal with reported in 
vivo data. The model revealed that at an exposure level of 0.04 mg/kg bw, a value reflecting 
estimated daily human dietary intake, trans-2-hexenal is rapidly detoxified predominantly by 
conjugation with glutathione (GSH) by glutathione S-transferases. At higher dose levels, depletion 
of GSH results in a shift to trans-2-hexenal oxidation and reduction as the major pathways for 
detoxification. The level of DNA adduct formation at current levels of human dietary intake was 
predicted to be more than 3 orders of magnitude lower than endogenous DNA adduct levels. 
These results support that rapid detoxification of trans-2-hexenal reduces the risk arising from 
trans-2-hexenal exposure and that at current dietary exposure levels, DNA adduct formation is 
negligible.
 
INTRODUCTION 
 
trans-2-Hexenal is an α,β-unsaturated aldehyde that occurs in a wide range of foods being a 
natural constituent of fruits, vegetables, and spices [1]. Its maximum level reported in food, 
amounting to 76 mg/kg, was found in banana [2]. Because of its grassy fresh odor, 
trans-2-hexenal is called a “leaf aldehyde” and has been used as a flavoring agent. The estimated 
daily intake of trans-2-hexenal from food consumption is 2,390 μg/person/day as a natural 
constituent and 57 μg/person/day as a food flavoring agent [1], corresponding to 40 and 1 μg/kg 
bw/day, respectively, for a 60 kg person. 
The α,β-unsaturated aldehyde moiety present in trans-2-hexenal has been considered a 
structural alert for genotoxicity [1, 3]. Because of this α,β-unsaturated aldehyde moiety, 
trans-2-hexenal may react with cellular macromolecules including DNA without the need for 
bioactivation. Numerous in vitro studies have indicated the genotoxicity of trans-2-hexenal in 
microorganisms or mammalian cells [4-6]. However, few in vivo genotoxicity studies on 
trans-2-hexenal are available. Schuler and Eder [7], using 32P-postlabeling, quantified DNA 
adduct formation in organs such as forestomach, liver, esophagus, and kidney after a single 
administration of 200 or 500 mg trans-2-hexenal/kg bw to male F344 rats by gavage, but DNA 
adduct formation was not detectable at 50 mg trans-2-hexenal/kg bw. Stout et al. [4] used more 
specific liquid chromatography tandem mass spectrometry (LC/MS/MS) for analysis of DNA 
adduct formation in forestomach, glandular stomach, and liver in male F344 rats. DNA adducts, 
namely, exocyclic 1,N2-propanodeoxyguanosine adducts (Hex-PdG), were quantifiable in the 
forestomach of animals exposed to 100 or 200 mg/kg bw/day for 1 or 4 weeks and in the liver 
from rats exposed to a single dose of 200 or 500 mg trans-2-hexenal/kg bw. It appears that DNA 
adduct formation occurs only at high irritating doses of trans-2-hexenal that are more than 3–4 
orders of magnitude higher than the estimated average human dietary intake in vivo. It has been 
suggested that the DNA adduct formation observed at these high dose levels may not be indicative 
for DNA adduct formation at lower dose levels because trans-2-hexenal might be sufficiently 
detoxified at lower levels of exposure. This detoxification of trans-2-hexenal can proceed by three 
detoxification pathways in rat liver (Figure 2.1) [5]. The major pathway is conjugation with 
reduced glutathione (GSH), chemically or catalyzed by glutathione S-transferases (GSTs). 
Furthermore, aldehyde dehydrogenases (ALDHs) efficiently oxidize trans-2-hexenal to 
2-hexenoic acid that is no longer DNA reactive. A third route includes reduction to 2-hexan-1-ol 
mediated by aldose reductases (ARs), which has been suggested to be less efficient than 
trans-2-hexenal oxidation or conjugation with GSH based on results from incubations with 
primary rat hepatocytes exposed to trans-2-hexenal [5]. 
A question that remains to be answered is whether at realistic dietary exposure levels the 
various α,β-unsaturated aldehydes will result in significant DNA adduct formation or whether the 
enzymatic processes are efficient enough to allow rapid detoxification and prevention of DNA 
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adduct formation. JECFA (Joint FAO/WHO Committee on Food Additives) and the Expert Panel 
of the FEMA (Flavor and Extract Manufacturers Association) concluded that α,β-unsaturated 
aldehydes including trans-2-hexenal do not present any safety concerns at estimated current 
intakes resulting from its use as a flavor based on the low level of use [1, 8]. The possible rapid 
detoxification of α,β-unsaturated aldehydes in vivo was specifically raised by FEMA as an 
argument in the establishment of GRAS (Generally Recognized as Safe) status. The European 
Food Safety Authority (EFSA), on the other hand, considered the α,β-unsaturated aldehyde 
structure to be an alert for genotoxicity, pointing out the need for especially in vivo data before 
any conclusions to be reached [3]. 
From these considerations, it becomes clear that understanding dose-dependent DNA 
adduct formation and detoxification in vivo is an important aspect in the safety evaluation of 
trans-2-hexenal as well as that of many other α,β-unsaturated aldehydes. The overall goal of this 
study was to characterize dose-dependent effects on detoxification and DNA adduct formation of 
trans-2-hexenal by developing a physiologically based kinetic and dynamic (PBK/D) model in 
rat, thereby contributing to obtaining insight in these important aspects in the safety evaluation of 
trans-2-hexenal as well as other α,β-unsaturated aldehydes. For the development of the PBK/D 
model, kinetic parameters for each detoxification pathway and DNA adduct formation were 
determined in vitro. Performance of the model was evaluated against available literature data on 
DNA adduct levels in rats exposed to high doses of trans-2-hexenal, with the PBK/D model 
enabling extrapolation to realistic dietary human exposure levels. The results obtained are 
discussed with respect to implications for the safety evaluation of trans-2-hexenal. 
 
 
   
Figure 2.1 Metabolism of trans-2-hexenal.  
 
MATERIALS AND METHODS 
 
Chemicals and Biological Materials 
trans-2-Hexen-1-al (trans-2-hexenal), trans-2-hexen-1-ol (2-hexen-1-ol), trans-2-hexenoic acid 
(2-hexenoic acid), 2′-deoxyguanosine monohydrate (2′-dG), diamide, tris (hydroxymethyl) 
aminomethane, GSH, and GSH assay kit were purchased from Sigma-Aldrich (Zwijndrecht, The 
Netherlands). Reduced (NADPH) and oxidized (NAD+) β-nicotinamide adenine dinucleotide 
phosphate were obtained from Roche Diagnostics (Mannheim, Germany), and dimethyl sulfoxide 
(DMSO) was purchased from Acros Organic (NJ). Chromatography grade acetonitrile and 
methanol were purchased from Biosolve (Valkenswaard, The Netherlands). Chromatography 
grade trifluoroacetic acid (TFA) was obtained from J. T. Baker (Deventer, The Netherlands). 
Pooled liver S9 from male F344 rats was obtained from BD Gentest (Worburn, United States). Rat 
liver mitochondrial fraction and small intestine S9 were prepared in our laboratory from 
individual outbred male Wistar rats purchased from Harlan (Boxmeer, The Netherlands) as 
described below. 
 
Isolation of Rat Liver Mitochondrial Fraction and Small Intestine S9 
Rat liver mitochondrial fraction was obtained from a male Wistar rat of 365 g to determine the 
kinetic constants of mitochondrial ALDHs. The rat was sacrificed by inhalation of carbon dioxide. 
The liver was collected immediately and stored at −80 °C until further processing. After it was 
thawed on ice, the liver was homogenized, and the mitochondrial fraction was isolated as 
described elsewhere [9]. Briefly, the homogenized liver was first centrifuged at 500g for 10 min at 
4 °C, and the supernatant was removed. The pellet was then resuspended in ice-cold 
phosphate-buffered saline (PBS) and centrifuged at 10,000g for 10 min. The supernatant was 
removed, and the pellet was collected as mitochondrial fraction. The collected fraction was 
washed with PBS to examine contamination with cytosolic ALDHs. Because this additional 
washing step did not decrease the ALDHs capacity of the mitochondrial fraction, contamination of 
cytosolic ALDHs in the mitochondrial fraction was considered to be negligible. The obtained 
mitochondrial fraction was dissolved in PBS at 413 mg mitochondrial fraction/mL and stored at 
−80 °C. 
Rat small intestine S9 was obtained as described elsewhere [10] from a male Wistar rat 
of 372 g. The rat was sacrificed by inhalation of carbon dioxide. An incision was made lengthwise 
throughout the collected small intestine, and its mucosa was scraped off carefully. The collected 
mucosa was stored at −80 °C until further processing. After it was thawed on ice, the mucosa 
fraction was mixed with approximately 4 volumes of ice-cold PBS and homogenized using a 
Potter homogenizer with 15–20 strokes. The homogenized tissue was subsequently centrifuged at 
9,000g for 20 min at 4 °C . The supernatant was transferred to new Eppendorf tubes and stored at 
−80 °C. The protein concentration in this S9 preparation was determined by using QuantiPro BCA 
Assay Kit (Sigma-Aldrich). 
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Aldehyde Dehydrogenase (ALDH)-Mediated Oxidation of trans-2-Hexenal to 2-Hexenoic Acid 
The ALDH activities are known to be present in cytosol and mitochondria [11]. Therefore, 
incubations were performed with rat liver S9 or rat small intestine S9, which contain tissue 
cytosol and microsomes [12], or rat liver mitochondrial fraction to determine the kinetic constants 
for ALDH-mediated oxidation in these different tissue fractions. The incubation mixtures had a 
final volume of 100 μL, containing (final concentrations) NAD+ (2 mM) and liver S9 (0.2 mg 
protein/mL), small intestine S9 (0.34 mg protein/mL), or liver mitochondrial fraction (4.13 mg 
mitochondrial fraction/mL) in 0.1 M Tris-HCl (pH 7.4). After they were preincubated at 37 °C for 
2 min, the reactions were started by the addition of the substrate trans-2-hexenal (100–1,000 μM 
with liver or small intestine S9, 10–500 μM with liver mitochondrial fraction) from a 100 times 
concentrated stock solution in DMSO. The reactions were carried out for 5 min with liver or small 
intestine S9 and for 3 min with liver mitochondrial fraction and then terminated by adding 50 μL 
of ice-cold acetonitrile. The incubation mixtures were subsequently centrifuged for 3 min at 
16,000g at 4 °C to precipitate proteins. Blank incubations were performed without the cofactor 
NAD+ or tissue fractions. As trans-2-hexenal was also oxidized spontaneously to form 2-hexenoic 
acid during these incubations, the amount of 2-hexenoic acid formed in blank incubations without 
tissue fractions was subtracted as the background. 
The amount of 2-hexenoic acid in the samples was analyzed immediately after the 
incubation on an ultraperformance liquid chromatography with diode array detection 
(UPLC-DAD) system consisting of a Waters (Waters, Milford, MA) Acquity solvent manager, 
sample manager, and photodiode array detector, equipped with a Waters Acquity UPLC BEH C18 
column (1.7 μm, 2.1 mm × 50 mm). The gradient was made with acetonitrile and ultrapure water 
containing 0.1% (v/v) TFA. The flow rate was 0.6 mL/min, and a gradient was applied from 20 to 
30% acetonitrile over 3 min, after which the percentage of acetonitrile was increased to 100% 
over 0.2 min, kept at 100% for 0.5 min, lowered to 20% over 0.2 min, and kept at these initial 
conditions for 1.1 min for equilibration. Under these conditions, the retention time of 2-hexenoic 
acid was 1.3 min. Quantification of 2-hexenoic acid was achieved by comparison of the peak 
areas in the chromatograms obtained at a wavelength of 210 nm to the calibration curve made 
using the commercially available standard. 
 
AR-Mediated Reduction of trans-2-Hexenal to 2-Hexen-1-ol 
trans-2-Hexenal was incubated with rat liver S9 to determine the kinetic constants for reduction of 
trans-2-hexenal mediated by ARs. The incubation mixtures had a final volume of 100 μL, 
containing (final concentrations) liver S9 (1 mg protein/mL) in 0.1 M Tris-HCl (pH 7.4). After 
preincubation at 37 °C for 2 min, the reaction was started by the addition of NADPH (2.5 mM) 
from a 20 times concentrated stock solution in 0.1 M Tris-HCl (pH 7.4) and trans-2-hexenal (50–
500 μM) from a 100 times concentrated stock solution in DMSO. After 4 min, the reaction was 
 
terminated by adding 50 μL of ice-cold acetonitrile. Blank incubations were performed without 
cofactor NADPH or S9. The incubation mixtures were subsequently centrifuged for 3 min at 
16,000g at 4 °C to precipitate proteins. The samples were frozen in dry ice immediately after the 
centrifugation and kept at −20 °C to prevent evaporation of 2-hexen-1-ol. 
The amount of 2-hexen-1-ol was measured using a UPLC-DAD system equipped as 
described above. The gradient was made with acetonitrile and ultrapure water containing 0.1% 
(v/v) formic acid. The flow rate was 0.6 mL/min, and a gradient was applied from 0 to 10% 
acetonitrile over 10 min, after which the percentage of acetonitrile was increased to 100% over 
0.2 min, kept at 100% for 0.5 min, lowered to 0% over 0.3 min, and kept at these initial conditions 
for 1 min for equilibration. Under these conditions, the retention time of 2-hexen-1-ol was 9.1 
min. Quantification of 2-hexen-1-ol was achieved by comparison of the peak areas in the 
chromatogram obtained at a wavelength of 193 nm to the calibration curve made using the 
commercially available standard. 
 
GST-Mediated GSH Conjugation of trans-2-Hexenal 
Kinetic constants for GST-mediated formation of trans-2-hexenal GSH conjugates, namely 
S-[3-(1-oxohexyl)]-GSH (Hex-GSH), were determined by incubating trans-2-hexenal with rat 
liver or small intestine S9. The incubation mixture had a final volume of 100 μL, containing (final 
concentrations) liver S9 (0.2 mg protein/mL) or small intestine S9 (0.64 mg protein/mL) in 0.1 M 
Tris-HCl (pH 7.4). After preincubation at 37 °C for 2 min, the reaction was started by the addition 
of GSH (5 mM) from a 10 times concentrated stock solution in 0.1 M Tris-HCl (pH 7.4) and 
trans-2-hexenal (500–5000 μM) from a 100 times concentrated stock solution in DMSO. The 
reaction was carried out for 3 min with liver S9 and for 4 min with small intestine S9 and 
terminated by adding 50 μL of ice-cold acetonitrile. In parallel, incubations without S9 were 
carried out to quantify the chemical conjugation of trans-2-hexenal with GSH. The samples 
obtained from the incubations were centrifuged for 3 min at 16,000g at 4 °C to precipitate 
proteins, and the resulting supernatant was analyzed by UPLC-DAD immediately after 
centrifugation. 
The amount of Hex-GSH conjugates was measured using a UPLC-DAD system 
equipped as described above. The gradient was made with acetonitrile and ultrapure water 
containing 0.1% (v/v) TFA. The flow rate was 0.6 mL/min, and a gradient was applied from 5 to 
10% acetonitrile over 2.5 min, after which the percentage of acetonitrile was increased to 100% 
over 0.2 min, kept at 100% for 0.5 min, lowered to 0% over 0.3 min, kept at 0% over 0.3 min, 
increased to 5% over 0.2 min, and kept at these initial conditions for 1 min for equilibration. With 
this condition, two conjugates were found at retention times of 2.2 and 2.4 min, which were 
absent in incubations without either GSH or trans-2-hexenal. 
To characterize the products formed, a trans-2-hexenal (1 mM) incubation sample with 
GSH (5 mM) and liver S9 (1 mg protein/mL) and blank samples (without liver S9 or GSH) were 
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Aldehyde Dehydrogenase (ALDH)-Mediated Oxidation of trans-2-Hexenal to 2-Hexenoic Acid 
The ALDH activities are known to be present in cytosol and mitochondria [11]. Therefore, 
incubations were performed with rat liver S9 or rat small intestine S9, which contain tissue 
cytosol and microsomes [12], or rat liver mitochondrial fraction to determine the kinetic constants 
for ALDH-mediated oxidation in these different tissue fractions. The incubation mixtures had a 
final volume of 100 μL, containing (final concentrations) NAD+ (2 mM) and liver S9 (0.2 mg 
protein/mL), small intestine S9 (0.34 mg protein/mL), or liver mitochondrial fraction (4.13 mg 
mitochondrial fraction/mL) in 0.1 M Tris-HCl (pH 7.4). After they were preincubated at 37 °C for 
2 min, the reactions were started by the addition of the substrate trans-2-hexenal (100–1,000 μM 
with liver or small intestine S9, 10–500 μM with liver mitochondrial fraction) from a 100 times 
concentrated stock solution in DMSO. The reactions were carried out for 5 min with liver or small 
intestine S9 and for 3 min with liver mitochondrial fraction and then terminated by adding 50 μL 
of ice-cold acetonitrile. The incubation mixtures were subsequently centrifuged for 3 min at 
16,000g at 4 °C to precipitate proteins. Blank incubations were performed without the cofactor 
NAD+ or tissue fractions. As trans-2-hexenal was also oxidized spontaneously to form 2-hexenoic 
acid during these incubations, the amount of 2-hexenoic acid formed in blank incubations without 
tissue fractions was subtracted as the background. 
The amount of 2-hexenoic acid in the samples was analyzed immediately after the 
incubation on an ultraperformance liquid chromatography with diode array detection 
(UPLC-DAD) system consisting of a Waters (Waters, Milford, MA) Acquity solvent manager, 
sample manager, and photodiode array detector, equipped with a Waters Acquity UPLC BEH C18 
column (1.7 μm, 2.1 mm × 50 mm). The gradient was made with acetonitrile and ultrapure water 
containing 0.1% (v/v) TFA. The flow rate was 0.6 mL/min, and a gradient was applied from 20 to 
30% acetonitrile over 3 min, after which the percentage of acetonitrile was increased to 100% 
over 0.2 min, kept at 100% for 0.5 min, lowered to 20% over 0.2 min, and kept at these initial 
conditions for 1.1 min for equilibration. Under these conditions, the retention time of 2-hexenoic 
acid was 1.3 min. Quantification of 2-hexenoic acid was achieved by comparison of the peak 
areas in the chromatograms obtained at a wavelength of 210 nm to the calibration curve made 
using the commercially available standard. 
 
AR-Mediated Reduction of trans-2-Hexenal to 2-Hexen-1-ol 
trans-2-Hexenal was incubated with rat liver S9 to determine the kinetic constants for reduction of 
trans-2-hexenal mediated by ARs. The incubation mixtures had a final volume of 100 μL, 
containing (final concentrations) liver S9 (1 mg protein/mL) in 0.1 M Tris-HCl (pH 7.4). After 
preincubation at 37 °C for 2 min, the reaction was started by the addition of NADPH (2.5 mM) 
from a 20 times concentrated stock solution in 0.1 M Tris-HCl (pH 7.4) and trans-2-hexenal (50–
500 μM) from a 100 times concentrated stock solution in DMSO. After 4 min, the reaction was 
 
terminated by adding 50 μL of ice-cold acetonitrile. Blank incubations were performed without 
cofactor NADPH or S9. The incubation mixtures were subsequently centrifuged for 3 min at 
16,000g at 4 °C to precipitate proteins. The samples were frozen in dry ice immediately after the 
centrifugation and kept at −20 °C to prevent evaporation of 2-hexen-1-ol. 
The amount of 2-hexen-1-ol was measured using a UPLC-DAD system equipped as 
described above. The gradient was made with acetonitrile and ultrapure water containing 0.1% 
(v/v) formic acid. The flow rate was 0.6 mL/min, and a gradient was applied from 0 to 10% 
acetonitrile over 10 min, after which the percentage of acetonitrile was increased to 100% over 
0.2 min, kept at 100% for 0.5 min, lowered to 0% over 0.3 min, and kept at these initial conditions 
for 1 min for equilibration. Under these conditions, the retention time of 2-hexen-1-ol was 9.1 
min. Quantification of 2-hexen-1-ol was achieved by comparison of the peak areas in the 
chromatogram obtained at a wavelength of 193 nm to the calibration curve made using the 
commercially available standard. 
 
GST-Mediated GSH Conjugation of trans-2-Hexenal 
Kinetic constants for GST-mediated formation of trans-2-hexenal GSH conjugates, namely 
S-[3-(1-oxohexyl)]-GSH (Hex-GSH), were determined by incubating trans-2-hexenal with rat 
liver or small intestine S9. The incubation mixture had a final volume of 100 μL, containing (final 
concentrations) liver S9 (0.2 mg protein/mL) or small intestine S9 (0.64 mg protein/mL) in 0.1 M 
Tris-HCl (pH 7.4). After preincubation at 37 °C for 2 min, the reaction was started by the addition 
of GSH (5 mM) from a 10 times concentrated stock solution in 0.1 M Tris-HCl (pH 7.4) and 
trans-2-hexenal (500–5000 μM) from a 100 times concentrated stock solution in DMSO. The 
reaction was carried out for 3 min with liver S9 and for 4 min with small intestine S9 and 
terminated by adding 50 μL of ice-cold acetonitrile. In parallel, incubations without S9 were 
carried out to quantify the chemical conjugation of trans-2-hexenal with GSH. The samples 
obtained from the incubations were centrifuged for 3 min at 16,000g at 4 °C to precipitate 
proteins, and the resulting supernatant was analyzed by UPLC-DAD immediately after 
centrifugation. 
The amount of Hex-GSH conjugates was measured using a UPLC-DAD system 
equipped as described above. The gradient was made with acetonitrile and ultrapure water 
containing 0.1% (v/v) TFA. The flow rate was 0.6 mL/min, and a gradient was applied from 5 to 
10% acetonitrile over 2.5 min, after which the percentage of acetonitrile was increased to 100% 
over 0.2 min, kept at 100% for 0.5 min, lowered to 0% over 0.3 min, kept at 0% over 0.3 min, 
increased to 5% over 0.2 min, and kept at these initial conditions for 1 min for equilibration. With 
this condition, two conjugates were found at retention times of 2.2 and 2.4 min, which were 
absent in incubations without either GSH or trans-2-hexenal. 
To characterize the products formed, a trans-2-hexenal (1 mM) incubation sample with 
GSH (5 mM) and liver S9 (1 mg protein/mL) and blank samples (without liver S9 or GSH) were 
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analyzed by LC/MS/MS with postcolumn infusion system. The LC/MS/MS system consisted of a 
Perkin-Elmer 200 Series HPLC System (Perkin-Elmer, Waltham, MA) coupled to an API 3000 
system equipped with electrospray ionisation probe (Applied Biosystem, Foster City, CA). The 
flow through the analytical column was made with 0.15 mL/min ultrapure water containing 0.1% 
formic acid and 0.15 mL/min acetonitrile. The mass spectrometric analysis was performed in 
positive ion mode with the following settings: nebulizer gas, 10 psi; ion spray voltage, 5000 V; 
ion source temperature, 350 °C; declustering potential, 20 V; focusing potential, 250 V; entrance 
potential, 14 V; and collision cell exit, 15 V. Nitrogen was used as the sheath gas turbo, ion spray, 
with a pressure of 7000 L/h. The samples were infused postcolumn with the syringe pump at a 
flow rate of 1000 μL/h. The full scan electrospray mass spectra at a collision energy of 15 eV 
were recorded. 
For quantification of Hex-GSH, a calibration curve was prepared by reacting 
trans-2-hexenal with increasing concentrations of GSH. To this end, 10 mM trans-2-hexenal was 
incubated with increasing concentrations of GSH ranging from 50 to 500 μM in 0.1 M Tris-HCl 
(pH 8.6). The reactions were performed for 60 min at 37 °C resulting in maximum formation of 
conjugates. The residual GSH was confirmed to be negligible by using a GSH assay kit 
(Sigma-Aldrich, Zwijndrecht, The Netherlands). The peak area of two conjugates at wavelength 
210 nm in the UPLC chromatograms was summated and related to the quantity of GSH used in 
the reactions. 
Kinetic Analysis 
The data for the rate of formation of 2-hexenoic acid and 2-hexen-1-ol with increasing 
trans-2-hexenal concentration were fitted to the standard Michaelis–Menten equation with [S] 
being the substrate concentration: 
  v = Vmax× [S] / (Km+[S]) 
The GSH and trans-2-hexenal concentration-dependent rate of Hex-GSH formation catalyzed by 
GSTs was fitted to a two-substrate model Michaelis–Menten equation simulating the ordered 
sequential ping–pong mechanism [13, 14], with [GSH] and [S] being GSH and trans-2-hexenal 
concentrations, respectively: 
 v = Vmax×[S]×[GSH] / (Km_H×[GSH] + Km_G×[S] + [S] ×[GSH]) 
The apparent maximum velocities (Vmax) and the apparent Michaelis–Menten constants (Km) were 
determined by fitting the data to the respective equations using GraphPad Prism (version 5.04, 
GraphPad Software, Inc., La Jolla, CA). 
 
Rate Constant for Nonenzymatic GSH Conjugation to trans-2-Hexenal 
The second-order rate constant for the nonenzymatic conjugation of GSH to trans-2-hexenal was 
determined based on a method described by Potter and Tran [15]. Briefly, the time-dependent 
conjugation between trans-2-hexenal and GSH was examined by incubating 0.2 mM 
trans-2-hexenal with 0.5 mM GSH in 0.1 M Tris-HCl (pH 7.4) for 0–30 min at 37 °C. The 
 
reaction was initiated by the addition of trans-2-hexenal from a 100 times concentrated stock 
solution in DMSO and was terminated by adding 4 mM diamide (final concentration) from a 5 
times concentrated stock solution in 0.1 M Tris-HCl (pH 7.4). The Hex-GSH formed was 
quantified immediately after the incubation as described above. The rate constant obtained for the 
reaction between trans-2-hexenal and GSH was also used to describe the second-order rate 
constant for the reaction between trans-2-hexenal and protein reactive sites in the liver and small 
intestine (see PBK/D Model Structure). 
 
Rate Constant for Binding of trans-2-Hexenal to 2′-dG 
The second-order rate constant for binding of trans-2-hexenal to 2′-dG was determined by 
examining the time-dependent formation of exocyclic 1,N2-propanodeoxyguanosine adducts 
(Hex-PdG). trans-2-Hexenal (25 mM) was reacted with 2′-dG (1.95 mM) in 0.1 M Tris-HCl (pH 
7.4) for 0–40 min at 37 °C. After 2 min of preincubation, the reaction was started by adding 
trans-2-hexenal from a 40 times concentrated stock in DMSO. The reaction was terminated by 
injecting the reaction mixture to the UPLC-DAD system equipped as described above for 
quantification of the Hex-PdG formed. The gradient was made with acetonitrile and ultrapure 
water containing 0.1% (v/v) TFA. The flow rate was 0.6 mL/min, and a gradient was applied from 
8.5 to 10% acetonitrile over 5 min, after which the percentage of acetonitrile was increased to 
100% over 0.2 min, kept at 100% for 0.3 min, lowered to 0% over 0.2 min, kept at 0% over 0.3 
min, increased to 8.5% over 0.2 min, and equilibrated at these initial conditions for 0.5 min. 
Under these conditions, two conjugates were found at retention times of 2.6 and 2.8 min, which 
were absent in the blank incubations without either trans-2-hexenal or 2′-dG. These peaks had the 
same UV spectra as those of Hex-PdG reported previously [7]. 
Because the UV absorption pattern of Hex-PdG is comparable to that of 2′-dG [7], they 
were assumed to have the same molecular extinction coefficient at the respective wavelength of 
maximum absorption. Quantification of Hex-PdG was achieved by comparison of the peak area of 
Hex-PdG obtained in UPLC-DAD analysis to the calibration curve of 2′-dG, each at their 
respective absorption maximum, which amounted to 262 nm for Hex-PdG and 252 nm for 2′-dG. 
 
PBK/D Model Structure 
A schematic diagram of the PBK/D model developed is shown in Figure 2.2, and the mass 
balance equations including a list of abbreviations used in the equations can be found as 
Supporting Information. The final model includes separate compartments for the liver and small 
intestine, which were both involved in the metabolism of trans-2-hexenal (see Results). A separate 
compartment for fat tissue was included to take into account the relatively higher partition 
coefficient of trans-2-hexenal in fat tissue. All other tissues were lumped into a rapidly perfused 
tissue group, comprising tissues such as adrenals, brain, and heart, and a slowly perfused tissue 
group, comprising tissues such as muscle and skin [16]. The uptake of trans-2-hexenal from the 
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analyzed by LC/MS/MS with postcolumn infusion system. The LC/MS/MS system consisted of a 
Perkin-Elmer 200 Series HPLC System (Perkin-Elmer, Waltham, MA) coupled to an API 3000 
system equipped with electrospray ionisation probe (Applied Biosystem, Foster City, CA). The 
flow through the analytical column was made with 0.15 mL/min ultrapure water containing 0.1% 
formic acid and 0.15 mL/min acetonitrile. The mass spectrometric analysis was performed in 
positive ion mode with the following settings: nebulizer gas, 10 psi; ion spray voltage, 5000 V; 
ion source temperature, 350 °C; declustering potential, 20 V; focusing potential, 250 V; entrance 
potential, 14 V; and collision cell exit, 15 V. Nitrogen was used as the sheath gas turbo, ion spray, 
with a pressure of 7000 L/h. The samples were infused postcolumn with the syringe pump at a 
flow rate of 1000 μL/h. The full scan electrospray mass spectra at a collision energy of 15 eV 
were recorded. 
For quantification of Hex-GSH, a calibration curve was prepared by reacting 
trans-2-hexenal with increasing concentrations of GSH. To this end, 10 mM trans-2-hexenal was 
incubated with increasing concentrations of GSH ranging from 50 to 500 μM in 0.1 M Tris-HCl 
(pH 8.6). The reactions were performed for 60 min at 37 °C resulting in maximum formation of 
conjugates. The residual GSH was confirmed to be negligible by using a GSH assay kit 
(Sigma-Aldrich, Zwijndrecht, The Netherlands). The peak area of two conjugates at wavelength 
210 nm in the UPLC chromatograms was summated and related to the quantity of GSH used in 
the reactions. 
Kinetic Analysis 
The data for the rate of formation of 2-hexenoic acid and 2-hexen-1-ol with increasing 
trans-2-hexenal concentration were fitted to the standard Michaelis–Menten equation with [S] 
being the substrate concentration: 
  v = Vmax× [S] / (Km+[S]) 
The GSH and trans-2-hexenal concentration-dependent rate of Hex-GSH formation catalyzed by 
GSTs was fitted to a two-substrate model Michaelis–Menten equation simulating the ordered 
sequential ping–pong mechanism [13, 14], with [GSH] and [S] being GSH and trans-2-hexenal 
concentrations, respectively: 
 v = Vmax×[S]×[GSH] / (Km_H×[GSH] + Km_G×[S] + [S] ×[GSH]) 
The apparent maximum velocities (Vmax) and the apparent Michaelis–Menten constants (Km) were 
determined by fitting the data to the respective equations using GraphPad Prism (version 5.04, 
GraphPad Software, Inc., La Jolla, CA). 
 
Rate Constant for Nonenzymatic GSH Conjugation to trans-2-Hexenal 
The second-order rate constant for the nonenzymatic conjugation of GSH to trans-2-hexenal was 
determined based on a method described by Potter and Tran [15]. Briefly, the time-dependent 
conjugation between trans-2-hexenal and GSH was examined by incubating 0.2 mM 
trans-2-hexenal with 0.5 mM GSH in 0.1 M Tris-HCl (pH 7.4) for 0–30 min at 37 °C. The 
 
reaction was initiated by the addition of trans-2-hexenal from a 100 times concentrated stock 
solution in DMSO and was terminated by adding 4 mM diamide (final concentration) from a 5 
times concentrated stock solution in 0.1 M Tris-HCl (pH 7.4). The Hex-GSH formed was 
quantified immediately after the incubation as described above. The rate constant obtained for the 
reaction between trans-2-hexenal and GSH was also used to describe the second-order rate 
constant for the reaction between trans-2-hexenal and protein reactive sites in the liver and small 
intestine (see PBK/D Model Structure). 
 
Rate Constant for Binding of trans-2-Hexenal to 2′-dG 
The second-order rate constant for binding of trans-2-hexenal to 2′-dG was determined by 
examining the time-dependent formation of exocyclic 1,N2-propanodeoxyguanosine adducts 
(Hex-PdG). trans-2-Hexenal (25 mM) was reacted with 2′-dG (1.95 mM) in 0.1 M Tris-HCl (pH 
7.4) for 0–40 min at 37 °C. After 2 min of preincubation, the reaction was started by adding 
trans-2-hexenal from a 40 times concentrated stock in DMSO. The reaction was terminated by 
injecting the reaction mixture to the UPLC-DAD system equipped as described above for 
quantification of the Hex-PdG formed. The gradient was made with acetonitrile and ultrapure 
water containing 0.1% (v/v) TFA. The flow rate was 0.6 mL/min, and a gradient was applied from 
8.5 to 10% acetonitrile over 5 min, after which the percentage of acetonitrile was increased to 
100% over 0.2 min, kept at 100% for 0.3 min, lowered to 0% over 0.2 min, kept at 0% over 0.3 
min, increased to 8.5% over 0.2 min, and equilibrated at these initial conditions for 0.5 min. 
Under these conditions, two conjugates were found at retention times of 2.6 and 2.8 min, which 
were absent in the blank incubations without either trans-2-hexenal or 2′-dG. These peaks had the 
same UV spectra as those of Hex-PdG reported previously [7]. 
Because the UV absorption pattern of Hex-PdG is comparable to that of 2′-dG [7], they 
were assumed to have the same molecular extinction coefficient at the respective wavelength of 
maximum absorption. Quantification of Hex-PdG was achieved by comparison of the peak area of 
Hex-PdG obtained in UPLC-DAD analysis to the calibration curve of 2′-dG, each at their 
respective absorption maximum, which amounted to 262 nm for Hex-PdG and 252 nm for 2′-dG. 
 
PBK/D Model Structure 
A schematic diagram of the PBK/D model developed is shown in Figure 2.2, and the mass 
balance equations including a list of abbreviations used in the equations can be found as 
Supporting Information. The final model includes separate compartments for the liver and small 
intestine, which were both involved in the metabolism of trans-2-hexenal (see Results). A separate 
compartment for fat tissue was included to take into account the relatively higher partition 
coefficient of trans-2-hexenal in fat tissue. All other tissues were lumped into a rapidly perfused 
tissue group, comprising tissues such as adrenals, brain, and heart, and a slowly perfused tissue 
group, comprising tissues such as muscle and skin [16]. The uptake of trans-2-hexenal from the 
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intestinal cavity into the small intestine compartment was described by a first-order process. The 
absorption rate constant (Ka) was set to 5.0 h–1 based on the value used for uptake of acrylamide 
in a PBK model for acrylamide and its metabolite glycidamide [17], resulting in a rapid 
absorption of trans-2-hexenal from the gastrointestinal cavity. On the basis of the in vitro kinetic 
data conversion of trans-2-hexenal to 2-hexenoic acid and GSH conjugates (Hex-GSH) mediated 
by ALDHs and GSTs, respectively, was described in the liver and small intestine compartments, 
whereas conversion of trans-2-hexenal to 2-hexen-1-ol by ARs was described in the liver 
compartment only. The kinetic constants for the enzymatic metabolite formations were 
determined in vitro in the present study. The Vmax values for the different pathways in the liver, 
expressed as nmol/ min/(mg S9 protein), were scaled to the liver using a S9 protein yield of 143 
mg/g liver as scaling factor as derived previously based on the cytosolic and microsomal protein 
yield [18]. The Vmax values for the different metabolic pathways in the small intestine were scaled 
accordingly using an estimated S9 protein yield of 11.4 mg/g small intestine as scaling factor [10]. 
The Vmax values for the formation of 2-hexenoic acid in the liver mitochondrial fraction were 
scaled using a mitochondrial fraction yield of 269 mg mitochondrial fraction/g liver as scaling 
factor, which was determined in the present study. The chemical reaction of trans-2-hexenal with 
GSH and protein was included in both the liver and the small intestine compartment. Hex-PdG, 
the DNA adduct of trans-2-hexenal, was described to be formed chemically in the liver. The 
second-order rate constants of the reactions between trans-2-hexenal with GSH or 2′-dG (kGSH and 
kDNA) were determined in vitro in this study. The reaction of trans-2-hexenal with protein in the 
liver and small intestine was also described by second-order kinetics with a rate that depends on 
the concentration of trans-2-hexenal and of protein reaction sites in the tissue [19]. The 
second-order rate constant for this reaction, kPRO, was set to the same value as kGSH, based on 
previous studies [15, 19]. In a study by Potter and Tran [15], second-order rate constants for 
conjugation of ethyl acrylate, an α,β-unsaturated ether, and protein reactive sites were determined 
for tissue homogenates from different organs, which each consisted of a mixture of different 
protein. The second-order rate constants for the reaction of ethyl acrylate with GSH, or with liver 
or small intestine protein reactive sites were found to be 33, 33, and 32 M/min, respectively, 
revealing these values to be comparable. On the basis of this observation, in the present study, the 
second-order rate constant for the reaction between trans-2-hexenal and GSH was assumed to also 
adequately describe the second-order rate constant for the reaction between trans-2-hexenal and 
tissue proteins. For the different metabolites including 2-hexenoic acid, 2-hexen-1-ol, and 
Hex-GSH, only the formation was taken into account, and no further conversion of these 
metabolites was modeled. Furthermore, distribution of these metabolites in the body was not 
taken into account, since this would not affect the ultimate predictions for the detoxification of 
trans-2-hexenal or its binding to DNA. 
Equations to describe GSH levels in the liver or small intestine were integrated in the 
PBK/D model to quantitate the dose-dependent trans-2-hexenal-induced depletion of GSH. GSH 
 
was divided into cytosolic and mitochondrial pools since the mitochondrial GSH pool, which 
usually accounts for 10% of GSH in the liver, is known to be well sequestered and to have a very 
long half-life as compared to the cytosolic pool that can be depleted more easily [20]. In the 
model, the mitochondrial GSH pool was therefore not subject to trans-2-hexenal-induced GSH 
depletion, and it only contributed to the total concentration of GSH in the tissue [14]. The 
reactions reflecting biosynthesis and degradation of GSH due to its regular cellular turnover were 
described by zero-order production and first-order elimination as described elsewhere [14, 19, 
21]. The first-order elimination constant of GSH in a tissue (kGLOS_Ti) and the zero-order GSH 
synthesis rate constant (GSYNTi) were derived from Potter and Tran [21]. Ninety percent of the 
synthesized GSH was described to be directed to cytosol, while the rest is used to maintain the 
GSH levels in mitochondria. 
 
 
 
 
Figure 2.2 Diagram of the proposed PBK/D model for trans-2-hexenal in rat. Solid and dashed 
lines represent the movement of trans-2-hexenal and GSH respectively. 
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intestinal cavity into the small intestine compartment was described by a first-order process. The 
absorption rate constant (Ka) was set to 5.0 h–1 based on the value used for uptake of acrylamide 
in a PBK model for acrylamide and its metabolite glycidamide [17], resulting in a rapid 
absorption of trans-2-hexenal from the gastrointestinal cavity. On the basis of the in vitro kinetic 
data conversion of trans-2-hexenal to 2-hexenoic acid and GSH conjugates (Hex-GSH) mediated 
by ALDHs and GSTs, respectively, was described in the liver and small intestine compartments, 
whereas conversion of trans-2-hexenal to 2-hexen-1-ol by ARs was described in the liver 
compartment only. The kinetic constants for the enzymatic metabolite formations were 
determined in vitro in the present study. The Vmax values for the different pathways in the liver, 
expressed as nmol/ min/(mg S9 protein), were scaled to the liver using a S9 protein yield of 143 
mg/g liver as scaling factor as derived previously based on the cytosolic and microsomal protein 
yield [18]. The Vmax values for the different metabolic pathways in the small intestine were scaled 
accordingly using an estimated S9 protein yield of 11.4 mg/g small intestine as scaling factor [10]. 
The Vmax values for the formation of 2-hexenoic acid in the liver mitochondrial fraction were 
scaled using a mitochondrial fraction yield of 269 mg mitochondrial fraction/g liver as scaling 
factor, which was determined in the present study. The chemical reaction of trans-2-hexenal with 
GSH and protein was included in both the liver and the small intestine compartment. Hex-PdG, 
the DNA adduct of trans-2-hexenal, was described to be formed chemically in the liver. The 
second-order rate constants of the reactions between trans-2-hexenal with GSH or 2′-dG (kGSH and 
kDNA) were determined in vitro in this study. The reaction of trans-2-hexenal with protein in the 
liver and small intestine was also described by second-order kinetics with a rate that depends on 
the concentration of trans-2-hexenal and of protein reaction sites in the tissue [19]. The 
second-order rate constant for this reaction, kPRO, was set to the same value as kGSH, based on 
previous studies [15, 19]. In a study by Potter and Tran [15], second-order rate constants for 
conjugation of ethyl acrylate, an α,β-unsaturated ether, and protein reactive sites were determined 
for tissue homogenates from different organs, which each consisted of a mixture of different 
protein. The second-order rate constants for the reaction of ethyl acrylate with GSH, or with liver 
or small intestine protein reactive sites were found to be 33, 33, and 32 M/min, respectively, 
revealing these values to be comparable. On the basis of this observation, in the present study, the 
second-order rate constant for the reaction between trans-2-hexenal and GSH was assumed to also 
adequately describe the second-order rate constant for the reaction between trans-2-hexenal and 
tissue proteins. For the different metabolites including 2-hexenoic acid, 2-hexen-1-ol, and 
Hex-GSH, only the formation was taken into account, and no further conversion of these 
metabolites was modeled. Furthermore, distribution of these metabolites in the body was not 
taken into account, since this would not affect the ultimate predictions for the detoxification of 
trans-2-hexenal or its binding to DNA. 
Equations to describe GSH levels in the liver or small intestine were integrated in the 
PBK/D model to quantitate the dose-dependent trans-2-hexenal-induced depletion of GSH. GSH 
 
was divided into cytosolic and mitochondrial pools since the mitochondrial GSH pool, which 
usually accounts for 10% of GSH in the liver, is known to be well sequestered and to have a very 
long half-life as compared to the cytosolic pool that can be depleted more easily [20]. In the 
model, the mitochondrial GSH pool was therefore not subject to trans-2-hexenal-induced GSH 
depletion, and it only contributed to the total concentration of GSH in the tissue [14]. The 
reactions reflecting biosynthesis and degradation of GSH due to its regular cellular turnover were 
described by zero-order production and first-order elimination as described elsewhere [14, 19, 
21]. The first-order elimination constant of GSH in a tissue (kGLOS_Ti) and the zero-order GSH 
synthesis rate constant (GSYNTi) were derived from Potter and Tran [21]. Ninety percent of the 
synthesized GSH was described to be directed to cytosol, while the rest is used to maintain the 
GSH levels in mitochondria. 
 
 
 
 
Figure 2.2 Diagram of the proposed PBK/D model for trans-2-hexenal in rat. Solid and dashed 
lines represent the movement of trans-2-hexenal and GSH respectively. 
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The amount of Hex-PdG in the liver was described by second-order formation and 
first-order elimination due to DNA repair. The half-life of Hex-PdG in the liver (T1/2) was derived 
from data obtained in an in vivo study where a time-dependent decrease of Hex-PdG in the liver 
of male F344 rats was measured after the animals were exposed to high amount of 
trans-2-hexenal by gavage [7] (see the Results). 
The physiological parameters such as organ volumes and blood flows were obtained 
from the literature [22]. Partition coefficients were estimated from the logKow based on a method 
of DeJongh et al. [23] (Table 2.1). The logKow value for trans-2-hexenal was estimated with 
Estimation Program Interface (EPI) Suite version 4.10 provided by the U.S. Environmental 
Protection Agency and amounted to 1.58. Model equations were coded and numerically integrated 
in Berkeley Madonna 8.3.18 (Macey and Oster, UC Berkeley, CA), using the Rosenbrock's 
algorithm for stiff systems. 
 
Sensitivity Analysis 
To identify the key parameters that influence the model output the most, a sensitivity analysis was 
performed. Normalized sensitivity coefficients (SC) were determined according to the following 
equation: SC = (C′–C)/(P′–P) × (P/C), where C is the initial value of the model output, C′ is the 
modified value of the model output resulting from an increase in parameter value, P is the initial 
parameter value, and P′ is the modified parameter value [18, 24-26]. On the basis of the literature, 
a 5% increase in parameter values was chosen, to analyze the effect of a change in parameter on 
the formation of Hex-PdG in liver [24]. Each parameter was analyzed individually, keeping the 
other parameters to their initial values. 
  
 
Table 2.1 Physico-chemical and physiological parameters used in the PBK/D model for 
trans-2-hexenal in rat 
 
Parameters Symbols Values  Parameters Symbols Values 
Physico-chemical Parameters    Blood flow to tissue (% cardiac output) 
[22] 
fat/blood  PF 9.92  fat QFc 7.0 
liver/blood  PL 1.11  liver (excluding 
portal vein fraction) 
QLc 13.2 
small 
intestine/blood  
PSi 1.11  small intestine QSIc 11.8 
richly perfused 
tissues/blood  
PR 1.11  richly perfused  QRc 51.0 
slowly perfused 
tissues/blood  
PS 0.55  slowly perfused QSc 17.0 
Physiological Parameters   Initial GSH concentration (μmol/kg tissue) 
[21] 
  Body weight (kg) 
[22] 
BW 0.25  liver InitGSHL 6120 
  Tissue volumes (% body weight) [22]  small intestine InitGSHSi 1780 
 fat VFc 7.0   GSH synthesis (μmol/kg tissue/h) [21]  
 liver VLc 3.4  liver GSYNL 869 
 small intestine VSIc 1.4  small intestine GSYNSi 78 
 arterial blood VAc 1.85  Apparent first order rate constant for GSH 
turnover (/h) [21] 
 venous blood VVc 5.55  liver kL_GLOS 0.142 
 richly perfused  VRc 4.2  small intestine kSi_GLOS 0.044 
 slowly perfused VSc 67.6  Protein reactive sites (μmol/kg tissue) [15] 
       liver CPROL 5319 
Cardiac output (L/h) 
[22, 27] 
QC 5.4     small intestine CPROSi 245 
 
 
RESULTS 
 
Enzymatic Oxidation and Reduction of trans-2-Hexenal 
UPLC analysis of incubations of trans-2-hexenal in the presence of rat liver or small intestine S9 
fractions, which contain both the microsomal and the cytosolic fraction of the cells and NAD+ as a 
cofactor, showed that rat liver and small intestine S9 convert trans-2-hexenal to 2-hexenoic acid. 
The peak at retention time 1.3 min was confirmed to be 2-hexenoic acid on the basis of 
comparison of its UV spectrum and retention time to those of the commercially available standard 
compound. Conversion of trans-2-hexenal to 2-hexenoic acid was also observed in incubations 
with the mitochondrial fraction derived from male Wistar rat liver. Figure 2.3A shows the rate of 
formation of 2-hexenoic acid in incubations with the rat liver S9 or mitochondrial fraction or with 
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The amount of Hex-PdG in the liver was described by second-order formation and 
first-order elimination due to DNA repair. The half-life of Hex-PdG in the liver (T1/2) was derived 
from data obtained in an in vivo study where a time-dependent decrease of Hex-PdG in the liver 
of male F344 rats was measured after the animals were exposed to high amount of 
trans-2-hexenal by gavage [7] (see the Results). 
The physiological parameters such as organ volumes and blood flows were obtained 
from the literature [22]. Partition coefficients were estimated from the logKow based on a method 
of DeJongh et al. [23] (Table 2.1). The logKow value for trans-2-hexenal was estimated with 
Estimation Program Interface (EPI) Suite version 4.10 provided by the U.S. Environmental 
Protection Agency and amounted to 1.58. Model equations were coded and numerically integrated 
in Berkeley Madonna 8.3.18 (Macey and Oster, UC Berkeley, CA), using the Rosenbrock's 
algorithm for stiff systems. 
 
Sensitivity Analysis 
To identify the key parameters that influence the model output the most, a sensitivity analysis was 
performed. Normalized sensitivity coefficients (SC) were determined according to the following 
equation: SC = (C′–C)/(P′–P) × (P/C), where C is the initial value of the model output, C′ is the 
modified value of the model output resulting from an increase in parameter value, P is the initial 
parameter value, and P′ is the modified parameter value [18, 24-26]. On the basis of the literature, 
a 5% increase in parameter values was chosen, to analyze the effect of a change in parameter on 
the formation of Hex-PdG in liver [24]. Each parameter was analyzed individually, keeping the 
other parameters to their initial values. 
  
 
Table 2.1 Physico-chemical and physiological parameters used in the PBK/D model for 
trans-2-hexenal in rat 
 
Parameters Symbols Values  Parameters Symbols Values 
Physico-chemical Parameters    Blood flow to tissue (% cardiac output) 
[22] 
fat/blood  PF 9.92  fat QFc 7.0 
liver/blood  PL 1.11  liver (excluding 
portal vein fraction) 
QLc 13.2 
small 
intestine/blood  
PSi 1.11  small intestine QSIc 11.8 
richly perfused 
tissues/blood  
PR 1.11  richly perfused  QRc 51.0 
slowly perfused 
tissues/blood  
PS 0.55  slowly perfused QSc 17.0 
Physiological Parameters   Initial GSH concentration (μmol/kg tissue) 
[21] 
  Body weight (kg) 
[22] 
BW 0.25  liver InitGSHL 6120 
  Tissue volumes (% body weight) [22]  small intestine InitGSHSi 1780 
 fat VFc 7.0   GSH synthesis (μmol/kg tissue/h) [21]  
 liver VLc 3.4  liver GSYNL 869 
 small intestine VSIc 1.4  small intestine GSYNSi 78 
 arterial blood VAc 1.85  Apparent first order rate constant for GSH 
turnover (/h) [21] 
 venous blood VVc 5.55  liver kL_GLOS 0.142 
 richly perfused  VRc 4.2  small intestine kSi_GLOS 0.044 
 slowly perfused VSc 67.6  Protein reactive sites (μmol/kg tissue) [15] 
       liver CPROL 5319 
Cardiac output (L/h) 
[22, 27] 
QC 5.4     small intestine CPROSi 245 
 
 
RESULTS 
 
Enzymatic Oxidation and Reduction of trans-2-Hexenal 
UPLC analysis of incubations of trans-2-hexenal in the presence of rat liver or small intestine S9 
fractions, which contain both the microsomal and the cytosolic fraction of the cells and NAD+ as a 
cofactor, showed that rat liver and small intestine S9 convert trans-2-hexenal to 2-hexenoic acid. 
The peak at retention time 1.3 min was confirmed to be 2-hexenoic acid on the basis of 
comparison of its UV spectrum and retention time to those of the commercially available standard 
compound. Conversion of trans-2-hexenal to 2-hexenoic acid was also observed in incubations 
with the mitochondrial fraction derived from male Wistar rat liver. Figure 2.3A shows the rate of 
formation of 2-hexenoic acid in incubations with the rat liver S9 or mitochondrial fraction or with 
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small intestine S9 with increasing concentrations of trans-2-hexenal. From these curves, assuming 
first-order Michaelis–Menten kinetics, the apparent kinetic parameters (Km and Vmax) of 
trans-2-hexenal oxidation by the different tissue fractions were determined and are presented in 
Table 2.2. 
Conversion of trans-2-hexenal to 2-hexen-1-ol occurred in the incubations with rat liver 
S9 in the presence of NADPH, whereas no formation of 2-hexen-1-ol was observed in incubations 
with small intestine S9. The peak at retention time 9.1 min was confirmed to be 2-hexen-1-ol on 
the basis of comparison of its UV spectrum and retention time to those of the commercially 
available standard compound. Figure 2.3B shows the rate of formation of 2-hexen-1-ol in 
incubations with rat tissue fractions and increasing concentrations of trans-2-hexenal. From these 
curves, assuming first-order Michaelis–Menten kinetics, the apparent kinetic parameters (Km and 
Vmax) for trans-2-hexenal reduction were determined and are presented in Table 2.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. trans-2-Hexenal concentration dependent 
rate of formation of metabolites by rat tissue fractions. 
Formation rate of (A) 2-hexenoic acid by rat liver S9 
(●),  liver mitochondrial fraction (■), or by rat small 
intestine S9 (♦), (B) 2-hexen-1-ol by rat liver S9 and (C) 
Hex-GSH by rat liver (●) and small intestine S9 (▲). 
 
GST-Mediated Conjugation of trans-2-Hexenal with GSH 
trans-2-Hexenal is known to react with GSH to form GSH conjugates. UPLC analysis revealed 
that two conjugates are formed (conjugate 1 and conjugate 2) when trans-2-hexenal is incubated 
with a physiologically relevant concentration of GSH (5 mM) at 37 °C in the absence of tissue 
fractions. The addition of liver or small intestine S9 to these incubations appeared to increase the 
formation of conjugate 1 but not of conjugate 2, suggesting GSTs of these organs to be involved 
only in the formation of conjugate 1. The incubation samples were also analyzed by electrospray 
mass spectrometry to characterize the conjugates formed. Full-scan electrospray mass spectra 
showed higher levels of formation of ions at m/z 406 in the incubation sample of trans-2-hexenal 
with GSH in the presence of rat liver S9 than in incubations without S9. The m/z 406 corresponds 
to the [M + H]+ value expected for protonated Hex-GSH [5]. The ion at m/z 406 was absent in the 
blank incubation without GSH. MS/MS of the protonated molecule [M + H]+ established the ions 
at m/z 259 and 331 as arising from m/z 406 by loss of 147 and 75, which can be ascribed to the 
loss of glutamic acid and glycine, respectively, corroborating that the ion at m/z 406 contains a 
GSH moiety. Because chemical conjugation of GSH to an α,β-unsaturated aldehyde will result in 
a set of stereoisomers [28], conjugate 1 and conjugate 2 were concluded to be a set of 
stereochemical product at C3 position of Hex-GSH (see Figure 2.1 for the structure). 
 
Table 2.2  Kinetic parameters for metabolism of trans-2-hexenal 
 
Metabolite Km
a,b Vmax
a Scaled Vmax
e In vivo catalytic 
efficiencyf 
liver S9 fraction 
  Hex-GSH 
 
9247 ± 5237 
 
649 ± 265c 
 
92807 
 
10.0 
  2-hexenoic acid 230 ± 45 18.5 ± 1.1c 2646 11.5 
  2-hexen-1-ol 400  ± 70 39.9 ± 3.8c 5706 14.3 
liver mitochondria fraction 
  2-hexenoic acid 410 ± 88 3.8 ± 0.5d 1022 2.5 
small intestine S9 fraction 
  Hex-GSH 2172 ± 869 496 ± 87 c 5674 2.6 
  2-hexenoic acid 156 ± 116 0.95 ± 0.18c 10.9 0.07 
aMean ± SD. bμM. cnmol/min/(mg S9 protein). dnmol/min/(mg mitochondria fraction). eVmax
 
scaled to a tissue expressed as nmol/min/(g tissue). Scaling factors of 143, 35 and 11.4 mg/(g 
tissue) were used for the liver S9, liver mitochondria and the small intestine S9 fraction 
respectively. f Scaled Vmax/Km expressed as mL/min/(g tissue) 
 
Further kinetic analysis of GST-mediated trans-2-hexenal GSH conjugation focused on 
the formation of conjugate 1. The reaction was assumed to follow ping–pong kinetics described 
by a two substrate Michaelis–Menten equation. The required Km toward GSH (Km, Ti_GST_G) was 
set at 100 μM in the liver and small intestine being a representative value obtained in kinetic 
studies on GSTs using different substrates [13, 14]. Vmax and Km toward trans-2-hexenal (Km, 
Ti_GST_H) for the GST-mediated formation of Hex-GSH were determined in vitro by using a 
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small intestine S9 with increasing concentrations of trans-2-hexenal. From these curves, assuming 
first-order Michaelis–Menten kinetics, the apparent kinetic parameters (Km and Vmax) of 
trans-2-hexenal oxidation by the different tissue fractions were determined and are presented in 
Table 2.2. 
Conversion of trans-2-hexenal to 2-hexen-1-ol occurred in the incubations with rat liver 
S9 in the presence of NADPH, whereas no formation of 2-hexen-1-ol was observed in incubations 
with small intestine S9. The peak at retention time 9.1 min was confirmed to be 2-hexen-1-ol on 
the basis of comparison of its UV spectrum and retention time to those of the commercially 
available standard compound. Figure 2.3B shows the rate of formation of 2-hexen-1-ol in 
incubations with rat tissue fractions and increasing concentrations of trans-2-hexenal. From these 
curves, assuming first-order Michaelis–Menten kinetics, the apparent kinetic parameters (Km and 
Vmax) for trans-2-hexenal reduction were determined and are presented in Table 2.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. trans-2-Hexenal concentration dependent 
rate of formation of metabolites by rat tissue fractions. 
Formation rate of (A) 2-hexenoic acid by rat liver S9 
(●),  liver mitochondrial fraction (■), or by rat small 
intestine S9 (♦), (B) 2-hexen-1-ol by rat liver S9 and (C) 
Hex-GSH by rat liver (●) and small intestine S9 (▲). 
 
GST-Mediated Conjugation of trans-2-Hexenal with GSH 
trans-2-Hexenal is known to react with GSH to form GSH conjugates. UPLC analysis revealed 
that two conjugates are formed (conjugate 1 and conjugate 2) when trans-2-hexenal is incubated 
with a physiologically relevant concentration of GSH (5 mM) at 37 °C in the absence of tissue 
fractions. The addition of liver or small intestine S9 to these incubations appeared to increase the 
formation of conjugate 1 but not of conjugate 2, suggesting GSTs of these organs to be involved 
only in the formation of conjugate 1. The incubation samples were also analyzed by electrospray 
mass spectrometry to characterize the conjugates formed. Full-scan electrospray mass spectra 
showed higher levels of formation of ions at m/z 406 in the incubation sample of trans-2-hexenal 
with GSH in the presence of rat liver S9 than in incubations without S9. The m/z 406 corresponds 
to the [M + H]+ value expected for protonated Hex-GSH [5]. The ion at m/z 406 was absent in the 
blank incubation without GSH. MS/MS of the protonated molecule [M + H]+ established the ions 
at m/z 259 and 331 as arising from m/z 406 by loss of 147 and 75, which can be ascribed to the 
loss of glutamic acid and glycine, respectively, corroborating that the ion at m/z 406 contains a 
GSH moiety. Because chemical conjugation of GSH to an α,β-unsaturated aldehyde will result in 
a set of stereoisomers [28], conjugate 1 and conjugate 2 were concluded to be a set of 
stereochemical product at C3 position of Hex-GSH (see Figure 2.1 for the structure). 
 
Table 2.2  Kinetic parameters for metabolism of trans-2-hexenal 
 
Metabolite Km
a,b Vmax
a Scaled Vmax
e In vivo catalytic 
efficiencyf 
liver S9 fraction 
  Hex-GSH 
 
9247 ± 5237 
 
649 ± 265c 
 
92807 
 
10.0 
  2-hexenoic acid 230 ± 45 18.5 ± 1.1c 2646 11.5 
  2-hexen-1-ol 400  ± 70 39.9 ± 3.8c 5706 14.3 
liver mitochondria fraction 
  2-hexenoic acid 410 ± 88 3.8 ± 0.5d 1022 2.5 
small intestine S9 fraction 
  Hex-GSH 2172 ± 869 496 ± 87 c 5674 2.6 
  2-hexenoic acid 156 ± 116 0.95 ± 0.18c 10.9 0.07 
aMean ± SD. bμM. cnmol/min/(mg S9 protein). dnmol/min/(mg mitochondria fraction). eVmax
 
scaled to a tissue expressed as nmol/min/(g tissue). Scaling factors of 143, 35 and 11.4 mg/(g 
tissue) were used for the liver S9, liver mitochondria and the small intestine S9 fraction 
respectively. f Scaled Vmax/Km expressed as mL/min/(g tissue) 
 
Further kinetic analysis of GST-mediated trans-2-hexenal GSH conjugation focused on 
the formation of conjugate 1. The reaction was assumed to follow ping–pong kinetics described 
by a two substrate Michaelis–Menten equation. The required Km toward GSH (Km, Ti_GST_G) was 
set at 100 μM in the liver and small intestine being a representative value obtained in kinetic 
studies on GSTs using different substrates [13, 14]. Vmax and Km toward trans-2-hexenal (Km, 
Ti_GST_H) for the GST-mediated formation of Hex-GSH were determined in vitro by using a 
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physiologically relevant concentration of GSH (5 mM) and increasing concentrations of 
trans-2-hexenal. The amount of Hex-GSH (conjugate 1) formed in the enzymatic incubations was 
corrected for the amount of Hex-GSH (conjugate 1) formed due to the chemical reaction as 
determined in incubation without tissue fractions. Figure 2.3C shows the rate of formation of 
Hex-GSH (conjugate 1) in incubations with rat liver and small intestine S9 and increasing 
concentrations of trans-2-hexenal. From these sets of data, assuming the GST reactions follow 
ping–pong kinetics, the apparent kinetic parameters [Km toward trans-2-hexenal (Km, Ti_GST_H) and 
Vmax] for GST-mediated trans-2-hexenal conjugation with GSH were determined and are 
presented in Table 2.2. 
 
Comparison of the Catalytic Efficiency of Different trans-2-Hexenal Detoxification Pathways 
Table 2.2 presents a summary of the kinetic parameters (Vmax and Km) for trans-2-hexenal 
detoxification by rat tissue fractions. To make the parameters comparable, the Vmax values of 
oxidation, reduction, and GSH conjugation expressed as nmol/min/(mg S9 protein) or 
nmol/min/(mg mitochondrial pellet) were converted to nmol/min/(g tissue) by using scaling 
factors. The in vivo catalytic efficiencies derived from the liver S9 incubations expressed per 
gram liver tissue for oxidation and reduction of trans-2-hexenal were 1.2 and 1.4 times the 
catalytic efficiencies for GST-mediated conversion, respectively, which indicates that for liver S9 
formation of 2-hexen-1-ol is the most efficient pathway followed by formation of 2-hexenoic acid 
and Hex-GSH. The catalytic efficiencies derived from the incubations with small intestine S9 and 
liver mitochondrial fraction were calculated to be 1–3 orders of magnitude lower than those 
obtained for liver S9, indicating that in male rat the major enzymatic conversion of 
trans-2-hexenal, when orally ingested, will occur in the liver. 
 
Nonenzymatic Binding of trans-2-Hexenal to 2′-dG, GSH, and Protein 
trans-2-Hexenal is known to chemically react with nucleophilic macromolecules including DNA, 
GSH, and protein, resulting in covalent adducts. To integrate these reactions into the model, the 
second-order rate constants for the reaction of trans-2-hexenal with 2′-dG or GSH were measured 
based on in vitro incubations at physiological pH. UPLC analysis of incubations of 
trans-2-hexenal with GSH showed two peaks, which were absent in blank incubations performed 
without either trans-2-hexenal or GSH. The areas of these two peaks measured at their absorption 
maximum (199 nm) were comparable, and both increased with increasing concentrations of 
trans-2-hexenal or GSH. On the basis of these facts, it was concluded that the two peaks represent 
a set of stereoisomers of trans-2-hexenal GSH conjugates, and the summation of the two peaks 
was used to determine the second-order rate constant for the reaction of trans-2-hexenal with 
GSH, which was found to amount to 5.8×10–4 /μM/h. This value was also used as the 
second-order rate constant for the reaction of trans-2-hexenal with tissue protein in the liver and 
small intestine in line with the assumptions described elsewhere (see PBK/D Model Structure) 
 
[15, 19]. The trans-2-hexenal adducts with 2′-dG are known to consist of a set of two 
diastereomers (Hex-PdG) (Figure 2.4A) [29]. When trans-2-hexenal was chemically reacted with 
2′-dG, no clear difference was observed in the amount formed between the diastereomers (Figure 
2.4B). The rate constant for the reaction of trans-2-hexenal with 2′-dG to form the diastereomers 
was determined to be 1.6×10–7 /μM/h. Comparison of this second-order rate constant for 2′-dG 
adduct formation to that for GSH adduct formation reveals that chemical reaction of 
trans-2-hexenal with GSH is more than 1,000 times faster than with 2′-dG. This was well 
expected as electrophile reactivity of trans-2-hexenal was reported to be higher with thiol 
moieties, which are soft nucleophiles than with amine groups that are hard nucleophiles [30]. 
 
DNA Adduct Elimination by DNA Repair 
DNA adduct formed in the liver was assumed to be reversible due to DNA repair. A half-life of 
DNA adducts (T1/2) was determined based on a study by Schuler and Eder [7] where male F344 
rats were exposed to 500 mg trans-2-hexenal/kg bw by gavage and Hex-PdG in the liver was 
quantified at 24, 48, and 96 h after the dosing by using 32P-postlabeling. Assuming first-order 
elimination of the Hex-PdG after the amount of Hex-PdG reached the highest level at 48 h after 
the dosing, the half-life of DNA adducts in the liver was estimated by fitting an exponential curve 
to the reported data and was thus determined to be 38.5 h. 
 
 
 
 
 
Figure 2.4. Molecular structures of 
Hex-PdG [7] (A) and a typical UPLC 
chromatogram of an incubation of 
trans-2-hexenal (86.2 mM) and 2ʹ-dG 
(10.5 mM) (B). Peaks marked with an 
asterisk were also present in the blank 
incubations performed without either 
2ʹ-dG or trans-2-hexenal. 
 
Performance of the PBK/D Model 
With the kinetic constants obtained, the PBK/D model was constructed, which enables prediction 
of trans-2-hexenal detoxification, as well as formation and subsequent elimination of 
trans-2-hexenal DNA adducts (Hex-PdG) in the liver. To evaluate the performance of the PBK/D 
model, predicted Hex-PdG levels in the liver were compared with in vivo data derived from 
literature [4, 7]. In the in vivo studies available, DNA adduct levels were quantified in the liver of 
male F344 rats exposed by gavage to a single dose of 200 or 500 mg trans-2-hexenal/kg bw 48 h 
after the exposure by using 32P-postlabeling [7] or 24 h after dosing by LC/MS/MS [4]. The level 
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physiologically relevant concentration of GSH (5 mM) and increasing concentrations of 
trans-2-hexenal. The amount of Hex-GSH (conjugate 1) formed in the enzymatic incubations was 
corrected for the amount of Hex-GSH (conjugate 1) formed due to the chemical reaction as 
determined in incubation without tissue fractions. Figure 2.3C shows the rate of formation of 
Hex-GSH (conjugate 1) in incubations with rat liver and small intestine S9 and increasing 
concentrations of trans-2-hexenal. From these sets of data, assuming the GST reactions follow 
ping–pong kinetics, the apparent kinetic parameters [Km toward trans-2-hexenal (Km, Ti_GST_H) and 
Vmax] for GST-mediated trans-2-hexenal conjugation with GSH were determined and are 
presented in Table 2.2. 
 
Comparison of the Catalytic Efficiency of Different trans-2-Hexenal Detoxification Pathways 
Table 2.2 presents a summary of the kinetic parameters (Vmax and Km) for trans-2-hexenal 
detoxification by rat tissue fractions. To make the parameters comparable, the Vmax values of 
oxidation, reduction, and GSH conjugation expressed as nmol/min/(mg S9 protein) or 
nmol/min/(mg mitochondrial pellet) were converted to nmol/min/(g tissue) by using scaling 
factors. The in vivo catalytic efficiencies derived from the liver S9 incubations expressed per 
gram liver tissue for oxidation and reduction of trans-2-hexenal were 1.2 and 1.4 times the 
catalytic efficiencies for GST-mediated conversion, respectively, which indicates that for liver S9 
formation of 2-hexen-1-ol is the most efficient pathway followed by formation of 2-hexenoic acid 
and Hex-GSH. The catalytic efficiencies derived from the incubations with small intestine S9 and 
liver mitochondrial fraction were calculated to be 1–3 orders of magnitude lower than those 
obtained for liver S9, indicating that in male rat the major enzymatic conversion of 
trans-2-hexenal, when orally ingested, will occur in the liver. 
 
Nonenzymatic Binding of trans-2-Hexenal to 2′-dG, GSH, and Protein 
trans-2-Hexenal is known to chemically react with nucleophilic macromolecules including DNA, 
GSH, and protein, resulting in covalent adducts. To integrate these reactions into the model, the 
second-order rate constants for the reaction of trans-2-hexenal with 2′-dG or GSH were measured 
based on in vitro incubations at physiological pH. UPLC analysis of incubations of 
trans-2-hexenal with GSH showed two peaks, which were absent in blank incubations performed 
without either trans-2-hexenal or GSH. The areas of these two peaks measured at their absorption 
maximum (199 nm) were comparable, and both increased with increasing concentrations of 
trans-2-hexenal or GSH. On the basis of these facts, it was concluded that the two peaks represent 
a set of stereoisomers of trans-2-hexenal GSH conjugates, and the summation of the two peaks 
was used to determine the second-order rate constant for the reaction of trans-2-hexenal with 
GSH, which was found to amount to 5.8×10–4 /μM/h. This value was also used as the 
second-order rate constant for the reaction of trans-2-hexenal with tissue protein in the liver and 
small intestine in line with the assumptions described elsewhere (see PBK/D Model Structure) 
 
[15, 19]. The trans-2-hexenal adducts with 2′-dG are known to consist of a set of two 
diastereomers (Hex-PdG) (Figure 2.4A) [29]. When trans-2-hexenal was chemically reacted with 
2′-dG, no clear difference was observed in the amount formed between the diastereomers (Figure 
2.4B). The rate constant for the reaction of trans-2-hexenal with 2′-dG to form the diastereomers 
was determined to be 1.6×10–7 /μM/h. Comparison of this second-order rate constant for 2′-dG 
adduct formation to that for GSH adduct formation reveals that chemical reaction of 
trans-2-hexenal with GSH is more than 1,000 times faster than with 2′-dG. This was well 
expected as electrophile reactivity of trans-2-hexenal was reported to be higher with thiol 
moieties, which are soft nucleophiles than with amine groups that are hard nucleophiles [30]. 
 
DNA Adduct Elimination by DNA Repair 
DNA adduct formed in the liver was assumed to be reversible due to DNA repair. A half-life of 
DNA adducts (T1/2) was determined based on a study by Schuler and Eder [7] where male F344 
rats were exposed to 500 mg trans-2-hexenal/kg bw by gavage and Hex-PdG in the liver was 
quantified at 24, 48, and 96 h after the dosing by using 32P-postlabeling. Assuming first-order 
elimination of the Hex-PdG after the amount of Hex-PdG reached the highest level at 48 h after 
the dosing, the half-life of DNA adducts in the liver was estimated by fitting an exponential curve 
to the reported data and was thus determined to be 38.5 h. 
 
 
 
 
 
Figure 2.4. Molecular structures of 
Hex-PdG [7] (A) and a typical UPLC 
chromatogram of an incubation of 
trans-2-hexenal (86.2 mM) and 2ʹ-dG 
(10.5 mM) (B). Peaks marked with an 
asterisk were also present in the blank 
incubations performed without either 
2ʹ-dG or trans-2-hexenal. 
 
Performance of the PBK/D Model 
With the kinetic constants obtained, the PBK/D model was constructed, which enables prediction 
of trans-2-hexenal detoxification, as well as formation and subsequent elimination of 
trans-2-hexenal DNA adducts (Hex-PdG) in the liver. To evaluate the performance of the PBK/D 
model, predicted Hex-PdG levels in the liver were compared with in vivo data derived from 
literature [4, 7]. In the in vivo studies available, DNA adduct levels were quantified in the liver of 
male F344 rats exposed by gavage to a single dose of 200 or 500 mg trans-2-hexenal/kg bw 48 h 
after the exposure by using 32P-postlabeling [7] or 24 h after dosing by LC/MS/MS [4]. The level 
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of DNA adducts reported by Stout et al. was 2 orders of magnitude lower than the levels obtained 
by Schuler and Eder, which may in part be due to the different analytical methods used or the 
different study design with respect to whether animals were possibly fasted [7] or not [4]. The 
Hex-PdG level at 200 and 500 mg trans-2-hexenal/kg bw was predicted by the PBK/D model to 
amount to 101 and 580 Hex-PdG/108 nucleotides (nt) after 24 h and 65 and 377 Hex-PdG/108 nt 
after 48 h, respectively (Table 2.3). At a dose of 200 mg trans-2-hexenal/kg bw, the predicted 
value was 4.1-fold higher than the value reported by Schuler and Eder but 3 orders of magnitude 
higher than the value reported by Stout et al. Also at 500 mg/kg bw, the discrepancy between the 
predicted and the observed value of Stout et al. was 3 orders of magnitude, whereas at this dose 
level the predicted value was only 2.1-fold higher than the value of 179 adducts/108 nt reported by 
Schuler and Eder. 
 
Table 2.3 Predicted and observed formation of  DNA adduct (Hex-PdG) in the liver of a rat after 
trans-2-hexenal exposure 
 
Dose and time point of DNA adduct 
quantification after dosing 
Predicted  
(adducts/108 nt)a 
In vivo data 
(adducts/108 nt) 
200 mg/kg bw, 24h [4] 101 0.2b 
500 mg/kg bw, 24h [4] 580 0.099b 
200 mg/kg bw, 48h [7] 65 16 ± 12c 
500 mg/kg bw, 48h [7] 376 179 ± 52c 
aPredicted amount of Hex-PdG in the liver in μmol was converted to adducts/108 nt by using a 
DNA content of 1.8 mg/(g liver) [31] and the average molecular weight of four nucleotides 
(adenine, guanine, cytosine, thymine) of 330. bThe value in fmol/(μg DNA) was converted to 
adducts/108 nt by using the average molecular weight of nucleotides of 330. cMean ± SD. 
 
The model was also evaluated by comparison of the predicted extent of GSH adduct 
formation to in vivo data for excretion of mercapturic acids for male Wistar rats exposed to 
2-propenal (acrolein) or 4-hydroxy-2-nonenal, which are comparable α,β-unsaturated aldehydes 
[32, 33]. To make the predicted values comparable to the in vivo data, the amount of 
α,β-unsaturated aldehyde conjugates with GSH formed in the liver was assumed to be equal to the 
mercapturic acids excreted in the urine. In the case of 2-propenal, excretion of mercapturic acid 
conjugates has been reported to be 10–32% of the dose in male Wistar rats at dose levels ranging 
from 0.47 to 4.0 mg 2-propenal/kg bw [32]. Because these rats were exposed via intraperitoneal 
injection, the PBK/D model, which was made to model oral dosing, was modified to model 
intraperitoneal dosing to allow comparison. To this end, the Vmax of the detoxification pathways in 
the small intestine compartment were all set to zero so that trans-2-hexenal reaches the liver 
without being enzymatically converted in the small intestine compartment. The modified model 
predicted 27% of the α,β-unsaturated aldehyde to be converted to GSH conjugates at a dose level 
up to 71 μmol/kg bw (c.a. 7.0 mg trans-2-hexenal/kg bw and 4.0 mg 2-propenal/kg bw). In the 
 
case of 4-hydroxy-2-nonenal [33], excretion of mercapturic acid conjugates has been reported to 
be 27 ± 5% of the applied intravenous dose of 3.5 μg/kg bw in male Wistar rats after 48 h. At 
comparable conditions, taking into account intravenous exposure, the model predicted 43% 
formation of GSH conjugates at this level of exposure. Another study on 4-hydroxy-2-nonenal 
[34] reported 5.4% excretion as known mercapturic acid conjugates in male Wistar rats exposed to 
25 μg/kg bw of 4-hydroxy-2-nonenal via intraperitoneal injection within 12 h. After adjusting the 
model for intraperitoneal injection the PBK/D model predicted 27% formation of GSH conjugates 
at this level of exposure. 
 
Sensitivity Analysis 
A sensitivity analysis was performed to identify key parameters that mostly determine the amount 
of Hex-PdG in the liver 24 h after the exposure. Normalized SCs were calculated for all 
parameters at trans-2-hexenal doses of 0.04 mg/kg bw, a level that corresponds to the average 
human dietary exposure, and 200 mg/kg bw, a level at which DNA adduct formation in the liver 
was reported in rats [4, 7]. The parameters for which the |SC| exceeded 0.1 are shown in Figure 
2.5. The results obtained reveal that the levels of Hex-PdG in the liver are influenced significantly 
by parameters that determine the formation and elimination rate of Hex-PdG, such as the 
second-order rate constant for the reaction of trans-2-hexenal with 2′-dG (kDNA) and the half-life 
of the DNA adducts (T1/2). Parameters determining the trans-2-hexenal catalytic detoxification 
rate in the liver such as Vmax for oxidation or reduction by liver S9 (Vmax, LS9_HA and Vmax, 
LS9_HO)and the scaling factor for liver S9 (S9PL) were found to have a considerable higher impact 
on the level of Hex-PdG at 200 mg trans-2-hexenal/kg bw than at 0.04 mg/kg bw, while those 
determining the detoxification rate in the small intestine such as Vmax for GST-mediated 
trans-2-hexenal conjugation with GSH (Vmax,Si_GST) and the scaling factor of small intestine S9 
(S9PSi) have a greater influence on the Hex-PdG level at 0.04 mg trans-2-hexenal/kg bw than at 
200 mg/kg bw. 
 
Model Predictions 
Figure 2.6 shows the time-dependent predicted liver concentrations of trans-2-hexenal (Figure 
2.6A and 2.6B), and the GSH concentrations in the liver and small intestine in male rat (Figure 
2.6C and 2.6D) upon exposure to 0.04 mg/kg bw, a level that corresponds to the average human 
dietary exposure (Figure 2.6A and 2.6C), or 200 mg/kg bw trans-2-hexenal (Figure 2.6B and 
2.6D) at which DNA adduct formation in the liver was reported in rats [4, 7]. The predicted 
time-dependent trans-2-hexenal concentration in the liver showed that the trans-2-hexenal 
concentration reached a maximum value around 0.14 and 187 μM at a dose of 0.04 and 200 
mg/kg bw, respectively (Figure 2.6A and 2.6B). At both dose levels, trans-2-hexenal is fully 
converted within 3 h after dosing; therefore, no accumulation of trans-2-hexenal in the intestine or 
liver is expected if a rat would be exposed repeatedly to the same amount of trans-2-hexenal at 24 
32620 Reiko Kiwamoto.indd   48 17-03-15   15:35
2A PBK/D model for trans-2-hexenal in rat
4948 
 
of DNA adducts reported by Stout et al. was 2 orders of magnitude lower than the levels obtained 
by Schuler and Eder, which may in part be due to the different analytical methods used or the 
different study design with respect to whether animals were possibly fasted [7] or not [4]. The 
Hex-PdG level at 200 and 500 mg trans-2-hexenal/kg bw was predicted by the PBK/D model to 
amount to 101 and 580 Hex-PdG/108 nucleotides (nt) after 24 h and 65 and 377 Hex-PdG/108 nt 
after 48 h, respectively (Table 2.3). At a dose of 200 mg trans-2-hexenal/kg bw, the predicted 
value was 4.1-fold higher than the value reported by Schuler and Eder but 3 orders of magnitude 
higher than the value reported by Stout et al. Also at 500 mg/kg bw, the discrepancy between the 
predicted and the observed value of Stout et al. was 3 orders of magnitude, whereas at this dose 
level the predicted value was only 2.1-fold higher than the value of 179 adducts/108 nt reported by 
Schuler and Eder. 
 
Table 2.3 Predicted and observed formation of  DNA adduct (Hex-PdG) in the liver of a rat after 
trans-2-hexenal exposure 
 
Dose and time point of DNA adduct 
quantification after dosing 
Predicted  
(adducts/108 nt)a 
In vivo data 
(adducts/108 nt) 
200 mg/kg bw, 24h [4] 101 0.2b 
500 mg/kg bw, 24h [4] 580 0.099b 
200 mg/kg bw, 48h [7] 65 16 ± 12c 
500 mg/kg bw, 48h [7] 376 179 ± 52c 
aPredicted amount of Hex-PdG in the liver in μmol was converted to adducts/108 nt by using a 
DNA content of 1.8 mg/(g liver) [31] and the average molecular weight of four nucleotides 
(adenine, guanine, cytosine, thymine) of 330. bThe value in fmol/(μg DNA) was converted to 
adducts/108 nt by using the average molecular weight of nucleotides of 330. cMean ± SD. 
 
The model was also evaluated by comparison of the predicted extent of GSH adduct 
formation to in vivo data for excretion of mercapturic acids for male Wistar rats exposed to 
2-propenal (acrolein) or 4-hydroxy-2-nonenal, which are comparable α,β-unsaturated aldehydes 
[32, 33]. To make the predicted values comparable to the in vivo data, the amount of 
α,β-unsaturated aldehyde conjugates with GSH formed in the liver was assumed to be equal to the 
mercapturic acids excreted in the urine. In the case of 2-propenal, excretion of mercapturic acid 
conjugates has been reported to be 10–32% of the dose in male Wistar rats at dose levels ranging 
from 0.47 to 4.0 mg 2-propenal/kg bw [32]. Because these rats were exposed via intraperitoneal 
injection, the PBK/D model, which was made to model oral dosing, was modified to model 
intraperitoneal dosing to allow comparison. To this end, the Vmax of the detoxification pathways in 
the small intestine compartment were all set to zero so that trans-2-hexenal reaches the liver 
without being enzymatically converted in the small intestine compartment. The modified model 
predicted 27% of the α,β-unsaturated aldehyde to be converted to GSH conjugates at a dose level 
up to 71 μmol/kg bw (c.a. 7.0 mg trans-2-hexenal/kg bw and 4.0 mg 2-propenal/kg bw). In the 
 
case of 4-hydroxy-2-nonenal [33], excretion of mercapturic acid conjugates has been reported to 
be 27 ± 5% of the applied intravenous dose of 3.5 μg/kg bw in male Wistar rats after 48 h. At 
comparable conditions, taking into account intravenous exposure, the model predicted 43% 
formation of GSH conjugates at this level of exposure. Another study on 4-hydroxy-2-nonenal 
[34] reported 5.4% excretion as known mercapturic acid conjugates in male Wistar rats exposed to 
25 μg/kg bw of 4-hydroxy-2-nonenal via intraperitoneal injection within 12 h. After adjusting the 
model for intraperitoneal injection the PBK/D model predicted 27% formation of GSH conjugates 
at this level of exposure. 
 
Sensitivity Analysis 
A sensitivity analysis was performed to identify key parameters that mostly determine the amount 
of Hex-PdG in the liver 24 h after the exposure. Normalized SCs were calculated for all 
parameters at trans-2-hexenal doses of 0.04 mg/kg bw, a level that corresponds to the average 
human dietary exposure, and 200 mg/kg bw, a level at which DNA adduct formation in the liver 
was reported in rats [4, 7]. The parameters for which the |SC| exceeded 0.1 are shown in Figure 
2.5. The results obtained reveal that the levels of Hex-PdG in the liver are influenced significantly 
by parameters that determine the formation and elimination rate of Hex-PdG, such as the 
second-order rate constant for the reaction of trans-2-hexenal with 2′-dG (kDNA) and the half-life 
of the DNA adducts (T1/2). Parameters determining the trans-2-hexenal catalytic detoxification 
rate in the liver such as Vmax for oxidation or reduction by liver S9 (Vmax, LS9_HA and Vmax, 
LS9_HO)and the scaling factor for liver S9 (S9PL) were found to have a considerable higher impact 
on the level of Hex-PdG at 200 mg trans-2-hexenal/kg bw than at 0.04 mg/kg bw, while those 
determining the detoxification rate in the small intestine such as Vmax for GST-mediated 
trans-2-hexenal conjugation with GSH (Vmax,Si_GST) and the scaling factor of small intestine S9 
(S9PSi) have a greater influence on the Hex-PdG level at 0.04 mg trans-2-hexenal/kg bw than at 
200 mg/kg bw. 
 
Model Predictions 
Figure 2.6 shows the time-dependent predicted liver concentrations of trans-2-hexenal (Figure 
2.6A and 2.6B), and the GSH concentrations in the liver and small intestine in male rat (Figure 
2.6C and 2.6D) upon exposure to 0.04 mg/kg bw, a level that corresponds to the average human 
dietary exposure (Figure 2.6A and 2.6C), or 200 mg/kg bw trans-2-hexenal (Figure 2.6B and 
2.6D) at which DNA adduct formation in the liver was reported in rats [4, 7]. The predicted 
time-dependent trans-2-hexenal concentration in the liver showed that the trans-2-hexenal 
concentration reached a maximum value around 0.14 and 187 μM at a dose of 0.04 and 200 
mg/kg bw, respectively (Figure 2.6A and 2.6B). At both dose levels, trans-2-hexenal is fully 
converted within 3 h after dosing; therefore, no accumulation of trans-2-hexenal in the intestine or 
liver is expected if a rat would be exposed repeatedly to the same amount of trans-2-hexenal at 24 
32620 Reiko Kiwamoto.indd   49 17-03-15   15:35
Chapter 2
50 50 
 
h intervals. The results also indicated that at a dose of 0.04 mg/kg bw, the GSH level of both liver 
and small intestine is not affected to a significant extent (Figure 2.6C). At a dose of 200 mg 
trans-2-hexenal/kg bw, the GSH concentration in the small intestine dropped rapidly and 
amounted to only 65% of the initial level after 24 h (Figure 2.6D). In contrast, GSH levels in the 
liver were predicted to be depleted but restored within 24 h upon dosing at 200 mg/kg bw. Thus, 
protective levels of GSH are predicted to be unaffected at low doses, whereas the model predicted 
that at high dose levels significant depletion of GSH occurs, with the incomplete recovery of GSH 
levels in the small intestine after 24 h pointing at possible exacerbation of the effect if the same 
amount of 200 mg of trans-2-hexenal would be dosed to the animal after a 24 h interval. 
 
 
Figure 2.5. Sensitivity of the predicted amount of Hex-PdG in the liver to different model 
parameters at 24 hours after the exposure. White bars correspond to the normalized sensitivity 
coefficients at a dose of 0.04 mg/kg bw and black bars at a dose of 200 mg/kg bw. The parameters 
listed include : body weight (BW); fraction of liver (VLc) and small intestine (VSic); blood flow 
rates (Qc); fraction of blood flow to small intestine (QSic); linear uptake rate of trans-2-hexenal 
(Ka); scaling factor of liver S9 (S9PL), liver mitochondrial fraction (MTL) and small intestine S9 
(S9PSi); Vmax and Km measured with liver S9 (LS9), liver mitochondrial fraction (LMT) or small 
intestine S9 (Si) to form 2-hexenoic acid (HA) or 2-hexen-1-ol (HO);Vmax to form Hex-GSH 
measured with liver S9(Vmax, LS9_GST) or small intestine S9 (Vmax, Si_GST); Km toward 
trans-2-hexenal to form Hex-GSH measured with liver S9 (Km, LS9_GST_H) or with small intestine 
S9 (Km, Si_GST_H); second-order rate constant of trans-2-hexenal binding to 2ʹ-dG (kDNA); half-life 
of DNA adduct in the liver (T1/2); and initial GSH concentration in the liver (InitGSHL). 
 
 
 
 
Figure 2.6.  Time dependent PBK/D model predicted concentrations of (A and B) 
trans-2-hexenal in the liver, and (C and D) GSH in the liver (solid line) and small intestine 
(dashed line) following exposure to 0.04 mg/kg bw  (A and C) or 200 mg/kg bw (B and D) of 
trans-2-hexenal. 
 
Figure 2.7. The PBK/D model predicted dose-dependent amount of 2-hexenoic acid, 2-hexen-1-ol 
and Hex-GSH (chemically or catalyzed by GSTs) in (A) the liver and in (B) the small intestine, 
and (C) the amount of 2-hexenoic acid, 2-hexen-1-ol and Hex-GSH compared to the administered 
trans-2-hexenal dose at 24 hours after the exposure in a rat, and (D) the predicted percentage of 
contribution to trans-2-hexenal detoxification by the liver and the small intestine compartment. 
The inserted windows show the same dose-dependent values up to 10 mg trans-2-hexenal/kg bw. 
32620 Reiko Kiwamoto.indd   50 17-03-15   15:35
2A PBK/D model for trans-2-hexenal in rat
5150 
 
h intervals. The results also indicated that at a dose of 0.04 mg/kg bw, the GSH level of both liver 
and small intestine is not affected to a significant extent (Figure 2.6C). At a dose of 200 mg 
trans-2-hexenal/kg bw, the GSH concentration in the small intestine dropped rapidly and 
amounted to only 65% of the initial level after 24 h (Figure 2.6D). In contrast, GSH levels in the 
liver were predicted to be depleted but restored within 24 h upon dosing at 200 mg/kg bw. Thus, 
protective levels of GSH are predicted to be unaffected at low doses, whereas the model predicted 
that at high dose levels significant depletion of GSH occurs, with the incomplete recovery of GSH 
levels in the small intestine after 24 h pointing at possible exacerbation of the effect if the same 
amount of 200 mg of trans-2-hexenal would be dosed to the animal after a 24 h interval. 
 
 
Figure 2.5. Sensitivity of the predicted amount of Hex-PdG in the liver to different model 
parameters at 24 hours after the exposure. White bars correspond to the normalized sensitivity 
coefficients at a dose of 0.04 mg/kg bw and black bars at a dose of 200 mg/kg bw. The parameters 
listed include : body weight (BW); fraction of liver (VLc) and small intestine (VSic); blood flow 
rates (Qc); fraction of blood flow to small intestine (QSic); linear uptake rate of trans-2-hexenal 
(Ka); scaling factor of liver S9 (S9PL), liver mitochondrial fraction (MTL) and small intestine S9 
(S9PSi); Vmax and Km measured with liver S9 (LS9), liver mitochondrial fraction (LMT) or small 
intestine S9 (Si) to form 2-hexenoic acid (HA) or 2-hexen-1-ol (HO);Vmax to form Hex-GSH 
measured with liver S9(Vmax, LS9_GST) or small intestine S9 (Vmax, Si_GST); Km toward 
trans-2-hexenal to form Hex-GSH measured with liver S9 (Km, LS9_GST_H) or with small intestine 
S9 (Km, Si_GST_H); second-order rate constant of trans-2-hexenal binding to 2ʹ-dG (kDNA); half-life 
of DNA adduct in the liver (T1/2); and initial GSH concentration in the liver (InitGSHL). 
 
 
 
 
Figure 2.6.  Time dependent PBK/D model predicted concentrations of (A and B) 
trans-2-hexenal in the liver, and (C and D) GSH in the liver (solid line) and small intestine 
(dashed line) following exposure to 0.04 mg/kg bw  (A and C) or 200 mg/kg bw (B and D) of 
trans-2-hexenal. 
 
Figure 2.7. The PBK/D model predicted dose-dependent amount of 2-hexenoic acid, 2-hexen-1-ol 
and Hex-GSH (chemically or catalyzed by GSTs) in (A) the liver and in (B) the small intestine, 
and (C) the amount of 2-hexenoic acid, 2-hexen-1-ol and Hex-GSH compared to the administered 
trans-2-hexenal dose at 24 hours after the exposure in a rat, and (D) the predicted percentage of 
contribution to trans-2-hexenal detoxification by the liver and the small intestine compartment. 
The inserted windows show the same dose-dependent values up to 10 mg trans-2-hexenal/kg bw. 
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The developed model was also used to predict the trans-2-hexenal dose-dependent 
metabolites formation (Figure 2.7A–C). The predictions indicated that at dose levels below 80 
mg/kg bw, all three pathways for trans-2-hexenal, including reduction to 2-hexen-1-ol, oxidation 
to 2-hexenoic acid, and conjugation to GSH, contribute to trans-2-hexenal detoxification in the 
liver (Figure 2.7A). The model predicted that the relative percentage of trans-2-hexenal detoxified 
by GSTs in the liver decreases at trans-2-hexenal dose levels above 80 mg/kg bw due to the 
complete depletion of liver cytosolic GSH. In the small intestine, on the other hand, the 
conjugation to GSH catalyzed by GSTs was the most important detoxification pathway, followed 
by oxidation to 2-hexenoic acid (Figure 2.7B). At trans-2-hexenal dose levels higher than 5 mg 
trans-2-hexenal/kg bw, the GSH in the small intestine was completely depleted, and the amount of 
Hex-GSH formed by GSTs plateaued at around 6 μmol. Hex-GSH formation by chemical 
conjugation accounted for less than 1.2% of the total Hex-GSH formation in both compartments 
(Figure 2.7A and 2.7B). Altogether, it was predicted that the major trans-2-hexenal metabolite 
formed in both the liver and the small intestine of a male rat is GSH-Hex at dose levels below 30 
mg trans-2-hexenal/kg bw and that 2-hexen-1-ol and 2-hexenoic acid become the major 
metabolites at higher dose levels up to 200 mg/kg bw (Figure 2.7C). The relative contribution of 
the liver and the small intestine to trans-2-hexenal detoxification was also examined (Figure 
2.7D). At a dose of 0.04 mg/kg bw a considerable part (48% of the dose) of trans-2-hexenal is 
detoxified in the small intestine before reaching the liver, but the contribution of the small 
intestine decreases rapidly and the role is taken over by the liver at dose levels above 5 mg/kg bw. 
The percentage of detoxification by the small intestine then rapidly decreases to less than 9% at 
dose levels around 30 mg/kg bw and is further reduced to 1.5% at 200 mg/kg bw. 
The trans-2-hexenal dose-dependent DNA adduct formation in the liver 24 and 48 h after 
the oral exposure as well as the maximum amount of DNA adducts predicted to be formed after 
exposure to trans-2-hexenal was examined (Figure 2.8). The model predicted formation of DNA 
adducts in the liver at a maximum level of 0.01 adducts per 108 nt upon exposure to 0.04 mg 
trans-2-hexenal/kg bw, corresponding to 0.47×10–5% of the applied dose. At a dose of 200 mg/kg 
bw, this value amounted to a maximum of 151 adducts per 108 nt, corresponding to 1.4×10–5% of 
the applied dose. This relative increase in DNA adduct formation with the dose is mainly due to 
cytosolic GSH depletion occurring in the small intestine at dose levels above 5 mg/kg bw and in 
the liver at dose levels above 80 mg/kg bw. 
 
  
 
 
 
 
Figure 2.8. The PBK/D model predicted 
dose-dependent Hex-PdG level in the liver 
observed at different time points including 
Tmax (    ), 24 hours (    ) or 48 hours   
(    ) after dosing. The insert shows the 
same values up to 10 mg/kg bw. In vivo 
DNA adduct formations at dose 200 mg/kg 
bw observed 24 hours (◊) [4] and 48 hours 
(●) [7] after administration are also 
indicated.  
 
DISCUSSION 
 
trans-2-Hexenal is an α,β-unsaturated aldehyde present in our diet as natural constituent and a 
flavoring agent. Because of the presence of an α,β-unsaturated aldehyde moiety, trans-2-hexenal 
may react with cellular macromolecules including GSH, protein and DNA [3]. Adverse effects 
may occur as a result of protein adduct formation because protein adducts may disrupt the 
structure and/or function of the protein. Yet, formation of DNA adducts raises concerns for 
genotoxicity and is therefore key to the risk assessment of various α,β-unsaturated aldehydes used 
for flavoring including trans-2-hexenal [3]. It remains controversial, however, whether the 
genotoxicity that has been observed in numerous in vitro studies will actually occur in vivo upon 
exposure to the low amounts of trans-2-hexenal found in the diet. It especially has been suggested 
that swift detoxification in vivo during first-pass metabolism prevents the reactivity of 
trans-2-hexenal to be displayed in vivo [1]. Still, there is no experimental evidence showing that 
such a swift detoxification of trans-2-hexenal indeed occurs in vivo. In the present study, a 
PBK/D model describing dose-dependent detoxification and DNA adduct formation of 
trans-2-hexenal in male rat liver was developed to obtain insights in the kinetics of 
trans-2-hexenal including its time- and dose-dependent detoxification. 
To evaluate the performance of the developed PBK/D model, the predicted DNA adduct 
(Hex-PdG) levels in the liver were compared to results from two in vivo studies, in which male 
F344 rats were orally exposed to high single doses of trans-2-hexenal (200 or 500 mg/kg bw). 
The amount of Hex-PdG predicted by the model to be formed in the liver was 4.1-fold higher at 
200 mg trans-2-hexenal/kg bw and was only 2.1-fold higher at 500 mg/kg bw in comparison with 
the data reported by Schuler and Eder [7], indicating that the constructed model captures the 
critical kinetic and dynamic reactions of trans-2-hexenal. On the other hand, the prediction was 2–
3 orders of magnitude higher than the data obtained by Stout et al. [4] at both doses. Stout et al. 
attributed the striking gap between their own data and those reported by Schuler and Eder [7] to 
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The developed model was also used to predict the trans-2-hexenal dose-dependent 
metabolites formation (Figure 2.7A–C). The predictions indicated that at dose levels below 80 
mg/kg bw, all three pathways for trans-2-hexenal, including reduction to 2-hexen-1-ol, oxidation 
to 2-hexenoic acid, and conjugation to GSH, contribute to trans-2-hexenal detoxification in the 
liver (Figure 2.7A). The model predicted that the relative percentage of trans-2-hexenal detoxified 
by GSTs in the liver decreases at trans-2-hexenal dose levels above 80 mg/kg bw due to the 
complete depletion of liver cytosolic GSH. In the small intestine, on the other hand, the 
conjugation to GSH catalyzed by GSTs was the most important detoxification pathway, followed 
by oxidation to 2-hexenoic acid (Figure 2.7B). At trans-2-hexenal dose levels higher than 5 mg 
trans-2-hexenal/kg bw, the GSH in the small intestine was completely depleted, and the amount of 
Hex-GSH formed by GSTs plateaued at around 6 μmol. Hex-GSH formation by chemical 
conjugation accounted for less than 1.2% of the total Hex-GSH formation in both compartments 
(Figure 2.7A and 2.7B). Altogether, it was predicted that the major trans-2-hexenal metabolite 
formed in both the liver and the small intestine of a male rat is GSH-Hex at dose levels below 30 
mg trans-2-hexenal/kg bw and that 2-hexen-1-ol and 2-hexenoic acid become the major 
metabolites at higher dose levels up to 200 mg/kg bw (Figure 2.7C). The relative contribution of 
the liver and the small intestine to trans-2-hexenal detoxification was also examined (Figure 
2.7D). At a dose of 0.04 mg/kg bw a considerable part (48% of the dose) of trans-2-hexenal is 
detoxified in the small intestine before reaching the liver, but the contribution of the small 
intestine decreases rapidly and the role is taken over by the liver at dose levels above 5 mg/kg bw. 
The percentage of detoxification by the small intestine then rapidly decreases to less than 9% at 
dose levels around 30 mg/kg bw and is further reduced to 1.5% at 200 mg/kg bw. 
The trans-2-hexenal dose-dependent DNA adduct formation in the liver 24 and 48 h after 
the oral exposure as well as the maximum amount of DNA adducts predicted to be formed after 
exposure to trans-2-hexenal was examined (Figure 2.8). The model predicted formation of DNA 
adducts in the liver at a maximum level of 0.01 adducts per 108 nt upon exposure to 0.04 mg 
trans-2-hexenal/kg bw, corresponding to 0.47×10–5% of the applied dose. At a dose of 200 mg/kg 
bw, this value amounted to a maximum of 151 adducts per 108 nt, corresponding to 1.4×10–5% of 
the applied dose. This relative increase in DNA adduct formation with the dose is mainly due to 
cytosolic GSH depletion occurring in the small intestine at dose levels above 5 mg/kg bw and in 
the liver at dose levels above 80 mg/kg bw. 
 
  
 
 
 
 
Figure 2.8. The PBK/D model predicted 
dose-dependent Hex-PdG level in the liver 
observed at different time points including 
Tmax (    ), 24 hours (    ) or 48 hours   
(    ) after dosing. The insert shows the 
same values up to 10 mg/kg bw. In vivo 
DNA adduct formations at dose 200 mg/kg 
bw observed 24 hours (◊) [4] and 48 hours 
(●) [7] after administration are also 
indicated.  
 
DISCUSSION 
 
trans-2-Hexenal is an α,β-unsaturated aldehyde present in our diet as natural constituent and a 
flavoring agent. Because of the presence of an α,β-unsaturated aldehyde moiety, trans-2-hexenal 
may react with cellular macromolecules including GSH, protein and DNA [3]. Adverse effects 
may occur as a result of protein adduct formation because protein adducts may disrupt the 
structure and/or function of the protein. Yet, formation of DNA adducts raises concerns for 
genotoxicity and is therefore key to the risk assessment of various α,β-unsaturated aldehydes used 
for flavoring including trans-2-hexenal [3]. It remains controversial, however, whether the 
genotoxicity that has been observed in numerous in vitro studies will actually occur in vivo upon 
exposure to the low amounts of trans-2-hexenal found in the diet. It especially has been suggested 
that swift detoxification in vivo during first-pass metabolism prevents the reactivity of 
trans-2-hexenal to be displayed in vivo [1]. Still, there is no experimental evidence showing that 
such a swift detoxification of trans-2-hexenal indeed occurs in vivo. In the present study, a 
PBK/D model describing dose-dependent detoxification and DNA adduct formation of 
trans-2-hexenal in male rat liver was developed to obtain insights in the kinetics of 
trans-2-hexenal including its time- and dose-dependent detoxification. 
To evaluate the performance of the developed PBK/D model, the predicted DNA adduct 
(Hex-PdG) levels in the liver were compared to results from two in vivo studies, in which male 
F344 rats were orally exposed to high single doses of trans-2-hexenal (200 or 500 mg/kg bw). 
The amount of Hex-PdG predicted by the model to be formed in the liver was 4.1-fold higher at 
200 mg trans-2-hexenal/kg bw and was only 2.1-fold higher at 500 mg/kg bw in comparison with 
the data reported by Schuler and Eder [7], indicating that the constructed model captures the 
critical kinetic and dynamic reactions of trans-2-hexenal. On the other hand, the prediction was 2–
3 orders of magnitude higher than the data obtained by Stout et al. [4] at both doses. Stout et al. 
attributed the striking gap between their own data and those reported by Schuler and Eder [7] to 
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differences in study methodology such as in the technique used to quantify DNA adducts; 
LC/MS/MS in the study of Stout et al. [4] and 32P-postlabeling in the study reported by Schuler 
and Eder. [29] In addition, while animals were not fasted before dosing in the study by Stout et 
al., fasting before dosing may have been applied in the study of Schuler and Eder since there is no 
indication on whether or not animals were fasted before dosing [4]. A difference in animal fasting 
might explain the discrepancy between predicted DNA adduct levels by the developed model and 
the data of Schuler and Eder [29] on the one hand and the data reported by Stout et al. [4] on the 
other hand because trans-2-hexenal is well capable of reacting with protein thiol groups of other 
contents in the gastrointestinal tract, and such a matrix effect could reduce the actual level of 
exposure and resulting DNA adduct formation. If, for instance, 99% of trans-2-hexenal would 
react with the food contents in the gastrointestinal tract and thus only 1% of the administered dose 
would be taken up by the small intestine compartment, the predicted Hex-PdG adduct formation 
at a dose of 200 and 500 mg/kg bw would be only 1.7- and 8.9-fold higher than the observed 
DNA adduct levels reported by Stout et al. [4] at the same dose levels, respectively. It should 
furthermore be noted that in both the study of Stout et al. [4] and of Schuler and Eder [29] part of 
the trans-2-hexenal was probably not taken up completely in the in vivo studies due to severe 
damage to the mucosal tissue of the gastrointestinal tract at 200 and 500 mg/kg bw [4], whereas 
swift and complete absorption of trans-2-hexenal was assumed in our model. 
The constructed model was further evaluated by comparison of the predicted percentage 
of the trans-2-hexenal dose administered converted to GSH conjugates and comparing this 
percentage to the percentage of mercapturic acid excreted in the urine of rats exposed to the 
related α,β-unsaturated aldehydes 2-propenal [32] or 4-hydroxy-2-nonenal [33, 34]. The fact that 
the predicted proportion of GSH conjugates to the total administered dose was within 4-fold of the 
levels reported further supports the adequate performance of the PBK/D model constructed in this 
study. 
The current study is the first attempt to show the quantitative integration and comparison 
of different metabolic routes of trans-2-hexenal in an in vivo model for different exposure levels. 
So far, trans-2-hexenal has been considered to be metabolized predominantly to 2-hexenoic acid, 
followed by conversion to Hex-GSH and to 2-hexen-1-ol to a minor extent [1, 4, 5] based on in 
vivo data using other aliphatic α,β-unsaturated aldehydes than trans-2-hexenal or related 
compounds [35, 36] and an in vitro study where a fixed concentration of trans-2-hexenal was used 
[5]. The model developed in this study revealed that the formation of different metabolites 
changes depending on the administered trans-2-hexenal dose. Hex-GSH was observed to be the 
most abundant at exposure levels below 30 mg/kg bw. Formation of this metabolite amounted to 
60% of the dose at a dose level of 0.04 mg/kg bw, which corresponds to the average dietary 
human intake of trans-2-hexenal, but decreased to 32% of the dose at a dose level of 30 mg/kg 
bw. 
 
 
The effect of the observed dose-dependent changes in detoxification reactions on DNA 
adduct formation could be evaluated with the developed PBK/D model, allowing us to obtain 
insight in the shape of the dose–response behavior at dose levels that cannot be obtained 
experimentally. The complete depletion of GSH in the small intestine at 5 mg/kg bw and the liver 
at 80 mg/kg bw resulted in relative increased DNA adduct formation with further increasing 
doses, which is in line with what has been proposed previously in vivo [37] (Figure 2.8). Yet, the 
dose-dependent effects in DNA adduct formation can be considered small and may not provide an 
argument against linear extrapolation of DNA adduct formation observed in animal experiments at 
high doses to dose levels that are relevant for the human situation. The relevance of such low 
levels of DNA adducts in terms of risk might be evaluated by comparing these levels to 
background levels of DNA adduct formation. The model predicted formation of a maximum level 
of DNA adducts in the liver of 0.01 adducts per 108 nt after exposure to 0.04 mg 
trans-2-hexenal/kg bw, a dose level that corresponds to the average daily intake of 
trans-2-hexenal [1]. This level is 3 orders of magnitude lower than the general background levels 
of endogenous DNA adducts for small molecular weight alkylating electrophiles reported to 
amount to 10–100 adducts/108 nt [38-41]. For high consumers (95th percentile) of fruits, the daily 
intake of trans-2-hexenal has been estimated to correspond to 0.178 mg/kg bw/day for a person of 
60 kg [37]. At this dose level, the maximum Hex-PdG formation was predicted to be around 4.6 
times higher than the maximum adduct level observed with 0.04 mg trans-2-hexenal/kg bw but 
still 3 orders of magnitude lower than background DNA adduct level. This suggests that the risks 
from trans-2-hexenal DNA adduct formation in the liver at dose levels relevant for dietary human 
intake might be negligible. It also should be noted that the model developed in the present study 
represents a worst case scenario in terms of exposure to trans-2-hexenal, assuming complete 
uptake of trans-2-hexenal as a bolus dose without taking matrix effects into account, whereas in 
real life, exposure to trans-2-hexenal from the diet may be spread over a day and occurs in a 
complex food matrix with a variety of scavenging thiol moieties. 
When comparing the predicted DNA adduct formation to background levels, it is 
important to take any uncertainty in the model predictions into account. The present study aimed 
at integrating in vitro-derived kinetic and dynamic parameters to predict in vivo dose-dependent 
DNA adduct formation. Uncertainty can occur in the usage and scaling of in vitro-derived 
parameters. In vitro incubations were, for instance, performed at saturating cofactor 
concentrations and might overestimate reaction rates to some extent when cofactor levels are not 
saturating in vivo [42]. Additional in vitro experiments examining the rate of metabolism at 
different cofactor concentrations revealed that especially reduction of trans-2-hexenal by ARs 
may be lower when cofactor levels are not saturating in vivo. Lower levels of reduction of 
trans-2-hexenal observed at physiologically relevant concentration of NADPH (0.25 mM) [42] 
would result in a 4-fold increase in the predicted amount of DNA adduct formation in the liver, 
which is still 3 orders of magnitude lower than background levels of DNA adducts. Alternatively, 
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differences in study methodology such as in the technique used to quantify DNA adducts; 
LC/MS/MS in the study of Stout et al. [4] and 32P-postlabeling in the study reported by Schuler 
and Eder. [29] In addition, while animals were not fasted before dosing in the study by Stout et 
al., fasting before dosing may have been applied in the study of Schuler and Eder since there is no 
indication on whether or not animals were fasted before dosing [4]. A difference in animal fasting 
might explain the discrepancy between predicted DNA adduct levels by the developed model and 
the data of Schuler and Eder [29] on the one hand and the data reported by Stout et al. [4] on the 
other hand because trans-2-hexenal is well capable of reacting with protein thiol groups of other 
contents in the gastrointestinal tract, and such a matrix effect could reduce the actual level of 
exposure and resulting DNA adduct formation. If, for instance, 99% of trans-2-hexenal would 
react with the food contents in the gastrointestinal tract and thus only 1% of the administered dose 
would be taken up by the small intestine compartment, the predicted Hex-PdG adduct formation 
at a dose of 200 and 500 mg/kg bw would be only 1.7- and 8.9-fold higher than the observed 
DNA adduct levels reported by Stout et al. [4] at the same dose levels, respectively. It should 
furthermore be noted that in both the study of Stout et al. [4] and of Schuler and Eder [29] part of 
the trans-2-hexenal was probably not taken up completely in the in vivo studies due to severe 
damage to the mucosal tissue of the gastrointestinal tract at 200 and 500 mg/kg bw [4], whereas 
swift and complete absorption of trans-2-hexenal was assumed in our model. 
The constructed model was further evaluated by comparison of the predicted percentage 
of the trans-2-hexenal dose administered converted to GSH conjugates and comparing this 
percentage to the percentage of mercapturic acid excreted in the urine of rats exposed to the 
related α,β-unsaturated aldehydes 2-propenal [32] or 4-hydroxy-2-nonenal [33, 34]. The fact that 
the predicted proportion of GSH conjugates to the total administered dose was within 4-fold of the 
levels reported further supports the adequate performance of the PBK/D model constructed in this 
study. 
The current study is the first attempt to show the quantitative integration and comparison 
of different metabolic routes of trans-2-hexenal in an in vivo model for different exposure levels. 
So far, trans-2-hexenal has been considered to be metabolized predominantly to 2-hexenoic acid, 
followed by conversion to Hex-GSH and to 2-hexen-1-ol to a minor extent [1, 4, 5] based on in 
vivo data using other aliphatic α,β-unsaturated aldehydes than trans-2-hexenal or related 
compounds [35, 36] and an in vitro study where a fixed concentration of trans-2-hexenal was used 
[5]. The model developed in this study revealed that the formation of different metabolites 
changes depending on the administered trans-2-hexenal dose. Hex-GSH was observed to be the 
most abundant at exposure levels below 30 mg/kg bw. Formation of this metabolite amounted to 
60% of the dose at a dose level of 0.04 mg/kg bw, which corresponds to the average dietary 
human intake of trans-2-hexenal, but decreased to 32% of the dose at a dose level of 30 mg/kg 
bw. 
 
 
The effect of the observed dose-dependent changes in detoxification reactions on DNA 
adduct formation could be evaluated with the developed PBK/D model, allowing us to obtain 
insight in the shape of the dose–response behavior at dose levels that cannot be obtained 
experimentally. The complete depletion of GSH in the small intestine at 5 mg/kg bw and the liver 
at 80 mg/kg bw resulted in relative increased DNA adduct formation with further increasing 
doses, which is in line with what has been proposed previously in vivo [37] (Figure 2.8). Yet, the 
dose-dependent effects in DNA adduct formation can be considered small and may not provide an 
argument against linear extrapolation of DNA adduct formation observed in animal experiments at 
high doses to dose levels that are relevant for the human situation. The relevance of such low 
levels of DNA adducts in terms of risk might be evaluated by comparing these levels to 
background levels of DNA adduct formation. The model predicted formation of a maximum level 
of DNA adducts in the liver of 0.01 adducts per 108 nt after exposure to 0.04 mg 
trans-2-hexenal/kg bw, a dose level that corresponds to the average daily intake of 
trans-2-hexenal [1]. This level is 3 orders of magnitude lower than the general background levels 
of endogenous DNA adducts for small molecular weight alkylating electrophiles reported to 
amount to 10–100 adducts/108 nt [38-41]. For high consumers (95th percentile) of fruits, the daily 
intake of trans-2-hexenal has been estimated to correspond to 0.178 mg/kg bw/day for a person of 
60 kg [37]. At this dose level, the maximum Hex-PdG formation was predicted to be around 4.6 
times higher than the maximum adduct level observed with 0.04 mg trans-2-hexenal/kg bw but 
still 3 orders of magnitude lower than background DNA adduct level. This suggests that the risks 
from trans-2-hexenal DNA adduct formation in the liver at dose levels relevant for dietary human 
intake might be negligible. It also should be noted that the model developed in the present study 
represents a worst case scenario in terms of exposure to trans-2-hexenal, assuming complete 
uptake of trans-2-hexenal as a bolus dose without taking matrix effects into account, whereas in 
real life, exposure to trans-2-hexenal from the diet may be spread over a day and occurs in a 
complex food matrix with a variety of scavenging thiol moieties. 
When comparing the predicted DNA adduct formation to background levels, it is 
important to take any uncertainty in the model predictions into account. The present study aimed 
at integrating in vitro-derived kinetic and dynamic parameters to predict in vivo dose-dependent 
DNA adduct formation. Uncertainty can occur in the usage and scaling of in vitro-derived 
parameters. In vitro incubations were, for instance, performed at saturating cofactor 
concentrations and might overestimate reaction rates to some extent when cofactor levels are not 
saturating in vivo [42]. Additional in vitro experiments examining the rate of metabolism at 
different cofactor concentrations revealed that especially reduction of trans-2-hexenal by ARs 
may be lower when cofactor levels are not saturating in vivo. Lower levels of reduction of 
trans-2-hexenal observed at physiologically relevant concentration of NADPH (0.25 mM) [42] 
would result in a 4-fold increase in the predicted amount of DNA adduct formation in the liver, 
which is still 3 orders of magnitude lower than background levels of DNA adducts. Alternatively, 
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uncertainty in other parameters may have an opposite effect on DNA adduct formation. 
Uncertainty can, for instance, occur in the estimation of the rate of DNA repair, for which the 
half-life was estimated to be 38.5 h based on an in vivo study. A shorter half-life for DNA repair 
of less than 3 h has been observed for an α,β-unsaturated aldehyde 4-hydroxy-2-nonenal in vitro 
[43]. Such differences DNA repair kinetics have been reported to occur when DNA repair kinetics 
are biphasic, resulting in a fast removal at first with half-lives ranging from 15 min to 2 h, which 
then slows down to a half-life of 48 h [44, 45]. No indication can be given at present whether 
DNA repair kinetics of trans-2-hexenal adducts are biphasic. A more efficient DNA repair would 
result in lower DNA adduct levels. 
The rat PBK/D model developed in this study can form a basis for the development of a 
PBK/D model for trans-2-hexenal detoxification and DNA adduct formation in humans to obtain 
insight in possible species differences in kinetics and dynamics of this compound. Furthermore, 
the model developed in the current study might form a basis for PBK/D models for other dietary 
α,β-unsaturated aldehydes. This is especially relevant considering that a number of compounds 
were categorized to possess structural alerts for genotoxicity by EFSA, and in vivo testing on 
these compounds is required before conclusions on their safety can be reached in case of positive 
in vitro genotoxicity data [3]. Overall, the current study supports rapid in vivo detoxification of 
trans-2-hexenal and reveals that at dose levels representative for estimated human dietary intake 
DNA adduct formation in male rat liver is negligible. 
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uncertainty in other parameters may have an opposite effect on DNA adduct formation. 
Uncertainty can, for instance, occur in the estimation of the rate of DNA repair, for which the 
half-life was estimated to be 38.5 h based on an in vivo study. A shorter half-life for DNA repair 
of less than 3 h has been observed for an α,β-unsaturated aldehyde 4-hydroxy-2-nonenal in vitro 
[43]. Such differences DNA repair kinetics have been reported to occur when DNA repair kinetics 
are biphasic, resulting in a fast removal at first with half-lives ranging from 15 min to 2 h, which 
then slows down to a half-life of 48 h [44, 45]. No indication can be given at present whether 
DNA repair kinetics of trans-2-hexenal adducts are biphasic. A more efficient DNA repair would 
result in lower DNA adduct levels. 
The rat PBK/D model developed in this study can form a basis for the development of a 
PBK/D model for trans-2-hexenal detoxification and DNA adduct formation in humans to obtain 
insight in possible species differences in kinetics and dynamics of this compound. Furthermore, 
the model developed in the current study might form a basis for PBK/D models for other dietary 
α,β-unsaturated aldehydes. This is especially relevant considering that a number of compounds 
were categorized to possess structural alerts for genotoxicity by EFSA, and in vivo testing on 
these compounds is required before conclusions on their safety can be reached in case of positive 
in vitro genotoxicity data [3]. Overall, the current study supports rapid in vivo detoxification of 
trans-2-hexenal and reveals that at dose levels representative for estimated human dietary intake 
DNA adduct formation in male rat liver is negligible. 
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SUPPORTING INFORMATION 
 
PBK/D model equations  
 
(1) Uptake from GI cavity  
The uptake of trans-2-hexenal from the intestinal cavity into the small intestine compartment was described 
by a first-order process as follows: 
dAGI/dt =-Ka*AGI      
InitAGI = DOSE 
where 
AGI  Amount of trans-2-hexenal remaining in GI cavity (μmol) 
Ka  Linear uptake rate (/h) 
DOSE Amount of trans-2-hexenal administered in a rat (μmol). 
 
(2) Slowly perfused tissue, richly perfused tissue and fat   
Amount trans-2-hexenal in slowly perfused tissue, richly perfused tissue or fat compartment was described 
as follows:        
dATi/dt = QTi*(CA-CVTi)     
CTi = ATi/VTi 
CVTi = CTi/PTi 
where 
ATi  Amount of trans-2-hexenal in a tissue (μmol) 
QTi  Blood flow into a tissue (L/h) 
CA   Concentration of trans-2-hexenal in arterial blood perfusing a tissue (μmol/L) 
CVTi  Concentration of trans-2-hexenal in venous blood leaving a tissue (μmol/L) 
CTi  Concentration of trans-2-hexenal in a tissue (μmol/kg) 
VTi  Volume of a tissue (kg) 
PTi  Tissue/blood partition coefficient of trans-2-hexenal 
 
(3) Liver  
Amount trans-2-hexenal in the liver (AL, μmol) is described as follows:  
dAL/dt 
 = QL*CA +QSi*CVSi - (QL+QSi) *CVL - (eq.1 + eq.2 + eq.3 + eq.4 + eq.5+ eq.6) 
CL = AL/VL 
CVL = CL/PL 
where 
QL  Blood flow into the liver (L/h) 
QSi  Blood flow into the small intestine (L/h) 
CVSi Concentration of trans-2-hexenal in venous blood leaving the small intestine (μmol/L) 
CVL Concentration of trans-2-hexenal in venous blood leaving the liver (μmol/L) 
CL  Concentration of trans-2-hexenal in the liver (μmol/L) 
PL  Liver/blood partition coefficient of trans-2-hexenal 
 
Amount trans-2-hexenal oxidized to 2-hexenoic acid enzymatically in the liver (AMLHA, μmol) is 
described to follow Michaelis-Menten equation: 
dAMLHA/dt  
= Vsmax, LS9_HA * CVL / (Km,LS9_HA + CVL) + Vsmax, LMT_HA * CVL / (Km,LMT_HA + CVL)   
---------------- eq. 1 
where 
Vsmax,LS9_HA Scaled Vmax for enzymatic oxidation of trans-2-hexenal in the liver cytosol of microsomes 
(μmol/h)  
Km, LS9_HA  Km for enzymatic oxidation of trans-2-hexenal in cytosol or microsomes in the liver cytosol 
of microsomes (μM) 
Vsmax, LMT_HA  Scaled Vmax for enzymatic oxidation of trans-2-hexenal in the liver mitochondria (μmol/h) 
Km, LMT_HA  Km for enzymatic oxidation of trans-2-hexenal in the liver mitochondria (μM) 
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Amount trans-2-hexenal reduced to 2-hexen-1-ol in the liver (AMLHO, μmol) is described to follow 
Michaelis-Menten-equation: 
dAMLHO/dt = Vsmax, L_HO*CVL/(Km,L_HO + CVL)         ---------------- eq. 2 
where 
Vsmax,L_HO Scaled Vmax for enzymatic reduction of trans-2-hexenal in the liver (μmol/h) 
Km,L_HO Km for enzymatic reduction of trans-2-hexenal in the liver (μM) 
 
Amount trans-2-hexenal metabolized in liver to GSH conjugation by GSTs (AMLHGGST, μmol) is 
described by a two substrate ping-pong model:  
dAMLHGGST/dt = 
Vsmax, L_Hex-GSH * CVL * CLcGSH / 
 (Km,L_Hex-GSH_G*CVL + Km,L_Hex-GSH_H*CLcGSH + CLcGSH*CVL ) ---------------- eq.3 
where 
Vsmax, L_GST Scaled Vmax for enzymatic conjugation of trans-2-hexenal in the liver (μmol/h) 
CLcGSH Concentration of GSH in the liver cytosol (μmol/kg)  
Km, L_GST _H Km toward trans-2-hexenal for enzymatic conjugation of trans-2-hexenal in the liver (μM)  
Km, L_ GST _G Km toward GSH for enzymatic conjugation of trans-2-hexenal in the liver (μM) 
 
Amount trans-2-hexenal chemically bound in liver to GSH (AMLHGchem, μmol) is described as following: 
dAMLHGchem/dt = kGSH*CVL*CLcGSH*VL       ---------------- eq.4 
where 
kGSH  First order rate constant of trans-2-hexenal binding to GSH (/μmol/h) 
VL  Volume of the liver (kg) 
 
Amount trans-2-hexenal protein adducts in the liver (AMLHP, μmol) is described as following: 
dAMLHP/dt = kPRO*CVL*CPROL*VL       ---------------- eq.5 
where 
kPRO First order rate constant of trans-2-hexenal binding to protein reaction sites in a tissue 
(/μmol/h) 
CPROL Concentration of protein reaction sites in the liver (μmol/kg liver)  
 
Amount of DNA adduct (Hex-PdG) in liver (AMLHPdG, μmol) is described by subtracting elimination of 
DNA adduct from the formation: 
dAMLHPdG/dt=  kDNA*CVL*CLdG*VL- AMLHPdG* (ln2/ T1/2) ---------------- eq.6       
where 
kDNA First order rate constant of trans-2-hexenal binding to 2ʹ-dG (/μmol/h) 
CLdG Concentration of 2ʹ-dG in the liver (μmol/kg liver) 
T1/2 Half-life of Hex-PdG in the liver (h)  
 
CLdG was caluculated to be 1,36 μmol/kg liver by using the average molecular weight of nucleotides (330 
g/mol) and reported concentration of DNA in a rat liver (ALDNA, 1.8 g/kg liver). 
 
Amount of GSH present in liver cytosol (AMLcGSH, μmol) is described by zero-order synthesis and 
reduction by first-order elimination due to turnover and depletion by trans-2-hexenal: 
dAMLcGSH = GSYNL*VL*0.9 - (eq.3 + eq.4+ kGLOS_L*AMLcGSH) ---------------- eq.7 
Init AMLcGSH = InitGSHL *VL*0.9 
CLcGSH = AMLcGSH/VL   
where 
GSYNL Rate of GSH synthesis in the liver (μmol/h) 
kGLOS_L First-order rate of GSH turnover in the liver (/h) 
InitGSHL Initial concentration of GSH in the liver (μmol/kg liver) 
 
When eq.7 gave negative values, the value zero was used as the amount of GSH in the liver cytosol.   
 
(4) Small intestine  
The amount trans-2-hexenal in small intestine tissue, (ASi, μmol) is described as follows: 
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PL  Liver/blood partition coefficient of trans-2-hexenal 
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Amount trans-2-hexenal reduced to 2-hexen-1-ol in the liver (AMLHO, μmol) is described to follow 
Michaelis-Menten-equation: 
dAMLHO/dt = Vsmax, L_HO*CVL/(Km,L_HO + CVL)         ---------------- eq. 2 
where 
Vsmax,L_HO Scaled Vmax for enzymatic reduction of trans-2-hexenal in the liver (μmol/h) 
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Amount trans-2-hexenal chemically bound in liver to GSH (AMLHGchem, μmol) is described as following: 
dAMLHGchem/dt = kGSH*CVL*CLcGSH*VL       ---------------- eq.4 
where 
kGSH  First order rate constant of trans-2-hexenal binding to GSH (/μmol/h) 
VL  Volume of the liver (kg) 
 
Amount trans-2-hexenal protein adducts in the liver (AMLHP, μmol) is described as following: 
dAMLHP/dt = kPRO*CVL*CPROL*VL       ---------------- eq.5 
where 
kPRO First order rate constant of trans-2-hexenal binding to protein reaction sites in a tissue 
(/μmol/h) 
CPROL Concentration of protein reaction sites in the liver (μmol/kg liver)  
 
Amount of DNA adduct (Hex-PdG) in liver (AMLHPdG, μmol) is described by subtracting elimination of 
DNA adduct from the formation: 
dAMLHPdG/dt=  kDNA*CVL*CLdG*VL- AMLHPdG* (ln2/ T1/2) ---------------- eq.6       
where 
kDNA First order rate constant of trans-2-hexenal binding to 2ʹ-dG (/μmol/h) 
CLdG Concentration of 2ʹ-dG in the liver (μmol/kg liver) 
T1/2 Half-life of Hex-PdG in the liver (h)  
 
CLdG was caluculated to be 1,36 μmol/kg liver by using the average molecular weight of nucleotides (330 
g/mol) and reported concentration of DNA in a rat liver (ALDNA, 1.8 g/kg liver). 
 
Amount of GSH present in liver cytosol (AMLcGSH, μmol) is described by zero-order synthesis and 
reduction by first-order elimination due to turnover and depletion by trans-2-hexenal: 
dAMLcGSH = GSYNL*VL*0.9 - (eq.3 + eq.4+ kGLOS_L*AMLcGSH) ---------------- eq.7 
Init AMLcGSH = InitGSHL *VL*0.9 
CLcGSH = AMLcGSH/VL   
where 
GSYNL Rate of GSH synthesis in the liver (μmol/h) 
kGLOS_L First-order rate of GSH turnover in the liver (/h) 
InitGSHL Initial concentration of GSH in the liver (μmol/kg liver) 
 
When eq.7 gave negative values, the value zero was used as the amount of GSH in the liver cytosol.   
 
(4) Small intestine  
The amount trans-2-hexenal in small intestine tissue, (ASi, μmol) is described as follows: 
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dASi/dt = QSI*(CA -CVSi) – Ka*AGI - (eq.8 + eq.9 + eq.10 + eq.11) 
CSi = ASi/VSi 
CVSi = CSi/PSi 
where 
CSi Concentration of trans-2-hexenal in the small intestine (μmol/L) 
VSi Volume of the small intestine (kg) 
PSi Small intestine/blood partition coefficient of trans-2-hexenal 
 
Amount trans-2-hexenal enzymatically oxidized 2-hexenoic acid (AMSiHA, μmol) in the small intestine is 
described by Michaelis-Menten equation: 
dAMSiHA/dt = Vsmax,Si_HA*CVSi/(Km, Si_HA + CVSi)   ---------------- eq.8 
where 
Vsmax,Si_HA Scaled Vmax for enzymatic oxidation of trans-2-hexenal in the small intestine (μmol/h) 
Km, Si_HA  Km for enzymatic oxidation of trans-2-hexenal in small intestine (μM). 
 
Amount 2-hexenal metabolized in the small intestine to GSH conjugation by GSTs (AMSiHGGST, μmol) is 
described in the same way as in the liver (see eq. 6):  
        
dAMSiHGGST/dt = 
Vsmax, Si_GST * CVSi * CSicGSH / 
 (Km,Si_GST_G*CVSi + Km,Si_GST_H*CSicGSH + CSicGSH*CVSi)    ---------------- eq.9 
where 
Vsmax, Si_GST Scaled Vmax for enzymatic conjugation of trans-2-hexenal in the small intestine (μmol/h) 
CSicGSH Concentration of GSH in the small intestine cytosol (μmol/kg) 
Km, Si_GST_H Km toward trans-2-hexenal for enzymatic conjugation of trans-2-hexenal in the small 
intestine (μM)  
Km, Si_GST_G Km toward GSH for enzymatic conjugation of trans-2-hexenal in the small intestine (μM) 
 
Amount trans-2-hexenal chemically bound in the small intestine to GSH (AMSiHGchem, μmol) is described 
as following: 
dAMSiHGchem/dt = kGSH*CVSi*CSicGSH*VSi         --------------- eq.10 
where 
kGSH  First order rate constant of trans-2-hexenal binding to GSH (/μmol/h) 
VSi  Volume of the small intestine (kg) 
 
Amount trans-2-hexenal chemically bound to protein reaction sites in the small intestine (AMSiHP, μmol) 
is described as following: 
dAMSiHP/dt = kPRO*CVSi*CPROSi*VSi    --------------- eq.11 
where 
kPRO First order rate constant of trans-2-hexenal binding to protein reaction sites in a tissue 
(/μmol/h) 
CPROSi Concentration of protein reaction sites in the liver (μmol/kg liver)  
 
Amount of GSH present in the small intestine cytosol (AMSicGSH, μmol) is described in the same way as 
in the liver (eq 10): 
 dAMSicGSH = GSYNSi *VSi*0.9- (eq.9 + eq.10+ kGLOS_Si*AMSicGSH) --------------- eq.12 
Init AMSicGSH = InitGSHSi *VSi*0.9  
CSicGSH = AMSicGSH/VSi   
where 
GSYNSi Rate of GSH synthesis in the small intestine (μmol/h) 
kGLOS_Si First-order rate of GSH turnover in the small intestine (/h) 
InitGSHSi Initial concentration of GSH in the small intestine (μmol/kg liver) 
 
As was the case in the liver, the value zero was used as the amount of GSH in the small intestine cytosol 
when eq.12 gave negative values. 
  
(5) Venous blood and arterial blood 
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Concentration of trans-2-hexenal in venous blood (CV) and in arterial blood (CV,  both in μmol/L) was 
described as follows: 
dAV/dt = (QF*CVF + (QL+QSi)*CVL + QR*CVR + QS*CVS - QC*CV) 
CV = AV/VV  
CV = CA 
where 
AV Amount of trans-2-hexenal in venous blood (μmol) 
QF Blood flow into fat (L/h) 
CVF Concentration of trans-2-hexenal in venous blood leaving fat (μmol/L) 
QR Blood flow into richly perfused tissue (L/h) 
CVR Concentration of trans-2-hexenal in venous blood leaving richly perfused tissue (μmol/L) 
QS Blood flow into slowly perfused tissue (L/h) 
CVS Concentration of trans-2-hexenal in venous blood leaving slowly perfused tissue (μmol/L)  
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ABSTRACT  
 
A number of α,β-unsaturated aldehydes are present in food both as natural constituents and as 
flavouring agents. Their reaction with DNA due to their electrophilic α,β-unsaturated aldehyde 
moiety may result in genotoxicity as observed in some in vitro models, thereby raising a safety 
concern. A question that remains is whether in vivo detoxification would be efficient enough to 
prevent DNA adduct formation and genotoxicity. In this study, a human physiologically based 
kinetic/dynamic (PBK/D) model of trans-2-hexenal, a selected model α,β-unsaturated aldehyde, 
was developed to examine dose-dependent detoxification and DNA adduct formation in humans 
upon dietary exposure. The kinetic model parameters for detoxification were quantified using 
relevant pooled human tissue fractions as well as tissue fractions from 11 different individual 
subjects. In addition, Monte Carlo simulations were performed so that the impact of 
interindividual variation in trans-2-hexenal detoxification on the DNA adduct formation in the 
population as a whole could be examined. The PBK/D model revealed that DNA adduct formation 
due to trans-2-hexenal exposure was 0.039 adducts/108 nucleotides (nt) at the estimated average 
trans-2-hexenal dietary intake (0.04 mg/kg bw) and 0.18 adducts/108 nt at the 95th percentile of 
the dietary intake (0.178 mg/kg bw) in the most sensitive people. These levels are three orders of 
magnitude lower than natural background DNA adduct levels that have been reported in 
disease-free humans (6.8–110 adducts/108 nt), suggesting that the genotoxicity risk for the human 
population at realistic dietary daily intakes of trans-2-hexenal may be negligible. 
  
A PBK/D model for trans-2-hexenal in human 
 
INTRODUCTION 
 
A number of α,β-unsaturated aldehydes such as trans-2-hexenal, trans-2-nonenal, and trans, 
trans-2,4-hexadienal are present in our diet as natural constituents and may also be intentionally 
added as pure compounds to food as flavouring ingredients [1]. Due to their α,β-unsaturated 
aldehyde moiety, α,β-unsaturated aldehydes can react with cellular macromolecules including 
DNA without the need for bioactivation [2]. Their reaction with DNA may result in genotoxicity 
as shown in some in vitro models, thereby raising a safety concern. The European Food Safety 
Authority (EFSA) regarded the α,β-unsaturated aldehyde moiety as a structural alert for 
genotoxicity and concluded that data on genotoxicity of several α,β-unsaturated aldehydes were 
required to overrule the concerns over genotoxicity when considering the use of these compounds 
as food flavouring agents [3].A question that remains is whether in vivo detoxification of the 
α,β-unsaturated aldehyde would be efficient enough to prevent DNA adduct formation. Such an 
argument would be in line with that of the Joint FAO/WHO Committee on Food Additives 
(JECFA) and the Expert Panel of the Flavor and Extract Manufacturers Association (FEMA), who 
concluded that various α,β-unsaturated aldehydes that are of interest as flavouring ingredients do 
not present any safety concerns at estimated current intakes due to the low level of use in food and 
possible rapid detoxification at low dietary exposure [1, 4]. Based on these considerations, the aim 
of the present study was to provide an insight into dose-dependent detoxification and DNA adduct 
formation upon dietary exposure to trans-2-hexenal, a selected model α,β-unsaturated aldehyde, 
by developing a human physiologically based kinetic/dynamic (PBK/D) model. trans-2-Hexenal 
is one of the most prominent α,β-unsaturated aldehydes in our diet [1]. trans-2-Hexenal is present 
in a wide range of plant-based foods including vegetables, fruits, and beverages as a natural 
constituent [5, 6]. trans-2-Hexenal has also been used as a food flavouring agent due to its grassy 
fresh odour [1]. The estimated daily intake of trans-2-hexenal from food consumption is 2,390 
μg/person/day as a natural constituent and 57 μg/person/day as a food flavouring agent [1], 
corresponding to 40 and 1 μg/kg bw/day for a 60-kg person. Genotoxicity of trans-2-hexenal has 
been observed in in vitro studies using bacterial or mammalian cells [7-9]. trans-2-Hexenal is 
detoxified via three pathways: oxidation to 2-hexenoic acid by aldehyde dehydrogenases 
(ALDHs), reduction to 2-hexen-1-ol by aldose reductases (ARs), and conjugation with reduced 
glutathione (GSH) either chemically or catalysed by glutathione S-transferases (GSTs) (Figure. 
3.1) [8]. In vivo studies using male F344 rats revealed that exocyclic 
1,N2-propanodeoxyguanosine (Hex–PdG) adducts, trans-2-hexenal DNA adducts, are formed in 
the liver upon the administration of high irritating doses of trans-2-hexenal (200 or 500 mg/kg 
bw), but not at doses of 50 mg/kg bw and lower [10, 11]. This observation suggests that 
trans-2-hexenal may be swiftly detoxified in vivo at the levels representative for the estimated 
human dietary intake, and DNA adduct formation upon oral exposure to trans-2-hexenal at these 
levels may be insignificant or at least below the detection limit of the method applied for the 
measurement of the DNA adducts. 
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(ALDHs), reduction to 2-hexen-1-ol by aldose reductases (ARs), and conjugation with reduced 
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measurement of the DNA adducts. 
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To quantitatively integrate the dose-dependent metabolic conversion of trans-2-hexenal 
via different detoxification routes and to determine the impact of these reactions on DNA adduct 
formation in vivo, we have previously developed a physiologically based kinetic/dynamic 
(PBK/D) model for trans-2-hexenal in rat [12]. In the present study, a human PBK/D model for 
trans-2-hexenal detoxification and DNA binding was defined, taking interindividual differences in 
detoxification into account. The results obtained provided an insight into the genotoxicity in 
humans arising from exposure to low realistic dietary levels of trans-2-hexenal present in our diet, 
which cannot be examined experimentally in vivo. 
 
 
Figure 3.1. Metabolism of trans-2-hexenal. The asterisk represents a chiral centre. 
 
MATERIALS AND METHODS 
 
Materials and chemicals 
trans-2-Hexen-1-al (trans-2-hexenal), trans-2-hexen-1-ol (2-hexen-1-ol), trans-2-hexenoic acid 
(2-hexenoic acid), 2′-deoxyguanosine (2′-dG), tris (hydroxymethyl) aminomethane, and GSH 
were purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands). Reduced (NADPH) and 
oxidized (NAD+) β-nicotinamide adenine dinucleotide phosphates were obtained from Roche 
Diagnostics (Mannheim, Germany), and dimethyl sulphoxide (DMSO) was purchased from Acros 
Organic (NJ, USA). Acetonitrile (ULC/MS) and methanol (HPLC Supra-gradient) were purchased 
from Biosolve (Valkenswaard, the Netherlands). Trifluoroacetic acid (TFA) was obtained from 
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VWR International (Darmstadt, Germany). Pooled human liver S9 was obtained from Celsis 
(Baltimore, USA). Pooled human small intestine S9 of mixed gender and eleven individual human 
liver S9 samples were purchased from Xenotech (Lenexa, USA).  
 
Aldehyde dehydrogenase (ALDH)-catalysed oxidation of trans-2-hexenal to 2-hexenoic acid 
trans-2-Hexenal was incubated with human liver or small intestine S9 to determine the kinetic 
constants for ALDH-mediated oxidation of trans-2-hexenal. The final volume of the incubation 
mixtures was 100 μl. Each incubation mixture contained (final concentrations) pooled human 
liver S9 (0.42 mg protein/ml), individual human liver S9 (0.4 mg protein/ml), or pooled human 
small intestine S9 (0.4 mg protein/ml) and NAD+ (2 mM) in 0.1 M Tris–HCl (pH 7.4). After 
pre-incubation at 37 °C for 2 min, the reactions were initiated by the addition of the substrate 
trans-2-hexenal (50–750 μM) from 100 times concentrated stock solutions in DMSO. The 
mixtures were incubated at 37 °C for 5 min with pooled or individual liver S9 and 6 min with 
pooled small intestine S9. The reactions were terminated by adding 50 μl ice-cold acetonitrile. 
The incubation mixtures were subsequently centrifuged for 3 min at 13,000×g at 4 °C to 
precipitate the proteins. Blank incubations were performed without the cofactor NAD+ or without 
S9. Because trans-2-hexenal also oxidizes spontaneously to form 2-hexenoic acid during these 
incubations, the amount of 2-hexenoic acid present in blank incubations without S9 was 
subtracted as background. The amount of 2-hexenoic acid in the samples was analysed 
immediately after the incubation using an ultra-performance liquid chromatography diode array 
detection (UPLC-DAD) system consisting of a Waters Acquity solvent manager, sample manager, 
and photodiode array detector (Waters, Milford, MA, USA), equipped with a Waters Acquity 
UPLC BEH C18 column (1.7 μm, 2.1 × 50 mm) as described previously [12]. 
 
Aldose reductase (AR)-catalysed reduction of trans-2-hexenal to 2-hexen-1-ol 
trans-2-Hexenal was incubated with human liver or small intestine S9 to determine the kinetic 
constants for AR-mediated reduction of trans-2-hexenal. The final volume of the incubation 
mixtures was 100 μl. Each incubation mixture contained (final concentrations) pooled human 
liver S9 (0.42 mg protein/ml), individual human liver S9 (0.4 mg protein/ml), or pooled human 
small intestine S9 (0.4 mg protein/ml) in 0.1 M Tris–HCl (pH 7.4). After pre-incubation at 37 °C 
for 3 min, the reactions were initiated by the addition of NADPH (2.5 mM) from a 20 times 
concentrated stock solution in 0.1 M Tris–HCl (pH 7.4) and trans-2-hexenal (50–750 μM) from 
100 times concentrated stock solutions in DMSO. After 6 min, the reactions were terminated by 
adding 50 μl ice-cold acetonitrile. Blank incubations were performed without the cofactor 
NADPH or without S9. The incubation mixtures were subsequently centrifuged for 3 min at 
13,000×g at 4 °C to precipitate the proteins. The resulting supernatants were immediately frozen 
in dry ice and stored at −80 °C until analysis to prevent evaporation of 2-hexen-1-ol. The amount 
of 2-hexen-1-ol was measured using a UPLC-DAD system as described previously [12]. 
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To quantitatively integrate the dose-dependent metabolic conversion of trans-2-hexenal 
via different detoxification routes and to determine the impact of these reactions on DNA adduct 
formation in vivo, we have previously developed a physiologically based kinetic/dynamic 
(PBK/D) model for trans-2-hexenal in rat [12]. In the present study, a human PBK/D model for 
trans-2-hexenal detoxification and DNA binding was defined, taking interindividual differences in 
detoxification into account. The results obtained provided an insight into the genotoxicity in 
humans arising from exposure to low realistic dietary levels of trans-2-hexenal present in our diet, 
which cannot be examined experimentally in vivo. 
 
 
Figure 3.1. Metabolism of trans-2-hexenal. The asterisk represents a chiral centre. 
 
MATERIALS AND METHODS 
 
Materials and chemicals 
trans-2-Hexen-1-al (trans-2-hexenal), trans-2-hexen-1-ol (2-hexen-1-ol), trans-2-hexenoic acid 
(2-hexenoic acid), 2′-deoxyguanosine (2′-dG), tris (hydroxymethyl) aminomethane, and GSH 
were purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands). Reduced (NADPH) and 
oxidized (NAD+) β-nicotinamide adenine dinucleotide phosphates were obtained from Roche 
Diagnostics (Mannheim, Germany), and dimethyl sulphoxide (DMSO) was purchased from Acros 
Organic (NJ, USA). Acetonitrile (ULC/MS) and methanol (HPLC Supra-gradient) were purchased 
from Biosolve (Valkenswaard, the Netherlands). Trifluoroacetic acid (TFA) was obtained from 
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VWR International (Darmstadt, Germany). Pooled human liver S9 was obtained from Celsis 
(Baltimore, USA). Pooled human small intestine S9 of mixed gender and eleven individual human 
liver S9 samples were purchased from Xenotech (Lenexa, USA).  
 
Aldehyde dehydrogenase (ALDH)-catalysed oxidation of trans-2-hexenal to 2-hexenoic acid 
trans-2-Hexenal was incubated with human liver or small intestine S9 to determine the kinetic 
constants for ALDH-mediated oxidation of trans-2-hexenal. The final volume of the incubation 
mixtures was 100 μl. Each incubation mixture contained (final concentrations) pooled human 
liver S9 (0.42 mg protein/ml), individual human liver S9 (0.4 mg protein/ml), or pooled human 
small intestine S9 (0.4 mg protein/ml) and NAD+ (2 mM) in 0.1 M Tris–HCl (pH 7.4). After 
pre-incubation at 37 °C for 2 min, the reactions were initiated by the addition of the substrate 
trans-2-hexenal (50–750 μM) from 100 times concentrated stock solutions in DMSO. The 
mixtures were incubated at 37 °C for 5 min with pooled or individual liver S9 and 6 min with 
pooled small intestine S9. The reactions were terminated by adding 50 μl ice-cold acetonitrile. 
The incubation mixtures were subsequently centrifuged for 3 min at 13,000×g at 4 °C to 
precipitate the proteins. Blank incubations were performed without the cofactor NAD+ or without 
S9. Because trans-2-hexenal also oxidizes spontaneously to form 2-hexenoic acid during these 
incubations, the amount of 2-hexenoic acid present in blank incubations without S9 was 
subtracted as background. The amount of 2-hexenoic acid in the samples was analysed 
immediately after the incubation using an ultra-performance liquid chromatography diode array 
detection (UPLC-DAD) system consisting of a Waters Acquity solvent manager, sample manager, 
and photodiode array detector (Waters, Milford, MA, USA), equipped with a Waters Acquity 
UPLC BEH C18 column (1.7 μm, 2.1 × 50 mm) as described previously [12]. 
 
Aldose reductase (AR)-catalysed reduction of trans-2-hexenal to 2-hexen-1-ol 
trans-2-Hexenal was incubated with human liver or small intestine S9 to determine the kinetic 
constants for AR-mediated reduction of trans-2-hexenal. The final volume of the incubation 
mixtures was 100 μl. Each incubation mixture contained (final concentrations) pooled human 
liver S9 (0.42 mg protein/ml), individual human liver S9 (0.4 mg protein/ml), or pooled human 
small intestine S9 (0.4 mg protein/ml) in 0.1 M Tris–HCl (pH 7.4). After pre-incubation at 37 °C 
for 3 min, the reactions were initiated by the addition of NADPH (2.5 mM) from a 20 times 
concentrated stock solution in 0.1 M Tris–HCl (pH 7.4) and trans-2-hexenal (50–750 μM) from 
100 times concentrated stock solutions in DMSO. After 6 min, the reactions were terminated by 
adding 50 μl ice-cold acetonitrile. Blank incubations were performed without the cofactor 
NADPH or without S9. The incubation mixtures were subsequently centrifuged for 3 min at 
13,000×g at 4 °C to precipitate the proteins. The resulting supernatants were immediately frozen 
in dry ice and stored at −80 °C until analysis to prevent evaporation of 2-hexen-1-ol. The amount 
of 2-hexen-1-ol was measured using a UPLC-DAD system as described previously [12]. 
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Glutathione S-transferase (GST)-catalysed conjugation of GSH with trans-2-hexenal 
Kinetic constants for GST-mediated formation of trans-2-hexenal–GSH conjugates 
(S-[3-(1-oxohexyl)]-GSH (Hex–GSH)) were determined by incubating trans-2-hexenal in the 
presence of human liver or small intestine S9. The final volume of the incubation mixtures was 
100 μl. The incubation mixtures contained (final concentrations) pooled human liver S9 (0.84 mg 
protein/ml), individual human liver S9 (0.8 mg protein/ml), or pooled human small intestine S9 
(0.4 mg protein/ml) in 0.1 M Tris–HCl. For the incubations with liver S9, a lower pH (7.0) was 
used than for the incubations with small intestine (7.4) to reduce the background chemical 
formation of Hex–GSH and to accurately determine the formation catalysed by liver GSTs, which 
activity (nmol/min/mg S9 protein) was observed to be lower than that by small intestine GSTs 
(supporting information 3.1C). After pre-incubation at 37 °C for 3 min, the reaction was initiated 
by the addition of GSH (2.5 mM) from a 10 times concentrated stock solution in 0.1 M Tris–HCl 
(pH 7.0 with liver S9 and pH 7.4 with small intestine S9) and trans-2-hexenal (1,000–3,000 μM 
with liver S9 and 500–3,000 μM with small intestine S9) from 100 times concentrated stock 
solutions in DMSO. Incubations were carried out for 4 min with liver S9 or 3 min with small 
intestine S9. The reactions were terminated by adding 50 μl ice-cold acetonitrile. In parallel, 
mixtures without S9 were incubated to quantify background levels of Hex–GSH that were 
chemically formed during the incubation. The samples obtained from the incubations were 
centrifuged for 3 min at 13,000×g at 4 °C to precipitate the S9 proteins, and the resulting 
supernatant was analysed by UPLC-DAD as described previously [12] immediately after 
centrifugation. 
 
Kinetic analysis 
The Km and Vmax values for the formation of 2-hexenoic acid and 2-hexen-1-ol were determined 
by fitting the data of the rate of the reaction with increasing trans-2-hexenal concentration 
to the standard Michaelis–Menten equation with [Hex] being the trans-2-hexenal concentration: 
 v = Vmax× [S] / (Km+[S]) 
The trans-2-hexenal-concentration-dependent rate of liver GST-mediated Hex–GSH formation 
showed no saturation and a linear increase with trans-2-hexenal concentrations up to 3,000 μM 
trans-2-hexenal in the presence of saturating concentration of GSH (2.5 mM) (see supporting 
information 3.1C). The first-order rate constant (K) of trans-2-hexenal conjugation with GSH 
mediated by human liver GSTs was obtained from this plot. The formation of GST-mediated Hex–
GSH in the small intestine depending on the concentrations of GSH and trans-2-hexenal was 
described by ping-pong kinetics [13, 14] with the following equation, where [Hex] and [GSH] 
represent the concentration of trans-2-hexenal and GSH, respectively, and Km_G and Km_H the Km 
values towards GSH and trans-2-hexenal, respectively: 
 v = Vmax×[Hex]×[GSH] / (Km_G×[Hex] + Km_H×[GSH] + [Hex] ×[GSH]) 
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The apparent maximum velocities (Vmax), the apparent Michaelis–Menten constants (Km), and the 
apparent first order rate constant (K) were determined by fitting the data to the respective 
equations using GraphPad Prism (version 5.04, GraphPad Software, Inc., La Jolla, USA).  
 
PBK/D model structure 
A human PBK/D model describing the trans-2-hexenal detoxification and DNA adduct formation 
in the liver was developed based on the previously defined PBK/D model for trans-2-hexenal in 
male rats [12]. The schematic diagram of the human model is shown in Figure 3.2. The mass 
balance equations including a list of abbreviations used in the equations are presented as 
supporting information 3.2. The human model includes separate compartments for liver and small 
intestine as tissues that were involved in enzymatic detoxification of trans-2-hexenal. A separate 
compartment for fat tissue was included to account for the relatively high partition coefficient of 
trans-2-hexenal in fat tissue. Other tissues were lumped into a rapidly perfused tissue group (e.g. 
adrenals, brain, heart) and a slowly perfused tissue group (e.g. muscle, skin) [15]. The 
physiological parameters such as organ volumes and blood flows were obtained from the 
literature [16]. Partition coefficients were estimated from the logKow based on a method of 
DeJongh et al. [17] (Table 3.1). The logKow value for trans-2-hexenal was estimated with 
estimation program interface (EPI) Suite version 4.10 provided by the US Environmental 
Protection Agency and amounted to 0.25. Model equations were coded and numerically integrated 
in Berkeley Madonna 8.3.18 (Macey and Oster, UC Berkeley, CA, USA) using the Rosenbrock’s 
algorithm for stiff systems. 
The uptake of trans-2-hexenal from the intestinal lumen into the small intestine 
compartment was described by a first order process with the absorption rate constant 5.0 /h. This 
value was used previously for the uptake of acrylamide in the PBK model for acrylamide and its 
metabolite glycidamide, resulting in a rapid absorption of the ingested compound [18]. 
Conversion of trans-2-hexenal to 2-hexenoic acid or to 2-hexen-1-ol, and GST-mediated 
trans-2-hexenal conjugation with GSH were described in the liver and small intestine 
compartments based on the results of trans-2-hexenal incubations with tissue fractions. Neither 
further conversion nor distribution of trans-2-hexenal metabolites in the body was modeled 
because none of these would affect the predictions of the trans-2-hexenal detoxification and DNA 
adduct formation. The kinetic constants for the enzymatic metabolite formations were determined 
in vitro in the present study. The Vmax and K values expressed as nmol/min/(mg S9 protein) or 
ml/min/(mg S9 protein) were scaled to (g tissue) using S9 protein yields of 143 mg/(g liver) or 
11.4 mg/(g small intestine) as scaling factors as described previously [19, 20]. The non-enzymatic 
reaction of trans-2-hexenal with GSH and protein was included in the liver and small intestine 
[21]. The second-order rate constants for trans-2-hexenal reaction with GSH (kGSH) was obtained 
previously for the rat PBK/D model for trans-2-hexenal [12]. The second-order rate constant for 
trans-2-hexenal binding to protein reactive sites (kPRO) was set to the same value as kGSH based on 
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Glutathione S-transferase (GST)-catalysed conjugation of GSH with trans-2-hexenal 
Kinetic constants for GST-mediated formation of trans-2-hexenal–GSH conjugates 
(S-[3-(1-oxohexyl)]-GSH (Hex–GSH)) were determined by incubating trans-2-hexenal in the 
presence of human liver or small intestine S9. The final volume of the incubation mixtures was 
100 μl. The incubation mixtures contained (final concentrations) pooled human liver S9 (0.84 mg 
protein/ml), individual human liver S9 (0.8 mg protein/ml), or pooled human small intestine S9 
(0.4 mg protein/ml) in 0.1 M Tris–HCl. For the incubations with liver S9, a lower pH (7.0) was 
used than for the incubations with small intestine (7.4) to reduce the background chemical 
formation of Hex–GSH and to accurately determine the formation catalysed by liver GSTs, which 
activity (nmol/min/mg S9 protein) was observed to be lower than that by small intestine GSTs 
(supporting information 3.1C). After pre-incubation at 37 °C for 3 min, the reaction was initiated 
by the addition of GSH (2.5 mM) from a 10 times concentrated stock solution in 0.1 M Tris–HCl 
(pH 7.0 with liver S9 and pH 7.4 with small intestine S9) and trans-2-hexenal (1,000–3,000 μM 
with liver S9 and 500–3,000 μM with small intestine S9) from 100 times concentrated stock 
solutions in DMSO. Incubations were carried out for 4 min with liver S9 or 3 min with small 
intestine S9. The reactions were terminated by adding 50 μl ice-cold acetonitrile. In parallel, 
mixtures without S9 were incubated to quantify background levels of Hex–GSH that were 
chemically formed during the incubation. The samples obtained from the incubations were 
centrifuged for 3 min at 13,000×g at 4 °C to precipitate the S9 proteins, and the resulting 
supernatant was analysed by UPLC-DAD as described previously [12] immediately after 
centrifugation. 
 
Kinetic analysis 
The Km and Vmax values for the formation of 2-hexenoic acid and 2-hexen-1-ol were determined 
by fitting the data of the rate of the reaction with increasing trans-2-hexenal concentration 
to the standard Michaelis–Menten equation with [Hex] being the trans-2-hexenal concentration: 
 v = Vmax× [S] / (Km+[S]) 
The trans-2-hexenal-concentration-dependent rate of liver GST-mediated Hex–GSH formation 
showed no saturation and a linear increase with trans-2-hexenal concentrations up to 3,000 μM 
trans-2-hexenal in the presence of saturating concentration of GSH (2.5 mM) (see supporting 
information 3.1C). The first-order rate constant (K) of trans-2-hexenal conjugation with GSH 
mediated by human liver GSTs was obtained from this plot. The formation of GST-mediated Hex–
GSH in the small intestine depending on the concentrations of GSH and trans-2-hexenal was 
described by ping-pong kinetics [13, 14] with the following equation, where [Hex] and [GSH] 
represent the concentration of trans-2-hexenal and GSH, respectively, and Km_G and Km_H the Km 
values towards GSH and trans-2-hexenal, respectively: 
 v = Vmax×[Hex]×[GSH] / (Km_G×[Hex] + Km_H×[GSH] + [Hex] ×[GSH]) 
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The apparent maximum velocities (Vmax), the apparent Michaelis–Menten constants (Km), and the 
apparent first order rate constant (K) were determined by fitting the data to the respective 
equations using GraphPad Prism (version 5.04, GraphPad Software, Inc., La Jolla, USA).  
 
PBK/D model structure 
A human PBK/D model describing the trans-2-hexenal detoxification and DNA adduct formation 
in the liver was developed based on the previously defined PBK/D model for trans-2-hexenal in 
male rats [12]. The schematic diagram of the human model is shown in Figure 3.2. The mass 
balance equations including a list of abbreviations used in the equations are presented as 
supporting information 3.2. The human model includes separate compartments for liver and small 
intestine as tissues that were involved in enzymatic detoxification of trans-2-hexenal. A separate 
compartment for fat tissue was included to account for the relatively high partition coefficient of 
trans-2-hexenal in fat tissue. Other tissues were lumped into a rapidly perfused tissue group (e.g. 
adrenals, brain, heart) and a slowly perfused tissue group (e.g. muscle, skin) [15]. The 
physiological parameters such as organ volumes and blood flows were obtained from the 
literature [16]. Partition coefficients were estimated from the logKow based on a method of 
DeJongh et al. [17] (Table 3.1). The logKow value for trans-2-hexenal was estimated with 
estimation program interface (EPI) Suite version 4.10 provided by the US Environmental 
Protection Agency and amounted to 0.25. Model equations were coded and numerically integrated 
in Berkeley Madonna 8.3.18 (Macey and Oster, UC Berkeley, CA, USA) using the Rosenbrock’s 
algorithm for stiff systems. 
The uptake of trans-2-hexenal from the intestinal lumen into the small intestine 
compartment was described by a first order process with the absorption rate constant 5.0 /h. This 
value was used previously for the uptake of acrylamide in the PBK model for acrylamide and its 
metabolite glycidamide, resulting in a rapid absorption of the ingested compound [18]. 
Conversion of trans-2-hexenal to 2-hexenoic acid or to 2-hexen-1-ol, and GST-mediated 
trans-2-hexenal conjugation with GSH were described in the liver and small intestine 
compartments based on the results of trans-2-hexenal incubations with tissue fractions. Neither 
further conversion nor distribution of trans-2-hexenal metabolites in the body was modeled 
because none of these would affect the predictions of the trans-2-hexenal detoxification and DNA 
adduct formation. The kinetic constants for the enzymatic metabolite formations were determined 
in vitro in the present study. The Vmax and K values expressed as nmol/min/(mg S9 protein) or 
ml/min/(mg S9 protein) were scaled to (g tissue) using S9 protein yields of 143 mg/(g liver) or 
11.4 mg/(g small intestine) as scaling factors as described previously [19, 20]. The non-enzymatic 
reaction of trans-2-hexenal with GSH and protein was included in the liver and small intestine 
[21]. The second-order rate constants for trans-2-hexenal reaction with GSH (kGSH) was obtained 
previously for the rat PBK/D model for trans-2-hexenal [12]. The second-order rate constant for 
trans-2-hexenal binding to protein reactive sites (kPRO) was set to the same value as kGSH based on 
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a study where the second-order rate constants for the reaction of ethyl acrylate with GSH, liver, or 
small intestine protein reactive sites were found to be comparable to each other (33, 33, and 
32/M/min, respectively) [22]. 
 
 
 
Figure 3.2. Diagram of the proposed PBK/D model for trans-2-hexenal in human. The solid and 
dashed lines represent the movement of trans-2-hexenal and GSH, respectively. 
 
 
  
A PBK/D model for trans-2-hexenal in human 
 
Table 3.1 Parameters used in the PBK/D model for trans-2-hexenal in human 
 
Parameters Symbols Values  Parameters Symbols Values 
Physico-chemical Parametersa  small intestine QSic 8.6 
fat/blood  PF 26.1  richly perfused  QRc 47.3 
liver/blood  PL 1.6  slowly perfused QSc 24.8 
small 
intestine/blood  
PSI 1.6  Initial GSH concentration (μmol/kg tissue) 
richly perfused 
tissues/blood  
PR 1.6  liverc  InitGSHL 5639 
slowly perfused 
tissues/blood  
PS 1.3  small intestined InitGSHSi 1250 
Physiological Parameters  GSH synthesis (μmol/kg tissue/h) e 
  Body weight (kg)a BW 60       liver GSYNL 1122 
  Tissue volumes (% body weight)a       small intestine GSYNSi 27 
 fat VFc 21.4  Apparent first order rate constant for GSH 
turnover (rat) (/h) e 
 liver VLc 2.6  liver kL_GLOS 0.142 
 small intestine VSic 0.9  small intestine kSi_GLOS 0.044 
 arterial blood VAc 2.0  Protein reactive sites (rat) (μmol/kg tissue)f 
 venous blood VVc 5.9  liver CPROL 3000 
 richly perfused  VRc 4.1  small intestine CPROSi 774 
 slowly perfused VSc 51.7  Biochemical Parameters 
Cardiac output  
(L/h) a,b 
QC 310  Second order rate constant for chemical reaction 
with trans-2-hexenal (μM/h)g 
Blood flow to tissue (% cardiac output) a  GSH kGSH 5.8×10
-4 
   fat QFc 5.2  2ʹ-dG kDNA 1.6×10
-7 
liver (excluding 
portal vein fraction) 
QLc 14.1  Protein reaction sites 
in different tissues 
kPRO 5.8×10
-4 
a Brown et al. [16], bKrishnan and Andersen [23], cSweeney et al. [24], dAssimakopoulos et al. 
[25], ePotter and Tran [26], fPotter and Tran [22], gKiwamoto et al. [12] 
 
Equations to describe GSH levels in the liver or small intestine were integrated in the 
PBK/D model to examine the influence of trans-2-hexenal-induced depletion of GSH on the 
model outcomes. The GSH pools were divided into cytosolic and mitochondrial pools. Only the 
cytosolic GSH was used to scavenge trans-2-hexenal and was therefore subject to depletion upon 
exposure to trans-2-hexenal [13]. The reactions reflecting biosynthesis and degradation of GSH 
due to its regular cellular turnover were described by zero-order synthesis and first-order 
elimination as described elsewhere [13, 21, 26]. Ninety per cent of the synthesized GSH was 
directed to cytosol, while the rest (10 %) was directed to mitochondria as an input for the regular 
GSH turnover in the mitochondrial pool. The amount of Hex–PdG in the liver was described by 
second order formation and first-order elimination due to DNA repair. The half-life (T1/2) 38.5 h 
was used for DNA adducts elimination as described previously for the PBK/D model for 
trans-2-hexenal in rat [12]. 
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a study where the second-order rate constants for the reaction of ethyl acrylate with GSH, liver, or 
small intestine protein reactive sites were found to be comparable to each other (33, 33, and 
32/M/min, respectively) [22]. 
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Table 3.1 Parameters used in the PBK/D model for trans-2-hexenal in human 
 
Parameters Symbols Values  Parameters Symbols Values 
Physico-chemical Parametersa  small intestine QSic 8.6 
fat/blood  PF 26.1  richly perfused  QRc 47.3 
liver/blood  PL 1.6  slowly perfused QSc 24.8 
small 
intestine/blood  
PSI 1.6  Initial GSH concentration (μmol/kg tissue) 
richly perfused 
tissues/blood  
PR 1.6  liverc  InitGSHL 5639 
slowly perfused 
tissues/blood  
PS 1.3  small intestined InitGSHSi 1250 
Physiological Parameters  GSH synthesis (μmol/kg tissue/h) e 
  Body weight (kg)a BW 60       liver GSYNL 1122 
  Tissue volumes (% body weight)a       small intestine GSYNSi 27 
 fat VFc 21.4  Apparent first order rate constant for GSH 
turnover (rat) (/h) e 
 liver VLc 2.6  liver kL_GLOS 0.142 
 small intestine VSic 0.9  small intestine kSi_GLOS 0.044 
 arterial blood VAc 2.0  Protein reactive sites (rat) (μmol/kg tissue)f 
 venous blood VVc 5.9  liver CPROL 3000 
 richly perfused  VRc 4.1  small intestine CPROSi 774 
 slowly perfused VSc 51.7  Biochemical Parameters 
Cardiac output  
(L/h) a,b 
QC 310  Second order rate constant for chemical reaction 
with trans-2-hexenal (μM/h)g 
Blood flow to tissue (% cardiac output) a  GSH kGSH 5.8×10
-4 
   fat QFc 5.2  2ʹ-dG kDNA 1.6×10
-7 
liver (excluding 
portal vein fraction) 
QLc 14.1  Protein reaction sites 
in different tissues 
kPRO 5.8×10
-4 
a Brown et al. [16], bKrishnan and Andersen [23], cSweeney et al. [24], dAssimakopoulos et al. 
[25], ePotter and Tran [26], fPotter and Tran [22], gKiwamoto et al. [12] 
 
Equations to describe GSH levels in the liver or small intestine were integrated in the 
PBK/D model to examine the influence of trans-2-hexenal-induced depletion of GSH on the 
model outcomes. The GSH pools were divided into cytosolic and mitochondrial pools. Only the 
cytosolic GSH was used to scavenge trans-2-hexenal and was therefore subject to depletion upon 
exposure to trans-2-hexenal [13]. The reactions reflecting biosynthesis and degradation of GSH 
due to its regular cellular turnover were described by zero-order synthesis and first-order 
elimination as described elsewhere [13, 21, 26]. Ninety per cent of the synthesized GSH was 
directed to cytosol, while the rest (10 %) was directed to mitochondria as an input for the regular 
GSH turnover in the mitochondrial pool. The amount of Hex–PdG in the liver was described by 
second order formation and first-order elimination due to DNA repair. The half-life (T1/2) 38.5 h 
was used for DNA adducts elimination as described previously for the PBK/D model for 
trans-2-hexenal in rat [12]. 
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Sensitivity analysis 
To identify the key parameters that influence the model output, a sensitivity analysis was 
performed. Normalized sensitivity coefficients (SC) were determined according to the following 
equation: SC = (C′ − C)/(P′ − P) × (P/C), where C is the initial value of the model output, C′ is the 
modified value of the model output resulting from an increase in parameter value, P is the initial 
parameter value, and P′ is the modified parameter value [27-30]. Based on the literature [27], a 5 
% increase in parameter values was chosen to analyse the effect of a change in parameter on 
maximum levels of trans-2-hexenal DNA adducts (Hex–PdG) in liver at a dose relevant to the 
estimated average trans-2-hexenal dietary intake (0.04 mg/kg bw). Each parameter was analysed 
individually, keeping the other parameters to their initial values. 
 
Monte Carlo simulation 
To predict the impact of interindividual variability in the kinetic parameters for the various 
trans-2-hexenal detoxification reactions on DNA adduct formation in the liver in the human 
population, a total number of 10,000 simulations were performed, assuming that the variation 
observed in the 11 individuals is representative of the whole population [31, 32]. For each 
simulation, the Vmax, Km, and K values were randomly selected from a log-normal distribution that 
was defined by the kinetic parameters obtained from the 11 individuals. The Vmax, Km, and K 
values were observed to vary independently from each other. The mean μw and standard deviation 
σw describing the log-normal distribution of each parameter in the liver were derived from the 
mean μx and coefficient of variation of the non-ln-transformed data using the following equation 
[32, 33]: 
μw =  ln[μ / √(1+ CV
2) ]  and  σw 
2= ln(1+ CV
2) 
where CVχ is the coefficient of variation of the non-lntransformed Vmax, Km, and K values as 
observed with the 11 individual human subjects of the present study. For Km and Vmax values in 
the small intestine, mean μχ was set to the values obtained from the pooled human small intestine 
S9. Due to the limited availability of small intestine S9 from different individuals, the kinetic 
parameters in the small intestine were not determined for the different individual subjects. To 
calculate the standard deviation σw and the mean μw, the reactions in the small intestine were 
assumed to have the same coefficient of variation (CVχ) as those of the same reaction in the liver, 
which ranged between 0.24 and 0.78 (Table 3.3). These values are comparable or higher than 0.3, 
which is a value generally applied when no information on the coefficient of variation is available 
[34]. The equations of the model are presented as supporting information 3.3. 
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in the formation of both Hex–GSH stereoisomers was observed (data not shown). Further kinetic 
analysis of human GST-mediated formation of Hex–GSH therefore focused on the formation of 
both stereoisomers together. The trans-2-hexenal-concentration-dependent formation rate of Hex–
GSH mediated by liver GSTs showed no saturation and a linear increase with trans-2-hexenal 
concentrations up to 3,000 μM (supporting information 3.1C). The apparent first-order rate 
constant K for the formation rate of Hex–GSH depending on trans-2-hexenal concentrations was 
0.0071 ± 0.0006 ml/min/(mg S9 protein). In case of small intestine, the formation of Hex–GSH 
mediated by GST present in the human pooled small intestine S9 was fitted to the ping-pong 
model, which is a two-substrate Michaelis–Menten equation. The apparent Vmax and Km towards 
trans-2-hexenal were determined and are presented in Table 3.2. The apparent Km towards GSH 
was set at 100 μM based on literature, being a representative value obtained using various 
substrates [13, 14]. 
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Comparison of the catalytic efficiency of trans-2-hexenal detoxification pathways by humans 
and male rats 
Table 3.2 provides a comparison of the kinetic parameters for trans-2-hexenal detoxification by 
pooled human S9 fractions with those obtained with pooled male rat S9 fractions as reported 
previously [12]. To make the parameters comparable, the Vmax and K values expressed as 
nmol/min/(mg S9 protein) or ml/min/(mg S9 protein) were converted to nmol/min/(g tissue) or 
ml/min/(g tissue) using scaling factors as defined in the “Materials and methods” section. In the 
liver, interspecies differences were especially observed in trans-2-hexenal reduction and 
GST-mediated formation of Hex–GSH. The Km for reduction of trans-2-hexenal was 2.8-fold 
lower for human compared with rat, resulting in a 2.4-fold higher catalytic efficiency in reduction 
of trans-2-hexenal by human liver compared with rat liver. The GST-mediated formation of Hex–
GSH was linear with increasing concentrations of trans-2-hexenal up to 3,000 μM in human liver, 
but not in rat liver. Comparing the in vivo GST catalytic efficiency (Vmax/Km) for rat liver and the 
scaled K for human liver, the rat liver appeared to be ten-fold more efficient than human liver in 
catalyzing conjugation of trans-2-hexenal with GSH. In the small intestine, interspecies 
differences were mainly observed in GST mediated trans-2-hexenal conjugation with GSH and in 
reduction to 2-hexen-1-ol. The in vivo catalytic efficiency for Hex–GSH formation by human 
small intestine was 4.8-fold lower compared with rat intestine, mainly due to a 14 times lower 
Vmax for GSH conjugation by human small intestine. In case of reduction to 2-hexen-1-ol, the 
comparison of in vivo catalytic efficiencies revealed that whereas reduction of trans-2-hexenal 
was not observed in rat small intestine, this reaction was the most efficient detoxification pathway 
in human small intestine. 
 
Performance of the human PBK/D model 
To evaluate the performance of the human PBK/D model, the model outcomes need to be 
compared with relevant observed human data. Because there are no human in vivo data available 
on trans-2-hexenal kinetics or DNA adduct formation in the liver, human data for acrolein, a 
structurally related α,β-unsaturated aldehyde, were used for the evaluation [36]. In the in vivo 
study by Watzek et al., a male person was dosed with 7.5 μg/kg bw acrolein in drinking water. 
2-Propenal (acrolein) excretion in urine as mercapturic acids 
[N-acetyl-S-(3-hydroxypropyl)cysteine and N-acetyl-S-(carboxyethyl)cysteine] was quantified 
using liquid chromatography–tandem mass spectrometry (LC/MS/MS). The study reported 26 % 
of the administered acrolein to be excreted as mercapturic acids within 24 h. To allow comparison 
between the observed human in vivo data and the PBK/D model outcome, the amount of 
α,β-unsaturated aldehyde excreted in urine as mercapturic acids was considered to be equal to the 
amount of the α,β-unsaturated aldehyde conjugates with GSH in the liver or small intestine. The 
human PBK/D model predicted 30 % of the α,β-unsaturated aldehyde to conjugate with GSH at a 
dose level 0.13 μmol/kg bw (c.a. 7.5 μg 2-propenal/kg bw and 13 μg trans-2-hexenal/kg bw), 
which was only 1.1-fold higher than the observed level. 
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Sensitivity analysis 
A sensitivity analysis was performed to identify key parameters that determine the amount of 
trans-2-hexenal DNA adducts (Hex–PdG) in the liver at Tmax, the time when the maximum DNA 
adduct level is predicted to be reached after administration of trans-2-hexenal. Normalized SC 
were calculated for all parameters at a trans-2-hexenal dose of 0.04 mg/kg bw, which is a level 
corresponding to the estimated average human dietary intake. The parameters for which the 
sensitivity coefficient exceeded 0.1 in absolute value are presented as supporting information 3.4. 
The sensitivity analysis of the human model showed that the predicted level of Hex–PdG in the 
human liver was influenced significantly by the second-order rate constant for the reaction of 
trans-2-hexenal with 2′-dG. The parameters that determine the detoxification rate in the liver, 
namely Vmax and Km for oxidation and reduction, and the scaling factor of liver S9 also showed a
significant impact on the predicted Hex–PdG level. In addition, the kinetic parameters of 
reduction and conjugation of trans-2-hexenal with GSH in the human small intestine as well as 
the scaling factor of small intestine S9 were also found to be important determinants. 
 
The human PBK/D model predictions 
The human-PBK/D model-based predictions for metabolite formation in the liver and small 
intestine as percentage of the administered dose are presented in Figure 3.3A. The human model 
revealed that at 0.04 mg/kg bw, the estimated average human dietary intake, 50 % of the 
trans-2-hexenal is reduced to 2-hexen-1-ol. Twenty-nine per cent of the administered 
trans-2-hexenal was predicted to be conjugated with GSH, and 21 % to be oxidized to 2-hexenoic 
acid. Cytosolic GSH in the small intestine was predicted to be completely depleted at a dose of 4 
mg/kg bw and above. As a result, detoxification of trans-2-hexenal via GSH conjugation rapidly 
decreased compared to the other pathways at doses higher than 4 mg/kg bw. Of the administered 
dose of 0.04 mg/kg bw trans-2-hexenal, 58 % was detoxified in the small intestine before 
reaching the liver compartment (Figure 3.3B). The liver was shown to detoxify more than half of 
the administered trans-2-hexenal at doses higher than 5 mg/kg bw. Although there were some 
differences in the detoxification kinetics between human and rat, the predicted interspecies 
differences in the dose-dependent DNA adduct formation in the liver were limited (Figure 3.3C). 
Up to 163 mg/kg bw, the maximum DNA adduct formation in the human liver did not exceed 110 
adducts/108 nt, which is considered as natural background level of DNA adducts in the liver (see 
“Discussion” section). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. The human PBK/D model predictions. 
The PBK/D model-based predicted dose-dependent 
(A) formation of trans-2-hexenal metabolites in 
human presented as percentage of the administered 
dose 24 h after exposure, (B) contribution to 
trans-2-hexenal detoxification in human by the liver 
and small intestine, and (C) maximum formation of 
trans-2-hexenal DNA adducts (Hex-PdG) in the liver 
at Tmax in human (solid line) and in rat (dashed line), 
the latter taken from our previous work [12]. 
 
Interindividual variation in trans-2-hexenal detoxification and its influence on DNA adduct 
formation 
Table 3.3 shows the kinetic constants for detoxification of trans-2-hexenal via different metabolic 
routes as determined with incubations with liver S9 fractions of 11 individual human subjects. The 
in vivo catalytic efficiencies for trans-2-hexenal oxidation to 2-hexenoic acid and reduction to 
2-hexen-1-ol varied from 5.5 to 28.7 ml/min/(g liver) and from 2.4 to 36.1 ml/min/(g liver), 
respectively. The scaled apparent first order rate constant K for GST-mediated GSH conjugation 
in the liver varied between 1.01 and 2.68 ml/min/(g liver) for eight individuals, but the K of the 
remaining three individuals (H0291, H0297, and H0393) was remarkably lower. 
DNA adduct formation in the liver of the 11 individual human subjects upon oral 
exposure to trans-2-hexenal was estimated by replacing the Vmax, Km, and K values in the liver 
compartment of the PBK/D model with the parameters obtained using liver S9 of each individual 
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subject. Because kinetic parameters in small intestine were not determined for different individual 
subjects, the Vmax and Km values in the small intestine were kept to the values obtained using 
pooled human small intestine S9. At a trans-2-hexenal dose of 0.04 mg/kg bw, the estimated 
average human dietary intake, the maximum DNA adduct formation after oral exposure ranged 
from 0.007 to 0.033 adducts/108 nt within the 11 individuals (Table 3.3). These values are four 
orders of magnitude lower than natural background DNA adduct level found in disease-free 
human liver (6.8–110 adducts/108 nt) (see “Discussion” section). The maximum DNA adduct 
formation in the liver was also examined at a dose of 0.178 mg/kg bw, which represents the 95th 
percentile of the estimated daily intake of trans-2-hexenal for a human of 60 kg (Eder and Schuler 
2000) (Table 3.3). At this exposure level, the predicted maximum DNA adduct formation in the 
liver amounted to 0.032–0.147 adducts/108 nt among the 11 individuals and was thus shown to be 
still three orders of magnitude lower than natural background DNA adduct levels. Subsequently, 
Monte Carlo simulations were performed to investigate possible interindividual variation in 
trans-2-hexenal DNA adduct formation in the liver for the human population caused by 
interindividual variation in trans-2-hexenal detoxification efficiencies. The probability 
distributions used for these Monte Carlo simulations were derived from Vmax, Km, or K values of 
three detoxification pathways in the liver determined in this study. Figure 3.4 shows the results 
obtained from the Monte Carlo simulation at a dose of 0.04 and 0.178 mg trans-2-hexenal/kg bw. 
The 50th and 99th percentiles were 0.015 and 0.039 adducts/108 nt, respectively, at 0.04 mg/kg bw, 
and 0.065 and 0.18 adducts/108 nt, respectively, at 0.178 mg/kg bw.  
 
 
Figure 3.4. Results from Monte Carlo simulations predicting the frequency distribution of 
maximum Hex-PdG levels for the general population at trans-2-hexenal doses of 0.04 mg/kg bw 
(open circles) and 0.178 mg/kg bw (closed circles). The grey range indicates the natural 
background levels of exocyclic guanine adducts reported in disease-free human livers (6.8 to 110 
DNA adducts/108 nt). 
32620 Reiko Kiwamoto.indd   80 17-03-15   15:35
3A PBK/D model for trans-2-hexenal in human
81
 
80 
 
subject. Because kinetic parameters in small intestine were not determined for different individual 
subjects, the Vmax and Km values in the small intestine were kept to the values obtained using 
pooled human small intestine S9. At a trans-2-hexenal dose of 0.04 mg/kg bw, the estimated 
average human dietary intake, the maximum DNA adduct formation after oral exposure ranged 
from 0.007 to 0.033 adducts/108 nt within the 11 individuals (Table 3.3). These values are four 
orders of magnitude lower than natural background DNA adduct level found in disease-free 
human liver (6.8–110 adducts/108 nt) (see “Discussion” section). The maximum DNA adduct 
formation in the liver was also examined at a dose of 0.178 mg/kg bw, which represents the 95th 
percentile of the estimated daily intake of trans-2-hexenal for a human of 60 kg (Eder and Schuler 
2000) (Table 3.3). At this exposure level, the predicted maximum DNA adduct formation in the 
liver amounted to 0.032–0.147 adducts/108 nt among the 11 individuals and was thus shown to be 
still three orders of magnitude lower than natural background DNA adduct levels. Subsequently, 
Monte Carlo simulations were performed to investigate possible interindividual variation in 
trans-2-hexenal DNA adduct formation in the liver for the human population caused by 
interindividual variation in trans-2-hexenal detoxification efficiencies. The probability 
distributions used for these Monte Carlo simulations were derived from Vmax, Km, or K values of 
three detoxification pathways in the liver determined in this study. Figure 3.4 shows the results 
obtained from the Monte Carlo simulation at a dose of 0.04 and 0.178 mg trans-2-hexenal/kg bw. 
The 50th and 99th percentiles were 0.015 and 0.039 adducts/108 nt, respectively, at 0.04 mg/kg bw, 
and 0.065 and 0.18 adducts/108 nt, respectively, at 0.178 mg/kg bw.  
 
 
Figure 3.4. Results from Monte Carlo simulations predicting the frequency distribution of 
maximum Hex-PdG levels for the general population at trans-2-hexenal doses of 0.04 mg/kg bw 
(open circles) and 0.178 mg/kg bw (closed circles). The grey range indicates the natural 
background levels of exocyclic guanine adducts reported in disease-free human livers (6.8 to 110 
DNA adducts/108 nt). 
81
 
 
T
ab
le
 3
.3
 K
in
et
ic
 v
al
ue
s 
of
 f
or
m
at
io
n 
of
 2
-h
ex
en
oi
c 
ac
id
, 2
-h
ex
en
-1
-o
l a
nd
 H
ex
-G
SH
 in
 h
um
an
 in
di
vi
du
al
 in
 th
e 
li
ve
r 
1
 
C
od
e 
A
ge
 
G
en
de
r 
2-
he
xe
no
ic
 a
ci
d 
 
2-
he
xe
n-
1-
ol
 
 
H
ex
-G
S
H
 
 
P
re
di
ct
ed
 D
N
A
 a
dd
uc
t l
ev
el
  
at
 T
m
ax
 
K
m
 
(μ
M
) 
V
m
ax
 
(n
m
ol
/m
in
/m
g 
S
9 
pr
ot
ei
n)
 
C
E
 
(m
l/
m
in
/
g 
ti
ss
ue
)a
,b
 
 
K
m
 
(μ
M
) 
V
m
ax
 
(n
m
ol
/m
in
/m
g 
S
9 
pr
ot
ei
n)
 
C
E
 
(m
l/
m
in
/
g 
ti
ss
ue
) 
a,
b  
 
K
 
(m
l/
m
in
/m
g 
S
9 
pr
ot
ei
n)
 
S
ca
le
d 
K
 
(m
l/
m
in
/g
 
li
ve
r)
b  
 
0.
04
 m
g/
kg
 
bw
 
 (
/1
08
 n
t)
c  
0.
17
8 
m
g/
kg
 
bw
 
(/
10
8  
nt
)c
 
H
04
28
d  
57
 
F
 
10
6 
14
.4
 
19
.3
 
 
23
1 
58
.3
 
36
.1
 
 
0.
01
5 
2.
17
 
 
0.
00
7 
0.
03
2 
H
04
22
 
69
 
M
 
79
 
8.
8 
15
.9
 
 
27
4 
27
.4
 
14
.3
 
 
0.
01
2 
1.
70
 
 
0.
00
9 
0.
03
8 
H
02
97
 
4 
F
 
69
 
13
.8
 
28
.7
 
 
23
2 
13
.3
 
8.
2 
 
<
0.
00
6 
<
0.
86
 
 
0.
01
1 
0.
05
0 
H
02
80
d  
36
 
F
 
78
 
10
.8
 
19
.8
 
 
34
8 
31
.8
 
13
.1
 
 
0.
01
9 
2.
68
 
 
0.
01
2 
0.
05
1 
H
04
32
 
60
 
M
 
14
5 
8.
1 
8.
0 
 
14
7 
25
.5
 
24
.8
 
 
0.
00
9 
1.
34
 
 
0.
01
2 
0.
05
4 
H
03
93
 
30
 
F
 
99
 
11
.8
 
17
.2
 
 
32
0 
30
.0
 
13
.4
 
 
<
0.
00
6 
<
0.
86
 
 
0.
01
3 
0.
06
0 
H
03
11
d  
21
 
M
 
10
1 
11
.2
 
15
.8
 
 
41
8 
28
.4
 
9.
7 
 
0.
01
5 
2.
13
 
 
0.
01
5 
0.
06
6 
H
02
36
 
17
 
M
 
12
0 
9.
1 
10
.9
 
 
22
3 
20
.5
 
13
.1
 
 
0.
00
8 
1.
13
 
 
0.
01
6 
0.
07
2 
H
02
91
d  
18
 
F
 
10
1 
7.
0 
9.
9 
 
16
1 
10
.2
 
9.
1 
 
<
0.
00
6 
<
0.
86
 
 
0.
02
1 
0.
09
5 
H
03
22
 
1 
M
 
24
1 
9.
3 
5.
5 
 
13
7 
10
.6
 
11
.1
 
 
0.
00
7 
1.
01
 
 
0.
02
3 
0.
10
3 
H
04
20
d  
42
 
M
 
12
2 
7.
5 
8.
8 
 
56
4 
9.
4 
2.
4 
 
0.
00
7 
1.
02
 
 
 0
.0
33
 
0.
14
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
ea
n±
S
D
 
n.
a.
f  
n.
a.
 
11
5±
47
 
10
.2
±2
.5
 
14
.5
±6
.7
 
 
27
8±
12
9 
24
.1
±1
4.
2 
14
.1
±9
.1
 
 
0.
00
8±
0.
00
7c
 
1.
2±
0.
9c
 
 
n.
a.
 
n.
a.
 
C
V
e  (
%
) 
n.
a.
 
n.
a.
 
41
.2
 
24
.2
 
46
.4
 
 
46
.4
 
58
.9
 
64
.4
 
 
77
.7
 
77
.7
 
 
n.
a.
 
n.
a.
 
a I
n 
vi
vo
 c
at
al
yt
ic
 e
ff
ic
ie
nc
ie
s 
(s
ca
le
d 
V
m
ax
/K
m
).
 b
V
m
ax
 o
r 
K
 o
bt
ai
ne
d 
w
as
 s
ca
le
d 
to
 n
m
ol
/m
in
/g
 l
iv
er
 o
r 
m
l/m
in
/g
 l
iv
er
 u
si
ng
 s
ca
li
ng
 f
ac
to
r 
of
 1
43
 m
g 
, 
2
 
S9
 p
ro
te
in
/g
 l
iv
er
. 
c C
al
cu
la
te
d 
as
su
m
in
g 
th
e 
K
 o
f 
H
02
97
, 
H
03
93
 a
nd
 H
02
91
 w
er
e 
0,
  
d R
ec
en
t 
sm
ok
er
s,
  
e c
oe
ff
ic
ie
nt
 o
f 
va
ri
at
io
n,
 f
n.
a.
 =
 n
ot
 
3
 
ap
pl
ic
ab
le
 
4
 
32620 Reiko Kiwamoto.indd   81 17-03-15   15:35
Chapter 3
82
 
82 
 
DISCUSSION 
 
In the present study, detoxification and subsequent DNA adduct formation in the liver upon oral 
exposure to trans-2-hexenal, a prominent α,β-unsaturated aldehyde in food, at realistic dietary 
exposure levels were examined by developing a human PBK/D model. The structure of the human 
model was based on the rat trans-2-hexenal PBK/D model, which was previously developed [12]. 
The parameters for the human PBK/D model were derived from literature or in vitro experiments 
using human tissue fractions. The model predicted that 30 % of the administered trans-2-hexenal 
conjugates to GSH at a dose of 0.13 μmol/kg bw, which was only 1.1-fold higher than the in vivo 
data obtained from a human exposed to acrolein, a related α,β-unsaturated aldehyde. This result 
indicates that the human model captured the critical kinetics of trans-2-hexenal adequately at the 
examined level of exposure.  
To investigate the relative importance of DNA adduct formation due to trans-2-hexenal 
exposure, a comparison can be made to natural background DNA adduct levels that is 
continuously present in the human body as a consequence of endogenous processes and oxidative 
stress [37, 38]. Lower DNA adduct levels than relevant endogenous levels may suggest a limited 
genotoxicity risk of a xenobiotic, trans-2-hexenal in this case. Caution should, however, be taken 
when performing such a comparison because the ultimate cancer risk depends on the mutagenic 
potential of the DNA adduct, which may not necessarily be the same for xenobiotics of interest 
and endogenous compounds [39]. In case of trans-2-hexenal, a set of two diastereomers of 
exocyclic guanine adducts (Hex–PdG) in rat [10, 11] are formed that are structurally similar to the 
exocyclic guanine adducts formed by crotonaldehyde and malondialdehyde, which are 
endogenous metabolites formed upon lipid peroxidation [37, 38]. The background level of 
crotonaldehyde adducts has previously been reported to amount to 0.27–1.37 μmol/mol guanine 
(i.e. 6.8–34.3 adducts/108 nt) [38], and that of malondialdehyde adducts to 50–110 adducts/108 nt 
in disease-free human liver [37]. Based on these studies, the natural background levels of 
exocyclic guanine adducts can be estimated to range from 6.8 to 110 adducts/108 nt. The human 
PBK/D model predicted a maximum DNA adduct formation in the liver of 0.008 and 0.034 
adducts/108 nt at doses of 0.04 and 0.178 mg/kg bw, respectively. These two doses correspond to 
the 50th and the 95th percentile daily intakes of trans-2-hexenal from our diet for a 60-kg person 
[40]. Furthermore, the impact of interindividual variation in trans-2-hexenal detoxification kinetic 
parameters on DNA adduct formation was examined by measuring liver kinetic parameters in 11 
individual human subjects. To generate a general population distribution in DNA adduct 
formation, the Monte Carlo simulation approach was used, assuming that the variation observed 
with these 11 individuals represents the variation in the human population. Among the most 
sensitive people (the 99th percentile of the population), DNA adduct formation was simulated to 
be up to 0.18 adducts/108 nt at 0.178 mg/kg bw. These results indicate that even in a person whose 
trans-2-hexenal detoxification efficiency is at the lowest percentile of the population, dietary 
 
exposure to trans-2-hexenal at the current levels of intake does not increase DNA adduct levels in 
human liver by more than 3 % (6.98 compared to 6.80 adducts/108 nt) from the natural 
background levels. 
The Monte Carlo simulations showed that these most sensitive persons displayed low 
catalytic efficiencies especially in the reduction of trans-2-hexenal in the liver, GST-catalysed 
conjugation with GSH in the small intestine, and oxidation in the liver compared to the average 
population (32, 44, and 49 % of the average population, respectively). The catalytic efficiencies of 
the other reactions remained between 62 and 94 % of those of the average population. This 
observation suggests that interindividual variation in trans-2-hexenal reduction in the liver may 
play the most important role in trans-2-hexenal detoxification, especially when low efficiency in 
the reduction is not compensated by high GST-mediated GSH conjugation or by oxidation.  
Overall, when DNA adduct levels are predicted, it is important to take any uncertainties 
in the model into consideration. For example, the kinetic parameters were derived in vitro using 
saturated concentrations of cofactors, and this might result in underestimation in the formation of 
DNA adducts. On the other hand, the choices of other parameters such as a long half-life of 
trans-2-hexenal DNA adducts might have led to overestimation of DNA adduct levels in the liver 
[12]. Also, trans-2-hexenal reacts with protein thiol groups in the food component present in 
human gastrointestinal mucosa and thus may only partly be absorbed in vivo, while the human 
model assumed complete and swift absorption of administered trans-2-hexenal. If an uncertainty 
factor of 10 would be applied to account for such uncertainties in the extrapolation of in silico to 
the in vivo situation, the formation of DNA adducts due to trans-2-hexenal exposure would be 1.8 
instead of 0.18 at 0.178 mg/kg bw in the most sensitive people, which is still lower than the 
natural background DNA adduct levels. 
Altogether, the present study elucidates a possible negligible risk upon oral exposure to 
trans-2-hexenal at realistic dietary exposure levels for the human general population including 
individuals whose trans-2-hexenal detoxification efficiencies are low. Furthermore, the present 
study provides a proof of principle for the use of a PBK/D model to predict DNA adduct 
formation in an individual or the population as a whole. 
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SUPPORTING INFORMATION 
 
Supporting Information 3.1.  trans-2-Hexenal concentration-dependent formation rate of 
metabolites by human tissue fractions. The formation rate of 2-hexenoic acid (A),  2-hexen-1-ol 
(B), and GST mediated formation rate of Hex-GSH (C) in human liver (closed circles, solid lines) 
and small intestine (open circles, dashed lines). 
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Supporting Information 3.2. Human PBK/D model equations.  
  
(1) Uptake from GI cavity   
The uptake of trans-2-hexenal from the intestinal cavity into the small intestine compartment  was 
described by a first-order process as follows:   
dAGI/dt =-Ka*AGI   
InitAGI = DOSE    
where   
AGI  Amount of trans-2-hexenal remaining in GI cavity (μmol)   
Ka  Linear uptake rate (/h)   
DOSE  Amount of trans-2-hexenal administered in a rat (μmol).   
  
(2) Slowly perfused tissue, richly perfused tissue and fat   
Amount trans-2-hexenal in slowly perfused tissue, richly perfused tissue or fat compartment was described 
as follows:    
dATi/dt = QTi*(CA-CVTi)   
CTi = ATi/VTi   
CVTi = CTi/PTi    
where  
ATi  Amount of trans-2-hexenal in a tissue (μmol)  
QTi  Blood flow into a tissue (L/h)   
CA  Concentration of trans-2-hexenal in arterial blood perfusing a tissue (μmol/L)   
CVTi  Concentration of trans-2-hexenal in venous blood leaving a tissue (μmol/L)   
CTi  Concentration of trans-2-hexenal in a tissue (μmol/kg)  
VTi  Volume of a tissue (kg)   
PTi  Tissue/blood partition coefficient of trans-2-hexenal  
  
(3) Liver   
Amount trans-2-hexenal in the liver (AL, μmol) is described as follows:    
dAL/dt   
= QL*CA +QSi*CVSi - (QL+QSi) *CVL- (eq.1 + eq.2 + eq.3 + eq.4 + eq.5+ eq.6)   
CL = AL/VL   
CVL = CL/PL    
where  
QL   Blood flow into the liver (L/h)   
QSi  Blood flow into the small intestine (L/h)   
CVSi  Concentration of trans-2-hexenal in venous blood leaving the small intestine  (μmol/L)   
CVL  Concentration of trans-2-hexenal in venous blood leaving the liver (μmol/L)   
CL   Concentration of trans-2-hexenal in the liver (μmol/L)   
PL   Liver/blood partition coefficient of trans-2-hexenal  
 
Amount trans-2-hexenal oxidized to 2-hexenoic acid enzymatically in the liver (AMLHA, μmol) is 
described to follow Michaelis-Menten equation:   
dAMLHA/dt = Vsmax, L_HA * CVL / (Km,L_HA + CVL)  ---------------- eq. 1   
where 
Vsmax,L_HA  Scaled Vmax for enzymatic oxidation of trans-2-hexenal in the liver (μmol/h)   
Km, L_HA  Km for enzymatic oxidation of trans-2-hexenal in the liver (μM)   
 
Amount trans-2-hexenal reduced to 2-hexen-1-ol in the liver (AMLHO, μmol) is described to  follow 
Michaelis-Menten-equation:    
dAMLHO/dt = Vsmax, L_HO*CVL/(Km,L_HO + CVL)    ---------------- eq. 2    
where   
Vsmax,L_HO  Scaled Vmax for enzymatic reduction of trans-2-hexenal in the liver (μmol/h)   
Km,L_HO  Km for enzymatic reduction of trans-2-hexenal in the liver (μM)   
 
Amount trans-2-hexenal metabolized in liver to GSH conjugation by GSTs (AMLHGGST, μmol) is 
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described as following :  
dAMLHGGST/dt =  Ks*CVL     ---------------- eq.3   
where   
Ks  Scaled first order rate constant derived in this study for enzymatic conjugation of 2-hexanl with 
GSH in the liver (μM)   
  
Amount trans-2-hexenal chemically bound in liver to GSH (AMLHGchem, μmol) is described as following:   
 dAMLHGchem/dt = kGSH*CVL*CGSHLC*VL    ---------------- eq.4    
where   
kGSH  Second order rate constant of trans-2-hexenal binding to GSH (/μmol/h)   
VL   Volume of the liver (kg)  
CGSHLC Concentration of GSH in the liver cytosol (μmol/kg liver) 
  
Amount trans-2-hexenal protein adducts in the liver (AMLHP, μmol) is described as following:   
dAMLHP/dt = kPRO*CVL*CPROL*VL     ---------------- eq.5  
where   
kPRO  Second order rate constant of trans-2-hexenal binding to protein reaction sites in a tissue 
(/μmol/h)   
CPROL  Concentration of protein reaction sites in the liver (μmol/kg liver)   
  
The formation of DNA adduct (Hex-PdG) in the liver (AMLHPform) was described as following:  
dAMLHPform/dt = kDNA*CVL*CdGL*VL    ---------------- eq.6   
where  
kDNA   Second order rate constant of trans-2-hexenal binding to 2ʹ-dG (/μmol/h)   
CdGL   Concentration of 2ʹ-dG in the liver (μmol/kg liver)   
 
CdGL was caluculated to be 1.36 μmol/kg liver using the average molecular weight of  nucleotides (330 
g/mol) and reported concentration of DNA in a rat liver (1.8 g/kg liver).  
 
Amount of DNA adduct (Hex-PdG) in liver (AMLHP, μmol) is described by subtracting elimination of 
DNA adduct from the formation:    
dAMLHP/dt= eq.6- AMLHP* (ln2/ T1/2)    
where  
T1/2   Half-life of Hex-PdG in the liver (h)    
 
Amount of GSH present in the liver cytosol (AMGSHLC, μmol) is described by zero-order  synthesis and 
reduction by first-order elimination due to turnover and depletion by trans-2-hexenal:   
d AMGSHLC = GSYNL*VL*0.9 - (eq.3 + eq.4+ kL_GLOS* AMGSHLC) ---------------- eq.7   
Init AMGSHLC = InitGSHL *VL*0.9   
CGSHLC = AMLcGSH/VL   
where  
GSYNL  Rate of GSH synthesis in the liver (μmol/h)   
kL_GLOS  First-order rate of GSH turnover in the liver (/h)   
InitGSHL  Initial concentration of GSH in the liver (μmol/kg liver)  
 
When eq.7 gave negative values, the value zero was used as the amount of GSH in the liver cytosol.  
  
(4) Small intestine   
The amount trans-2-hexenal in small intestine tissue, (ASi, μmol) is described as follows:    
dASi/dt = QSi*(CA -CVSi) + Ka*AGI - (eq.8 + eq.9 + eq.10 + eq.11+eq.12)   
CSi = ASi/VSi  
CVSi = CSi/PSi  
where   
CSi  Concentration of trans-2-hexenal in the small intestine (μmol/L)   
VSi  Volume of the small intestine (kg)   
PSi  Small intestine/blood partition coefficient of trans-2-hexenal  
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Amount trans-2-hexenal enzymatically oxidized 2-hexenoic acid (AMSiHA, μmol) in the small intestine is 
described by Michaelis-Menten equation:   
dAMSiHA/dt = Vsmax,Si_HA*CVSi/(Km, Si_HA + CVSi)   ---------------- eq.8 
where   
Vsmax,Si_HA  Scaled Vmax for enzymatic oxidation of trans-2-hexenal in the small intestine  (μmol/h)   
Km, Si_HA  Km for enzymatic oxidation of trans-2-hexenal in small intestine (μM).   
  
Amount trans-2-hexenal reduced to 2-hexen-1-ol in the small intestine (AMSiHO, μmol) is described to  
follow Michaelis-Menten-equation:    
dAMLHO/dt = Vsmax, Si_HO*CVSi/(Km,Si_HO + CVSi)   ---------------- eq. 9  
where   
Vsmax,Si_HO  Scaled Vmax for enzymatic reduction of trans-2-hexenal in the small intestine (μmol/h)   
Km,Si_HO  Km for enzymatic reduction of trans-2-hexenal in the small intestine (μM)   
 
Amount trans-2-hexenal metabolized in the small intestine to GSH conjugation by GST  (AMSiHGGST, 
μmol) is described by a two substrate ping-pong model:    
dAMSiHGGST/dt =   
Vsmax, Si_GST * CVSi * CGSHSiC /   
(Km,Si_GST_G*CVSi + Km,Si_GST_H* CGSHSiC + CGSHSiC *CVSi )     --------------- eq.10   
where  
Vsmax, Si_GST  Scaled Vmax for enzymatic conjugation of trans-2-hexenal in the small intestine (μmol/h)  
CGSHSiC  Concentration of GSH in the small intestine cytosol (μmol/kg)   
Km, Si_GST_H  Km toward trans-2-hexenal for enzymatic conjugation of trans-2-hexenal in the small 
intestine (μM)   
Km, Si_GST_G  Km toward GSH for enzymatic conjugation of trans-2-hexenal in the small intestine (μM)   
 
Amount trans-2-hexenal chemically bound in the small intestine to GSH (AMSiHGchem, μmol) is described 
as following:   
dAMSiHGchem/dt = kGSH*CVSi* CGSHSiC *VSi    --------------- eq.11   
where  
kGSH  First order rate constant of trans-2-hexenal binding to GSH (/μmol/h)   
VSi  Volume of the small intestine (kg)   
  
Amount trans-2-hexenal chemically bound to protein reaction sites in the small intestine  (AMSiHP, 
μmol) is described as following:    
dAMSiHP/dt = kPRO*CVSi*CPROSi*VSi    --------------- eq.12   
where  
kPRO  First order rate constant of trans-2-hexenal binding to protein reaction sites in a tissue 
(/μmol/h)   
CPROSi  Concentration of protein reaction sites in the liver (μmol/kg liver)  
 
Amount of GSH present in the small intestine cytosol (AMGSHSiC, μmol) is described in the same way as 
in the liver (eq 10):   
dAMGSHSiC = GSYNSi *VSi*0.9- (eq.10 + eq.11+ kGLOS_Si*AMGSHSiC) --------------- eq.13   
Init AMGSHSiC = InitGSHSi *VSi*0.9  
CGSHSiC = AMSicGSH/VSi   
where   
GSYNSi  Rate of GSH synthesis in the small intestine (μmol/h)   
kGLOS_Si  First-order rate of GSH turnover in the small intestine (/h)   
InitGSHSi  Initial concentration of GSH in the small intestine (μmol/kg liver)   
  
As was the case in the liver, the value zero was used as the amount of GSH in the small  intestine cytosol 
when eq.13 gave negative values.   
  
(5) Venous blood and arterial blood   
Concentration of trans-2-hexenal in venous blood (CV) and in arterial blood (CA, both in μmol/L) was 
described as follows:   
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described as following :  
dAMLHGGST/dt =  Ks*CVL     ---------------- eq.3   
where   
Ks  Scaled first order rate constant derived in this study for enzymatic conjugation of 2-hexanl with 
GSH in the liver (μM)   
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CdGL was caluculated to be 1.36 μmol/kg liver using the average molecular weight of  nucleotides (330 
g/mol) and reported concentration of DNA in a rat liver (1.8 g/kg liver).  
 
Amount of DNA adduct (Hex-PdG) in liver (AMLHP, μmol) is described by subtracting elimination of 
DNA adduct from the formation:    
dAMLHP/dt= eq.6- AMLHP* (ln2/ T1/2)    
where  
T1/2   Half-life of Hex-PdG in the liver (h)    
 
Amount of GSH present in the liver cytosol (AMGSHLC, μmol) is described by zero-order  synthesis and 
reduction by first-order elimination due to turnover and depletion by trans-2-hexenal:   
d AMGSHLC = GSYNL*VL*0.9 - (eq.3 + eq.4+ kL_GLOS* AMGSHLC) ---------------- eq.7   
Init AMGSHLC = InitGSHL *VL*0.9   
CGSHLC = AMLcGSH/VL   
where  
GSYNL  Rate of GSH synthesis in the liver (μmol/h)   
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Amount trans-2-hexenal enzymatically oxidized 2-hexenoic acid (AMSiHA, μmol) in the small intestine is 
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Km, Si_GST_G  Km toward GSH for enzymatic conjugation of trans-2-hexenal in the small intestine (μM)   
 
Amount trans-2-hexenal chemically bound in the small intestine to GSH (AMSiHGchem, μmol) is described 
as following:   
dAMSiHGchem/dt = kGSH*CVSi* CGSHSiC *VSi    --------------- eq.11   
where  
kGSH  First order rate constant of trans-2-hexenal binding to GSH (/μmol/h)   
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Amount trans-2-hexenal chemically bound to protein reaction sites in the small intestine  (AMSiHP, 
μmol) is described as following:    
dAMSiHP/dt = kPRO*CVSi*CPROSi*VSi    --------------- eq.12   
where  
kPRO  First order rate constant of trans-2-hexenal binding to protein reaction sites in a tissue 
(/μmol/h)   
CPROSi  Concentration of protein reaction sites in the liver (μmol/kg liver)  
 
Amount of GSH present in the small intestine cytosol (AMGSHSiC, μmol) is described in the same way as 
in the liver (eq 10):   
dAMGSHSiC = GSYNSi *VSi*0.9- (eq.10 + eq.11+ kGLOS_Si*AMGSHSiC) --------------- eq.13   
Init AMGSHSiC = InitGSHSi *VSi*0.9  
CGSHSiC = AMSicGSH/VSi   
where   
GSYNSi  Rate of GSH synthesis in the small intestine (μmol/h)   
kGLOS_Si  First-order rate of GSH turnover in the small intestine (/h)   
InitGSHSi  Initial concentration of GSH in the small intestine (μmol/kg liver)   
  
As was the case in the liver, the value zero was used as the amount of GSH in the small  intestine cytosol 
when eq.13 gave negative values.   
  
(5) Venous blood and arterial blood   
Concentration of trans-2-hexenal in venous blood (CV) and in arterial blood (CA, both in μmol/L) was 
described as follows:   
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dAV/dt = QF*CVF + (QL+QSi)*CVL + QR*CVR + QS*CVS - QC*CV   
CV = AV/(AV+VV)   
CV = CA   
where  
AV  Amount of trans-2-hexenal in venous blood (μmol)  
QF  Blood flow into fat (L/h)   
CVF  Concentration of trans-2-hexenal in venous blood leaving fat (μmol/L)   
QR  Blood flow into richly perfused tissue (L/h)   
CVR  Concentration of trans-2-hexenal in venous blood leaving richly perfused tissue  (μmol/L)   
QS  Blood flow into slowly perfused tissue (L/h)   
CVS  Concentration of trans-2-hexenal in venous blood leaving slowly perfused tissue (μmol/L)  
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Supporting Information 3.3. Equations added to the human PBK/D model to perform Monte Carlo 
simulations. 
The following equations were added to the equation 1 of supporting information 3.1 to perform 
Monte Carlo simulations:  
Vsmax,L_HA =  init (exp(normal(μw(Vmax,L_HA), σw(Vmax,L_HA)) 
Km,L_HA= init (exp(normal(μw(Km,L_HA), σw(Km,L_HA)) 
where Vsmax,L_HA  and Km,L_HA are scaled Vmax and Km for trans-2-hexenal oxidation in the liver, 
respectively. The same equations were added to the equation 2, 3, 8, 9 and 10 of the human 
PBK/D model in order to perform Monte Carlo simulations for Vsmax, Km and Ks values of 
trans-2-hexenal oxidation in the small intestine, and trans-2-hexenal reduction and GST mediated 
conjugation to GSH in the liver and the small intestine.  
 
  
Supporting Information 3.4. Sensitivity analysis of the predicted amount of Hex-PdG in the liver 
to different model parameters at Tmax to 0.04 mg trans-2-hexenal/kg bw.  
The parameters listed in the figures are the following: body weight (BW); fraction of the liver 
(VLc) and the small intestine (VSic); blood flow rate (QC); fraction of the blood flow to the small 
intestine (QSic); scaling factor of  liver S9 (S9PL); Vmax and Km in the liver to form 2-hexenoic 
acid (HA) or 2-hexen-1-ol (HO); scaling factor of small intestine S9 (S9PSi); Vmax and Km in the 
small intestine to form 2-hexen-1-ol (HO) or Hex-GSH; Km toward trans-2-hexenal in the small 
intestine to form Hex-GSH (Km, Si_GST_H);  and second-order rate constant of trans-2-hexenal 
binding to 2ʹ-dG (kDNA) 
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ABSTRACT  
 
Acyclic α,β-unsaturated aldehydes present in food raise a concern because the α,β-unsaturated 
aldehyde moiety is considered a structural alert for genotoxicity. However, controversy remains 
on whether in vivo at realistic dietary exposure DNA adduct formation is significant. The aim of 
the present study was to develop physiologically based kinetic/dynamic (PBK/D) models to 
examine dose-dependent detoxification and DNA adduct formation of a group of 18 food-borne 
acyclic α,β-unsaturated aldehydes without 2- or 3-alkylation, and with no more than one 
conjugated double bond. Parameters for the PBK/D models were obtained using quantitative 
structure–activity relationships (QSARs) defined with a training set of six selected aldehydes. 
Using the QSARs, PBK/D models for the other 12 aldehydes were defined. Results revealed that 
DNA adduct formation in the liver increases with decreasing bulkiness of the molecule especially 
due to less efficient detoxification. 2-Propenal (acrolein) was identified to induce the highest DNA 
adduct levels. At realistic dietary intake, the predicted DNA adduct levels for all aldehydes were 
two orders of magnitude lower than endogenous background levels observed in disease free 
human liver, suggesting that for all 18 aldehydes DNA adduct formation is negligible at the 
relevant levels of dietary intake. The present study provides a proof of principle for the use of 
QSAR-based PBK/D modelling to facilitate group evaluations and read-across in risk assessment. 
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INTRODUCTION 
 
A number of acyclic α,β-unsaturated aldehydes are present in different foods and beverages of 
plant origin as natural constituents. For instance, trans-2-hexenal can be found in banana, 
trans-2-cis-6-nonadienal in cucumber [1], and trans-2-octenal in orange oil [2] Due to their 
unique odour, many of such aldehydes are used as food flavouring agents. However, their 
α,β-unsaturated aldehyde moiety is considered a structural alert for genotoxicity raising a food 
safety concern [3]. In 2007, the European Food Safety Authority (EFSA) launched a risk 
assessment of 347 flavouring substances being α,β-unsaturated aldehydes or ketones and 
precursors which give rise to such carbonyl substances [3]. EFSA considered that there is a need 
for additional information on most of the substances, including especially in vivo genotoxicity 
data, before conclusions can be reached [3]. As a result, in EU the use of many acyclic 
α,β-unsaturated aldehydes as food flavouring agents has been suspended under Regulation (EC) 
No. 1334/2008. 
Numerous in vitro studies have shown the genotoxic and mutagenic potency of acyclic 
α,β-unsaturated aldehydes [4-6], but these in vitro models do not account for possible 
detoxification occurring in vivo. The aldehyde group (–CHO) present in the α,β-unsaturated 
aldehyde moiety can be oxidised to a carboxylic acid group (–COOH) by aldehyde 
dehydrogenases (ALDHs) [7, 8], or reduced to a hydroxyl group (–OH) by aldose reductases 
(ARs) [9]. In addition, α,β-unsaturated aldehydes react spontaneously with glutathione (GSH) 
forming GSH conjugates, which are no longer electrophilic, and this conjugation is enhanced by 
glutathione S-transferases (GSTs) [10, 11]. In 2008, the Expert Panel of the Flavor and Extract 
Manufacturers Association (FEMA) concluded the use of α,β-unsaturated aldehydes as food 
flavouring agents to be safe based on the low level of use as well as the possible rapid 
detoxification of the substances in vivo [12]. The question that remains to be answered is whether 
detoxification is indeed sufficient to prevent significant DNA adduct formation of acyclic 
α,β-unsaturated aldehydes in vivo. Using trans-2-hexenal as model compound, we have 
previously shown that physiologically based kinetic/dynamic (PBK/D) modelling gives insights in 
detoxification and DNA adduct formation of α,β-unsaturated aldehydes in vivo [13, 14]. The 
PBK/D models for trans-2-hexenal for rat and human revealed that DNA adduct formation in the 
liver due to intake of trans-2-hexenal at human dietary exposure levels would be three to six 
orders of magnitude lower than the natural background levels of structurally similar 
1,N2-exocyclic propanodeoxyguanosine adducts in disease free human liver. Based on this 
observation we concluded that at realistic dietary exposure levels the DNA adduct formation may 
be negligible [13, 14]. trans-2-Hexenal is, however, only one of the many α,β-unsaturated 
aldehydes present in diet and it remains unknown whether the results would be similar for the 
other acyclic α,β-unsaturated aldehydes. Detoxification and DNA binding efficiencies may be 
different depending on the molecular structure [4, 8, 10, 15]. The aim of the present study is to 
32620 Reiko Kiwamoto.indd   94 17-03-15   15:35
4An integrated QSAR-PBK/D modelling approach for 18 foor-borne α,β-unsaturated aldehydes
95
QSAR-PBK/D modelling approach for 18 acyclic α,β-unsaturated aldehydes 
 
94 
 
ABSTRACT  
 
Acyclic α,β-unsaturated aldehydes present in food raise a concern because the α,β-unsaturated 
aldehyde moiety is considered a structural alert for genotoxicity. However, controversy remains 
on whether in vivo at realistic dietary exposure DNA adduct formation is significant. The aim of 
the present study was to develop physiologically based kinetic/dynamic (PBK/D) models to 
examine dose-dependent detoxification and DNA adduct formation of a group of 18 food-borne 
acyclic α,β-unsaturated aldehydes without 2- or 3-alkylation, and with no more than one 
conjugated double bond. Parameters for the PBK/D models were obtained using quantitative 
structure–activity relationships (QSARs) defined with a training set of six selected aldehydes. 
Using the QSARs, PBK/D models for the other 12 aldehydes were defined. Results revealed that 
DNA adduct formation in the liver increases with decreasing bulkiness of the molecule especially 
due to less efficient detoxification. 2-Propenal (acrolein) was identified to induce the highest DNA 
adduct levels. At realistic dietary intake, the predicted DNA adduct levels for all aldehydes were 
two orders of magnitude lower than endogenous background levels observed in disease free 
human liver, suggesting that for all 18 aldehydes DNA adduct formation is negligible at the 
relevant levels of dietary intake. The present study provides a proof of principle for the use of 
QSAR-based PBK/D modelling to facilitate group evaluations and read-across in risk assessment. 
  
QSAR-PBK/D modelling approach for 18 acyclic α,β-unsaturated aldehydes 
 
95 
 
INTRODUCTION 
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Numerous in vitro studies have shown the genotoxic and mutagenic potency of acyclic 
α,β-unsaturated aldehydes [4-6], but these in vitro models do not account for possible 
detoxification occurring in vivo. The aldehyde group (–CHO) present in the α,β-unsaturated 
aldehyde moiety can be oxidised to a carboxylic acid group (–COOH) by aldehyde 
dehydrogenases (ALDHs) [7, 8], or reduced to a hydroxyl group (–OH) by aldose reductases 
(ARs) [9]. In addition, α,β-unsaturated aldehydes react spontaneously with glutathione (GSH) 
forming GSH conjugates, which are no longer electrophilic, and this conjugation is enhanced by 
glutathione S-transferases (GSTs) [10, 11]. In 2008, the Expert Panel of the Flavor and Extract 
Manufacturers Association (FEMA) concluded the use of α,β-unsaturated aldehydes as food 
flavouring agents to be safe based on the low level of use as well as the possible rapid 
detoxification of the substances in vivo [12]. The question that remains to be answered is whether 
detoxification is indeed sufficient to prevent significant DNA adduct formation of acyclic 
α,β-unsaturated aldehydes in vivo. Using trans-2-hexenal as model compound, we have 
previously shown that physiologically based kinetic/dynamic (PBK/D) modelling gives insights in 
detoxification and DNA adduct formation of α,β-unsaturated aldehydes in vivo [13, 14]. The 
PBK/D models for trans-2-hexenal for rat and human revealed that DNA adduct formation in the 
liver due to intake of trans-2-hexenal at human dietary exposure levels would be three to six 
orders of magnitude lower than the natural background levels of structurally similar 
1,N2-exocyclic propanodeoxyguanosine adducts in disease free human liver. Based on this 
observation we concluded that at realistic dietary exposure levels the DNA adduct formation may 
be negligible [13, 14]. trans-2-Hexenal is, however, only one of the many α,β-unsaturated 
aldehydes present in diet and it remains unknown whether the results would be similar for the 
other acyclic α,β-unsaturated aldehydes. Detoxification and DNA binding efficiencies may be 
different depending on the molecular structure [4, 8, 10, 15]. The aim of the present study is to 
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develop PBK/D models to examine dose-dependent detoxification and DNA adduct formation of a 
group of 18 acyclic α,β-unsaturated aldehydes, increasing the efficiency of the model 
development by obtaining the kinetic parameters for the PBK/D models using quantitative 
structure–activity relationships (QSARs). QSAR models were defined based on a training set of 
six selected aldehydes and PBK/D model parameters for the other 12 aldehydes were 
subsequently estimated using these QSARs. The α,β-unsaturated aldehydes investigated included 
18 food-borne acyclic α,β-unsaturated aldehydes without 2- or 3-alkylation, and with no more 
than one conjugated double bond [3] (Figure 4.1). The PBK/D models thus defined were used to 
characterize dose-dependent DNA adduct formation and to evaluate the possible risks arising from 
exposure to the aldehydes at realistic dietary exposure levels. 
 
 
Figure 4.1. The structure of the 18 food-borne acyclic α,β-unsaturated aldehydes included in the 
present study.  
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MATERIALS AND METHODS 
 
Chemicals and biological materials 
α,β-Unsaturated aldehydes, α,β-unsaturated carboxylic acids, α,β-unsaturated alcohols, 
2ʹ-deoxyguanosine (2ʹ-dG), tris (hydroxymethyl) aminomethane, and reduced glutathione (GSH) 
were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). Reduced (NADPH) and 
oxidised (NAD+) β-nicotinamide adenine dinucleotide phosphate were obtained from Roche 
Diagnostics (Mannheim, Germany). DMSO was purchased from Acros Organic (New Jersey, 
USA). Chromatography grade acetonitrile was purchased from Biosolve (Valkenswaard, The 
Netherlands). Chromatography grade trifluoroacetic acid (TFA) and formic acid were purchased 
from VWR International (Darmstadt, Germany). Pooled liver S9 from male F344 rats and pooled 
intestine S9 from male Sprague Dawley rats were obtained from BD Gentest (Worburn, USA) and 
XenoTech (Lenexa, USA), respectively. 
 
The selection of six training set compounds 
Among the 18 food-borne acyclic α,β-unsaturated aldehydes, six aldehydes were selected as 
training set from the aldehydes listed in FGE 1.1.1 by EFSA [3] (Figure 4.1). The number of 
compounds in the training set (n = 6) was such that it fulfils the requirement that the number of 
data points or compounds should preferably be at least five times the number of descriptors in 
order to prevent over-fitting of the data or generation of chance correlations [16, 17]. 2-Propenal 
was not included in the training set because it was expected to evaporate during the incubations at 
37 °C to obtain kinetic parameters due to its high volatility (269 Torr). Among the remaining 
compounds, six commercially available aldehydes (trans-2-pentenal, trans-2-hexenal, 
trans-2-octenal, trans-2-decenal, trans-2-dodecenal, and trans-2-cis-6-nonadienal) were selected 
to cover the widest range of the chain length within the training set to develop QSARs for the 
PBK/D model parameters. 
 
Aldehyde dehydrogenase (ALDH) mediated oxidation 
To determine the required PBK/D parameters the six aldehydes in the training set were 
individually incubated with rat liver or small intestine S9. The final volume of the incubation 
mixtures was 100 μl. The incubation mixtures contained (final concentrations) NAD+ (2 mM) and 
liver S9 (0.01–0.4 mg protein/ml) or small intestine S9 (0.12–0.6 mg protein/ml) in 0.1 M Tris–
HCl (pH 7.4). After pre-incubation for 2 min, the reactions were initiated by the addition of a 
substrate aldehyde from a 100 times concentrated stock solution in DMSO. The final 
concentrations of each aldehyde ranged from 1 to 10,000 μM, depending on the Km. The mixtures 
were incubated at 37 °C for 2 to 5 min. The formation of the corresponding carboxylic acids was 
linear with time and S9 protein concentration under the experimental conditions used (data not 
shown). The incubations were terminated by adding 50 μl ice-cold acetonitrile. The incubation 
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develop PBK/D models to examine dose-dependent detoxification and DNA adduct formation of a 
group of 18 acyclic α,β-unsaturated aldehydes, increasing the efficiency of the model 
development by obtaining the kinetic parameters for the PBK/D models using quantitative 
structure–activity relationships (QSARs). QSAR models were defined based on a training set of 
six selected aldehydes and PBK/D model parameters for the other 12 aldehydes were 
subsequently estimated using these QSARs. The α,β-unsaturated aldehydes investigated included 
18 food-borne acyclic α,β-unsaturated aldehydes without 2- or 3-alkylation, and with no more 
than one conjugated double bond [3] (Figure 4.1). The PBK/D models thus defined were used to 
characterize dose-dependent DNA adduct formation and to evaluate the possible risks arising from 
exposure to the aldehydes at realistic dietary exposure levels. 
 
 
Figure 4.1. The structure of the 18 food-borne acyclic α,β-unsaturated aldehydes included in the 
present study.  
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MATERIALS AND METHODS 
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was not included in the training set because it was expected to evaporate during the incubations at 
37 °C to obtain kinetic parameters due to its high volatility (269 Torr). Among the remaining 
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trans-2-octenal, trans-2-decenal, trans-2-dodecenal, and trans-2-cis-6-nonadienal) were selected 
to cover the widest range of the chain length within the training set to develop QSARs for the 
PBK/D model parameters. 
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To determine the required PBK/D parameters the six aldehydes in the training set were 
individually incubated with rat liver or small intestine S9. The final volume of the incubation 
mixtures was 100 μl. The incubation mixtures contained (final concentrations) NAD+ (2 mM) and 
liver S9 (0.01–0.4 mg protein/ml) or small intestine S9 (0.12–0.6 mg protein/ml) in 0.1 M Tris–
HCl (pH 7.4). After pre-incubation for 2 min, the reactions were initiated by the addition of a 
substrate aldehyde from a 100 times concentrated stock solution in DMSO. The final 
concentrations of each aldehyde ranged from 1 to 10,000 μM, depending on the Km. The mixtures 
were incubated at 37 °C for 2 to 5 min. The formation of the corresponding carboxylic acids was 
linear with time and S9 protein concentration under the experimental conditions used (data not 
shown). The incubations were terminated by adding 50 μl ice-cold acetonitrile. The incubation 
32620 Reiko Kiwamoto.indd   97 17-03-15   15:35
Chapter 4
98
QSAR-PBK/D modelling approach for 18 acyclic α,β-unsaturated aldehydes 
 
98 
 
mixtures were subsequently centrifuged for 3 min at 13,000 g at 4 °C to precipitate the proteins. 
The amount of carboxylic acids in each sample was determined immediately using a Waters 
Acquity ultra-performance liquid chromatography with diode array detection (UPLC-DAD) 
(Waters, Milford, MA), equipped with a Waters Acquity UPLC BEH C18 column (1.7 μm, 2.1×50 
mm). The UPLC methods applied are presented in supplementary information 1. The carboxylic 
acids were quantified at a wavelength of 210 nm using the calibration curve of commercially 
available trans-2-hexenoic acid. Because carboxylic acids were also found to some extent in blank 
incubations without NAD+ or tissue fractions, the amount in incubations without tissue fractions 
was subtracted as background. 
 
Aldose reductase (AR) mediated reduction 
The six aldehydes of the QSAR training set were individually incubated with rat liver S9. The 
final volume of the incubation mixtures was 100 μl. The incubation mixtures contained (final 
concentration) pooled rat liver S9 (1–2 mg protein/ml) in 0.1 M Tris–HCl (pH 7.4). After 
pre-incubation for 2 min, the reactions were initiated by the addition of NADPH (2.5 mM) from a 
20 times concentrated stock solution in 0.1 M Tris–HCl (pH 7.4), and a substrate aldehyde from a 
100 times concentrated stock solution in DMSO. The final concentrations of the aldehydes ranged 
between 50–1,000 μM. After incubation for 4 or 6 min, the reactions were terminated by adding 
50 μl ice-cold acetonitrile. The formation of alcohols was linear with incubation time and S9 
protein concentrations under these incubation conditions (data not shown). The incubation 
mixtures were centrifuged for 3 min at 13,000 g at 4 °C, and the resulting supernatants were kept 
on dry ice until further analysis by UPLC. The UPLC methods applied are presented in 
supplementary information 1. Quantification of the alcohols was achieved at a wavelength of 193 
nm using calibration curves of commercially available standard compounds for 
trans-2-penten-1-ol, trans-2-hexen-1-ol and trans-2, cis-6-nonadien-1-ol. A calibration curve of 
2-undecen-1-ol was used to quantify trans-2-decen-1-ol and trans-2-dodecen-1-ol. 
 
Glutathione S-transferase (GST) mediated GSH conjugation 
The apparent first-order constant (k) for GST mediated conjugation was determined by incubating 
different concentrations of the five out of six acyclic α,β-unsaturated aldehydes of the QSAR 
training set (Figure 4.1) individually in the presence of GSH and rat tissue fractions. The final 
volume of the incubation mixtures was 100 μl. The incubation mixtures contained rat liver S9 
(0.05–0.15 mg protein/ml) or small intestine S9 (0.12–0.2 mg protein/ml) in 0.1 M Tris–HCl (pH 
7.4). After pre-incubation for 2 min, the reaction was initiated by adding GSH (3 mM) from a 17 
times concentrated stock solution in 0.1 M Tris–HCl (pH 7.4) and a substrate aldehyde from a 100 
times concentrated stock solution in DMSO. The final concentrations of the aldehyde ranged from 
50 to 1,000 μM. After 3 min, the incubations were terminated by adding 50 μl ice-cold 
acetonitrile. The formation of GSH conjugates catalysed by GSTs was linear with time and S9 
QSAR-PBK/D modelling approach for 18 acyclic α,β-unsaturated aldehydes 
 
99 
 
protein concentrations under the experimental conditions applied (data not shown). The samples 
were centrifuged for 3 min at 13,000 g at 4 °C and the resulting supernatant was analysed by 
UPLC-DAD immediately. The UPLC methods applied are presented in supplementary 
information 4.1. A calibration curve to quantify the GSH conjugates was obtained for each 
aldehyde by reacting an aldehyde (10 mM) with different lower concentrations of GSH (100–500 
μM) in 0.1 M Tris–HCl (pH 8.6) [13]. The conjugates were quantified based on the peak areas 
determined at a wavelength of 200 nm. Because the aldehydes also react chemically with GSH, 
chemical formation of GSH conjugates in the blank incubations without tissue fractions was 
subtracted as background from the amount measured in the enzymatic incubations. The 
second-order rate constants for chemical binding of the aldehydes to GSH were determined in 
separate experiments performed as described below. 
 
Chemical conjugation with 2′-dG 
The second-order rate constant for binding of acyclic α,β-unsaturated aldehydes to 2′-dG (kDNA) 
was determined by examining the time-dependent formation of 2′-dG adducts for four out of the 
six aldehydes of the QSAR training set. The kDNA for trans-2-hexenal was taken from the previous 
study [13]. A fixed concentration of trans-2-pentenal, trans-2-octenal, trans-2-decenal or 
trans-2-cis-6-nonadienal (1, 0.87, 0.85, and 0.86 mM, respectively) was incubated with 2′-dG 
(1.95 mM) in 0.1 M Tris–HCl (pH 7.4) at 37 °C for up to 50, 60, 105, or 135 min, respectively. 
The formation of 2′-dG adducts was linear with time and substrate concentrations under these 
experimental conditions (data not shown). After 2 min of pre-incubation, the reactions were 
started by adding the aldehyde from a 100 times concentrated stock in DMSO. The reactions were 
terminated by injection to the UPLC-DAD system. The 2′-dG adducts were quantified as 
described previously to quantify 2′-dG adducts of trans-2-hexenal (Hex-PdG) [13]. The UPLC 
methods used are described in supplementary information 4.1. 
 
Chemical conjugation with GSH 
The second-order rate constant for binding of the aldehydes to GSH (kGSH) was determined by 
examining the time-dependent formation of GSH conjugates for trans-2-octenal, trans-2-decenal, 
trans-2-dodecenal and trans-2-cis-6-nonadienal. Each aldehyde (0.4 mM) was incubated with 1 
mM GSH in 0.1 M Tris–HCl (pH 7.4) at 37 °C for up to 30 min. After 5 min of pre-incubation, 
the reactions were started by adding the aldehyde from a 100 times concentrated stock in DMSO. 
The final volume of the incubation samples was 1,000 μl. Every 3 or 5 min, 100 μl of the sample 
was taken and mixed with 25 μl of 20 mM diamide dissolved in 0.1 M Tris–HCl (pH 7.4) to 
terminate the reaction. GSH conjugates in the samples were quantified immediately as described 
above using a UPLC-DAD system. The kGSH for trans-2-hexenal was taken from the previous 
study [13]. 
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final volume of the incubation mixtures was 100 μl. The incubation mixtures contained (final 
concentration) pooled rat liver S9 (1–2 mg protein/ml) in 0.1 M Tris–HCl (pH 7.4). After 
pre-incubation for 2 min, the reactions were initiated by the addition of NADPH (2.5 mM) from a 
20 times concentrated stock solution in 0.1 M Tris–HCl (pH 7.4), and a substrate aldehyde from a 
100 times concentrated stock solution in DMSO. The final concentrations of the aldehydes ranged 
between 50–1,000 μM. After incubation for 4 or 6 min, the reactions were terminated by adding 
50 μl ice-cold acetonitrile. The formation of alcohols was linear with incubation time and S9 
protein concentrations under these incubation conditions (data not shown). The incubation 
mixtures were centrifuged for 3 min at 13,000 g at 4 °C, and the resulting supernatants were kept 
on dry ice until further analysis by UPLC. The UPLC methods applied are presented in 
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(0.05–0.15 mg protein/ml) or small intestine S9 (0.12–0.2 mg protein/ml) in 0.1 M Tris–HCl (pH 
7.4). After pre-incubation for 2 min, the reaction was initiated by adding GSH (3 mM) from a 17 
times concentrated stock solution in 0.1 M Tris–HCl (pH 7.4) and a substrate aldehyde from a 100 
times concentrated stock solution in DMSO. The final concentrations of the aldehyde ranged from 
50 to 1,000 μM. After 3 min, the incubations were terminated by adding 50 μl ice-cold 
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protein concentrations under the experimental conditions applied (data not shown). The samples 
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information 4.1. A calibration curve to quantify the GSH conjugates was obtained for each 
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μM) in 0.1 M Tris–HCl (pH 8.6) [13]. The conjugates were quantified based on the peak areas 
determined at a wavelength of 200 nm. Because the aldehydes also react chemically with GSH, 
chemical formation of GSH conjugates in the blank incubations without tissue fractions was 
subtracted as background from the amount measured in the enzymatic incubations. The 
second-order rate constants for chemical binding of the aldehydes to GSH were determined in 
separate experiments performed as described below. 
 
Chemical conjugation with 2′-dG 
The second-order rate constant for binding of acyclic α,β-unsaturated aldehydes to 2′-dG (kDNA) 
was determined by examining the time-dependent formation of 2′-dG adducts for four out of the 
six aldehydes of the QSAR training set. The kDNA for trans-2-hexenal was taken from the previous 
study [13]. A fixed concentration of trans-2-pentenal, trans-2-octenal, trans-2-decenal or 
trans-2-cis-6-nonadienal (1, 0.87, 0.85, and 0.86 mM, respectively) was incubated with 2′-dG 
(1.95 mM) in 0.1 M Tris–HCl (pH 7.4) at 37 °C for up to 50, 60, 105, or 135 min, respectively. 
The formation of 2′-dG adducts was linear with time and substrate concentrations under these 
experimental conditions (data not shown). After 2 min of pre-incubation, the reactions were 
started by adding the aldehyde from a 100 times concentrated stock in DMSO. The reactions were 
terminated by injection to the UPLC-DAD system. The 2′-dG adducts were quantified as 
described previously to quantify 2′-dG adducts of trans-2-hexenal (Hex-PdG) [13]. The UPLC 
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Kinetic analysis 
The data for the rate of oxidation and reduction with increasing α,β-unsaturated aldehydes 
concentration were fitted to the standard Michaelis–Menten equation with [S] being the 
concentration of the acyclic α,β-unsaturated aldehyde substrate: 
v = Vmax× [S] / (Km+[S]) 
The formation of GST mediated GSH conjugates was described to depend on the concentrations 
of GSH and of the α,β-unsaturated aldehydes by the following equation, where [GSH] and Km_G 
represent the concentration of cytosolic GSH, and the Km for GSH, respectively: 
v = k •[S]•[GSH]/(Km_G +[GSH]) 
The apparent Vmax, Km and k values were determined by fitting the data to the respective equations 
using GraphPad Prism (version 5.04, GraphPad Software, Inc. (La Jolla, USA)) except for Km_G, 
which was set to 100 μM based on literature data obtained with various substrates [18, 19]. 
 
QSAR model development and statistical analysis 
QSAR models for the Km for oxidation and the k for GSH conjugation were described using linear 
regression in Microsoft® Excel 2010 (Microsoft, Redmond, USA), relating the experimentally 
derived Km or k to molecular descriptors. The equations were in the form 
Ln Km or Ln k = a × (molecular descriptor) + b 
where a and b were fitting parameters. With six model aldehydes in the training set to define the 
QSARs, no more than one descriptor could be included in an equation, because the number of 
data points/compounds (n) should be at least five times the number of molecular descriptors (d) 
included (n/d ≥ 5) [17]. Both logKow and the molecular refractivity (MR) were tested as possible 
molecular descriptors. logKow values were estimated with Estimation Program Interface (EPI) 
Suite version 4.10 provided by the US Environmental Protection Agency, and MR values were 
obtained with ChemBioDraw Ultra version 12.0 (Perkin Elmer, Massachusetts, USA). 
The quality of the QSAR models was characterised by r2, s, and the internally cross-validated 
coefficient of determination (r2int). Cross validation of the models was performed using a 
leave-one-out (LOO) method, and calculated according to the formula: 
r2int=1−(PRESS/SSD) 
where predictive sum of squares (PRESS) is the sum of the squared differences between actual 
and predicted kinetic parameters when a compound is omitted from the regression and SSD is the 
sum-of-squares deviation for each actual kinetic parameter from the mean parameter value of all 
the compounds in the training set [17, 20]. A QSAR model is considered acceptable when r2int ≥ 
0.5 [17, 21]. 
 
PBK/D model structure 
The same structure as the rat PBK/D model for trans-2-hexenal developed in our previous study 
[13] was applied with modifications (Figure 4.2). The physiological parameters such as organ 
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volumes and blood flows were obtained from the literature [22] and are presented in Table 4.1. 
Tissue:blood partition coefficients were estimated based on a method of DeJongh et al. [23] from 
the logKow (supplementary information 4.2). Model equations (supplementary information 4.3) 
were coded and numerically integrated in Berkeley Madonna 8.3.18 (Macey and Oster, UC 
Berkeley, CA, USA), using the Rosenbrock's algorithm for stiff systems. The uptake of aldehydes 
into the small intestine compartment was described by a first-order process with the absorption 
rate constant 5.0 h−1, resulting in a rapid absorption [24]. Detoxification was described in the liver 
and small intestine compartments. The Vmax values expressed as nmol/min/(mg S9 protein) and k 
values expressed as ml/min/(mg S9 protein) were scaled to be expressed as nmol/min/(g tissue) 
and ml/min/(g tissue) respectively, using S9 protein yields of 143 mg/(g liver) or 11.4 mg/(g small 
intestine) as scaling factors [13, 25, 26]. Chemical conjugation of the aldehydes with GSH or 
protein reactive sites in the liver or small intestine was described as previously reported [13, 14]. 
Equations to describe GSH levels in the liver and small intestine were included as previously 
described [13] to examine possible depletion of GSH induced by the dietary aldehydes. The 
amount of DNA adducts formed in the liver was described by second-order formation and 
first-order elimination due to DNA repair. The half-life of the DNA adducts was set for all 
aldehydes to be 38.5 h based on the results obtained in an in vivo study using trans-2-hexenal 
[27]. 
 
[28]  
Figure 4.2. The schematic diagram of the PBK/D models for α,β-unsaturated aldehydes in rat. The 
solid and dashed lines represent the flow of α,β-unsaturated aldehyde and GSH, respectively. 
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Kinetic analysis 
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v = Vmax× [S] / (Km+[S]) 
The formation of GST mediated GSH conjugates was described to depend on the concentrations 
of GSH and of the α,β-unsaturated aldehydes by the following equation, where [GSH] and Km_G 
represent the concentration of cytosolic GSH, and the Km for GSH, respectively: 
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which was set to 100 μM based on literature data obtained with various substrates [18, 19]. 
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derived Km or k to molecular descriptors. The equations were in the form 
Ln Km or Ln k = a × (molecular descriptor) + b 
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The quality of the QSAR models was characterised by r2, s, and the internally cross-validated 
coefficient of determination (r2int). Cross validation of the models was performed using a 
leave-one-out (LOO) method, and calculated according to the formula: 
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and predicted kinetic parameters when a compound is omitted from the regression and SSD is the 
sum-of-squares deviation for each actual kinetic parameter from the mean parameter value of all 
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0.5 [17, 21]. 
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and small intestine compartments. The Vmax values expressed as nmol/min/(mg S9 protein) and k 
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Table 4.1 Parameters used in the PBK/D models  
 
Parameters Symbols Values 
Body weight (kg)a BW 0.25 
Tissue volumes (% body weight)a 
 fat VFc 7.0 
 liver VLc 3.4 
 small intestine VSIc 1.4 
 arterial blood VAc 1.85 
 venous blood VVc 5.55 
 richly perfused  VRc 4.2 
 slowly perfused VSc 67.6 
Cardiac output (L/h)a,b QC 5.4 
Blood flow to tissue (% cardiac output)a 
 fat QFc 7.0 
liver (excluding portal vein 
fraction) 
QLc 13.2 
small intestine QSIc 11.8 
richly perfused  QRc 51.0 
slowly perfused QSc 17.0 
Initial GSH concentration (μmol/kg tissue) 
liverc  InitGSHL 6120 
small intestinec InitGSHSi 1780 
GSH synthesis (μmol/kg tissue/h) 
liver GSYNL 869 
small intestine GSYNSi 78 
Apparent first order rate constant for GSH turnover  (/h)c 
liver kL_GLOS 0.142 
small intestine kSi_GLOS 0.044 
Protein reactive sites (μmol/kg tissue)d  
liver CPROL 5319 
small intestine CPROSi 245 
aBrown et al.[22], bKrishnan and Andersen [29], cPotter and Tran [30], dPotter amd Tran  
 
For the PBK/D models that are developed for the training set of six aldehydes, the values 
for Vmax, Km and k for aldehyde oxidation, aldehyde reduction or GST mediated GSH conjugation, 
and values for kGSH and kDNA were obtained based on results from in vitro incubations. For the 
PBK/D models for the other 12 aldehydes the Km for aldehyde oxidation and the k for GST 
mediated GSH conjugation were set to the values calculated with the QSARs developed in this 
study. The Vmax for aldehyde reduction and oxidation, the Km for aldehyde reduction, kGSH and the 
kDNA were set at the average values obtained with the aldehydes in the training set, since the 
values for the training set aldehydes were comparable and were not significantly influenced by the 
aldehyde structure (see Results section). The models thus obtained for the 12 structurally related 
aldehydes are referred to as the “QSAR-based PBK/D models” throughout the article. 
 
QSAR-PBK/D modelling approach for 18 acyclic α,β-unsaturated aldehydes 
 
103 
 
Sensitivity analysis 
Normalised sensitivity coefficients (SC) were determined according to the equation: SC = (C′ − 
C)/(P′ − P) × (P/C), where P and P′ are the initial and modified parameter values respectively, and 
C and C′ are the initial and modified values of the model output resulting from an increase in 
parameter value respectively [31, 32]. A 5% increase in parameter values was chosen to analyze 
the effect of a change in parameter on maximum DNA adduct levels in the liver caused by each 
aldehyde. The estimated dietary intake as listed in Table 4.5 was used for the analysis. When the 
intake level for a compound is not known, the estimated dietary intake for 2-propenal (0.017 
mg/kg bw) was used as the highest intake value from the series of aldehydes examined in the 
present study. Each parameter was analyzed individually, keeping the other parameters to their 
initial values. 
 
RESULTS 
 
Detoxification parameters 
Chemical specific detoxification parameters were derived by in vitro incubations for the six 
acyclic α,β-unsaturated aldehydes (Figure 4.1) in the training set. The rat liver and small intestine 
S9 converted the six aldehydes into the related carboxylic acids. The reduction to alcohols was 
observed with pooled liver S9 but not with small intestine S9. The formation of metabolites was 
plotted against substrate concentrations (supplementary information 4.4A–C), and from these data 
the apparent kinetic parameters (Km and Vmax) were derived (Table 4.2). α,β-Unsaturated 
aldehydes chemically bind to GSH to form GSH conjugates. The second-order rate constants 
(kGSH) for the chemical binding were determined and are presented in Table 4.2. The binding of 
α,β-unsaturated aldehydes with GSH is accelerated by GST [10, 33]. In vitro incubations with rat 
liver or small intestine S9 revealed that the formation rate of GSH conjugates mediated by GST 
increased linearly with increasing concentrations of aldehydes (supplementary information 4.4D 
and E). The apparent first-order rate constants obtained from the plots (k) are presented in Table 
4.2. The Vmax and Km for reduction of trans-2-octenal to trans-2-octen-1-ol and the second-order 
rate constant for the chemical reaction between trans-2-pentenal and GSH (kGSH) were not 
determined because the peaks of the products could not be seperated with the UPLC analysis from 
the peaks of other compounds present in the incubation samples. 
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aldehydes are referred to as the “QSAR-based PBK/D models” throughout the article. 
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Sensitivity analysis 
Normalised sensitivity coefficients (SC) were determined according to the equation: SC = (C′ − 
C)/(P′ − P) × (P/C), where P and P′ are the initial and modified parameter values respectively, and 
C and C′ are the initial and modified values of the model output resulting from an increase in 
parameter value respectively [31, 32]. A 5% increase in parameter values was chosen to analyze 
the effect of a change in parameter on maximum DNA adduct levels in the liver caused by each 
aldehyde. The estimated dietary intake as listed in Table 4.5 was used for the analysis. When the 
intake level for a compound is not known, the estimated dietary intake for 2-propenal (0.017 
mg/kg bw) was used as the highest intake value from the series of aldehydes examined in the 
present study. Each parameter was analyzed individually, keeping the other parameters to their 
initial values. 
 
RESULTS 
 
Detoxification parameters 
Chemical specific detoxification parameters were derived by in vitro incubations for the six 
acyclic α,β-unsaturated aldehydes (Figure 4.1) in the training set. The rat liver and small intestine 
S9 converted the six aldehydes into the related carboxylic acids. The reduction to alcohols was 
observed with pooled liver S9 but not with small intestine S9. The formation of metabolites was 
plotted against substrate concentrations (supplementary information 4.4A–C), and from these data 
the apparent kinetic parameters (Km and Vmax) were derived (Table 4.2). α,β-Unsaturated 
aldehydes chemically bind to GSH to form GSH conjugates. The second-order rate constants 
(kGSH) for the chemical binding were determined and are presented in Table 4.2. The binding of 
α,β-unsaturated aldehydes with GSH is accelerated by GST [10, 33]. In vitro incubations with rat 
liver or small intestine S9 revealed that the formation rate of GSH conjugates mediated by GST 
increased linearly with increasing concentrations of aldehydes (supplementary information 4.4D 
and E). The apparent first-order rate constants obtained from the plots (k) are presented in Table 
4.2. The Vmax and Km for reduction of trans-2-octenal to trans-2-octen-1-ol and the second-order 
rate constant for the chemical reaction between trans-2-pentenal and GSH (kGSH) were not 
determined because the peaks of the products could not be seperated with the UPLC analysis from 
the peaks of other compounds present in the incubation samples. 
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Table 4.2  Biochemical parameters determined by in vitro incubations. 
 
Metabolites 
/products 
 trans-2- 
pentenal 
trans-2- 
hexenal 
trans-2- 
octenal 
trans-2- 
decenal 
trans-2- 
dodecenal 
trans-2-cis-6
-nonadienal 
Average 
Carboxylic acid  
( liver )    
Km
a,b 5101 230 7.4 2.0 1.6 9.4 892 
Vmax
a,c 36.6 18.5 34.2 26.5 21.1 20.2 27.6 
Carboxylic acid 
(small intestine) 
Km
a,b 5430 737 22.8 4.4 2.9 43.7 1040 
Vmax
a,c 4.8 7.0 3.4 2.3 2.7 5.6 4.3 
Alcohol ( liver )    Km
a,b 361 169 N.D.f 66.3 75.6 88.3 152 
Vmax
a,c 13.7 28.0 N.D.f 21.5 16.5 12.4 18.4 
GSH conjugates  
( liver )    
ka,d 
0.07 
0.35 2.1 3.9 5.4 2.2 
2.4 
GSH conjugates 
(small intestine) 
ka,d 
0.03 
0.12 0.74 1.5 3.6 0.74 
1.2 
2ʹ-dG adducts kDNA
a,e 4.8×10-7 1.6×10-7 3.8×10-7 1.3×10-7 N.D.f 5.4×10-7 3.4×10-7 
GSH chemical 
conjugation 
kGSH
a,e N.D.f 5.8×10-4 9.3×10-4 8.5×10-4 3.7×10-4 10.5×10-4 7.6×10-4 
aMean of duplicate or triplicate measurements, bμM, cnmol/min/(mg S9 protein), dml/min/(mg S9 
protein), e/μM/h, fN.D.= not determined 
 
Chemical binding to 2′-dG 
Acyclic α,β-unsaturated aldehydes bind covalently to DNA, resulting in formation of exocyclic 
1,N2-propanodeoxyguanosine adducts [27, 34-36]. UPLC analysis revealed that one or two peaks 
appear when an aldehyde was incubated with 2′-dG, and that the peaks were absent in blank 
incubations without either the aldehyde or 2′-dG (supplementary information 4.5). The 
second-order rate constants for binding of the aldehydes with 2′-dG (kDNA) were determined and 
are presented in Table 4.2. The value of kDNA for trans-2-dodecenal was not determined, because 
the 2′-dG adduct formation was insufficient to be quantified using UPLC. 
 
QSAR models for detoxification parameters 
The Km for oxidation and the k for GST mediated GSH conjugation varied more than ten times 
when comparing the values for the six aldehydes in the training set (Table 4.2). QSAR models 
were therefore developed for these two chemical specific biochemical parameters (Figure 4.3), 
and were assessed statistically for their goodness-of-fit (r2 and standard deviation) and robustness 
(r2int) (Table 4.3) [17, 20]. The natural logarithm of the Km values for oxidation correlated 
quantitatively with logKow or MR, and decreased with increasing hydrophobicity (logKow) or 
bulkiness (MR) of the molecule. The natural logarithm of the k for GST mediated GSH 
conjugation also correlated with logKow or MR, increasing with increasing hydrophobicity or 
bulkiness. The statistical analysis (Table 4.3) showed that the fit of the QSAR models (r2) and the 
robustness (r2int) were both good for the four models with MR as a descriptor (r
2–r2int< 0.3, r
2
int > 
0.5) [17], and therefore these QSARs were considered adequate for further predictions. No QSAR 
model was developed for the other chemical specific biochemical parameters including Vmax and 
Km for reduction, and the second-order rate constant of aldehyde binding to GSH (kGSH) or to 
DNA (kDNA), because the differences in these values for the training set aldehydes were less than 
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ten-fold, and no significant influence of the aldehyde structures was observed. These parameters 
were therefore considered to be best described by the average values observed for the aldehydes 
in the training set. 
 
Table 4.3 Statistical analysis of the QSAR models 
 
Metabolite 
Kinetic 
parameter 
Descriptor r2a sb r2int
c 
Carboxylic acid (liver) Km LogKow 0.84 1.4 0.4 
 MR 0.90 1.1 0.7 
Carboxylic acid 
(small intestine) 
Km LogKow 0.91 1.0 0.7 
 MR 0.92 0.9 0.8 
GSH conjugates (liver) k LogKow 0.86 0.7 0.6 
 MR 0.92 0.5 0.9 
GSH conjugates  
(small intestine) 
k LogKow 0.94 0.5 0.8 
 MR 0.97 0.3 0.9 
aCoefficient of determination, bStandard error of estimate, cCross validated correlation coefficient 
 
 
Figure 4.3 QSAR models correlating the Km of ALDH mediated oxidation with logKow (A) or 
molecular refraction (MR) (B), and the k of GST mediated GSH conjugation with logKow (C) or 
MR (D). The closed and open circles represent the in vitro derived data obtained using rat liver S9 
and small intestine S9, respectively. 
 
Evaluation of the PBK/D models 
The performance of the QSAR-based PBK/D models was evaluated by comparing the predicted 
values with in vivo data reported by Linhart et al. [37] for 2-propenal. In this study, 2-propenal 
32620 Reiko Kiwamoto.indd   104 17-03-15   15:35
4An integrated QSAR-PBK/D modelling approach for 18 foor-borne α,β-unsaturated aldehydes
105
QSAR-PBK/D modelling approach for 18 acyclic α,β-unsaturated aldehydes 
 
104 
 
Table 4.2  Biochemical parameters determined by in vitro incubations. 
 
Metabolites 
/products 
 trans-2- 
pentenal 
trans-2- 
hexenal 
trans-2- 
octenal 
trans-2- 
decenal 
trans-2- 
dodecenal 
trans-2-cis-6
-nonadienal 
Average 
Carboxylic acid  
( liver )    
Km
a,b 5101 230 7.4 2.0 1.6 9.4 892 
Vmax
a,c 36.6 18.5 34.2 26.5 21.1 20.2 27.6 
Carboxylic acid 
(small intestine) 
Km
a,b 5430 737 22.8 4.4 2.9 43.7 1040 
Vmax
a,c 4.8 7.0 3.4 2.3 2.7 5.6 4.3 
Alcohol ( liver )    Km
a,b 361 169 N.D.f 66.3 75.6 88.3 152 
Vmax
a,c 13.7 28.0 N.D.f 21.5 16.5 12.4 18.4 
GSH conjugates  
( liver )    
ka,d 
0.07 
0.35 2.1 3.9 5.4 2.2 
2.4 
GSH conjugates 
(small intestine) 
ka,d 
0.03 
0.12 0.74 1.5 3.6 0.74 
1.2 
2ʹ-dG adducts kDNA
a,e 4.8×10-7 1.6×10-7 3.8×10-7 1.3×10-7 N.D.f 5.4×10-7 3.4×10-7 
GSH chemical 
conjugation 
kGSH
a,e N.D.f 5.8×10-4 9.3×10-4 8.5×10-4 3.7×10-4 10.5×10-4 7.6×10-4 
aMean of duplicate or triplicate measurements, bμM, cnmol/min/(mg S9 protein), dml/min/(mg S9 
protein), e/μM/h, fN.D.= not determined 
 
Chemical binding to 2′-dG 
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1,N2-propanodeoxyguanosine adducts [27, 34-36]. UPLC analysis revealed that one or two peaks 
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were therefore developed for these two chemical specific biochemical parameters (Figure 4.3), 
and were assessed statistically for their goodness-of-fit (r2 and standard deviation) and robustness 
(r2int) (Table 4.3) [17, 20]. The natural logarithm of the Km values for oxidation correlated 
quantitatively with logKow or MR, and decreased with increasing hydrophobicity (logKow) or 
bulkiness (MR) of the molecule. The natural logarithm of the k for GST mediated GSH 
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bulkiness. The statistical analysis (Table 4.3) showed that the fit of the QSAR models (r2) and the 
robustness (r2int) were both good for the four models with MR as a descriptor (r
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0.5) [17], and therefore these QSARs were considered adequate for further predictions. No QSAR 
model was developed for the other chemical specific biochemical parameters including Vmax and 
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ten-fold, and no significant influence of the aldehyde structures was observed. These parameters 
were therefore considered to be best described by the average values observed for the aldehydes 
in the training set. 
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Figure 4.3 QSAR models correlating the Km of ALDH mediated oxidation with logKow (A) or 
molecular refraction (MR) (B), and the k of GST mediated GSH conjugation with logKow (C) or 
MR (D). The closed and open circles represent the in vitro derived data obtained using rat liver S9 
and small intestine S9, respectively. 
 
Evaluation of the PBK/D models 
The performance of the QSAR-based PBK/D models was evaluated by comparing the predicted 
values with in vivo data reported by Linhart et al. [37] for 2-propenal. In this study, 2-propenal 
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(acrolein) was administered to rats by intraperitoneal (i.p.) injection. To account for the difference 
in the administration route, the Vmax and k values in the small intestine of the PBK/D model were 
set to zero so that 2-propenal administered via i.p. injection would reach the liver without being 
detoxified in the small intestine. In addition, it was assumed that all GSH conjugates would be 
further converted to mercapturic acids. The comparison revealed that the PBK/D model predicted 
level of 2-propenal GSH conjugates was only up to 3.3-fold higher than the in vivo reported level 
excreted as mercapturic acids [37] (Table 4.4). To further evaluate the PBK/D models, the 
formation of DNA adducts was compared with in vivo data for DNA adduct formation upon 
exposure of rats to 2-butenal (crotonaldehyde) [36] or trans-2-hexenal [27, 38](Table 4.4). The 
PBK/D models overestimated the DNA adduct levels by 947-fold and 9717-fold compared to the 
data reported by Budiawan et al. on 2-butenal [36] and by Stout et al. on trans-2-hexenal [38], 
respectively. However, the overestimation was only 3.5-fold when the predicted values were 
compared with the data reported by Schuler and Eder on trans-2-hexenal DNA adduct formation 
[27]. 
 
Table 4.4 Comparison of the PBK/D model outcomes and data obtained from rat studies 
 
Reference Compounds 
Rats/ 
Routes 
Dose 
(mg/kgbw) 
Outcome/ 
Time 
point 
Observed 
levels 
PBK/D 
model 
outcome 
Linhart et 
al. [37]   
2-propenal 
(acrolein)  
Wistar (M)/ 
i.p. 
injection 
0.47-4.0  Mercaptur
ic acids/ 
24h 
10-32% of 
dose 
32.3-32.6% 
of dose 
Budiawan 
and Eder, 
[36] 
2-butenal 
(crotonalde
hyde)  
F344 (F)/ 
gavage 
 
200, 300  DNA 
adducts in 
the liver/ 
20h 
2.9 and 3.4 
adducts/108 
nt  
1240 and 
3220 
adducts/108 
nt 
Stout et al. 
[38] 
trans-2-hex
enal  
F344 (M)/ 
gavage 
200, 500  DNA 
adducts in 
the liver/ 
24h 
0.2 and 0.099 
adducts/108 
nt 
94 and 962 
adducts/108 
nt  
Schuler and 
Eder [27] 
trans-2-hex
enal  
F344 (M)/ 
gavage 
 
200, 500  DNA 
adducts in 
the liver/ 
48h 
16 and 179 
adducts/108 
nt 
61 and 625 
adducts/108 
nt 
 
 
PBK/D model based predictions on DNA adduct formation 
Figure 4.4A shows the dose-dependent maximum DNA adduct formation in the liver predicted by 
the PBK/D models for the six compounds in the QSAR training set. DNA adduct formation 
decreased with increasing bulkiness. Overall, the PBK/D models predicted that trans-2-pentenal is 
most potent in forming DNA adducts among the six aldehydes in the training set. At 0.04 mg/kg 
bw, the level corresponding to the average human dietary intake of trans-2-hexenal [12], the 
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maximum predicted DNA adduct formation in the liver was 0.15, 0.006, 0.0007, 0.0004, 0.00002 
and 0.00002 adducts/108 nt for trans-2-pentenal, trans-2-hexenal, trans-2-cis-6-nonadienal, 
trans-2-octenal, trans-2-decenal, and trans-2-dodecenal, respectively. These levels are at least an 
order of magnitude lower than natural background levels of structurally similar 1,N2-exocyclic 
propanodeoxyguanosine adducts observed in disease free human liver (6.8–110 adducts/108 nt) 
[39, 40]. 
 
Figure 4.4. Dose-dependent maximum levels of DNA adducts in the liver as predicted by PBK/D 
models using in vitro derived parameters for the six aldehydes of the training set (A) and by 
QSAR-based PBK/D models for the remaining 12 aldehydes included in the study (B). 
 
Dose-dependent DNA adduct formation was also examined using the QSAR-based 
PBK/D models for a range of food flavouring acyclic α,β-unsaturated aldehydes. For this 
examination, α,β-unsaturated aldehydes listed in subgroup 1.1.1 of EFSA Flavouring Group 
Evaluation (FGE) 19 were selected except for 4,5-epoxydec-2(trans)-enal [3], which was not 
considered to be in the applicability domain of the QSAR models because of its epoxide group. 
The QSAR-based PBK/D models predicted that 2-propenal induces the highest DNA adduct 
levels among the 18 aldehydes (Figure 4.4B), primarily due to its low detoxification efficiency via 
oxidation or GST mediated GSH conjugation. Furthermore, the DNA adduct formation at the 
intake levels that are relevant for human dietary exposure for each acyclic α,β-unsaturated 
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(acrolein) was administered to rats by intraperitoneal (i.p.) injection. To account for the difference 
in the administration route, the Vmax and k values in the small intestine of the PBK/D model were 
set to zero so that 2-propenal administered via i.p. injection would reach the liver without being 
detoxified in the small intestine. In addition, it was assumed that all GSH conjugates would be 
further converted to mercapturic acids. The comparison revealed that the PBK/D model predicted 
level of 2-propenal GSH conjugates was only up to 3.3-fold higher than the in vivo reported level 
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Figure 4.4A shows the dose-dependent maximum DNA adduct formation in the liver predicted by 
the PBK/D models for the six compounds in the QSAR training set. DNA adduct formation 
decreased with increasing bulkiness. Overall, the PBK/D models predicted that trans-2-pentenal is 
most potent in forming DNA adducts among the six aldehydes in the training set. At 0.04 mg/kg 
bw, the level corresponding to the average human dietary intake of trans-2-hexenal [12], the 
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maximum predicted DNA adduct formation in the liver was 0.15, 0.006, 0.0007, 0.0004, 0.00002 
and 0.00002 adducts/108 nt for trans-2-pentenal, trans-2-hexenal, trans-2-cis-6-nonadienal, 
trans-2-octenal, trans-2-decenal, and trans-2-dodecenal, respectively. These levels are at least an 
order of magnitude lower than natural background levels of structurally similar 1,N2-exocyclic 
propanodeoxyguanosine adducts observed in disease free human liver (6.8–110 adducts/108 nt) 
[39, 40]. 
 
Figure 4.4. Dose-dependent maximum levels of DNA adducts in the liver as predicted by PBK/D 
models using in vitro derived parameters for the six aldehydes of the training set (A) and by 
QSAR-based PBK/D models for the remaining 12 aldehydes included in the study (B). 
 
Dose-dependent DNA adduct formation was also examined using the QSAR-based 
PBK/D models for a range of food flavouring acyclic α,β-unsaturated aldehydes. For this 
examination, α,β-unsaturated aldehydes listed in subgroup 1.1.1 of EFSA Flavouring Group 
Evaluation (FGE) 19 were selected except for 4,5-epoxydec-2(trans)-enal [3], which was not 
considered to be in the applicability domain of the QSAR models because of its epoxide group. 
The QSAR-based PBK/D models predicted that 2-propenal induces the highest DNA adduct 
levels among the 18 aldehydes (Figure 4.4B), primarily due to its low detoxification efficiency via 
oxidation or GST mediated GSH conjugation. Furthermore, the DNA adduct formation at the 
intake levels that are relevant for human dietary exposure for each acyclic α,β-unsaturated 
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aldehyde was examined (Table 4.5). The estimated daily intake levels used for these predictions 
were derived from data reported by the Joint FAO/WHO Expert Committee on Food Additives 
(JECFA) based on the annual production volumes of each aldehyde [41, 42]. The intake was 
estimated for populations in Europe and the US, and the highest value of either of the two regions 
is listed in Table 4.5. For 2-propenal, no exposure levels based on the production volumes were 
found but an estimated exposure of 0.017 mg/kg bw/day from food consumption has been 
reported [43]. The PBK/D models predicted 0.036 adducts/108 nt for 2-propenal and values 
between 10−10 and 10−3 adducts/108 nt for the other 17 aldehydes (Table 4.5), which were well 
below the natural background levels of structurally similar 1,N2-exocyclic 
propanodeoxyguanosine adducts in disease free human liver [39, 40]. 
 
Table 4.5 Dietary exposure levels of acyclic α,β-unsaturated aldehydes listed as food flavouring 
agents by EFSA [3]. 
 
Compounds Levels 
(μg/kgbw/d) 
Predicted maximum 
DNA adduct levels 
(adduct/108nt) 
2-propenal 17 a 0.036 
2-pentenal 0.002b 7.4×10-6 
4-methyl-2-pentenal N.Ac - 
trans-2-hexenal 
cis-2-hexenal 
13.20b 2.0×10-3 
trans-2-heptenal 0.10b 1.2×10-5 
trans-2-octenal 0.50b 4.4×10-6 
trans-2-nonenal 
cis-2-nonenal 
0.07b 7.2×10-7 
trans-2-decenal 0.10b 4.9×10-8 
2-undecenal 0.007b 3.2×10-9 
trans-2-dodecenal 0.27b 1.3×10-7 
2-tridecenal 0.01b 1.3×10-10 
2-tetradecenal N.A. - 
trans-2-cis-6-octadienal N.A. - 
trans-2-cis-6-nonadienal 
trans-2-trans-6-nonadienal 
0.40d 
0.0001d 
7.1×10-6 
1.8×10-9 
2,6-dodecadienal 0.01d 5.0×10-10 
aEstimated amount present in food [43],  bEstimated amount consumed as food flavouring agent 
[42], cN.A.= not available in literature, dEstimated amount consumed as food flavouring agent 
[41] 
 
Sensitivity analysis 
A sensitivity analysis was performed to identify key parameters that determine the DNA adduct 
levels in the liver at Tmax, the time point at which the DNA adduct level was predicted to reach its 
maximum after administration of the aldehydes (Figure 4.5). The results showed that DNA adduct 
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formation is significantly influenced by the second-order rate constant for binding to 2′-dG 
(kDNA,), the volume of the liver (VLc), and the scaling factor for liver S9 (S9PL) for all 18 
compounds. The degree of influence of the other parameters, including four parameters for which 
QSARs were developed, varied depending on the compound. Among the four parameters 
estimated by QSARs, the median of the |SC| was the largest with the k for GSH conjugation in the 
small intestine (kSi). This parameter appeared to have a significant influence on the predicted liver 
DNA adduct levels for 2-dodecenal (|SC|= 0.71) but its influence was limited for the PBK/D 
model outcome for 2-propenal (|SC| < 0.1). The |SC| of the Km for oxidation in the liver and small 
intestine (Km,L_CA and Km,Si_CA) were large especially for the molecules with large MR such as 
2-tetradecenal, and the smallest |SC|s were observed for 2-propenal. The influence of k for GSH 
conjugation in the liver (kL) was the largest for 2-methylpentenal (|SC| = 0.58) and it was shown 
to be insignificant for the model outcome of 2-tetradecenal (|SC| < 0.1). 
 
 
Figure 4.5. Sensitivity analysis for the PBK/D model based predictions of the maximum amount 
of DNA adduct formation in the liver for the 18 α,β-unsaturated aldehyde. The normalized 
sensitivity coefficients (SC) were obtained at the estimated dietary exposure level to each 
compound as listed in Table 4.5, or at 0.017 mg/kg bw when the exposure level of a compound is 
unknown. The parameters which |SC| is larger than 0.1 are listed in the figure. The bottom and the 
top of the boxes represent the maximum and minimum normalized sensitivity coefficients (SCs) 
obtained among the 18 compounds, and the lines in the boxes represent the medians. The 
parameters listed in the figure are the following: body weight (BW), fraction of the liver (VLc) 
and the small intestine (VSic); blood flow rate (QC); fraction of the blood flow to the small 
intestine (Qsic); scaling factor of liver S9 (S9PL) or of small intestine S9 (S9PSi); Vmax and Km to 
form carboxylic acid in the liver (Vmax,L_CA,  Km,L_CA) or in the small intestine (Vmax,Si_CA,  
Km,Si_CA), or to form alcohol in the liver (Vmax,L_AO,  Km,L_AO); k for GST catalysed GSH 
conjugations in the liver (kL) and small intestine (kSi);  and second-order rate constant of the 
aldehydes binding with 2ʹ-dG (kDNA). 
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aldehyde was examined (Table 4.5). The estimated daily intake levels used for these predictions 
were derived from data reported by the Joint FAO/WHO Expert Committee on Food Additives 
(JECFA) based on the annual production volumes of each aldehyde [41, 42]. The intake was 
estimated for populations in Europe and the US, and the highest value of either of the two regions 
is listed in Table 4.5. For 2-propenal, no exposure levels based on the production volumes were 
found but an estimated exposure of 0.017 mg/kg bw/day from food consumption has been 
reported [43]. The PBK/D models predicted 0.036 adducts/108 nt for 2-propenal and values 
between 10−10 and 10−3 adducts/108 nt for the other 17 aldehydes (Table 4.5), which were well 
below the natural background levels of structurally similar 1,N2-exocyclic 
propanodeoxyguanosine adducts in disease free human liver [39, 40]. 
 
Table 4.5 Dietary exposure levels of acyclic α,β-unsaturated aldehydes listed as food flavouring 
agents by EFSA [3]. 
 
Compounds Levels 
(μg/kgbw/d) 
Predicted maximum 
DNA adduct levels 
(adduct/108nt) 
2-propenal 17 a 0.036 
2-pentenal 0.002b 7.4×10-6 
4-methyl-2-pentenal N.Ac - 
trans-2-hexenal 
cis-2-hexenal 
13.20b 2.0×10-3 
trans-2-heptenal 0.10b 1.2×10-5 
trans-2-octenal 0.50b 4.4×10-6 
trans-2-nonenal 
cis-2-nonenal 
0.07b 7.2×10-7 
trans-2-decenal 0.10b 4.9×10-8 
2-undecenal 0.007b 3.2×10-9 
trans-2-dodecenal 0.27b 1.3×10-7 
2-tridecenal 0.01b 1.3×10-10 
2-tetradecenal N.A. - 
trans-2-cis-6-octadienal N.A. - 
trans-2-cis-6-nonadienal 
trans-2-trans-6-nonadienal 
0.40d 
0.0001d 
7.1×10-6 
1.8×10-9 
2,6-dodecadienal 0.01d 5.0×10-10 
aEstimated amount present in food [43],  bEstimated amount consumed as food flavouring agent 
[42], cN.A.= not available in literature, dEstimated amount consumed as food flavouring agent 
[41] 
 
Sensitivity analysis 
A sensitivity analysis was performed to identify key parameters that determine the DNA adduct 
levels in the liver at Tmax, the time point at which the DNA adduct level was predicted to reach its 
maximum after administration of the aldehydes (Figure 4.5). The results showed that DNA adduct 
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formation is significantly influenced by the second-order rate constant for binding to 2′-dG 
(kDNA,), the volume of the liver (VLc), and the scaling factor for liver S9 (S9PL) for all 18 
compounds. The degree of influence of the other parameters, including four parameters for which 
QSARs were developed, varied depending on the compound. Among the four parameters 
estimated by QSARs, the median of the |SC| was the largest with the k for GSH conjugation in the 
small intestine (kSi). This parameter appeared to have a significant influence on the predicted liver 
DNA adduct levels for 2-dodecenal (|SC|= 0.71) but its influence was limited for the PBK/D 
model outcome for 2-propenal (|SC| < 0.1). The |SC| of the Km for oxidation in the liver and small 
intestine (Km,L_CA and Km,Si_CA) were large especially for the molecules with large MR such as 
2-tetradecenal, and the smallest |SC|s were observed for 2-propenal. The influence of k for GSH 
conjugation in the liver (kL) was the largest for 2-methylpentenal (|SC| = 0.58) and it was shown 
to be insignificant for the model outcome of 2-tetradecenal (|SC| < 0.1). 
 
 
Figure 4.5. Sensitivity analysis for the PBK/D model based predictions of the maximum amount 
of DNA adduct formation in the liver for the 18 α,β-unsaturated aldehyde. The normalized 
sensitivity coefficients (SC) were obtained at the estimated dietary exposure level to each 
compound as listed in Table 4.5, or at 0.017 mg/kg bw when the exposure level of a compound is 
unknown. The parameters which |SC| is larger than 0.1 are listed in the figure. The bottom and the 
top of the boxes represent the maximum and minimum normalized sensitivity coefficients (SCs) 
obtained among the 18 compounds, and the lines in the boxes represent the medians. The 
parameters listed in the figure are the following: body weight (BW), fraction of the liver (VLc) 
and the small intestine (VSic); blood flow rate (QC); fraction of the blood flow to the small 
intestine (Qsic); scaling factor of liver S9 (S9PL) or of small intestine S9 (S9PSi); Vmax and Km to 
form carboxylic acid in the liver (Vmax,L_CA,  Km,L_CA) or in the small intestine (Vmax,Si_CA,  
Km,Si_CA), or to form alcohol in the liver (Vmax,L_AO,  Km,L_AO); k for GST catalysed GSH 
conjugations in the liver (kL) and small intestine (kSi);  and second-order rate constant of the 
aldehydes binding with 2ʹ-dG (kDNA). 
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DISCUSSION 
 
The aim of the present study was to build rat PBK/D models for a series of food-borne acyclic 
α,β-unsaturated aldehydes and to examine detoxification and DNA adduct formation especially at 
dose levels relevant for human dietary exposure. Considering the large number of α,β-unsaturated 
aldehydes, QSAR models were developed to estimate chemical specific parameters namely Km or 
k values for the detoxification pathways. The QSAR models revealed that the Km for ALDH 
mediated oxidation decreased and the k for GST mediated GSH conjugation increased with 
increasing hydrophobicity or bulkiness of the aldehyde substrate. These findings are in line with 
results reported in the literature [8, 10, 15]. For example, Klysov [8] showed that the longer the 
chain length of 2-alkanals the lower the Km of human cytosolic ALDH. Furthermore Danielson et 
al. [15] attributed the increased specificity constants (kcat/Km) of mammalian cytosolic GST with 
increasing hydrophobicity of 4-hydroxy-2-alkenals to the hydrophobic nature of the electrophilic 
substrate-binding site in GSTs. The presence of a hydrophobic binding site in GSTs corroborates 
the significant correlation observed between the k of GST and hydrophobicity of 2-alkenals in the 
present study. Other kinetic constants did not depend on the aldehyde structural characteristics 
within the six compounds in the training set. 
For evaluation of the PBK/D models the outcomes of the different PBK/D models were 
compared with reported in vivo data. The predicted proportion of 2-propenal excreted as 
mercapturic acids as well as the predicted DNA adduct levels in the liver upon exposure of rats to 
trans-2-hexenal matched well with the in vivo data reported by Linhart et al. [37] or by Schuler 
and Eder [27], respectively. However, predicted DNA adduct levels induced by 2-butenal and 
trans-2-hexenal were respectively three and four orders of magnitude higher compared with data 
reported by Budiawan and Eder [36] or Stout et al. [38]. These striking gaps may be explained by 
the animal feeding status in the in vivo studies. While the PBK/D models assumed the complete 
absorption of administered aldehyde, a part of the aldehyde in the in vivo studies might have been 
depleted by food matrix present in the stomach and small intestine lumen because the rats were 
not fasted in the study by Stout et al. [38], and might not have been fasted in the study by 
Budiawan and Eder [36] before the dosing. The PBK/D model based predictions can therefore be 
considered to provide worse case estimates of the DNA adduct formation assuming complete 
absorption of the administered aldehydes. 
The present study illustrated that the integration of QSARs with PBK/D modelling 
facilitates group evaluations and read-across among compounds with similar structures. However, 
it should be noted that the QSAR-based PBK/D models developed did not include possible 
differences in DNA repair efficiencies among different aldehydes, which could be subject for 
further studies. The PBK/D models developed for 18 acyclic α,β-unsaturated aldehydes revealed 
that with decreasing bulkiness increasing amounts of DNA adducts are formed in the liver, which 
appears to be primarily due to lower levels of aldehyde detoxification via oxidation or GST 
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mediated GSH conjugation. While EFSA has selected trans-2-hexenal, 2-octenal, and 
trans-2-cis-6-nonadienal as representative compounds to evaluate the genotoxicity of the 18 
aldehydes based on the length, lipophilicity, and results from an unpublished (Q)SAR study [44], 
our results suggest 2-propenal would be most potent in forming DNA adducts. For all 18 
aldehydes, the predicted DNA adduct levels were well below the natural background levels of 
structurally similar 1,N2-exocyclic deoxyguanosine adducts in disease free human liver (6.8–110 
adducts/108 nt) [39, 40]. Based on these results it is concluded that DNA adduct formation caused 
by the 18 food-borne acyclic α,β-unsaturated aldehydes may be negligible. This conclusion is in 
line with what was previously concluded for trans-2-hexenal [13, 14] and may be corroborated by 
findings of chronic studies with rats or mice orally exposed to 2-propenal [45-47] that did not 
reveal increased tumour development up to exposures of 10 mg 2-propenal/kg bw/day, whereas 
higher dose levels induced mortality within a week [47]. The PBK/D model predicted a formation 
of 27 adduct/108 nt in the liver at an exposure of 10 mg 2-propenal/kg bw, which is still within the 
natural background DNA adduct levels observed in disease free human liver. 
A fundamental assumption for the approach based on QSARs is that the series of 
compounds in the applicability domain show similar properties [21]. In the present study we 
limited the applicability domain to acyclic α,β-unsaturated aldehydes without 2- or 3-alkylation, 
with no more than one conjugated double bond, and without any extra functional group. The 18 
compounds used in the present study, either in the test set or in the training set, fall within this 
specific applicability domain. The molecular descriptor MR range in the test set (16.9–60.9) is 
mostly covered by that in the training set (22.8–59.6). The statistical analysis indicated that the 
goodness-of-fit and the robustness of the four QSAR models with MR as the molecular descriptor 
developed in the present study were all sufficient. We acknowledge that in QSAR development 
internal validation using the training/test set splitting technique or the leave-out-many cross 
validation method, with a significant % of the calibration compounds left out at each step and 
repeating this for different selections is often recommend and applied [16, 20]. However, such an 
approach would be in contrast to the aim of our study, which was not the development of the 
QSARs per se, but the description of correlations with sufficient quality to enable the prediction 
of PBK/D model parameters for other congeners in the series, eliminating the need to 
experimentally determine the parameters for all compounds in the series. Furthermore, one should 
keep in mind that the PBK/D model outcomes are only partially dependent on QSAR estimated 
parameters. The degree of the sensitivity of the PBK/D model outcomes to the QSAR estimated 
parameters varies for each compound. In case of the PBK/D model for 2-propenal, which was 
predicted to induce the highest DNA adduct levels among the 18 aldehydes, the sensitivity 
analysis revealed that among the four parameters estimated by QSARs the predicted DNA adduct 
level is the most sensitive to the k for GSH conjugation in the liver. The normalised |SC| was 0.31, 
indicating that the overestimation of 10-fold in this parameter would have resulted in the 
underestimation of 3.1-fold in the DNA adduct level in the liver. This level of difference in the 
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dose levels relevant for human dietary exposure. Considering the large number of α,β-unsaturated 
aldehydes, QSAR models were developed to estimate chemical specific parameters namely Km or 
k values for the detoxification pathways. The QSAR models revealed that the Km for ALDH 
mediated oxidation decreased and the k for GST mediated GSH conjugation increased with 
increasing hydrophobicity or bulkiness of the aldehyde substrate. These findings are in line with 
results reported in the literature [8, 10, 15]. For example, Klysov [8] showed that the longer the 
chain length of 2-alkanals the lower the Km of human cytosolic ALDH. Furthermore Danielson et 
al. [15] attributed the increased specificity constants (kcat/Km) of mammalian cytosolic GST with 
increasing hydrophobicity of 4-hydroxy-2-alkenals to the hydrophobic nature of the electrophilic 
substrate-binding site in GSTs. The presence of a hydrophobic binding site in GSTs corroborates 
the significant correlation observed between the k of GST and hydrophobicity of 2-alkenals in the 
present study. Other kinetic constants did not depend on the aldehyde structural characteristics 
within the six compounds in the training set. 
For evaluation of the PBK/D models the outcomes of the different PBK/D models were 
compared with reported in vivo data. The predicted proportion of 2-propenal excreted as 
mercapturic acids as well as the predicted DNA adduct levels in the liver upon exposure of rats to 
trans-2-hexenal matched well with the in vivo data reported by Linhart et al. [37] or by Schuler 
and Eder [27], respectively. However, predicted DNA adduct levels induced by 2-butenal and 
trans-2-hexenal were respectively three and four orders of magnitude higher compared with data 
reported by Budiawan and Eder [36] or Stout et al. [38]. These striking gaps may be explained by 
the animal feeding status in the in vivo studies. While the PBK/D models assumed the complete 
absorption of administered aldehyde, a part of the aldehyde in the in vivo studies might have been 
depleted by food matrix present in the stomach and small intestine lumen because the rats were 
not fasted in the study by Stout et al. [38], and might not have been fasted in the study by 
Budiawan and Eder [36] before the dosing. The PBK/D model based predictions can therefore be 
considered to provide worse case estimates of the DNA adduct formation assuming complete 
absorption of the administered aldehydes. 
The present study illustrated that the integration of QSARs with PBK/D modelling 
facilitates group evaluations and read-across among compounds with similar structures. However, 
it should be noted that the QSAR-based PBK/D models developed did not include possible 
differences in DNA repair efficiencies among different aldehydes, which could be subject for 
further studies. The PBK/D models developed for 18 acyclic α,β-unsaturated aldehydes revealed 
that with decreasing bulkiness increasing amounts of DNA adducts are formed in the liver, which 
appears to be primarily due to lower levels of aldehyde detoxification via oxidation or GST 
QSAR-PBK/D modelling approach for 18 acyclic α,β-unsaturated aldehydes 
 
111 
 
mediated GSH conjugation. While EFSA has selected trans-2-hexenal, 2-octenal, and 
trans-2-cis-6-nonadienal as representative compounds to evaluate the genotoxicity of the 18 
aldehydes based on the length, lipophilicity, and results from an unpublished (Q)SAR study [44], 
our results suggest 2-propenal would be most potent in forming DNA adducts. For all 18 
aldehydes, the predicted DNA adduct levels were well below the natural background levels of 
structurally similar 1,N2-exocyclic deoxyguanosine adducts in disease free human liver (6.8–110 
adducts/108 nt) [39, 40]. Based on these results it is concluded that DNA adduct formation caused 
by the 18 food-borne acyclic α,β-unsaturated aldehydes may be negligible. This conclusion is in 
line with what was previously concluded for trans-2-hexenal [13, 14] and may be corroborated by 
findings of chronic studies with rats or mice orally exposed to 2-propenal [45-47] that did not 
reveal increased tumour development up to exposures of 10 mg 2-propenal/kg bw/day, whereas 
higher dose levels induced mortality within a week [47]. The PBK/D model predicted a formation 
of 27 adduct/108 nt in the liver at an exposure of 10 mg 2-propenal/kg bw, which is still within the 
natural background DNA adduct levels observed in disease free human liver. 
A fundamental assumption for the approach based on QSARs is that the series of 
compounds in the applicability domain show similar properties [21]. In the present study we 
limited the applicability domain to acyclic α,β-unsaturated aldehydes without 2- or 3-alkylation, 
with no more than one conjugated double bond, and without any extra functional group. The 18 
compounds used in the present study, either in the test set or in the training set, fall within this 
specific applicability domain. The molecular descriptor MR range in the test set (16.9–60.9) is 
mostly covered by that in the training set (22.8–59.6). The statistical analysis indicated that the 
goodness-of-fit and the robustness of the four QSAR models with MR as the molecular descriptor 
developed in the present study were all sufficient. We acknowledge that in QSAR development 
internal validation using the training/test set splitting technique or the leave-out-many cross 
validation method, with a significant % of the calibration compounds left out at each step and 
repeating this for different selections is often recommend and applied [16, 20]. However, such an 
approach would be in contrast to the aim of our study, which was not the development of the 
QSARs per se, but the description of correlations with sufficient quality to enable the prediction 
of PBK/D model parameters for other congeners in the series, eliminating the need to 
experimentally determine the parameters for all compounds in the series. Furthermore, one should 
keep in mind that the PBK/D model outcomes are only partially dependent on QSAR estimated 
parameters. The degree of the sensitivity of the PBK/D model outcomes to the QSAR estimated 
parameters varies for each compound. In case of the PBK/D model for 2-propenal, which was 
predicted to induce the highest DNA adduct levels among the 18 aldehydes, the sensitivity 
analysis revealed that among the four parameters estimated by QSARs the predicted DNA adduct 
level is the most sensitive to the k for GSH conjugation in the liver. The normalised |SC| was 0.31, 
indicating that the overestimation of 10-fold in this parameter would have resulted in the 
underestimation of 3.1-fold in the DNA adduct level in the liver. This level of difference in the 
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DNA adduct level prediction does not affect the general conclusions of the present study about the 
significance of the DNA adducts formed by the 18 food-borne acyclic α,β-unsaturated aldehydes. 
Altogether, the present study elucidates a possible negligible DNA adduct formation in 
the liver upon oral exposure to a range of acyclic food-borne α,β-unsaturated aldehydes at relevant 
levels of dietary intake. Furthermore, the present study provides a proof of principle for the use of 
a combined QSAR-PBK/D modelling approach to facilitate group evaluations and read-across 
among compounds with similar structures. 
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DNA adduct level prediction does not affect the general conclusions of the present study about the 
significance of the DNA adducts formed by the 18 food-borne acyclic α,β-unsaturated aldehydes. 
Altogether, the present study elucidates a possible negligible DNA adduct formation in 
the liver upon oral exposure to a range of acyclic food-borne α,β-unsaturated aldehydes at relevant 
levels of dietary intake. Furthermore, the present study provides a proof of principle for the use of 
a combined QSAR-PBK/D modelling approach to facilitate group evaluations and read-across 
among compounds with similar structures. 
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SUPPORTING INFORMATION 
 
Supporting Information 4.1.  UPLC methods to quantify trans-2-pentenal, trans-2-hexenal, 
trans-2-octenal, trans-2-decenal, trans-2-dodecenal, and trans-2-cis-6-nonadienal metabolites 
(A-C) and 2ʹ-dG adducts (D) in incubation samples . 
 
(A) Carboxylic acids 
The gradient was made with acetonitrile and ultrapure water containing 0.1% (v/v) TFA. The flow 
rate was 0.6 mL/min. Each analysis was followed by the default cleaning and equilibration step 
(i.e. the percentage of acetonitrile was increased to 100% over 0.2 min, maintained for 0.2 min, 
lowered to 0% over 0.2 min, kept for 0.2 min, increased to the initial condition over 0.2 min and 
maintained for 1.0 min for equilibration). 
Aldehyde UPLC method Retention time  
trans-2-pentenal  From 10 to 10.5% acetonitrile over 2 min, or 
from  6 to 9% acetonitrile over 3 min. 
1.6 min 
2.3 min 
trans-2-hexenal From 20 to 30% acetonitrile over 2 min. 1.3 min 
trans-2-octenal From 32 to 47% acetonitrile over 2.5 min. 1.7 min 
trans-2-decenal From 46 to 62% acetonitrile over 2.5 min. 1.5 min 
trans-2-dodecenal From 56 to 68% acetonitrile over 2 min. 1.6 min 
trans-2-cis-6-nonadienal From 35 to 43% acetonitrile over 2 min. 1.4  min 
(B) Alcohols 
The gradient was made with acetonitrile and ultrapure water containing 0.1% (v/v) formic acid. 
The flow rate was 0.6 mL/min. Each analysis was followed by the default cleaning and 
equilibration step as described in (A). 
Aldehyde UPLC method Retention time  
trans-2-pentenal From 0 to 5% acetonitrile over 6 min. 5.3 min 
trans-2-hexenal From 0 to 10% acetonitrile over 10 min. 9.3 min 
trans-2-decenal From 30 to 39% acetonitrile over 9 min. 7.7 min 
trans-2-dodecenal From 37 to 50% acetonitrile over 13 min. 1.5 min 
trans-2-cis-6-nonadienal From 25 to 32% acetonitrile over 7 min. 3.9 min 
 (C) GSH conjugates 
The gradient was made with acetonitrile and ultrapure water containing 0.1% (v/v) TFA. The flow 
rate was 0.6 mL/min. Each analysis was followed by the default cleaning and equilibration step as 
described in (A). 
Aldehyde UPLC method Retention time  
trans-2-pentenal From 6 to 8% acetonitrile over 2 min. 0.82 and 0.91 
min 
trans-2-hexenal From 5 to 10% acetonitrile over 2.5 min. 2.2 and 2.4 min 
trans-2-octenal From 21 to 25% acetonitrile over 2 min. 0.9 and 1.0 min 
trans-2-decenal From 21 to 25% acetonitrile over 2 min. 1.4 and 1.5 min 
trans-2-dodecenal From 28 to 32% acetonitrile over 2 min. 1.5 and 1.6 min 
trans-2-cis-6-nonadienal From 16 to 17% acetonitrile over 2 min. 1.1 and 1.2 min 
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rate was 0.6 mL/min. Each analysis was followed by the default cleaning and equilibration step 
(i.e. the percentage of acetonitrile was increased to 100% over 0.2 min, maintained for 0.2 min, 
lowered to 0% over 0.2 min, kept for 0.2 min, increased to the initial condition over 0.2 min and 
maintained for 1.0 min for equilibration). 
Aldehyde UPLC method Retention time  
trans-2-pentenal  From 10 to 10.5% acetonitrile over 2 min, or 
from  6 to 9% acetonitrile over 3 min. 
1.6 min 
2.3 min 
trans-2-hexenal From 20 to 30% acetonitrile over 2 min. 1.3 min 
trans-2-octenal From 32 to 47% acetonitrile over 2.5 min. 1.7 min 
trans-2-decenal From 46 to 62% acetonitrile over 2.5 min. 1.5 min 
trans-2-dodecenal From 56 to 68% acetonitrile over 2 min. 1.6 min 
trans-2-cis-6-nonadienal From 35 to 43% acetonitrile over 2 min. 1.4  min 
(B) Alcohols 
The gradient was made with acetonitrile and ultrapure water containing 0.1% (v/v) formic acid. 
The flow rate was 0.6 mL/min. Each analysis was followed by the default cleaning and 
equilibration step as described in (A). 
Aldehyde UPLC method Retention time  
trans-2-pentenal From 0 to 5% acetonitrile over 6 min. 5.3 min 
trans-2-hexenal From 0 to 10% acetonitrile over 10 min. 9.3 min 
trans-2-decenal From 30 to 39% acetonitrile over 9 min. 7.7 min 
trans-2-dodecenal From 37 to 50% acetonitrile over 13 min. 1.5 min 
trans-2-cis-6-nonadienal From 25 to 32% acetonitrile over 7 min. 3.9 min 
 (C) GSH conjugates 
The gradient was made with acetonitrile and ultrapure water containing 0.1% (v/v) TFA. The flow 
rate was 0.6 mL/min. Each analysis was followed by the default cleaning and equilibration step as 
described in (A). 
Aldehyde UPLC method Retention time  
trans-2-pentenal From 6 to 8% acetonitrile over 2 min. 0.82 and 0.91 
min 
trans-2-hexenal From 5 to 10% acetonitrile over 2.5 min. 2.2 and 2.4 min 
trans-2-octenal From 21 to 25% acetonitrile over 2 min. 0.9 and 1.0 min 
trans-2-decenal From 21 to 25% acetonitrile over 2 min. 1.4 and 1.5 min 
trans-2-dodecenal From 28 to 32% acetonitrile over 2 min. 1.5 and 1.6 min 
trans-2-cis-6-nonadienal From 16 to 17% acetonitrile over 2 min. 1.1 and 1.2 min 
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(D) 2ʹ-dG adducts 
 The gradient was made with acetonitrile and ultrapure water containing 0.1% (v/v) TFA. The 
flow rate was 0.6 mL/min. Each analysis was followed by the default cleaning and equilibration 
step as described in (A).  
Aldehyde UPLC method Retention time  
trans-2-pentenal From 92 to 91 % acetonitrile over 5 min. 1.2 and 1.3 min 
trans-2-hexenal From 8.5 to 10% acetonitrile over 5 min. 3.0 min 
trans-2-octenal From 15 to 20% acetonitrile over 5 min. 3.9 min 
trans-2-decenal From 27 to 32% acetonitrile over 5 min. 2.8 min 
trans-2-cis-6-nonadienal From 15 to 20% acetonitrile over 5 min. 4.2 min 
 
 
 
Supporting Information 4.2. Tissue/blood partition coefficients 
Compounds Fat/blood Liver/blood 
Small intestine/blood 
Richly perfused 
tissues/blood 
Slowly perfused 
tissues/blood 
2-propenal 1.3 0.83 0.46 
2-pentenal 4.7 0.96 0.51 
4-methyl-2-pentenal 8.9 1.1 0.54 
2-hexenal 
trans-2-hexenal 
cis-2-hexenal 
9.9 1.1 0.55 
2-heptenal 
trans-2-heptenal 
20.5 1.3 0.60 
2-octenal 
trans-2-octenal 
40.5 1.7 0.68 
2-nonenal 
trans-2-nonenal 
cis-2-nonenal 
71.7 2.3 0.79 
2-decenal 
trans-2-decenal 
110 3.2 0.94 
2-undecenal 146 4.5 1.1 
trans-2-dodecenal 
2-dodecenal 
171 6.4 1.4 
2-tridecenal 186 8.3 1.7 
2-tetradecenal 193 10.7 2.2 
trans-2-cis-6-octadienal 30.3 1.5 0.64 
2,6-nonadienal 
trans-2-cis-6-nonadienal 
trans-2-trans-6-nonadienal 
56.3 2.0 0.74 
2,6-dodecadienal 92.6 2.8 0.86 
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Supporting Information 4.3. PBK/D model equations 
  
(1) Uptake from GI cavity   
The uptake of aldehyde from the intestinal cavity into the small intestine compartment  was described by a 
first-order process as follows:   
dAGI/dt =-Ka*AGI   
InitAGI = DOSE    
where   
AGI  Amount of aldehyde remaining in GI cavity (μmol)   
Ka   Linear uptake rate (/h)   
DOSE  Amount of aldehyde administered in a rat (μmol)  
  
(2) Slowly perfused tissue, richly perfused tissue and fat   
Amount aldehyde in slowly perfused tissue, richly perfused tissue or fat compartment was described as 
follows:    
dATi/dt = QTi*(CA-CVTi)   
CTi = ATi/VTi   
CVTi = CTi/PTi    
where  
ATi   Amount of aldehyde in a tissue (μmol)  
QTi  Blood flow into a tissue (L/h)   
CA   Concentration of aldehyde in arterial blood perfusing a tissue (μmol/L)   
CVTi  Concentration of aldehyde in venous blood leaving a tissue (μmol/L)   
CTi  Concentration of aldehyde in a tissue (μmol/kg)  
VTi  Volume of a tissue (kg)   
PTi   Tissue/blood partition coefficient of aldehyde 
  
(3) Liver   
Amount aldehyde in the liver (AL, μmol) is described as follows:    
dAL/dt   
= QL*CA +QSi*CVSi - (QL+QSi) *CVL - (eq.1 + eq.2 + eq.3 + eq.4 + eq.5 + eq.6)   
CL = AL/VL   
CVL = CL/PL    
where  
QL   Blood flow into the liver (L/h)   
QSi  Blood flow into the small intestine (L/h)   
CVSi   Concentration of aldehyde in venous blood leaving the small intestine  (μmol/L)   
CVL  Concentration of aldehyde in venous blood leaving the liver (μmol/L)   
CL   Concentration of aldehyde in the liver (μmol/L)   
PL   Liver/blood partition coefficient of aldehyde 
 
Amount aldehyde oxidized to carboxylic acid enzymatically in the liver (AMLCA, μmol) is described to 
follow Michaelis-Menten equation:   
dAMLCA/dt = Vsmax, L_CA * CVL / (Km,L_CA + CVL)     ---------------- eq. 1   
where 
Vsmax,L_CA  Scaled Vmax for enzymatic oxidation of aldehyde in the liver (μmol/h)   
Km, L_CA  Km for enzymatic oxidation of aldehyde in the liver (μM)   
 
Amount aldehyde reduced to alcohol in the liver (AMLAO, μmol) is described to follow 
Michaelis-Menten-equation:    
dAMLAO/dt = Vsmax, L_AO*CVL/(Km,L_AO + CVL)    ---------------- eq. 2    
where   
Vsmax,L_AO  Scaled Vmax for enzymatic reduction of aldehyde in the liver (μmol/h)   
Km,L_AO  Km for enzymatic reduction of aldehyde in the liver (μM)   
 
Amount aldehyde metabolized in liver to GSH conjugation by GSTs (AMLAGGST, μmol) is described as 
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(D) 2ʹ-dG adducts 
 The gradient was made with acetonitrile and ultrapure water containing 0.1% (v/v) TFA. The 
flow rate was 0.6 mL/min. Each analysis was followed by the default cleaning and equilibration 
step as described in (A).  
Aldehyde UPLC method Retention time  
trans-2-pentenal From 92 to 91 % acetonitrile over 5 min. 1.2 and 1.3 min 
trans-2-hexenal From 8.5 to 10% acetonitrile over 5 min. 3.0 min 
trans-2-octenal From 15 to 20% acetonitrile over 5 min. 3.9 min 
trans-2-decenal From 27 to 32% acetonitrile over 5 min. 2.8 min 
trans-2-cis-6-nonadienal From 15 to 20% acetonitrile over 5 min. 4.2 min 
 
 
 
Supporting Information 4.2. Tissue/blood partition coefficients 
Compounds Fat/blood Liver/blood 
Small intestine/blood 
Richly perfused 
tissues/blood 
Slowly perfused 
tissues/blood 
2-propenal 1.3 0.83 0.46 
2-pentenal 4.7 0.96 0.51 
4-methyl-2-pentenal 8.9 1.1 0.54 
2-hexenal 
trans-2-hexenal 
cis-2-hexenal 
9.9 1.1 0.55 
2-heptenal 
trans-2-heptenal 
20.5 1.3 0.60 
2-octenal 
trans-2-octenal 
40.5 1.7 0.68 
2-nonenal 
trans-2-nonenal 
cis-2-nonenal 
71.7 2.3 0.79 
2-decenal 
trans-2-decenal 
110 3.2 0.94 
2-undecenal 146 4.5 1.1 
trans-2-dodecenal 
2-dodecenal 
171 6.4 1.4 
2-tridecenal 186 8.3 1.7 
2-tetradecenal 193 10.7 2.2 
trans-2-cis-6-octadienal 30.3 1.5 0.64 
2,6-nonadienal 
trans-2-cis-6-nonadienal 
trans-2-trans-6-nonadienal 
56.3 2.0 0.74 
2,6-dodecadienal 92.6 2.8 0.86 
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Supporting Information 4.3. PBK/D model equations 
  
(1) Uptake from GI cavity   
The uptake of aldehyde from the intestinal cavity into the small intestine compartment  was described by a 
first-order process as follows:   
dAGI/dt =-Ka*AGI   
InitAGI = DOSE    
where   
AGI  Amount of aldehyde remaining in GI cavity (μmol)   
Ka   Linear uptake rate (/h)   
DOSE  Amount of aldehyde administered in a rat (μmol)  
  
(2) Slowly perfused tissue, richly perfused tissue and fat   
Amount aldehyde in slowly perfused tissue, richly perfused tissue or fat compartment was described as 
follows:    
dATi/dt = QTi*(CA-CVTi)   
CTi = ATi/VTi   
CVTi = CTi/PTi    
where  
ATi   Amount of aldehyde in a tissue (μmol)  
QTi  Blood flow into a tissue (L/h)   
CA   Concentration of aldehyde in arterial blood perfusing a tissue (μmol/L)   
CVTi  Concentration of aldehyde in venous blood leaving a tissue (μmol/L)   
CTi  Concentration of aldehyde in a tissue (μmol/kg)  
VTi  Volume of a tissue (kg)   
PTi   Tissue/blood partition coefficient of aldehyde 
  
(3) Liver   
Amount aldehyde in the liver (AL, μmol) is described as follows:    
dAL/dt   
= QL*CA +QSi*CVSi - (QL+QSi) *CVL - (eq.1 + eq.2 + eq.3 + eq.4 + eq.5 + eq.6)   
CL = AL/VL   
CVL = CL/PL    
where  
QL   Blood flow into the liver (L/h)   
QSi  Blood flow into the small intestine (L/h)   
CVSi   Concentration of aldehyde in venous blood leaving the small intestine  (μmol/L)   
CVL  Concentration of aldehyde in venous blood leaving the liver (μmol/L)   
CL   Concentration of aldehyde in the liver (μmol/L)   
PL   Liver/blood partition coefficient of aldehyde 
 
Amount aldehyde oxidized to carboxylic acid enzymatically in the liver (AMLCA, μmol) is described to 
follow Michaelis-Menten equation:   
dAMLCA/dt = Vsmax, L_CA * CVL / (Km,L_CA + CVL)     ---------------- eq. 1   
where 
Vsmax,L_CA  Scaled Vmax for enzymatic oxidation of aldehyde in the liver (μmol/h)   
Km, L_CA  Km for enzymatic oxidation of aldehyde in the liver (μM)   
 
Amount aldehyde reduced to alcohol in the liver (AMLAO, μmol) is described to follow 
Michaelis-Menten-equation:    
dAMLAO/dt = Vsmax, L_AO*CVL/(Km,L_AO + CVL)    ---------------- eq. 2    
where   
Vsmax,L_AO  Scaled Vmax for enzymatic reduction of aldehyde in the liver (μmol/h)   
Km,L_AO  Km for enzymatic reduction of aldehyde in the liver (μM)   
 
Amount aldehyde metabolized in liver to GSH conjugation by GSTs (AMLAGGST, μmol) is described as 
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following :  
dAMLAGGST/dt =  ks,L*CVL*CGSHLC/(Km_G+CGSHLC)  ---------------- eq.3  
where   
ks,L  Scaled first order rate constant derived in this study for enzymatic conjugation of aldehyde 
with GSH in the liver (ml/h)   
CGSHLC Concentration of GSH in liver cytosol (μmol/kg liver), calculated from eq.7 
Km_G Km toward GSH for enzymatic GSH conjugation of aldehyde (μM)   
   
Amount aldehyde chemically bound in liver to GSH (AMLAGchem, μmol) is described as following: 
dAMLAGchem/dt = kGSH*CVL*CGSHLC*VL   ---------------- eq.4 
where   
kGSH  Second order rate constant of aldehyde binding to GSH (/μmol/h)   
VL Volume of the liver (kg)  
 
Amount aldehyde protein adducts in liver (AMLAP, μmol) is described as following: 
dAMLAP/dt = kGSH*CVL*CPROL*VL    ---------------- eq.5 
where   
CPROL Concentration of protein reaction sites in the liver (μmol/kg liver) 
 
The formation of DNA adduct in the liver (AMLDAform) was described as following:  
dAMLDAform/dt = kDNA*CVL*CdGL*VL    ---------------- eq.6  
where  
kDNA  Second order rate constant of aldehyde binding to 2ʹ-dG (/μmol/h)   
CdGL  Concentration of 2ʹ-dG in the liver (μmol/kg liver)   
 
CdGL was caluculated to be 1.36 μmol/kg liver using the average molecular weight of  nucleotides (330 
g/mol) and reported concentration of DNA in a rat liver (1.8 g/kg liver).  
 
Amount of DNA adduct in liver (AMLDA, μmol) is described by subtracting elimination of DNA adduct 
from the formation:    
dAMLDA/dt= eq.6- AMLDA* (ln2/ T1/2)    
where  
T1/2  Half-life of DNA adduct in the liver (h)    
 
Amount of GSH present in the liver cytosol (AMGSHLC, μmol) is described by zero-order  synthesis and 
reduction by first-order elimination due to turnover and depletion by aldehyde:   
dAMGSHLC = GSYNL*VL*0.9 - (eq.3+ eq.4+  kL_GLOS* AMGSHLC)  ---------------- eq.7   
Init AMGSHLC = InitGSHL *VL*0.9   
CGSHLC = AMLcGSH/VL   
where  
GSYNL  Rate of GSH synthesis in the liver (μmol/h)   
kL_GLOS  First-order rate of GSH turnover in the liver (/h)   
InitGSHL  Initial concentration of GSH in the liver (μmol/kg liver)  
 
When eq.7 gave negative values, the value zero was used as the amount of GSH in the liver cytosol.  
  
(4) Small intestine   
The amount aldehyde in small intestine tissue, (ASi, μmol) is described as follows:    
dASi/dt = QSi*(CA -CVSi) + Ka*AGI - (eq.8 + eq.9 + eq.10 + eq.11)   
CSi = ASi/VSi  
CVSi = CSi/PSi  
where   
CSi  Concentration of aldehyde in the small intestine (μmol/L)   
VSi  Volume of the small intestine (kg)   
PSi   Small intestine/blood partition coefficient of aldehyde  
  
Amount aldehyde enzymatically oxidized carboxylic acid (AMSiCA, μmol) in the  small intestine is 
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described by Michaelis-Menten equation:   
dAMSiCA/dt = Vsmax,Si_CA*CVSi/(Km, Si_CA + CVSi)   ---------------- eq.8    
where   
Vsmax,Si_CA  Scaled Vmax for enzymatic oxidation of aldehyde in the small intestine (μmol/h)   
Km,Si_CA  Km for enzymatic oxidation of aldehyde in small intestine (μM) 
  
 
Amount aldehyde metabolized in small intestine to GSH conjugation by GSTs (AMSiAGGST, μmol) is 
described as following : 
   dAMSiAGGST/dt =  ks,Si*CVSi*CGSHSiC/(Km_G+CGSHSiC)  ---------------- eq.9  
where   
ks,Si  Scaled first order rate constant derived in this study for enzymatic conjugation of aldehyde 
with GSH in small intestine (ml/h)   
CGSHSiC Concentration of GSH in small intestine cytosol (μmol/kg small intestine), calculated from 
eq.8 
Km_G Km toward GSH for enzymatic GSH conjugation of aldehyde (μM)   
  
 
Amount aldehyde chemically bound in small intestine to GSH (AMSiAGchem, μmol) is described as 
following: 
dAMLAGchem/dt =  kGSH*CVSi*CGSHSiC*VSi   --------------- eq.10 
where   
kGSH  Second order rate constant of aldehyde binding to GSH (/μmol/h)   
VSi Volume of the small intestine (kg)  
 
Amount aldehyde protein adducts in small intestine (AMSiAP, μmol) is described as following: 
dAMSiAP/dt =  kGSH*CSiL*CPROSi*VSi   --------------- eq.11 
where   
CPROSi Concentration of protein reaction sites in the small intestine (μmol/kg liver) 
 
Amount of GSH present in small intestine cytosol (AMGSHSiC, μmol) is described in the same way as in 
the liver:   
dAMGSHSiC = GSYNSi *VSi*0.9- (eq.9 + eq. 10 + kGLOS_Si*AMGSHSiC)  ------------ eq. 12 
Init AMGSHSiC = InitGSHSi *VSi*0.9  
CGSHSiC = AMSicGSH/VSi   
where   
GSYNSi  Rate of GSH synthesis in small intestine (μmol/h)   
kGLOS_Si  First-order rate of GSH turnover in small intestine (/h)   
InitGSHSi  Initial concentration of GSH in small intestine (μmol/kg small intestine)   
  
As was the case in the liver, the value zero was used as the amount of GSH in the small  intestine cytosol 
when eq.12 gave negative values.   
  
(5) Venous blood and arterial blood   
Concentration of aldehyde in venous blood (CV) and in arterial blood (CA, both in μmol/L) was described 
as follows:   
dAV/dt = QF*CVF + (QL+QSi)*CVL + QR*CVR + QS*CVS - QC*CV   
CV = AV/(VA+VV)   
CV = CA   
where  
AV   Amount of aldehyde in venous blood (μmol)  
QF   Blood flow into fat (L/h)   
CVF  Concentration of aldehyde in venous blood leaving fat (μmol/L)   
QR  Blood flow into richly perfused tissue (L/h)   
CVR  Concentration of aldehyde in venous blood leaving richly perfused tissue  (μmol/L)   
QS   Blood flow into slowly perfused tissue (L/h)   
CVS  Concentration of aldehyde in venous blood leaving slowly perfused tissue (μmol/L)  
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following :  
dAMLAGGST/dt =  ks,L*CVL*CGSHLC/(Km_G+CGSHLC)  ---------------- eq.3  
where   
ks,L  Scaled first order rate constant derived in this study for enzymatic conjugation of aldehyde 
with GSH in the liver (ml/h)   
CGSHLC Concentration of GSH in liver cytosol (μmol/kg liver), calculated from eq.7 
Km_G Km toward GSH for enzymatic GSH conjugation of aldehyde (μM)   
   
Amount aldehyde chemically bound in liver to GSH (AMLAGchem, μmol) is described as following: 
dAMLAGchem/dt = kGSH*CVL*CGSHLC*VL   ---------------- eq.4 
where   
kGSH  Second order rate constant of aldehyde binding to GSH (/μmol/h)   
VL Volume of the liver (kg)  
 
Amount aldehyde protein adducts in liver (AMLAP, μmol) is described as following: 
dAMLAP/dt = kGSH*CVL*CPROL*VL    ---------------- eq.5 
where   
CPROL Concentration of protein reaction sites in the liver (μmol/kg liver) 
 
The formation of DNA adduct in the liver (AMLDAform) was described as following:  
dAMLDAform/dt = kDNA*CVL*CdGL*VL    ---------------- eq.6  
where  
kDNA  Second order rate constant of aldehyde binding to 2ʹ-dG (/μmol/h)   
CdGL  Concentration of 2ʹ-dG in the liver (μmol/kg liver)   
 
CdGL was caluculated to be 1.36 μmol/kg liver using the average molecular weight of  nucleotides (330 
g/mol) and reported concentration of DNA in a rat liver (1.8 g/kg liver).  
 
Amount of DNA adduct in liver (AMLDA, μmol) is described by subtracting elimination of DNA adduct 
from the formation:    
dAMLDA/dt= eq.6- AMLDA* (ln2/ T1/2)    
where  
T1/2  Half-life of DNA adduct in the liver (h)    
 
Amount of GSH present in the liver cytosol (AMGSHLC, μmol) is described by zero-order  synthesis and 
reduction by first-order elimination due to turnover and depletion by aldehyde:   
dAMGSHLC = GSYNL*VL*0.9 - (eq.3+ eq.4+  kL_GLOS* AMGSHLC)  ---------------- eq.7   
Init AMGSHLC = InitGSHL *VL*0.9   
CGSHLC = AMLcGSH/VL   
where  
GSYNL  Rate of GSH synthesis in the liver (μmol/h)   
kL_GLOS  First-order rate of GSH turnover in the liver (/h)   
InitGSHL  Initial concentration of GSH in the liver (μmol/kg liver)  
 
When eq.7 gave negative values, the value zero was used as the amount of GSH in the liver cytosol.  
  
(4) Small intestine   
The amount aldehyde in small intestine tissue, (ASi, μmol) is described as follows:    
dASi/dt = QSi*(CA -CVSi) + Ka*AGI - (eq.8 + eq.9 + eq.10 + eq.11)   
CSi = ASi/VSi  
CVSi = CSi/PSi  
where   
CSi  Concentration of aldehyde in the small intestine (μmol/L)   
VSi  Volume of the small intestine (kg)   
PSi   Small intestine/blood partition coefficient of aldehyde  
  
Amount aldehyde enzymatically oxidized carboxylic acid (AMSiCA, μmol) in the  small intestine is 
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described by Michaelis-Menten equation:   
dAMSiCA/dt = Vsmax,Si_CA*CVSi/(Km, Si_CA + CVSi)   ---------------- eq.8    
where   
Vsmax,Si_CA  Scaled Vmax for enzymatic oxidation of aldehyde in the small intestine (μmol/h)   
Km,Si_CA  Km for enzymatic oxidation of aldehyde in small intestine (μM) 
  
 
Amount aldehyde metabolized in small intestine to GSH conjugation by GSTs (AMSiAGGST, μmol) is 
described as following : 
   dAMSiAGGST/dt =  ks,Si*CVSi*CGSHSiC/(Km_G+CGSHSiC)  ---------------- eq.9  
where   
ks,Si  Scaled first order rate constant derived in this study for enzymatic conjugation of aldehyde 
with GSH in small intestine (ml/h)   
CGSHSiC Concentration of GSH in small intestine cytosol (μmol/kg small intestine), calculated from 
eq.8 
Km_G Km toward GSH for enzymatic GSH conjugation of aldehyde (μM)   
  
 
Amount aldehyde chemically bound in small intestine to GSH (AMSiAGchem, μmol) is described as 
following: 
dAMLAGchem/dt =  kGSH*CVSi*CGSHSiC*VSi   --------------- eq.10 
where   
kGSH  Second order rate constant of aldehyde binding to GSH (/μmol/h)   
VSi Volume of the small intestine (kg)  
 
Amount aldehyde protein adducts in small intestine (AMSiAP, μmol) is described as following: 
dAMSiAP/dt =  kGSH*CSiL*CPROSi*VSi   --------------- eq.11 
where   
CPROSi Concentration of protein reaction sites in the small intestine (μmol/kg liver) 
 
Amount of GSH present in small intestine cytosol (AMGSHSiC, μmol) is described in the same way as in 
the liver:   
dAMGSHSiC = GSYNSi *VSi*0.9- (eq.9 + eq. 10 + kGLOS_Si*AMGSHSiC)  ------------ eq. 12 
Init AMGSHSiC = InitGSHSi *VSi*0.9  
CGSHSiC = AMSicGSH/VSi   
where   
GSYNSi  Rate of GSH synthesis in small intestine (μmol/h)   
kGLOS_Si  First-order rate of GSH turnover in small intestine (/h)   
InitGSHSi  Initial concentration of GSH in small intestine (μmol/kg small intestine)   
  
As was the case in the liver, the value zero was used as the amount of GSH in the small  intestine cytosol 
when eq.12 gave negative values.   
  
(5) Venous blood and arterial blood   
Concentration of aldehyde in venous blood (CV) and in arterial blood (CA, both in μmol/L) was described 
as follows:   
dAV/dt = QF*CVF + (QL+QSi)*CVL + QR*CVR + QS*CVS - QC*CV   
CV = AV/(VA+VV)   
CV = CA   
where  
AV   Amount of aldehyde in venous blood (μmol)  
QF   Blood flow into fat (L/h)   
CVF  Concentration of aldehyde in venous blood leaving fat (μmol/L)   
QR  Blood flow into richly perfused tissue (L/h)   
CVR  Concentration of aldehyde in venous blood leaving richly perfused tissue  (μmol/L)   
QS   Blood flow into slowly perfused tissue (L/h)   
CVS  Concentration of aldehyde in venous blood leaving slowly perfused tissue (μmol/L)  
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Supporting information 4.4. α,β-Unsaturated aldehyde concentration-dependent rate of 
metabolite formation by rat tissue fractions. The figures show the enzymatic conversion rate of 
α,β-unsaturated aldehyde  to carboxylic acids in the liver (A) and small intestine (B), to alcohols 
in the liver (C), and to GSH conjugates in the liver (D) and  small intestine (E). The 
abbreviations stands for trans-2-pentenal (t-2PT), trans-2-hexenal (t-2HX), trans-2-octenal 
(t-2OC), trans-2-decenal (t-2DC), trans-2-dodecenal (t-2DD), and trans-2-cis-6-nonadienal (t-2, 
c-6ND). 
A.      B.      
 
C.    
 
D. E.  
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Supporting Information 4.5.  UPLC chromatograms of 2ʹ-dG adducts  
Each aldehyde (10 mM) was incubated with 1.95 mM 2ʹ-dG for 48 hrs at room temperature. The 
chromatograms were obtained at wavelength 262 nm. 
 
trans-2-pentenal  
 
trans-2-hexenal 
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Supporting information 4.4. α,β-Unsaturated aldehyde concentration-dependent rate of 
metabolite formation by rat tissue fractions. The figures show the enzymatic conversion rate of 
α,β-unsaturated aldehyde  to carboxylic acids in the liver (A) and small intestine (B), to alcohols 
in the liver (C), and to GSH conjugates in the liver (D) and  small intestine (E). The 
abbreviations stands for trans-2-pentenal (t-2PT), trans-2-hexenal (t-2HX), trans-2-octenal 
(t-2OC), trans-2-decenal (t-2DC), trans-2-dodecenal (t-2DD), and trans-2-cis-6-nonadienal (t-2, 
c-6ND). 
A.      B.      
 
C.    
 
D. E.  
 
 
Chapter 4 
 
 
121 
 
Supporting Information 4.5.  UPLC chromatograms of 2ʹ-dG adducts  
Each aldehyde (10 mM) was incubated with 1.95 mM 2ʹ-dG for 48 hrs at room temperature. The 
chromatograms were obtained at wavelength 262 nm. 
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ABSTRACT  
 
There are various α,β-unsaturated aldehydes present in our diet as natural constituents and food 
flavouring agents. Genotoxicity of α,β-unsaturated aldehydes shown in vitro may raise a concern 
for the use of the aldehydes as food flavourings, while in vivo at low dose exposures the 
formation of DNA adducts may be prevented by adequate detoxification. Unlike many 
α,β-unsaturated aldehydes for which in vivo data on genotoxicity and carcinogenicity are absent, 
cinnamaldehyde was shown not to be genotoxic or carcinogenic in vivo. The aim of the present 
study was to examine DNA adduct formation by cinnamaldehyde using physiologically based 
kinetic/dynamic (PBK/D) modelling, and to compare these cinnamaldehyde DNA adduct levels to 
those predicted previously for 18 other food-borne α,β-unsaturated aldehydes. The 
cinnamaldehyde PBK/D models were developed based on kinetic parameters obtained by 
performing in vitro incubations. In rats, cinnamaldehyde was shown to induce higher DNA 
adducts per exposure dose than 6 out of the 18 food borne acyclic α,β-unsaturated aldehydes, 
indicating these 6 aldehydes may also test negative for genotoxicity and carcinogenicity at high 
dose levels. At the highest cinnamaldehyde dose that was tested for carcinogenicity in vivo and 
tested negative, the DNA adduct formation by cinnamaldehyde was predicted to be at least three 
orders of magnitude higher than the predictions of DNA adduct formation by the 18 other 
food-borne aldehydes at their respective estimated daily intake. These result corroborate the 
conclusion that for all the 18 α,β-unsaturated aldehydes DNA adduct formation at doses relevant 
for human dietary exposure does not raise a safety concern. The present study furthermore 
illustrates that physiologically based in silico modelling approach facilitates a science-based 
comparison and read-across on the possible risks posed by food-borne DNA reactive agents.  
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INTRODUCTION 
 
There are various α,β-unsaturated aldehydes present in our diet as natural constituents and as 
intentionally added food flavouring agents. α,β-Unsaturated aldehydes are electrophilic due to 
their α,β-unsaturated aldehyde moiety and can react with electron rich macromolecules including 
DNA, leading to the formation of DNA adducts [1]. Various aldehydes have been found positive 
in a number of in vitro genotoxicity tests [2-4], which may raise a concern with respect to 
genotoxicity upon the use of α,β-unsaturated aldehydes as food flavouring agents. The European 
Food Safety Authority (EFSA) considers the α,β-unsaturated aldehyde moiety an alert for 
genotoxicity and requires in vivo genotoxicity data to overrule any positive in vitro genotoxicity 
results [5]. Consequently, the use of more than 70 α,β-unsaturated aldehydes and their related 
compounds, which may give rise to such aldehydes by metabolism in vivo as food flavouring 
agents, has been suspended in the EU since 2013 (Commission Implementing Regulation (EU) 
No. 872/2012 of 1 October 2012). The EFSA has requested more data, especially in vivo data on 
genotoxicity for further discussion [6]. In contrast, the Expert Panel of the Flavoring Extract 
Manufacturers' Association (FEMA) and the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA) have concluded that there is no significant risk associated with the use of 
α,β-unsaturated aldehydes and related compounds based on their low levels of use, and possible 
rapid detoxification [7-9].  
The highest exposure to α,β-unsaturated aldehydes via diet is attributed to cinnamaldehyde 
[10]. Cinnamaldehyde occurs naturally in cassia and cinnamon oils isolated from cinnamon trees 
as the primary ingredient [11]. It has a strong odour of cinnamon and a sweet taste, and therefore 
has been extensively used as flavouring agent in foods and beverages [11, 12]. The estimated 
daily intake (EDI) of cinnamaldehyde from addition as flavouring substance is up to 59,000 
μg/person/day in the US [13]. Unlike most α,β-unsaturated aldehydes, cinnamaldehyde was 
judged by EFSA not to be genotoxic or carcinogenic [14]. This conclusion was based on a 
negative animal genotoxicity and carcinogenicity study [11]. In this study, rats and mice were fed 
daily up to 4,100 ppm of trans-cinnamaldehyde in modified corn starch and sucrose 
microcapsules mixed in their feed [11], which corresponds approximately to 200 and 550 mg 
cinnamaldehyde/kg bw/day for rat and mice, respectively. After two years, there was no evidence 
of a statistically significant increase in the incidence of neoplasms in any group treated with 
cinnamaldehyde. 
An important question is whether the safety of dietary exposure to other α,β-unsaturated 
aldehydes, which have been shown to be genotoxic in vitro while in vivo genotoxicity and 
carcinogenicity data are limited, could be established based on read-across from these data on 
cinnamaldehyde. To this end, the level of DNA adducts formed in vivo by the different 
structurally similar compounds could be compared, taking chemical dependent differences in 
reactivity and detoxification efficiencies into account. Upon ingestion, α,β-unsaturated aldehydes 
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The highest exposure to α,β-unsaturated aldehydes via diet is attributed to cinnamaldehyde 
[10]. Cinnamaldehyde occurs naturally in cassia and cinnamon oils isolated from cinnamon trees 
as the primary ingredient [11]. It has a strong odour of cinnamon and a sweet taste, and therefore 
has been extensively used as flavouring agent in foods and beverages [11, 12]. The estimated 
daily intake (EDI) of cinnamaldehyde from addition as flavouring substance is up to 59,000 
μg/person/day in the US [13]. Unlike most α,β-unsaturated aldehydes, cinnamaldehyde was 
judged by EFSA not to be genotoxic or carcinogenic [14]. This conclusion was based on a 
negative animal genotoxicity and carcinogenicity study [11]. In this study, rats and mice were fed 
daily up to 4,100 ppm of trans-cinnamaldehyde in modified corn starch and sucrose 
microcapsules mixed in their feed [11], which corresponds approximately to 200 and 550 mg 
cinnamaldehyde/kg bw/day for rat and mice, respectively. After two years, there was no evidence 
of a statistically significant increase in the incidence of neoplasms in any group treated with 
cinnamaldehyde. 
An important question is whether the safety of dietary exposure to other α,β-unsaturated 
aldehydes, which have been shown to be genotoxic in vitro while in vivo genotoxicity and 
carcinogenicity data are limited, could be established based on read-across from these data on 
cinnamaldehyde. To this end, the level of DNA adducts formed in vivo by the different 
structurally similar compounds could be compared, taking chemical dependent differences in 
reactivity and detoxification efficiencies into account. Upon ingestion, α,β-unsaturated aldehydes 
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are converted to less electrophilic molecules via three pathways: oxidation, conjugation with 
glutathione (GSH) and reduction (Figure 5.1). α,β-Unsaturated aldehydes are oxidized to relevant 
carboxylic acids in a reaction catalysed by NAD+-dependent aldehyde dehydrogenases (ALDHs) 
[11, 13, 15-17]. Conjugation of the aldehydes with glutathione (GSH) occurs spontaneously and 
the reaction is significantly accelerated in the presence of glutathione S-transferases (GSTs) [18, 
19]. Reduction of the aldehydes is catalysed by aldose reductases (ARs), and the α,β-unsaturated 
alcohol metabolites formed upon this reduction may be oxidized back to α,β-unsaturated 
aldehydes by alcohol dehydrogenases (ADHs) [20, 21]. If the α,β-unsaturated aldehydes come 
into contact with DNA, they react primarily with 2ʹ-deoxyguanosine by Michael addition to form 
exocyclic 1,N2-propanodeoxyguanosine adducts [22-24]. While sharing a common mode of action 
within the group, detoxification efficiencies and the reaction efficiencies with DNA vary 
depending on the structure of the aldehyde [25]. This variation may result in different levels of 
DNA adducts and genotoxic potential of the compounds both in vitro as well as in vivo.  
 
 
Figure 5.1.  Metabolism of cinnamaldehyde 
 
This study aims at examining dose-dependent detoxification and DNA adduct formation 
of cinnamaldehyde using physiologically based kinetic/dynamic (PBK/D) models to facilitate a 
read-across of the data on cinnamaldehyde to other food-borne α,β-unsaturated aldehydes for 
which PBK/D models have already been defined in our previous work [25]. PBK/D modelling 
was shown to be a powerful tool to quantitatively integrate kinetic parameters for all biochemical 
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reactions and predict in vivo DNA adduct formation at different dose levels [16, 25, 26]. In the 
present study PBK/D models that predict DNA adduct formation by cinnamaldehyde in rat and 
human liver were developed based on kinetic parameters collected in experiments with in vitro 
incubations with relevant tissue fractions. The PBK/D-model based predictions for the level of 
DNA adducts formed in the liver upon exposure to cinnamaldehyde were then compared with the 
PBK/D-model based predictions for DNA adduct formation by the 18 other food-borne acyclic 
α,β-unsaturated aldehydes for which we defined PBK/D models previously [16, 25, 26]. The 
results obtained are discussed with respect to the application of read-across of the in vivo 
genotoxicity data for cinnamaldehyde to the other food-borne α,β-unsaturated aldehydes, for 
which in vivo data are limited. 
 
MATERIALS AND METHODS 
 
Chemicals and biological materials 
trans-Cinnamaldehyde (cinnamaldehyde), trans-cinnamic acid (cinnamic acid), trans-cinnamyl 
alcohol (cinnamyl alcohol), 2ʹ-deoxyguanosine monohydrate (2ʹ-dG), tris (hydroxymethyl) 
aminomethane, and reduced glutathione (GSH) were purchased from Sigma-Aldrich 
(Zwijndrecht, The Netherlands). Dimethyl sulfoxide (DMSO) was purchased from Acros Organic 
(New Jersey, USA). Chromatography grade acetonitrile was purchased from Biosolve 
(Valkenswaard, The Netherlands). Chromatography grade trifluoroacetic acid (TFA) was obtained 
from J.T.Baker (Deventer, The Netherlands). Pooled liver S9 from male F344 rats was obtained 
from BD Gentest (Worburn, USA), and pooled human liver S9 was obtained from Celsis 
(Baltimore, USA). Pooled intestine S9 from male Sprague Dawley rats and from human of mixed 
gender were purchased from Xenotech (Lenexa, USA). 
 
Aldehyde dehydrogenase (ALDH) mediated oxidation of cinnamaldehyde to cinnamic acid 
To determine the kinetic parameters for oxidation of cinnamaldehyde, incubations were performed 
with rat or human tissue S9. The final volume of the incubation mixtures was 100 μl. The 
incubation mixtures contained (final concentrations) NAD+ (2 mM) and liver S9 (1 mg 
protein/ml) or small intestine S9 (0.12 mg protein/ml) in 0.1 M Tris-HCl (pH 7.4). After 
pre-incubation for 2 min, the reactions were initiated by the addition of cinnamaldehyde from 100 
times concentrated stock solutions in DMSO. The final concentrations of the aldehyde ranged 
from 10 to 3000 μM. The mixtures were incubated at 37 ˚C for 5 min. The incubations were 
terminated by addition of 50 μl ice-cold acetonitrile. The incubation mixtures were subsequently 
centrifuged for 3 min at 13,000g at 4 ˚C to precipitate the proteins. The formation of cinnamic 
acid in each sample was analysed immediately using a Waters Acquity ultra-performance liquid 
chromatography with diode array detection (UPLC-DAD) (Waters, Milford, MA), equipped with 
a Waters Acquity UPLC BEH C18 column (1.7 μm, 2.1 × 50 mm). The gradient was made with 
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terminated by addition of 50 μl ice-cold acetonitrile. The incubation mixtures were subsequently 
centrifuged for 3 min at 13,000g at 4 ˚C to precipitate the proteins. The formation of cinnamic 
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acetonitrile and ultrapure water containing 0.1%. (v/v) TFA. The flow rate was 0.6 mL/min, and a 
gradient was applied from 25 to 29% acetonitrile over 2 min, after which the percentage of 
acetonitrile was increased to 100% over 0.2 min, kept at 100% for 0.2 min, lowered to 0% over 
0.2 min, kept at 0% for 0.2 min, increased to 25% in 0.2 min and kept at these initial conditions 
for 1 min for equilibration. The retention time of cinnamic acid was 1.3 min. Cinnamic acid was 
quantified based on peak areas obtained at a wavelength of 277 nm using a calibration curve made 
using commercially available cinnamic acid. Because cinnamic acid was also detected in blank 
incubations without NAD+ or tissue fractions, the amount in incubations without tissue fractions 
was subtracted as background. 
 
Aldose reductase (AR) mediated reduction of cinnamaldehyde to cinnamyl alcohol 
To determine the kinetic parameters for reduction, cinnamaldehyde was incubated with rat or 
human tissue S9. The final volume of the incubation mixtures was 100 μl. The incubation 
mixtures contained NADPH (2.5 mM) and liver S9 (0.6 mg protein/ml) or small intestine S9 (0.2 
mg protein/ml) in 0.1 M Tris-HCl (pH 7.4). After pre-incubation for 3 min, the reactions were 
initiated by the addition of cinnamaldehyde from 100 times concentrated stock solutions in 
DMSO. The final concentrations of cinnamaldehyde ranged from 100 to 1000 μM. The mixtures 
were incubated at 37 ˚C for 4 min. The incubations were terminated by addition of 50 μl ice-cold 
acetonitrile. The incubation mixtures were subsequently centrifuged for 3 min at 13,000g at 4 ˚C, 
and the supernatant was immediately frozen in dry ice to prevent the evaporation of the metabolite 
until further UPLC analysis. For the UPLC analysis, the same equipment and method as used to 
quantify cinnamic acid was applied (see above). The retention time of cinnamyl alcohol was 1.1 
min.  Cinnamyl alcohol was quantified at a wavelength of 250 nm using a calibration curve 
made using commercially available cinnamyl alcohol.  
 
Glutathione S-transferase (GST) mediated GSH conjugation of cinnamaldehyde 
The kinetic parameters for the GST mediated conjugation of cinnamaldehyde were determined by 
incubating different concentrations of cinnamaldehyde in the presence of GSH and tissue 
fractions. The final volume of the incubation mixtures was 100 μL. The incubation mixtures 
contained liver S9 (0.4 mg protein/ml) or small intestine S9 (0.16 mg protein/ml) in 0.1 M 
Tris-HCl (pH 7.4). After pre-incubation for 3 min, the reaction was initiated by the addition of 
GSH (3 mM) from a 17 times concentrated stock solution in 0.1 M Tris-HCl (pH 7.4) and 
cinnamaldehyde from 100 times concentrated stock solutions in DMSO. The final concentrations 
of cinnamaldehyde ranged from 250 to 3,000 μM. After 4 min, the incubations were terminated by 
the addition of 50 μl ice-cold acetonitrile. The samples were centrifuged for 3 min at 13,000 g at 
4˚C and the resulting supernatant was analysed by UPLC-DAD immediately. The gradient was 
made with acetonitrile and ultrapure water containing 0.1% (v/v) TFA. The flow rate was 0.6 
mL/min, and a gradient was applied from 12 to 14% acetonitrile over 1 min, after which the 
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percentage of acetonitrile was increased to 100% over 0.2 min, kept at 100% for 0.2 min, lowered 
to 0% over 0.2 min and kept at this condition for 0.2 min, increased to 12% over 0.2 min, and kept 
at these initial conditions for 1 min for equilibration. With this method, the retention times of two 
GSH conjugates formed were 0.46 and 0.53 min. A calibration curve to quantify the GSH 
conjugates was obtained by reacting cinnamaldehyde (10 mM) with different low concentrations 
of GSH (100-500 μM) in 0.1 M Tris-HCl (pH 8.6) as described previously [16]. The conjugates 
were quantified based on the peak areas determined at a wavelength of 200 nm. Because 
cinnamaldehyde spontaneously reacts with GSH, chemical formation of the GSH conjugates in 
the blank incubations without tissue fractions was subtracted as background from the amount 
measured in the enzymatic incubations. 
 
Alcohol dehydrogenase (ADH) mediated oxidation of cinnamyl alcohol to cinnamaldehyde  
The kinetic parameters for oxidation of cinnamyl alcohol back to cinnamaldehyde were 
determined by incubating cinnamyl alcohol with tissue fractions. The final volume of the 
incubation mixtures was 100 μl. The incubation mixtures contained NAD+ (2 mM) and liver S9 
(0.4 mg protein/ml for human and 1 mg protein/ml for rat) or small intestine S9 (0.2 mg 
protein/ml) in 0.1 M Tris-HCl (pH 7.4). After pre-incubation for 3 min, the reactions were 
initiated by the addition of cinnamyl alcohol from 100 times concentrated stock solutions in 
DMSO. The final concentrations of cinnamyl alcohol ranged from 100 to 1,000 μM. The mixtures 
were incubated at 37 ˚C for 1.5 min or 3 min. The incubations were terminated by addition of 50 
μl ice-cold acetonitrile. The incubation mixtures were subsequently centrifuged for 3 min at 
13,000 g at 4 ˚C to precipitate the proteins. The supernatants were frozen immediately on dry ice 
to prevent evaporation of the metabolites. The UPLC method that was used to quantify cinnamic 
acid was applied to quantify cinnamaldehyde, and cinnamic acid formed from cinnamaldehyde by 
NAD+-dependent ALDHs during the incubation (see above). The retention times of 
cinnamaldehyde and cinnamic acid were 1.6 min and 1.3 min, respectively. The amounts of 
cinnamaldehyde and cinnamic acid were quantified based on peak areas obtained at wavelengths 
of 290 nm and 277 nm respectively, using the calibration curves made using commercially 
available compounds. Blank incubations without tissue fractions were performed in parallel and 
the amount of the cinnamic acid and cinnamaldehyde measured in the blank incubations was 
subtracted as background.  
 
Chemical reaction of cinnamaldehyde with GSH 
The second-order rate constant for the nonenzymatic conjugation of cinnamaldehyde with GSH 
(kGSH) was determined based on a method described by Potter and Tran [27]. Briefly, the 
time-dependent conjugation between cinnamaldehyde and GSH was examined by incubating 0.2 
mM cinnamaldehyde with 0.5 mM GSH in 0.1 M Tris-HCl (pH 7.4) for 15−60 min at 37 °C. The 
reaction was initiated by the addition of cinnamaldehyde from a 100 times concentrated stock 
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acetonitrile and ultrapure water containing 0.1%. (v/v) TFA. The flow rate was 0.6 mL/min, and a 
gradient was applied from 25 to 29% acetonitrile over 2 min, after which the percentage of 
acetonitrile was increased to 100% over 0.2 min, kept at 100% for 0.2 min, lowered to 0% over 
0.2 min, kept at 0% for 0.2 min, increased to 25% in 0.2 min and kept at these initial conditions 
for 1 min for equilibration. The retention time of cinnamic acid was 1.3 min. Cinnamic acid was 
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Aldose reductase (AR) mediated reduction of cinnamaldehyde to cinnamyl alcohol 
To determine the kinetic parameters for reduction, cinnamaldehyde was incubated with rat or 
human tissue S9. The final volume of the incubation mixtures was 100 μl. The incubation 
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mg protein/ml) in 0.1 M Tris-HCl (pH 7.4). After pre-incubation for 3 min, the reactions were 
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Glutathione S-transferase (GST) mediated GSH conjugation of cinnamaldehyde 
The kinetic parameters for the GST mediated conjugation of cinnamaldehyde were determined by 
incubating different concentrations of cinnamaldehyde in the presence of GSH and tissue 
fractions. The final volume of the incubation mixtures was 100 μL. The incubation mixtures 
contained liver S9 (0.4 mg protein/ml) or small intestine S9 (0.16 mg protein/ml) in 0.1 M 
Tris-HCl (pH 7.4). After pre-incubation for 3 min, the reaction was initiated by the addition of 
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cinnamaldehyde from 100 times concentrated stock solutions in DMSO. The final concentrations 
of cinnamaldehyde ranged from 250 to 3,000 μM. After 4 min, the incubations were terminated by 
the addition of 50 μl ice-cold acetonitrile. The samples were centrifuged for 3 min at 13,000 g at 
4˚C and the resulting supernatant was analysed by UPLC-DAD immediately. The gradient was 
made with acetonitrile and ultrapure water containing 0.1% (v/v) TFA. The flow rate was 0.6 
mL/min, and a gradient was applied from 12 to 14% acetonitrile over 1 min, after which the 
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percentage of acetonitrile was increased to 100% over 0.2 min, kept at 100% for 0.2 min, lowered 
to 0% over 0.2 min and kept at this condition for 0.2 min, increased to 12% over 0.2 min, and kept 
at these initial conditions for 1 min for equilibration. With this method, the retention times of two 
GSH conjugates formed were 0.46 and 0.53 min. A calibration curve to quantify the GSH 
conjugates was obtained by reacting cinnamaldehyde (10 mM) with different low concentrations 
of GSH (100-500 μM) in 0.1 M Tris-HCl (pH 8.6) as described previously [16]. The conjugates 
were quantified based on the peak areas determined at a wavelength of 200 nm. Because 
cinnamaldehyde spontaneously reacts with GSH, chemical formation of the GSH conjugates in 
the blank incubations without tissue fractions was subtracted as background from the amount 
measured in the enzymatic incubations. 
 
Alcohol dehydrogenase (ADH) mediated oxidation of cinnamyl alcohol to cinnamaldehyde  
The kinetic parameters for oxidation of cinnamyl alcohol back to cinnamaldehyde were 
determined by incubating cinnamyl alcohol with tissue fractions. The final volume of the 
incubation mixtures was 100 μl. The incubation mixtures contained NAD+ (2 mM) and liver S9 
(0.4 mg protein/ml for human and 1 mg protein/ml for rat) or small intestine S9 (0.2 mg 
protein/ml) in 0.1 M Tris-HCl (pH 7.4). After pre-incubation for 3 min, the reactions were 
initiated by the addition of cinnamyl alcohol from 100 times concentrated stock solutions in 
DMSO. The final concentrations of cinnamyl alcohol ranged from 100 to 1,000 μM. The mixtures 
were incubated at 37 ˚C for 1.5 min or 3 min. The incubations were terminated by addition of 50 
μl ice-cold acetonitrile. The incubation mixtures were subsequently centrifuged for 3 min at 
13,000 g at 4 ˚C to precipitate the proteins. The supernatants were frozen immediately on dry ice 
to prevent evaporation of the metabolites. The UPLC method that was used to quantify cinnamic 
acid was applied to quantify cinnamaldehyde, and cinnamic acid formed from cinnamaldehyde by 
NAD+-dependent ALDHs during the incubation (see above). The retention times of 
cinnamaldehyde and cinnamic acid were 1.6 min and 1.3 min, respectively. The amounts of 
cinnamaldehyde and cinnamic acid were quantified based on peak areas obtained at wavelengths 
of 290 nm and 277 nm respectively, using the calibration curves made using commercially 
available compounds. Blank incubations without tissue fractions were performed in parallel and 
the amount of the cinnamic acid and cinnamaldehyde measured in the blank incubations was 
subtracted as background.  
 
Chemical reaction of cinnamaldehyde with GSH 
The second-order rate constant for the nonenzymatic conjugation of cinnamaldehyde with GSH 
(kGSH) was determined based on a method described by Potter and Tran [27]. Briefly, the 
time-dependent conjugation between cinnamaldehyde and GSH was examined by incubating 0.2 
mM cinnamaldehyde with 0.5 mM GSH in 0.1 M Tris-HCl (pH 7.4) for 15−60 min at 37 °C. The 
reaction was initiated by the addition of cinnamaldehyde from a 100 times concentrated stock 
32620 Reiko Kiwamoto.indd   131 17-03-15   15:36
Chapter 5
132
DNA adduct formation by cinnamaldehyde and other α,β-unsaturated aldehydes 
 
132 
 
solution in DMSO and was terminated by adding 4 mM diamide (final concentration) from a 5 
times concentrated stock solution in 0.1 M Tris-HCl (pH 7.4). The GSH conjugates were 
quantified immediately using UPLC as already described (see above).  
 
Chemical reaction of cinnamaldehyde with 2ʹ-dG 
The second-order rate constant for binding of cinnamaldehyde with 2′-dG (kDNA) was determined 
by examining the time-dependent formation of 1,N2-propanodeoxyguanosine adducts. 
Cinnamaldehyde (5 mM) was incubated with 2ʹ-dG (1.95 mM) in 0.1 M Tris-HCl (pH 7.4) for 1-5 
hours at 37 °C. After 2 min of preincubation, the reaction was started by addition of 
cinnamaldehyde from a 100 times concentrated stock in DMSO. The reaction was terminated by 
injecting the reaction mixture to the UPLC-DAD system. The gradient was made with acetonitrile 
and ultrapure water containing 0.1% (v/v) TFA. The flow rate was 0.6 mL/min, and a gradient was 
applied from 8 to 15% acetonitrile over 10 min, after which the percentage of acetonitrile was 
increased to 100% over 0.2 min, kept at 100% for 0.2 min, lowered to 0% over 0.2 min, kept at 
0% for 0.2 min, increased to 8% over 0.2 min, and equilibrated at these initial conditions for 1 
min. Peaks for two adducts were found at retention times of 4.6 and 5.0 min respectively. Both 
peaks were absent in the blank incubations without either cinnamaldehyde or 2′-dG. Because the 
UV absorption patterns of the 2′-dG adducts were comparable to that of 2′-dG, it was assumed 
that 2′-dG adducts and 2′-dG have the same molecular extinction coefficient at the respective 
wavelength of maximum absorption. Quantification of 2′-dG adducts could thus be achieved by 
comparison of the peak area of 2′-dG adducts obtained at a wavelength 262 nm to the calibration 
curve of 2′-dG obtained at a wavelength 252 nm. 
 
Kinetic analysis 
The data for the rate of ALDH-mediated oxidation and AR-mediated reduction with increasing 
cinnamaldehyde concentrations, and ADH-mediated oxidation with increasing concentrations of 
cinnamyl alcohol were fitted to the standard Michaelis-Menten equation with [S] being the 
concentration of the substrate aldehyde or alcohol: 
  v = Vmax • [S]/ (Km+[S]) 
The GSH and cinnamaldehyde concentration-dependent rate of GSH conjugate formation 
catalysed by GSTs was fitted to a two-substrate model Michaelis−Menten equation simulating the 
ordered sequential ping−pong mechanism, with [GSH] and [S] being GSH and cinnamaldehyde 
concentrations, respectively: 
v = Vmax •[S]•[GSH]/(Km_G•[S] + Km•[S]  +[GSH]•[S]) 
The apparent Vmax and Km values were determined by fitting the data to the respective equations 
using GraphPad Prism (version 5.04, GraphPad Software, Inc. (La Jolla, USA)) except for Km_G, 
which was set to 100 μM based on literature data obtained with various substrates [28, 29]. 
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PBK/D model development 
The PBK/D models for cinnamaldehyde in rat and human were developed based on the previously 
defined models for trans-2-hexenal [16, 26]. For both species, a submodel describing the 
formation, oxidation and distribution of cinnamyl alcohol was built and connected to the 
cinnamaldehyde model. The structure of the newly developed cinnamaldehyde models is 
displayed in Figure 5.2. The physiological parameters such as organ volumes were obtained from 
the literature [30] as presented in Table 5.1. Tissue:blood partition coefficients were estimated 
based on a method of DeJongh et al. [31] from the logKow. LogKow values were estimated with 
Estimation Program Interface (EPI) Suite version 4.10 provided by the US Environmental 
Protection Agency. Model equations (supporting information) were coded and numerically 
integrated in Berkeley Madonna 8.3.18 (Macey and Oster, UC Berkeley, CA, USA), using the 
Rosenbrock's algorithm for stiff systems. The uptake of cinnamaldehyde into the small intestine 
compartment was described by a first-order process with an absorption rate constant of 5.0 h−1, the 
same rate as used previously for trans-2-hexenal that represents a rapid uptake of the compounds 
[16, 26, 32]. Metabolism of cinnamaldehyde was described to occur in the liver and small 
intestine. The Vmax values expressed as nmol/min/(mg S9 protein) were scaled to be expressed as 
nmol/min/(g tissue) using S9 protein yields of 143 mg/g liver or 11.4 mg/g small intestine as 
scaling factors [16, 33, 34]. For cinnamic acid and GSH conjugates, no further reaction than the 
formation was modelled because these metabolites are not converted back to the parent compound 
and the further reaction of these metabolites does not influence the model outcome of interest. 
Chemical conjugation of cinnamaldehyde with GSH or protein reactive sites in the liver or small 
intestine was described as previously reported [16, 26]. Equations to describe GSH levels in the 
liver and small intestine were integrated in the model as previously described [16] to examine 
possible depletion of GSH induced by the aldehyde. The amount of DNA adducts formed in the 
liver was described by second-order formation and first-order elimination due to DNA repair. The 
half-life of the DNA adducts was set to be 38.5 hrs based on the results obtained in an in vivo 
study using trans-2-hexenal [35].     
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solution in DMSO and was terminated by adding 4 mM diamide (final concentration) from a 5 
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UV absorption patterns of the 2′-dG adducts were comparable to that of 2′-dG, it was assumed 
that 2′-dG adducts and 2′-dG have the same molecular extinction coefficient at the respective 
wavelength of maximum absorption. Quantification of 2′-dG adducts could thus be achieved by 
comparison of the peak area of 2′-dG adducts obtained at a wavelength 262 nm to the calibration 
curve of 2′-dG obtained at a wavelength 252 nm. 
 
Kinetic analysis 
The data for the rate of ALDH-mediated oxidation and AR-mediated reduction with increasing 
cinnamaldehyde concentrations, and ADH-mediated oxidation with increasing concentrations of 
cinnamyl alcohol were fitted to the standard Michaelis-Menten equation with [S] being the 
concentration of the substrate aldehyde or alcohol: 
  v = Vmax • [S]/ (Km+[S]) 
The GSH and cinnamaldehyde concentration-dependent rate of GSH conjugate formation 
catalysed by GSTs was fitted to a two-substrate model Michaelis−Menten equation simulating the 
ordered sequential ping−pong mechanism, with [GSH] and [S] being GSH and cinnamaldehyde 
concentrations, respectively: 
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The apparent Vmax and Km values were determined by fitting the data to the respective equations 
using GraphPad Prism (version 5.04, GraphPad Software, Inc. (La Jolla, USA)) except for Km_G, 
which was set to 100 μM based on literature data obtained with various substrates [28, 29]. 
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PBK/D model development 
The PBK/D models for cinnamaldehyde in rat and human were developed based on the previously 
defined models for trans-2-hexenal [16, 26]. For both species, a submodel describing the 
formation, oxidation and distribution of cinnamyl alcohol was built and connected to the 
cinnamaldehyde model. The structure of the newly developed cinnamaldehyde models is 
displayed in Figure 5.2. The physiological parameters such as organ volumes were obtained from 
the literature [30] as presented in Table 5.1. Tissue:blood partition coefficients were estimated 
based on a method of DeJongh et al. [31] from the logKow. LogKow values were estimated with 
Estimation Program Interface (EPI) Suite version 4.10 provided by the US Environmental 
Protection Agency. Model equations (supporting information) were coded and numerically 
integrated in Berkeley Madonna 8.3.18 (Macey and Oster, UC Berkeley, CA, USA), using the 
Rosenbrock's algorithm for stiff systems. The uptake of cinnamaldehyde into the small intestine 
compartment was described by a first-order process with an absorption rate constant of 5.0 h−1, the 
same rate as used previously for trans-2-hexenal that represents a rapid uptake of the compounds 
[16, 26, 32]. Metabolism of cinnamaldehyde was described to occur in the liver and small 
intestine. The Vmax values expressed as nmol/min/(mg S9 protein) were scaled to be expressed as 
nmol/min/(g tissue) using S9 protein yields of 143 mg/g liver or 11.4 mg/g small intestine as 
scaling factors [16, 33, 34]. For cinnamic acid and GSH conjugates, no further reaction than the 
formation was modelled because these metabolites are not converted back to the parent compound 
and the further reaction of these metabolites does not influence the model outcome of interest. 
Chemical conjugation of cinnamaldehyde with GSH or protein reactive sites in the liver or small 
intestine was described as previously reported [16, 26]. Equations to describe GSH levels in the 
liver and small intestine were integrated in the model as previously described [16] to examine 
possible depletion of GSH induced by the aldehyde. The amount of DNA adducts formed in the 
liver was described by second-order formation and first-order elimination due to DNA repair. The 
half-life of the DNA adducts was set to be 38.5 hrs based on the results obtained in an in vivo 
study using trans-2-hexenal [35].     
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Figure 5.2. Structural diagram of the cinnamaldehyde PBK/D models. The solid line represent the 
movement of cinnamaldehyde or cinnamyl alcohol, and the dashed lines represent the movement 
of GSH. 
 
Sensitivity analysis 
To identify the key parameters that influence the model output of the newly developed 
cinnamaldehyde models the most, a sensitivity analysis was performed. Normalized sensitivity 
coefficients (SC) were determined according to the following equation: SC = (C′ − C)/(P′ − P) × 
(P/C), where C is the initial value of the model output, C′ is the modified value of the model 
output resulting from an increase in parameter value, P is the initial parameter value, and P′ is the 
modified parameter value. On the basis of the literature, a 5% increase in parameter values was 
chosen to analyse the effect of a change in parameter on the formation of 2′-dG adducts in the 
liver. Each parameter was analysed individually, keeping the other parameters to their initial 
values.  
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Table 5.1 Physicochemical and physiological parameters of the cinnamaldehyde PBK/D models 
 
Parameters Symbols Rat Human 
Physico-chemical Parameters Cinnamaldehydea 
   fat/blood  PF 14.2 39.3 
liver/blood  PL 1.21 2.04 
small intestine/blood  PSI 1.21 2.04 
richly perfused 
tissues/blood  
PR 1.21 2.04 
slowly perfused 
tissues/blood  
PS 0.57 1.57 
Physico-chemical Parameters Cinnamyl Alcohola 
   fat/blood  PohF 14.6 40.5 
liver/blood  PohL 1.22 2.09 
small intestine/blood  PohSI 1.22 2.09 
richly perfused 
tissues/blood  
PohR 1.22 2.09 
slowly perfused 
tissues/blood  
PohS 0.57 1.60 
Physiological Parameters 
  Body weight (kg)a BW 0.25 70 
  Tissue volumes (% body weight)a 
 fat VFc 7 21.4 
 liver VLc 3.4 2.6 
 small intestine VSic 1.4 0.9 
 arterial blood VAc 1.9 2.0 
 venous blood VVc 5.6 5.9 
 richly perfused  VRc 4.2 4.1 
 slowly perfused VSc 67.6 51.7 
  Cardiac output (L/h)  QC 5.4 310 
Blood flow to tissue (% cardiac output) a 
 fat QFc 0.07 5.2 
 liver (excluding 
portal vein) 
QLc 0.13 14.1 
small intestine QSic 0.12 8.6 
richly perfused  QRc 0.64 47.3 
slowly perfused QSc 0.17 24.8 
Initial GSH concentration (μmol/kg tissue) 
Liverc  InitGSHL 6120 5639 
small intestined InitGSHSi 1780 1250 
GSH synthesis (μmol/kg tissue/h)d 
     liver GSYNL 6.6 1122 
     small intestine GSYNSi 0.25 27 
Apparent first order rate constant for GSH turnover (rat) (/h)e 
liver kL_GLOS 0.142 0.142 
small intestine kSi_GLOS 0.044 0.044 
Protein reactive sites (μmol/kg tissue)f 
liver CPROL 3000 3000 
small intestine CPROSi 774 774 
a Brown et al. [30], bJeffrey et al. [36],  dSweeney et al. [37], dAssimakopoulos et al. [38], ePotter 
and Tran [39], fPotter and Tran  [27] 
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RESULTS 
 
Enzyme mediated oxidation, GSH conjugation and reduction of cinnamaldehyde 
UPLC analysis of the incubations indicated that cinnamaldehyde is converted to cinnamic acid, 
GSH conjugates or cinnamyl alcohol in the presence of human or rat tissue fractions and relevant 
cofactors. The kinetic parameters obtained from these incubations for different detoxification 
reactions are presented in Table 5.2. The most remarkable species difference was observed in 
oxidation. The estimated in vivo catalytic efficiencies (CEs) in human were two orders of 
magnitude higher compared to rat both in the liver and small intestine, due to lower Km values in 
human. GST mediated conjugation of cinnamaldehyde with GSH was more efficient in rat than in 
human. The estimated in vivo CEs for reduction of cinnamaldehyde were comparable between the 
two species.  
  
Table 5.2 Kinetic parameters for oxidation, reduction and GSH conjugations of cinnamaldehyde 
in human and rat.  
 
Organ Metabolites Species Km
a,b Vmax
a,c 
Scaled 
Vmax
a,d 
In vivo 
CEe 
Liver Cinnamic 
acid 
Human 8.5 9.7 1387 163 
Rat 6332 64 9211 1.5 
 GSH 
conjugates 
Human 1681 37 5343 3.2 
 Rat 4927 457 65313 13 
 Cinnamyl 
alcohol 
Human 333 73 10460 31 
 Rat 124 29 4161 34 
Small 
intestine 
Cinnamic 
acid 
Human 70 21 236 3.4 
Rat 4094 25 291 0.07 
 GSH 
conjugates 
Human NDf ND ND ND 
 Rat 596 63 717 1.2 
 Cinnamyl 
alcohol 
Human 90 30 347 3.9 
 Rat 75 5.8 67 0.9 
aBest fit values. bμM. cnmol/min/(mg S9 protein). dVmax scaled to a tissue expressed as nmol/min/
 
(g tissue). Scaling factors of 143 and 11.4 mg S9 protein/(g tissue) were used for the liver and 
small intestine S9 fraction. eEstimated in vivo catalytic efficiency expressed as mL/min/(g tissue). 
Calculated from scaled Vmax/Km.  
fNot detected. 
 
Enzyme mediated oxidation of cinnamyl alcohol  
The UPLC analysis of the incubations indicated that cinnamyl alcohol is oxidized back to 
cinnamaldehyde and further to cinnamic acid when it is incubated in the presence of tissue 
fractions and NAD+. The kinetic parameters for this oxidation reaction are presented in Table 5.3.  
The estimated in vivo CEs for oxidation of cinnamyl alcohol to cinnamaldehyde were smaller 
than those for reduction of cinnamaldehyde to cinnamyl alcohol in both species. The relatively 
slow oxidation of cinnamyl alcohol compared to its formation, indicates that cinnamaldehyde is 
swiftly reduced to the alcohol and may circulate in the body in the form of the alcohol before its 
conversion back to the aldehyde.  
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Table 5.3 Kinetic parameters for oxidation of the alcohols in human and rat 
 
Organ Species Km
a,b Vmax
a,c 
Scaled 
Vmax
a,d 
In vivo CEe 
Liver Human 4167 221 31603 7.6 
Rat 1254 15 2114 1.6 
Small 
intestine 
Human 290 5.0 57 0.2 
Rat NDf ND ND ND 
aBest fit values. bμM. cnmol/min/(mg S9 protein). dVmax scaled to a tissue expressed as nmol/min/
 
(g tissue). Scaling factors of 143 and 11.4 mg S9 protein/(g tissue) were used for the liver and 
small intestine S9 fraction. e In vivo catalytic efficiency expressed as mL/min/(g tissue). 
Calculated from scaled Vmax/Km.  
fNot detected. 
 
Chemical reaction with GSH and 2ʹ-dG  
The second-order rate constant of the chemical reaction of cinnamaldehyde with GSH (kGSH) was 
6.6×10-4 /μM/h. This value is within the same range as the kGSH values of the 6 acyclic 
α,β-unsaturated aldehydes (i.e. trans-2-pentenal, trans-2-hexenal, trans-2-octenal, 
trans-2-decenal, trans-2-dodecenal., trans-2-cis-6-nonadienal) obtained in our previous study 
[16], which were between 3.7×10-4 and 10.5×10-4 /μM/h. The second-order rate constant of the 
reaction between cinnamaldehyde and 2ʹ-dG (kDNA), 1.6 ×10
-8 /μM/h, was smaller than the kDNA  
values of the 6 acyclic aldehydes, which ranged between 1.3×10-7 and  5.4×10-7 /μM/h [16].  
 
Performance of the PBK/D models 
In order to evaluate the performance of the newly developed PBK/D models for cinnamaldehyde, 
the results obtained with the rat model were compared with in vivo data reported in literature. As a 
first step, the proportion of cinnamaldehyde metabolized to cinnamic acid or GSH conjugates was 
examined (Table 5.4). There are three in vivo studies [15, 20, 40], where proportions of different 
metabolites excreted in urine were reported for rats exposed to single doses of 2 to 500 mg 
cinnamaldehyde/kg bw via gavage or intraperitoneal (ip) injection. In case a prediction was 
compared with in vivo data obtained upon ip injection, the cinnamaldehyde was modelled to enter 
directly into the liver in the rat PBK/D models.  
Peters et al. [15] and Sapienza et al. [40] reported the amounts of five urinary metabolites 
(i.e. hippuric acid, benzoyl glucronide, 3-hydroxy-3-phenylpropionic acid (HPPA), 
cinnamoylglycine, and benzoic acid), which are all produced following oxidation of 
cinnamaldehyde to cinnamic acid, excreted by rats exposed to cinnamaldehyde by gavage or ip 
injection. At exposure levels higher than 250 mg/kg bw, the prediction for cinnamaldehyde 
excretion via cinnamic acid matched best with the in vivo data on the sum of the excretion of the 
five aldehyde metabolites and the difference was less than 1.6-fold. At lower doses of 2 and 50 
mg/kg bw the differences between the prediction and observed data were higher, amounting to 5.4 
to 8.9-fold. A comparison was also made between the predicted formation of GSH conjugates and 
literature data on excretion of these metabolites as mercapturic acids, which are the ultimate 
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RESULTS 
 
Enzyme mediated oxidation, GSH conjugation and reduction of cinnamaldehyde 
UPLC analysis of the incubations indicated that cinnamaldehyde is converted to cinnamic acid, 
GSH conjugates or cinnamyl alcohol in the presence of human or rat tissue fractions and relevant 
cofactors. The kinetic parameters obtained from these incubations for different detoxification 
reactions are presented in Table 5.2. The most remarkable species difference was observed in 
oxidation. The estimated in vivo catalytic efficiencies (CEs) in human were two orders of 
magnitude higher compared to rat both in the liver and small intestine, due to lower Km values in 
human. GST mediated conjugation of cinnamaldehyde with GSH was more efficient in rat than in 
human. The estimated in vivo CEs for reduction of cinnamaldehyde were comparable between the 
two species.  
  
Table 5.2 Kinetic parameters for oxidation, reduction and GSH conjugations of cinnamaldehyde 
in human and rat.  
 
Organ Metabolites Species Km
a,b Vmax
a,c 
Scaled 
Vmax
a,d 
In vivo 
CEe 
Liver Cinnamic 
acid 
Human 8.5 9.7 1387 163 
Rat 6332 64 9211 1.5 
 GSH 
conjugates 
Human 1681 37 5343 3.2 
 Rat 4927 457 65313 13 
 Cinnamyl 
alcohol 
Human 333 73 10460 31 
 Rat 124 29 4161 34 
Small 
intestine 
Cinnamic 
acid 
Human 70 21 236 3.4 
Rat 4094 25 291 0.07 
 GSH 
conjugates 
Human NDf ND ND ND 
 Rat 596 63 717 1.2 
 Cinnamyl 
alcohol 
Human 90 30 347 3.9 
 Rat 75 5.8 67 0.9 
aBest fit values. bμM. cnmol/min/(mg S9 protein). dVmax scaled to a tissue expressed as nmol/min/
 
(g tissue). Scaling factors of 143 and 11.4 mg S9 protein/(g tissue) were used for the liver and 
small intestine S9 fraction. eEstimated in vivo catalytic efficiency expressed as mL/min/(g tissue). 
Calculated from scaled Vmax/Km.  
fNot detected. 
 
Enzyme mediated oxidation of cinnamyl alcohol  
The UPLC analysis of the incubations indicated that cinnamyl alcohol is oxidized back to 
cinnamaldehyde and further to cinnamic acid when it is incubated in the presence of tissue 
fractions and NAD+. The kinetic parameters for this oxidation reaction are presented in Table 5.3.  
The estimated in vivo CEs for oxidation of cinnamyl alcohol to cinnamaldehyde were smaller 
than those for reduction of cinnamaldehyde to cinnamyl alcohol in both species. The relatively 
slow oxidation of cinnamyl alcohol compared to its formation, indicates that cinnamaldehyde is 
swiftly reduced to the alcohol and may circulate in the body in the form of the alcohol before its 
conversion back to the aldehyde.  
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Table 5.3 Kinetic parameters for oxidation of the alcohols in human and rat 
 
Organ Species Km
a,b Vmax
a,c 
Scaled 
Vmax
a,d 
In vivo CEe 
Liver Human 4167 221 31603 7.6 
Rat 1254 15 2114 1.6 
Small 
intestine 
Human 290 5.0 57 0.2 
Rat NDf ND ND ND 
aBest fit values. bμM. cnmol/min/(mg S9 protein). dVmax scaled to a tissue expressed as nmol/min/
 
(g tissue). Scaling factors of 143 and 11.4 mg S9 protein/(g tissue) were used for the liver and 
small intestine S9 fraction. e In vivo catalytic efficiency expressed as mL/min/(g tissue). 
Calculated from scaled Vmax/Km.  
fNot detected. 
 
Chemical reaction with GSH and 2ʹ-dG  
The second-order rate constant of the chemical reaction of cinnamaldehyde with GSH (kGSH) was 
6.6×10-4 /μM/h. This value is within the same range as the kGSH values of the 6 acyclic 
α,β-unsaturated aldehydes (i.e. trans-2-pentenal, trans-2-hexenal, trans-2-octenal, 
trans-2-decenal, trans-2-dodecenal., trans-2-cis-6-nonadienal) obtained in our previous study 
[16], which were between 3.7×10-4 and 10.5×10-4 /μM/h. The second-order rate constant of the 
reaction between cinnamaldehyde and 2ʹ-dG (kDNA), 1.6 ×10
-8 /μM/h, was smaller than the kDNA  
values of the 6 acyclic aldehydes, which ranged between 1.3×10-7 and  5.4×10-7 /μM/h [16].  
 
Performance of the PBK/D models 
In order to evaluate the performance of the newly developed PBK/D models for cinnamaldehyde, 
the results obtained with the rat model were compared with in vivo data reported in literature. As a 
first step, the proportion of cinnamaldehyde metabolized to cinnamic acid or GSH conjugates was 
examined (Table 5.4). There are three in vivo studies [15, 20, 40], where proportions of different 
metabolites excreted in urine were reported for rats exposed to single doses of 2 to 500 mg 
cinnamaldehyde/kg bw via gavage or intraperitoneal (ip) injection. In case a prediction was 
compared with in vivo data obtained upon ip injection, the cinnamaldehyde was modelled to enter 
directly into the liver in the rat PBK/D models.  
Peters et al. [15] and Sapienza et al. [40] reported the amounts of five urinary metabolites 
(i.e. hippuric acid, benzoyl glucronide, 3-hydroxy-3-phenylpropionic acid (HPPA), 
cinnamoylglycine, and benzoic acid), which are all produced following oxidation of 
cinnamaldehyde to cinnamic acid, excreted by rats exposed to cinnamaldehyde by gavage or ip 
injection. At exposure levels higher than 250 mg/kg bw, the prediction for cinnamaldehyde 
excretion via cinnamic acid matched best with the in vivo data on the sum of the excretion of the 
five aldehyde metabolites and the difference was less than 1.6-fold. At lower doses of 2 and 50 
mg/kg bw the differences between the prediction and observed data were higher, amounting to 5.4 
to 8.9-fold. A comparison was also made between the predicted formation of GSH conjugates and 
literature data on excretion of these metabolites as mercapturic acids, which are the ultimate 
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metabolites of GSH conjugates excreted in the urine. Delbressine et al. reported that excreted 
mercapturic acids amounted to 14.8% of the applied dose of 250 mg cinnamaldehyde/kg bw in 
female Wistar rats [20]. The PBK/D model predicted that 41% of the administered 
cinnamaldehyde dose would be metabolized via conjugation to GSH, which is 2.8-fold higher 
than the in vivo data (Table 5.4).  
 
Table 5.4 Comparison of the rat cinnamaldehyde PBK/D model outcomes and in vivo observed 
data 
Referenc
e for in 
vivo data 
Type of 
rats, 
gender 
Dose 
(mg/kg 
bw) 
Exposure 
route 
Metabolites 
(Ultimate 
metabolites 
found in rat 
urine) 
Proportion of the 
metabolites to the 
administered dose 
(%) 
Predicted/
Observed 
Observed Predicted 
Peters 
[15] 
F344, male 2 ip injection Cinnamic acid 
(Hippuric acid, 
benzoyl 
glucuronide, 
HPPA, 
cinnamoyl 
glycine, benzoic 
acid) 
89.0 10 8.9 
F344, 
female 
2 ip injection 89.3 10 8.9 
F344, male 250 ip injection 83.8 59 1.4 
F344, 
female 
250 ip injection 88.1 59 1.5 
F344, male 250 oral 88.0 56 1.6 
Sapienza  
et al., 
[40] 
F344, male 50 oral 
idem 
86.8 16 5.4 
F344, male 500 oral 91.5 71 1.3 
Delbressi
ne et al. 
[20] 
Wistar, 
female 
250 ip injection 
GSH conjugates 
(mercapturic 
acids) 
14.8±1.9 41 2.8 
 
In the next step, the time-dependent prediction of cinnamaldehyde concentrations in blood 
in rat was compared with the values reported by Yuan et al., [41] or Zhao et al.[42] (Figure 5.3). 
In these in vivo studies, the time-dependent changes in cinnamaldehyde blood concentration in 
rats were monitored following the exposure to 250 or 500 mg/kg bw cinnamaldehyde by gavage 
or to 5 to 25 mg/kg bw cinnamaldehyde via intravenous (iv) injection. Upon iv injection (Figure 
5.3A-D), the cinnamaldehyde blood concentrations predicted for different doses adequately 
matched with the data reported except for the maximum concentration (Cmax). The predictions on 
Cmax following iv exposure were 10-17-fold higher than the data reported by Yuan et al., and 
450-fold higher than the data reported by Zhao et al. Results obtained for oral exposure revealed 
that the cinnamaldehyde concentrations in blood increase rapidly and reach Cmax within 0.1 hour 
after dosing (Figure 5.3E and F). After the Cmax is reached, the predicted concentrations declined 
rapidly at first, followed by a relatively slow decline phase. The rapid decline is due to the 
efficient conversion of the aldehyde via oxidation, reduction or conjugation with GSH, and then 
the blood level stabilizes because the metabolism of cinnamaldehyde and the oxidation of 
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cinnamyl alcohol to cinnamaldehyde tend to equilibrate, resulting in the relatively slow decline 
phase. The predicted Cmax values following oral administration were 204 and 896 μM at 250 and 
500 mg/kg bw, respectively. These values overestimated the in vivo observed values up to 48-fold 
when compared with Cmax values reported by Yuan et al. [41], and up to 545-fold when compared 
the Cmax reported by Zhao et al. [42]. During the slow decline phase, which was observed 
approximately 2 hours after the dosing, the PBK/D model based predicted cinnamaldehyde levels 
were up to 58-times higher than the values reported by Zhao et al. [42] but were within 6.4-fold 
compared to the values reported by Yuan et al. [41]. 
 
Figure 5.3. Comparison of the rat PBK/D model predicted cinnamaldehyde levels in blood and in 
vivo observed values. The closed and open circles represent the in vivo cinnamaldehyde levels in 
blood in rat reported by Yuan et al. [41] and Zhao et al. [42], respectively, upon cinnamaldehyde 
administration of (A) 5 mg/kg bw by iv injection, (B) 15 mg/kg bw by iv injection, (C) 25 mg/kg 
bw by iv injection, (D) 20 mg/kg bw by iv injection, (E) 250 mg/kg bw by gavage,  and (F) 500 
mg/kg bw by gavage,. The solid lines in all graphs represent the rat PBK/D model prediction.  
 
 
32620 Reiko Kiwamoto.indd   138 17-03-15   15:36
5DNA adduct formation by cinnamaldehyde predicted by PBK/D modelling
139
DNA adduct formation by cinnamaldehyde and other α,β-unsaturated aldehydes 
 
138 
 
metabolites of GSH conjugates excreted in the urine. Delbressine et al. reported that excreted 
mercapturic acids amounted to 14.8% of the applied dose of 250 mg cinnamaldehyde/kg bw in 
female Wistar rats [20]. The PBK/D model predicted that 41% of the administered 
cinnamaldehyde dose would be metabolized via conjugation to GSH, which is 2.8-fold higher 
than the in vivo data (Table 5.4).  
 
Table 5.4 Comparison of the rat cinnamaldehyde PBK/D model outcomes and in vivo observed 
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Dose 
(mg/kg 
bw) 
Exposure 
route 
Metabolites 
(Ultimate 
metabolites 
found in rat 
urine) 
Proportion of the 
metabolites to the 
administered dose 
(%) 
Predicted/
Observed 
Observed Predicted 
Peters 
[15] 
F344, male 2 ip injection Cinnamic acid 
(Hippuric acid, 
benzoyl 
glucuronide, 
HPPA, 
cinnamoyl 
glycine, benzoic 
acid) 
89.0 10 8.9 
F344, 
female 
2 ip injection 89.3 10 8.9 
F344, male 250 ip injection 83.8 59 1.4 
F344, 
female 
250 ip injection 88.1 59 1.5 
F344, male 250 oral 88.0 56 1.6 
Sapienza  
et al., 
[40] 
F344, male 50 oral 
idem 
86.8 16 5.4 
F344, male 500 oral 91.5 71 1.3 
Delbressi
ne et al. 
[20] 
Wistar, 
female 
250 ip injection 
GSH conjugates 
(mercapturic 
acids) 
14.8±1.9 41 2.8 
 
In the next step, the time-dependent prediction of cinnamaldehyde concentrations in blood 
in rat was compared with the values reported by Yuan et al., [41] or Zhao et al.[42] (Figure 5.3). 
In these in vivo studies, the time-dependent changes in cinnamaldehyde blood concentration in 
rats were monitored following the exposure to 250 or 500 mg/kg bw cinnamaldehyde by gavage 
or to 5 to 25 mg/kg bw cinnamaldehyde via intravenous (iv) injection. Upon iv injection (Figure 
5.3A-D), the cinnamaldehyde blood concentrations predicted for different doses adequately 
matched with the data reported except for the maximum concentration (Cmax). The predictions on 
Cmax following iv exposure were 10-17-fold higher than the data reported by Yuan et al., and 
450-fold higher than the data reported by Zhao et al. Results obtained for oral exposure revealed 
that the cinnamaldehyde concentrations in blood increase rapidly and reach Cmax within 0.1 hour 
after dosing (Figure 5.3E and F). After the Cmax is reached, the predicted concentrations declined 
rapidly at first, followed by a relatively slow decline phase. The rapid decline is due to the 
efficient conversion of the aldehyde via oxidation, reduction or conjugation with GSH, and then 
the blood level stabilizes because the metabolism of cinnamaldehyde and the oxidation of 
DNA adduct formation by cinnamaldehyde and other α,β-unsaturated aldehydes 
 
139 
 
cinnamyl alcohol to cinnamaldehyde tend to equilibrate, resulting in the relatively slow decline 
phase. The predicted Cmax values following oral administration were 204 and 896 μM at 250 and 
500 mg/kg bw, respectively. These values overestimated the in vivo observed values up to 48-fold 
when compared with Cmax values reported by Yuan et al. [41], and up to 545-fold when compared 
the Cmax reported by Zhao et al. [42]. During the slow decline phase, which was observed 
approximately 2 hours after the dosing, the PBK/D model based predicted cinnamaldehyde levels 
were up to 58-times higher than the values reported by Zhao et al. [42] but were within 6.4-fold 
compared to the values reported by Yuan et al. [41]. 
 
Figure 5.3. Comparison of the rat PBK/D model predicted cinnamaldehyde levels in blood and in 
vivo observed values. The closed and open circles represent the in vivo cinnamaldehyde levels in 
blood in rat reported by Yuan et al. [41] and Zhao et al. [42], respectively, upon cinnamaldehyde 
administration of (A) 5 mg/kg bw by iv injection, (B) 15 mg/kg bw by iv injection, (C) 25 mg/kg 
bw by iv injection, (D) 20 mg/kg bw by iv injection, (E) 250 mg/kg bw by gavage,  and (F) 500 
mg/kg bw by gavage,. The solid lines in all graphs represent the rat PBK/D model prediction.  
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Little has been reported about kinetics of cinnamaldehyde in human. Cocciara et al. [43] 
reviewed an unpublished study where two healthy male volunteers were orally exposed to 0.7 
mg/kg bw cinnamaldehyde capsulated in gelatine. It was reported that 96.2-96.5% of the 
recovered compounds were excreted in urine as either hippuric acid, benzoyl glucronide, HPPA or 
benzoyl acid, the ultimate metabolites of cinnamic acid. The human PBK/D model predicted 98 % 
of cinnamaldehyde to be oxidized to cinnamic acid at 0.7 mg/kg bw, which matched very well 
with the in vivo data. 
 
Sensitivity analysis 
A sensitivity analysis was performed to reveal which parameters influence the PBK/D model 
predicted DNA adduct formation in the liver at Tmax, the time when the maximum DNA adduct 
level is reached. This analysis was performed at the EDI of cinnamaldehyde of 0.99 mg/kg bw. 
Only the parameters which showed an absolute sensitivity coefficient higher than 0.1 (|SC| > 0.1) 
either in the rat or human model are presented in Figure 5.4. The results indicated that DNA 
adduct levels are significantly influenced by the second-order rate constant for the binding to 
2ʹ-dG (kDNA,), the volume of the liver (VLc), and the scaling factor for liver S9 (S9PL) as it was 
previously reported for trans-2-hexenal PBK/D models [16, 26] and for the rat models for the 18 
acyclic α,β-unsaturated aldehydes [25]. Apart from these three parameters, the analysis revealed 
that the model outcome is also influenced by the Vmax and Km of GST mediated conjugation with 
GSH in the liver (Vmax,L_GST and Km,L_GST) in rat, but this influence was insignificant in the human 
model. In contrast to the rat model, the human model outcome is significantly influenced by the 
Vmax and Km of oxidation in the liver (Vmax,L_CA and Km,L_CA). 
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Figure 5.4. Sensitivity analysis of the predicted amount of maximum DNA adducts in the liver at 
0.99 mg cinnamaldehyde/kg  bw for rat (grey bars) and  for human (while bars). The 
parameters listed in the figures are the following: body weight (BW); fraction of the liver (VLc) 
and the small intestine (VSic); blood flow rate (QC); fraction of the blood flow to the small 
intestine (QSic); scaling factor of  liver S9 (S9PL); Vmax and Km in the liver to form cinnamic 
acid (Vmax,L_CA and Km,L_CA) or GSH conjugations mediated by GSTs (Vmax,L_GST and Km,L_GST); 
scaling factor of small intestine S9 (S9PSi); Vmax and Km in the small intestine to form cinnamic 
acid (Vmax,Si_CA and Km,Si_CA), cinnamyl alcohol  (Vmax,Si_AO) or GSH conjugations mediated by 
GSTs (Vmax,Si_GST and Km,Si_GST);  and second-order rate constant of cinnamaldehyde binding to 
2ʹ-dG (kDNA) 
 
PBK/D model outcomes for cinnamaldehyde 
Using the PBK/D models, interspecies differences in detoxification and DNA adduct formation of 
cinnamaldehyde were examined (Figure 5.5).  In rat, the majority of cinnamaldehyde forms GSH 
conjugates and oxidation was revealed to be a minor metabolic route at exposure levels lower than 
200 mg/kg bw (Figure 5.5A). However, the oxidation of cinnamaldehyde was predicted to be the 
major pathway in human at all doses due to the high CEs of ALDHs (Figure 5.5B).  
Subsequently, the DNA adduct formation in the liver was plotted at different doses ranging 
between 0.99 mg/kg bw, a dose representing the EDI for a person of 70 kg [13], and 200 mg/kg 
bw, the highest dose at which level there was no development of neoplasm observed due to 
cinnamaldehyde in rats [11]  (Figure 5.5C). DNA adduct formation in human was predicted to be 
lower than in rat, primarily due to the lower Km for detoxification via oxidation of the aldehyde in 
human liver and small intestine. At 0.99 mg/kg bw, 0.065 and 0.008 adduct formation per 108 nt 
were predicted to occur in rat and human, respectively. At 200 mg/kg bw, the maximum DNA 
adduct level was predicted to be comparable for rat and human, amounting to 79 adducts/108 nt in 
rat and 68 adducts/108 nt in human.  
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Figure 5.4. Sensitivity analysis of the predicted amount of maximum DNA adducts in the liver at 
0.99 mg cinnamaldehyde/kg  bw for rat (grey bars) and  for human (while bars). The 
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and the small intestine (VSic); blood flow rate (QC); fraction of the blood flow to the small 
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GSTs (Vmax,Si_GST and Km,Si_GST);  and second-order rate constant of cinnamaldehyde binding to 
2ʹ-dG (kDNA) 
 
PBK/D model outcomes for cinnamaldehyde 
Using the PBK/D models, interspecies differences in detoxification and DNA adduct formation of 
cinnamaldehyde were examined (Figure 5.5).  In rat, the majority of cinnamaldehyde forms GSH 
conjugates and oxidation was revealed to be a minor metabolic route at exposure levels lower than 
200 mg/kg bw (Figure 5.5A). However, the oxidation of cinnamaldehyde was predicted to be the 
major pathway in human at all doses due to the high CEs of ALDHs (Figure 5.5B).  
Subsequently, the DNA adduct formation in the liver was plotted at different doses ranging 
between 0.99 mg/kg bw, a dose representing the EDI for a person of 70 kg [13], and 200 mg/kg 
bw, the highest dose at which level there was no development of neoplasm observed due to 
cinnamaldehyde in rats [11]  (Figure 5.5C). DNA adduct formation in human was predicted to be 
lower than in rat, primarily due to the lower Km for detoxification via oxidation of the aldehyde in 
human liver and small intestine. At 0.99 mg/kg bw, 0.065 and 0.008 adduct formation per 108 nt 
were predicted to occur in rat and human, respectively. At 200 mg/kg bw, the maximum DNA 
adduct level was predicted to be comparable for rat and human, amounting to 79 adducts/108 nt in 
rat and 68 adducts/108 nt in human.  
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Figure 5.5. Cinnamaldehyde PBK/D model outcomes 
on dose-dependent change in proportion of the 
metabolites to the administered cinnamaldehyde dose 
in rat (A) and in human (B), and on dose-dependent 
maximum DNA adduct formation in both species (C). 
 
 
DNA adduct levels for 18 acyclic α,β-unsaturated aldehydes compared to cinnamaldehyde in 
rats 
The dose-dependent DNA adduct formation in rat liver as predicted for cinnamaldehyde was 
compared with the results previously obtained for 18 acyclic α,β-unsaturated aldehydes [25]. 
Dose-dependent DNA adduct formation in rat liver by cinnamaldehyde as well as the 18 
aldehydes is presented in Figure 5.6. The values for the 18 aldehydes were predicted by the 
PBK/D models developed in our previous study [25]. These PBK/D models developed in the 
previous study contained no submodel for the respective alcohols. In order to harmonize the 
model structures between the 18 aldehydes and cinnamaldehyde, cinnamaldehyde PBK/D model 
outcomes without the cinnamyl alcohol submodel is also presented for the comparison in Figure 
5.6. The difference in DNA adduct levels predicted by the two models for cinnamaldehyde was 
less than 9-fold being lower for the model without the cinnamyl alcohol submodel. The results 
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revealed that, either with or without the cinnamyl alcohol submodel, DNA adduct formation by 6 
aldehydes (trans-2-dodecenal, undecenal, trans-2-decenal, 2,6-dodecadienal, 2-tridecenal, and 
2-tetradecenal) would be lower than that caused by cinnamaldehyde, and for 6 other aldehydes 
(2-propenal, 2-pentenal, 4-methyl-2-pentenal, trans-2-heptenal, and trans- and cis-2-hexenal) 
DNA adduct formation was predicted to be higher than that for cinnamaldehyde at doses up to 200 
mg/kg bw. For the remaining 6 aldehydes (trans-2-cis-6-octadienal, trans-2-cis-6-nonadienal, 
trans-2-trans-6-nonadienal, trans-2-nonenal, cis-2-nonenal, trans-2-octenal) DNA adduct levels 
were within the range of the cinnamaldehyde models  with or without the cinnamyl alcohol 
submodel. 
 
Figure 5.6. Dose-dependent DNA adduct formation by cinnamaldehyde and 18 food-borne acyclic 
α,β-unsaturated aldehydes in rat liver. The DNA adduct formation by the 18 aldehydes were 
derived from our previous study [25] and are presented with thin solid lines. In the cases where 
curves overlap, names of the respective aldehydes are presented on the same line in the boxes. 
The values for cinnamaldehyde predicted by the PBK/D models developed in the present study 
are presented with a thick solid line (model with the cinnamyl alcohol submodel) or with a thick 
dashed line (model without the cinnamyl alcohol submodel). 
 
The levels of DNA adducts predicted to be formed in rat liver upon exposure to the 18 
acyclic α,β-unsaturated aldehydes at their respective EDIs have previously been predicted by the 
PBK/D models [25] as summarized in Table 5.5. The DNA adduct levels for the acyclic 
α,β-unsaturated aldehydes varied between 1.3×10-10 and 0.036 adducts/108 nt at their EDI values 
[25]. These levels are 3 to 12 orders of magnitude lower than the DNA adduct levels of 
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Figure 5.5. Cinnamaldehyde PBK/D model outcomes 
on dose-dependent change in proportion of the 
metabolites to the administered cinnamaldehyde dose 
in rat (A) and in human (B), and on dose-dependent 
maximum DNA adduct formation in both species (C). 
 
 
DNA adduct levels for 18 acyclic α,β-unsaturated aldehydes compared to cinnamaldehyde in 
rats 
The dose-dependent DNA adduct formation in rat liver as predicted for cinnamaldehyde was 
compared with the results previously obtained for 18 acyclic α,β-unsaturated aldehydes [25]. 
Dose-dependent DNA adduct formation in rat liver by cinnamaldehyde as well as the 18 
aldehydes is presented in Figure 5.6. The values for the 18 aldehydes were predicted by the 
PBK/D models developed in our previous study [25]. These PBK/D models developed in the 
previous study contained no submodel for the respective alcohols. In order to harmonize the 
model structures between the 18 aldehydes and cinnamaldehyde, cinnamaldehyde PBK/D model 
outcomes without the cinnamyl alcohol submodel is also presented for the comparison in Figure 
5.6. The difference in DNA adduct levels predicted by the two models for cinnamaldehyde was 
less than 9-fold being lower for the model without the cinnamyl alcohol submodel. The results 
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revealed that, either with or without the cinnamyl alcohol submodel, DNA adduct formation by 6 
aldehydes (trans-2-dodecenal, undecenal, trans-2-decenal, 2,6-dodecadienal, 2-tridecenal, and 
2-tetradecenal) would be lower than that caused by cinnamaldehyde, and for 6 other aldehydes 
(2-propenal, 2-pentenal, 4-methyl-2-pentenal, trans-2-heptenal, and trans- and cis-2-hexenal) 
DNA adduct formation was predicted to be higher than that for cinnamaldehyde at doses up to 200 
mg/kg bw. For the remaining 6 aldehydes (trans-2-cis-6-octadienal, trans-2-cis-6-nonadienal, 
trans-2-trans-6-nonadienal, trans-2-nonenal, cis-2-nonenal, trans-2-octenal) DNA adduct levels 
were within the range of the cinnamaldehyde models  with or without the cinnamyl alcohol 
submodel. 
 
Figure 5.6. Dose-dependent DNA adduct formation by cinnamaldehyde and 18 food-borne acyclic 
α,β-unsaturated aldehydes in rat liver. The DNA adduct formation by the 18 aldehydes were 
derived from our previous study [25] and are presented with thin solid lines. In the cases where 
curves overlap, names of the respective aldehydes are presented on the same line in the boxes. 
The values for cinnamaldehyde predicted by the PBK/D models developed in the present study 
are presented with a thick solid line (model with the cinnamyl alcohol submodel) or with a thick 
dashed line (model without the cinnamyl alcohol submodel). 
 
The levels of DNA adducts predicted to be formed in rat liver upon exposure to the 18 
acyclic α,β-unsaturated aldehydes at their respective EDIs have previously been predicted by the 
PBK/D models [25] as summarized in Table 5.5. The DNA adduct levels for the acyclic 
α,β-unsaturated aldehydes varied between 1.3×10-10 and 0.036 adducts/108 nt at their EDI values 
[25]. These levels are 3 to 12 orders of magnitude lower than the DNA adduct levels of 
32620 Reiko Kiwamoto.indd   143 17-03-15   15:36
Chapter 5
144
DNA adduct formation by cinnamaldehyde and other α,β-unsaturated aldehydes 
 
144 
 
cinnamaldehyde at a dose of 200 mg/kg bw, the highest dose level tested that did not result in 
carcinogenicity in rats, amounting to 79 adducts/108 nt.  Upon exposure to cinnamaldehyde at its 
EDI, formation of 0.065 and 0.017 DNA adducts per 108 nt was predicted in rats by the PBK/D 
model with and without the cinnamyl alcohol submodel, respectively. These levels were 101 to 
108-fold higher than the values obtained for the other aldehydes except for 2-propenal, indicating 
that at realistic exposure levels cinnamaldehyde is expected to result in higher levels of DNA 
adduct formation than these 17 acyclic α,β-unsaturated aldehydes.   
 
Table 5.5 Predicted maximum DNA adduct formation in rat liver by 18 food-borne acyclic 
α,β-unsaturated aldehydes at their respective EDIs. The values for DNA adducts were derived 
from Kiwamoto et al. [25]. 
 
Compounds Levels 
(μg/kgbw/d) 
Predicted maximum 
DNA adduct levels 
(adduct/108nt) 
2-propenal 17 a 0.036 
2-pentenal 0.002b 7.4×10-6 
4-methyl-2-pentenal N.Ac - 
trans-2-hexenal 
cis-2-hexenal 
13.20b 2.0×10-3 
trans-2-heptenal 0.10b 1.2×10-5 
trans-2-octenal 0.50b 4.4×10-6 
trans-2-nonenal 
cis-2-nonenal,  
0.07b 7.2×10-7 
trans-2-decenal 0.10b 4.9×10-8 
2-undecenal 0.007b 3.2×10-9 
trans-2-dodecenal 0.27b 1.3×10-7 
2-tridecenal 0.01b 1.3×10-10 
2-tetradecenal N.A. - 
trans-2-cis-6-octadienal N.A. - 
trans-2-cis-6-nonadienal 
trans-2-trans-6-nonadienal 
0.40d 
0.0001d 
7.1×10-6 
1.8×10-9 
2,6-dodecadienal 0.01d 5.0×10-10 
 
aEstimated amount present in food [44].  bEstimated amount consumed as food flavouring agent 
[9]. cN.A.= not available in literature, dEstimated amount consumed as food flavouring agent [8] 
 
 
DISCUSSION 
 
Humans are ubiquitously exposed to numerous α,β-unsaturated aldehydes, with one of the major 
sources being food. Due to the electrophilic and therefore reactive nature of these compounds 
with DNA, the use of α,β-unsaturated aldehydes as food flavouring agents may present a food 
safety concern. While some α,β-unsaturated aldehydes such as cinnamaldehyde have been 
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observed not to be genotoxic or carcinogenic in vivo [11], the safety of many other 
α,β-unsaturated aldehydes is a matter for ongoing debate because no in vivo genotoxicity or 
carcinogenicity studies have been conducted on these compounds. To overrule the positive results 
obtained in in vitro genotoxicity tests with the α,β-unsaturated aldehydes, especially in vivo data 
have been requested by EFSA [6]. Cinnamaldehyde is one of the few α,β-unsaturated aldehydes 
for which genotoxicity and carcinogenicity have been tested in vivo [11]. In a chronic feeding 
study in rats, no carcinogenicity was observed after daily exposure of rats to cinnamaldehyde up 
to 200 mg/kg bw/day after two years.  
To facilitate a science-based comparison and read-across from the data on 
cinnamaldehyde, in the present study rat and human PBK/D models for cinnamaldehyde were 
developed based on in vitro derived kinetic parameters. These models could predict the level of 
DNA adduct formation expected at dose levels at which cinnamaldehyde was tested negative for 
genotoxicity and carcinogenicity in vivo. In these PBK/D models cinnamaldehyde was described 
to be metabolized via three enzyme-mediated pathways in the liver and small intestine. A 
submodel for the reduced metabolite cinnamyl alcohol was included because the alcohol 
metabolite enters the systemic circulation [42] and can be enzymatically converted back to the 
parent aldehyde, which will influence the predicted levels of DNA adducts formed in the liver. 
The rat cinnamaldehyde PBK/D model predictions matched well with in vivo observed data 
especially at doses higher than 250 mg/kg bw, when the predicted proportions of metabolites 
formed were compared with data found in literature. Comparison of the predictions on 
time-dependent cinnamaldehyde blood levels with in vivo data revealed that the difference was 
within 10-fold except for the peak concentrations (Cmax) that were reached immediately after the 
dosing. The difference up to 450-fold in Cmax between the predictions and the in vivo data upon iv 
injection may partly be explained by the 10-20 sec required for the sample injection and the 
subsequent time needed to flush the cannula inserted in the jugular vein in the in vivo studies [41, 
42]. The PBK/D model administration of all cinnamaldehyde via iv injection occurs at once. If the 
injection time of 20 sec is included in the PBK/D model, overestimations in the predicted Cmax are 
lowered from 10-17-fold to 4.4-7.4-fold compared to the data reported by Yuan et al. [41], and 
from 450 to 201-fold compared to the data reported by Zhao et al. [42]. Upon oral administration, 
the predicted Cmax were higher up to 545-fold than the observed values. While the 
cinnamaldehyde uptake was described only in small intestine in the model, in practice the 
aldehyde may partly be absorbed already in forestomach and glandular stomach upon gavage [45]. 
A PBK/D model that describes this prolonged uptake would improve the prediction for the 
time-dependent kinetics and Cmax. In general, the predicted cinnamaldehyde levels in blood 
matched better with the data reported by Yuan et al [41] but were higher up to two orders of 
magnitudes than the data reported by Zhao et al. [42]. In these two in vivo studies, the blood 
samples were processed differently after sampling: the samples were mixed with formaldehyde 
immediately after the sampling by Yuan et al. [41] to stabilize cinnamaldehyde, whereas this 
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cinnamaldehyde at a dose of 200 mg/kg bw, the highest dose level tested that did not result in 
carcinogenicity in rats, amounting to 79 adducts/108 nt.  Upon exposure to cinnamaldehyde at its 
EDI, formation of 0.065 and 0.017 DNA adducts per 108 nt was predicted in rats by the PBK/D 
model with and without the cinnamyl alcohol submodel, respectively. These levels were 101 to 
108-fold higher than the values obtained for the other aldehydes except for 2-propenal, indicating 
that at realistic exposure levels cinnamaldehyde is expected to result in higher levels of DNA 
adduct formation than these 17 acyclic α,β-unsaturated aldehydes.   
 
Table 5.5 Predicted maximum DNA adduct formation in rat liver by 18 food-borne acyclic 
α,β-unsaturated aldehydes at their respective EDIs. The values for DNA adducts were derived 
from Kiwamoto et al. [25]. 
 
Compounds Levels 
(μg/kgbw/d) 
Predicted maximum 
DNA adduct levels 
(adduct/108nt) 
2-propenal 17 a 0.036 
2-pentenal 0.002b 7.4×10-6 
4-methyl-2-pentenal N.Ac - 
trans-2-hexenal 
cis-2-hexenal 
13.20b 2.0×10-3 
trans-2-heptenal 0.10b 1.2×10-5 
trans-2-octenal 0.50b 4.4×10-6 
trans-2-nonenal 
cis-2-nonenal,  
0.07b 7.2×10-7 
trans-2-decenal 0.10b 4.9×10-8 
2-undecenal 0.007b 3.2×10-9 
trans-2-dodecenal 0.27b 1.3×10-7 
2-tridecenal 0.01b 1.3×10-10 
2-tetradecenal N.A. - 
trans-2-cis-6-octadienal N.A. - 
trans-2-cis-6-nonadienal 
trans-2-trans-6-nonadienal 
0.40d 
0.0001d 
7.1×10-6 
1.8×10-9 
2,6-dodecadienal 0.01d 5.0×10-10 
 
aEstimated amount present in food [44].  bEstimated amount consumed as food flavouring agent 
[9]. cN.A.= not available in literature, dEstimated amount consumed as food flavouring agent [8] 
 
 
DISCUSSION 
 
Humans are ubiquitously exposed to numerous α,β-unsaturated aldehydes, with one of the major 
sources being food. Due to the electrophilic and therefore reactive nature of these compounds 
with DNA, the use of α,β-unsaturated aldehydes as food flavouring agents may present a food 
safety concern. While some α,β-unsaturated aldehydes such as cinnamaldehyde have been 
DNA adduct formation by cinnamaldehyde and other α,β-unsaturated aldehydes 
 
145 
 
observed not to be genotoxic or carcinogenic in vivo [11], the safety of many other 
α,β-unsaturated aldehydes is a matter for ongoing debate because no in vivo genotoxicity or 
carcinogenicity studies have been conducted on these compounds. To overrule the positive results 
obtained in in vitro genotoxicity tests with the α,β-unsaturated aldehydes, especially in vivo data 
have been requested by EFSA [6]. Cinnamaldehyde is one of the few α,β-unsaturated aldehydes 
for which genotoxicity and carcinogenicity have been tested in vivo [11]. In a chronic feeding 
study in rats, no carcinogenicity was observed after daily exposure of rats to cinnamaldehyde up 
to 200 mg/kg bw/day after two years.  
To facilitate a science-based comparison and read-across from the data on 
cinnamaldehyde, in the present study rat and human PBK/D models for cinnamaldehyde were 
developed based on in vitro derived kinetic parameters. These models could predict the level of 
DNA adduct formation expected at dose levels at which cinnamaldehyde was tested negative for 
genotoxicity and carcinogenicity in vivo. In these PBK/D models cinnamaldehyde was described 
to be metabolized via three enzyme-mediated pathways in the liver and small intestine. A 
submodel for the reduced metabolite cinnamyl alcohol was included because the alcohol 
metabolite enters the systemic circulation [42] and can be enzymatically converted back to the 
parent aldehyde, which will influence the predicted levels of DNA adducts formed in the liver. 
The rat cinnamaldehyde PBK/D model predictions matched well with in vivo observed data 
especially at doses higher than 250 mg/kg bw, when the predicted proportions of metabolites 
formed were compared with data found in literature. Comparison of the predictions on 
time-dependent cinnamaldehyde blood levels with in vivo data revealed that the difference was 
within 10-fold except for the peak concentrations (Cmax) that were reached immediately after the 
dosing. The difference up to 450-fold in Cmax between the predictions and the in vivo data upon iv 
injection may partly be explained by the 10-20 sec required for the sample injection and the 
subsequent time needed to flush the cannula inserted in the jugular vein in the in vivo studies [41, 
42]. The PBK/D model administration of all cinnamaldehyde via iv injection occurs at once. If the 
injection time of 20 sec is included in the PBK/D model, overestimations in the predicted Cmax are 
lowered from 10-17-fold to 4.4-7.4-fold compared to the data reported by Yuan et al. [41], and 
from 450 to 201-fold compared to the data reported by Zhao et al. [42]. Upon oral administration, 
the predicted Cmax were higher up to 545-fold than the observed values. While the 
cinnamaldehyde uptake was described only in small intestine in the model, in practice the 
aldehyde may partly be absorbed already in forestomach and glandular stomach upon gavage [45]. 
A PBK/D model that describes this prolonged uptake would improve the prediction for the 
time-dependent kinetics and Cmax. In general, the predicted cinnamaldehyde levels in blood 
matched better with the data reported by Yuan et al [41] but were higher up to two orders of 
magnitudes than the data reported by Zhao et al. [42]. In these two in vivo studies, the blood 
samples were processed differently after sampling: the samples were mixed with formaldehyde 
immediately after the sampling by Yuan et al. [41] to stabilize cinnamaldehyde, whereas this 
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process was not included in the study by Zhao et al. [42]. Yuan et al. [41, 46] reported that the 
cinnamaldehyde concentrations decreased with a half-life of 9 min at 23 ºC after sampling without 
the addition of formaldehyde because cinnamaldehyde continued to bind with blood protein. This 
rapid cinnamaldehyde elimination after sampling may have caused the underestimation of the 
cinnamaldehyde blood levels in the study by Zhao et al. [42] and this may in part also explain the 
deviation of these data from the PBK/D predictions.  
Using the newly developed rat and human PBK/D models for cinnamaldehyde, 
interspecies differences in detoxification and DNA adduct formation of cinnamaldehyde were 
examined. The models revealed that the primary detoxification route shifts from conjugation with 
GSH to oxidation at exposure levels higher than 200 mg/kg bw in rat, while the major route 
remains to be oxidation throughout the examined dose range in human. The estimated in vivo CEs 
for cinnamaldehyde oxidation by human small intestine and liver were two orders of magnitude 
higher than those for rat. Considering that the estimated CEs for in vivo oxidation of 
trans-2-hexenal, a six carbon acyclic α,β-unsaturated aldehyde, in the liver were comparable 
between human and rat [26] the results suggest that different ALDH isoenzymes may play a role 
in the oxidation of cinnamaldehyde and trans-2-hexenal. The higher oxidation efficiencies of 
cinnamaldehyde in human resulted in lower levels of DNA adducts formed in human than in rat. 
The predicted levels were 8.6-fold and 1.2-fold higher in rat than in human at 0.99 mg/kg bw and 
200 mg/kg bw, respectively.  
The rat PBK/D model for cinnamaldehyde predicted the maximum DNA adduct formation 
at 200 mg/kg bw to be 79 adducts/108 nt in the liver, which is within the natural background levels 
of structurally similar 1,N2-exocyclic propanodeoxyguanosine adducts observed in diseased free 
human liver (6.8-110 adducts/108 nt) [47, 48]. This is in line with the findings in the long-term 
rodent study where cinnamaldehyde doses up to 200 mg/kg bw/day did not increase the 
occurrence of neoplasms despite the high levels of exposure [11]. At its EDI, 0.99 mg 
cinnamaldehyde/kg bw, formation of 0.008 DNA adducts per 108 nt was predicted in human. This 
level of DNA adduct is 4 orders of magnitude lower than the predicted value of 79 adducts/108 nt 
in rat liver at 200 mg cinnamaldehyde/kg bw, the exposure level where no carcinogenicity was 
observed in vivo, and 3 orders of magnitude lower than the natural background levels of 
structurally similar DNA adducts observed in diseased free human liver. These results support the 
conclusion that human dietary exposure to cinnamaldehyde is not of concern with respect to 
genotoxicity as was also concluded by FEMA, JECFA and EFSA [10, 13, 49]. Although it may be 
argued that even higher exposures to α,β-unsaturated aldehydes may still lead to significant DNA 
adduct formations, higher levels of exposure are not likely to occur due to the self-limiting use of 
flavouring agents, with higher exposure leading to off-flavours. 
The DNA adduct levels predicted for cinnamaldehyde were furthermore compared with 
DNA adduct formation predicted for 18 other food-borne acyclic α,β-unsaturated aldehydes in our 
previous study [25]. This comparison is of interest given that for these 18 α,β-unsaturated 
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aldehydes in vivo genotoxicity and carcinogenicity data are limited or even absent. The 
comparison may thus facilitate read-across from cinnamaldehyde for which negative in vivo data 
on genotoxicity and carcinogenicity are available. The PBK/D model based comparison in 
dose-dependent formation of DNA adducts, namely 1,N2-exocyclic propanodeoxyguanosine 
adducts in rat revealed that DNA adduct formation by 6 out of the 18 aldehydes (i.e. 
trans-2-dodecenal, undecenal, trans-2-decenal, 2,6-dodecadienal, 2-tridecenal, 2-tetradecenal) 
would be lower than by cinnamaldehyde at doses up to 200 mg/kg bw. Although the reactivity of 
the 6 aldehydes with DNA (kDNA) is higher than that of cinnamaldehyde, detoxification via 
oxidation and conjugation with GSH were estimated to be higher with these 6 aldehydes [25], 
leading to lower DNA adduct formation of these 6 aldehydes. These results highlight the 
importance to account for the overall kinetics of compounds in addition to their reactivity with 
DNA when studying genotoxicity of DNA reactive agents. Lower DNA adduct formation by the 6 
aldehydes than cinnamaldehyde suggests that these 6 aldehydes would also test negative for 
genotoxicity and carcinogenicity at high dose levels. To investigate in vivo genotoxicity or 
carcinogenicity of the other 12 aldehydes, an in vivo genotoxicity study using 2-propenal may be 
of use because 2-propenal represents the worst-case analogue given that it was predicted to induce 
the highest levels of DNA adduct formation within the series [25].  
At their respective EDI, the formation of DNA adducts by the acyclic α,β-unsaturated 
aldehydes appears to be 1 to 8 orders of magnitude lower than DNA adduct formed by 
cinnamaldehyde at its EDI, except for 2-propenal. DNA adduct formation by 2-propenal at its EDI 
(0.036 adducts/108 nt) was predicted to be about 2-fold higher than that by cinnamaldehyde (0.017 
adducts/108 nt) predicted using the rat PBK/D model without the cinnamyl alcohol submodel. 
Compared to the DNA adduct level of cinnamaldehyde at 200 mg/kg bw (79 adducts/108 nt), the 
dose that tested negative in the in vivo study, DNA adducts by all 18 acyclic α,β-unsaturated 
aldehydes at their EDI were 3 to 12 orders of magnitude lower. Considering that cinnamaldehyde 
at this exposure level of 200 mg/kg bw per day did not show carcinogenicity in vivo, these 
differences in the DNA adduct levels indicate that for all these 18 α,β-unsaturated aldehydes DNA 
adduct formation at doses relevant for human dietary exposure does not raise a safety concern. 
This further supports the conclusions obtained in our previous studies [16, 25, 26], where DNA 
adduct formation by the 18 aldehydes was compared with the natural background levels of 
structurally similar 1,N2-exocyclic propanodeoxyguanosine adducts, that DNA adduct formation 
is negligible for the 18 aldehydes at the relevant levels of dietary intake. It should be noted that 
the PBK/D models for the 18 other aldehydes did not contain the submodel for their reduced 
alcohol metabolites [25]. Comparison of such a model for cinnamaldehyde to the model 
containing a submodel for cinnamyl alcohol revealed that this may lead to an underestimation of 
at most 9-fold. This leads to the conclusion that the formation of DNA adducts by the 18 acyclic 
α,β-unsaturated aldehydes at their respective EDI would still be 2 to 11 orders of magnitude lower 
than the DNA adduct level of cinnamaldehyde at 200 mg/kg bw.  
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process was not included in the study by Zhao et al. [42]. Yuan et al. [41, 46] reported that the 
cinnamaldehyde concentrations decreased with a half-life of 9 min at 23 ºC after sampling without 
the addition of formaldehyde because cinnamaldehyde continued to bind with blood protein. This 
rapid cinnamaldehyde elimination after sampling may have caused the underestimation of the 
cinnamaldehyde blood levels in the study by Zhao et al. [42] and this may in part also explain the 
deviation of these data from the PBK/D predictions.  
Using the newly developed rat and human PBK/D models for cinnamaldehyde, 
interspecies differences in detoxification and DNA adduct formation of cinnamaldehyde were 
examined. The models revealed that the primary detoxification route shifts from conjugation with 
GSH to oxidation at exposure levels higher than 200 mg/kg bw in rat, while the major route 
remains to be oxidation throughout the examined dose range in human. The estimated in vivo CEs 
for cinnamaldehyde oxidation by human small intestine and liver were two orders of magnitude 
higher than those for rat. Considering that the estimated CEs for in vivo oxidation of 
trans-2-hexenal, a six carbon acyclic α,β-unsaturated aldehyde, in the liver were comparable 
between human and rat [26] the results suggest that different ALDH isoenzymes may play a role 
in the oxidation of cinnamaldehyde and trans-2-hexenal. The higher oxidation efficiencies of 
cinnamaldehyde in human resulted in lower levels of DNA adducts formed in human than in rat. 
The predicted levels were 8.6-fold and 1.2-fold higher in rat than in human at 0.99 mg/kg bw and 
200 mg/kg bw, respectively.  
The rat PBK/D model for cinnamaldehyde predicted the maximum DNA adduct formation 
at 200 mg/kg bw to be 79 adducts/108 nt in the liver, which is within the natural background levels 
of structurally similar 1,N2-exocyclic propanodeoxyguanosine adducts observed in diseased free 
human liver (6.8-110 adducts/108 nt) [47, 48]. This is in line with the findings in the long-term 
rodent study where cinnamaldehyde doses up to 200 mg/kg bw/day did not increase the 
occurrence of neoplasms despite the high levels of exposure [11]. At its EDI, 0.99 mg 
cinnamaldehyde/kg bw, formation of 0.008 DNA adducts per 108 nt was predicted in human. This 
level of DNA adduct is 4 orders of magnitude lower than the predicted value of 79 adducts/108 nt 
in rat liver at 200 mg cinnamaldehyde/kg bw, the exposure level where no carcinogenicity was 
observed in vivo, and 3 orders of magnitude lower than the natural background levels of 
structurally similar DNA adducts observed in diseased free human liver. These results support the 
conclusion that human dietary exposure to cinnamaldehyde is not of concern with respect to 
genotoxicity as was also concluded by FEMA, JECFA and EFSA [10, 13, 49]. Although it may be 
argued that even higher exposures to α,β-unsaturated aldehydes may still lead to significant DNA 
adduct formations, higher levels of exposure are not likely to occur due to the self-limiting use of 
flavouring agents, with higher exposure leading to off-flavours. 
The DNA adduct levels predicted for cinnamaldehyde were furthermore compared with 
DNA adduct formation predicted for 18 other food-borne acyclic α,β-unsaturated aldehydes in our 
previous study [25]. This comparison is of interest given that for these 18 α,β-unsaturated 
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aldehydes in vivo genotoxicity and carcinogenicity data are limited or even absent. The 
comparison may thus facilitate read-across from cinnamaldehyde for which negative in vivo data 
on genotoxicity and carcinogenicity are available. The PBK/D model based comparison in 
dose-dependent formation of DNA adducts, namely 1,N2-exocyclic propanodeoxyguanosine 
adducts in rat revealed that DNA adduct formation by 6 out of the 18 aldehydes (i.e. 
trans-2-dodecenal, undecenal, trans-2-decenal, 2,6-dodecadienal, 2-tridecenal, 2-tetradecenal) 
would be lower than by cinnamaldehyde at doses up to 200 mg/kg bw. Although the reactivity of 
the 6 aldehydes with DNA (kDNA) is higher than that of cinnamaldehyde, detoxification via 
oxidation and conjugation with GSH were estimated to be higher with these 6 aldehydes [25], 
leading to lower DNA adduct formation of these 6 aldehydes. These results highlight the 
importance to account for the overall kinetics of compounds in addition to their reactivity with 
DNA when studying genotoxicity of DNA reactive agents. Lower DNA adduct formation by the 6 
aldehydes than cinnamaldehyde suggests that these 6 aldehydes would also test negative for 
genotoxicity and carcinogenicity at high dose levels. To investigate in vivo genotoxicity or 
carcinogenicity of the other 12 aldehydes, an in vivo genotoxicity study using 2-propenal may be 
of use because 2-propenal represents the worst-case analogue given that it was predicted to induce 
the highest levels of DNA adduct formation within the series [25].  
At their respective EDI, the formation of DNA adducts by the acyclic α,β-unsaturated 
aldehydes appears to be 1 to 8 orders of magnitude lower than DNA adduct formed by 
cinnamaldehyde at its EDI, except for 2-propenal. DNA adduct formation by 2-propenal at its EDI 
(0.036 adducts/108 nt) was predicted to be about 2-fold higher than that by cinnamaldehyde (0.017 
adducts/108 nt) predicted using the rat PBK/D model without the cinnamyl alcohol submodel. 
Compared to the DNA adduct level of cinnamaldehyde at 200 mg/kg bw (79 adducts/108 nt), the 
dose that tested negative in the in vivo study, DNA adducts by all 18 acyclic α,β-unsaturated 
aldehydes at their EDI were 3 to 12 orders of magnitude lower. Considering that cinnamaldehyde 
at this exposure level of 200 mg/kg bw per day did not show carcinogenicity in vivo, these 
differences in the DNA adduct levels indicate that for all these 18 α,β-unsaturated aldehydes DNA 
adduct formation at doses relevant for human dietary exposure does not raise a safety concern. 
This further supports the conclusions obtained in our previous studies [16, 25, 26], where DNA 
adduct formation by the 18 aldehydes was compared with the natural background levels of 
structurally similar 1,N2-exocyclic propanodeoxyguanosine adducts, that DNA adduct formation 
is negligible for the 18 aldehydes at the relevant levels of dietary intake. It should be noted that 
the PBK/D models for the 18 other aldehydes did not contain the submodel for their reduced 
alcohol metabolites [25]. Comparison of such a model for cinnamaldehyde to the model 
containing a submodel for cinnamyl alcohol revealed that this may lead to an underestimation of 
at most 9-fold. This leads to the conclusion that the formation of DNA adducts by the 18 acyclic 
α,β-unsaturated aldehydes at their respective EDI would still be 2 to 11 orders of magnitude lower 
than the DNA adduct level of cinnamaldehyde at 200 mg/kg bw.  
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In conclusion, the results obtained in this study enabled read-across from cinnamaldehyde 
to 18 food borne acyclic α,β-unsaturated aldehydes and supported the conclusion that for all these 
18 α,β-unsaturated aldehydes DNA adduct formation at doses relevant for human dietary exposure 
does not raise a safety concern. The present study overall illustrated that physiologically based in 
silico modelling approach facilitates a science-based comparison and read-across on the possible 
risks posed by food-borne DNA reactive agents.  
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SUPPORTING INFORMATION 
 
Cinnamaldehyde PBK/D model equations  
 
(1) Uptake from GI cavity   
The uptake of cinnamaldehyde from the intestinal cavity into the small intestine compartment  was 
described by a first-order process as follows:   
dAGI/dt =-Ka*AGI   
InitAGI = DOSE    
where   
AGI  Amount of cinnamaldehyde remaining in GI cavity (μmol)   
Ka  Linear uptake rate (/h)   
DOSE  Amount of cinnamaldehyde administered in a rat (μmol)  
  
(2) Slowly perfused tissue, richly perfused tissue and fat   
Amount cinnamaldehyde in slowly perfused tissue, richly perfused tissue or fat compartment was described 
as follows:    
dATi/dt = QTi*(CA-CVTi)   
CTi = ATi/VTi   
CVTi = CTi/PTi    
where  
ATi  Amount of cinnamaldehyde in a tissue (μmol)  
QTi  Blood flow into a tissue (L/h)   
CA  Concentration of cinnamaldehyde in arterial blood perfusing a tissue (μmol/L)   
CVTi  Concentration of cinnamaldehyde in venous blood leaving a tissue (μmol/L)   
CTi  Concentration of cinnamaldehyde in a tissue (μmol/kg)  
VTi  Volume of a tissue (kg)   
PTi  Tissue/blood partition coefficient of cinnamaldehyde 
  
(3) Liver   
Amount cinnamaldehyde in the liver (AL, μmol) is described as follows:    
dAL/dt   
= QL*CA +QSi*CVSi - (QL+QSi)*CVL - (eq.1 + eq.2 + eq.3 + eq.4 + eq.5 + eq.6) + eq.14 
CL = AL/VL   
CVL = CL/PL    
where  
QL  Blood flow into the liver (L/h)   
QSi  Blood flow into the small intestine (L/h)   
CVSi   Concentration of cinnamaldehyde in venous blood leaving the small intestine  
(μmol/L)   
CVL  Concentration of cinnamaldehyde in venous blood leaving the liver (μmol/L)   
CL  Concentration of cinnamaldehyde in the liver (μmol/L)   
PALDL  Liver/blood partition coefficient of cinnamaldehyde 
 
Amount cinnamaldehyde oxidized to carboxylic acid enzymatically in the liver (AMLCA, μmol) is 
described to follow Michaelis-Menten equation:   
dAMLCA/dt = Vsmax, L_CA * CVL / (Km,L_CA + CVL)      ---------------- eq. 1   
where 
Vsmax,L_CA  Scaled Vmax for enzymatic oxidation of cinnamaldehyde in the liver (μmol/h)   
Km, L_CA  Km for enzymatic oxidation of cinnamaldehyde in the liver (μM)   
 
Amount cinnamaldehyde reduced to cinnamyl alcohol in the liver (AMLAO, μmol) is described to follow 
Michaelis-Menten-equation:    
dAMLAO/dt = Vsmax, L_AO*CVL/(Km,L_AO + CVL)    ---------------- eq. 2    
where   
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Vsmax,L_AO  Scaled Vmax for enzymatic reduction of cinnamaldehyde in the liver (μmol/h)   
Km,L_AO  Km for enzymatic reduction of cinnamaldehyde in the liver (μM)   
 
Amount cinnamaldehyde metabolized in liver to GSH conjugation by GSTs (AMLAGGST, μmol) is 
described by a two substrate ping-pong model:  
dAMLHGGST/dt = 
Vsmax, L_GST * CVL * CLcGSH / 
 (Km,L_GST_G*CVL + Km,L_GST*CLcGSH + CLcGSH*CVL )      ---------------- eq.3  
where 
Vsmax, L_GST Scaled Vmax for enzymatic conjugation of cinnamalcdehyde  in the liver (μmol/h) 
CLcGSH Concentration of GSH in the liver cytosol (μmol/kg)  
Km, L_GST  Km toward cinnamaldehyde for enzymatic conjugation of cinnamaldehyde in the liver (μM)  
Km, L_ GST _G Km toward GSH for enzymatic conjugation of cinnamaldehyde in the liver (μM) 
   
Amount cinnamaldehyde chemically bound in liver to GSH (AMLAGchem, μmol) is described as following: 
dAMLAGchem/dt =  kGSH*CVL*CGSHLC*VL   ---------------- eq.4 
where   
kGSH  Second order rate constant of cinnamaldehyde binding to GSH (/μmol/h)   
VL Volume of the liver (kg)  
 
Amount cinnamaldehyde protein adducts in liver (AMLAP, μmol) is described as following: 
dAMLAP/dt =  kGSH*CVL*CPROL*VL    ---------------- eq.5 
where   
CPROL Concentration of protein reaction sites in the liver (μmol/kg liver) 
 
The formation of DNA adduct in the liver (AMLDAform) was described as following:  
dAMLDAform/dt = kDNA*CVL*CdGL*VL    ---------------- eq.6  
where  
kDNA  Second order rate constant of aldehyde binding to 2ʹ-dG (/μmol/h)   
CdGL  Concentration of 2ʹ-dG in the liver (μmol/kg liver)   
 
CdGL was caluculated to be 1.36 μmol/kg liver using the average molecular weight of  nucleotides (330 
g/mol) and reported concentration of DNA in a rat liver (1.8 g/kg liver).  
 
Amount of DNA adduct in liver (AMLDA, μmol) is described by subtracting elimination of DNA adduct 
from the formation:    
dAMLDA/dt= eq.6- AMLDA* (ln2/ T1/2)    
where  
T1/2  Half-life of DNA adduct in the liver (h)    
 
Amount of GSH present in the liver cytosol (AMGSHLC, μmol) is described by zero-order  synthesis and 
reduction by first-order elimination due to turnover and depletion by aldehyde:   
dAMGSHLC = GSYNL*VL*0.9 - (eq.3+ eq.4+  kL_GLOS* AMGSHLC)  ---------------- eq.7   
Init AMGSHLC = InitGSHL *VL*0.9   
CGSHLC = AMLcGSH/VL   
where  
GSYNL  Rate of GSH synthesis in the liver (μmol/h)   
kL_GLOS  First-order rate of GSH turnover in the liver (/h)   
InitGSHL  Initial concentration of GSH in the liver (μmol/kg liver)  
 
When eq.7 gave negative values, the value zero was used as the amount of GSH in the liver cytosol.  
  
(4) Small intestine   
The amount cinnamaldehyde in small intestine tissue, (ASi, μmol) is described as follows:    
dASi/dt = QSi*(CA -CVSi) + Ka*AGI - (eq.8 + eq.9 + eq.10 + eq.11 + eq.12) + eq.15 
CSi = ASi/VSi  
CVSi = CSi/PSi  
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When eq.7 gave negative values, the value zero was used as the amount of GSH in the liver cytosol.  
  
(4) Small intestine   
The amount cinnamaldehyde in small intestine tissue, (ASi, μmol) is described as follows:    
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where   
CSi  Concentration of cinnamaldehyde in the small intestine (μmol/L)   
VSi  Volume of the small intestine (kg)   
PSi  Small intestine/blood partition coefficient of cinnamaldehyde  
  
Amount cinnamaldehyde enzymatically oxidized carboxylic acid (AMSiCA, μmol) in the  small intestine 
is described by Michaelis-Menten equation:   
dAMSiCA/dt = Vsmax,Si_CA*CVSi/(Km, Si_CA + CVSi)   ---------------- eq.8    
where   
Vsmax,Si_CA  Scaled Vmax for enzymatic oxidation of cinnamaldehyde in the small intestine  (μmol/h)   
Km,Si_CA  Km for enzymatic oxidation of cinnamaldehyde in small intestine (μM) 
  
 
Amount cinnamaldehyde reduced to cinnamyl alcohol in the small intestine (AMSiAO, μmol) is described 
to follow Michaelis-Menten-equation:    
dAMSiAO/dt = Vsmax, Si_AO*CVSi/(Km,Si_AO + CVSi)   ---------------- eq. 9    
where   
Vsmax,Si_AO  Scaled Vmax for enzymatic reduction of cinnamaldehyde in the small intestine (μmol/h)   
Km,Si_AO  Km for enzymatic reduction of cinnamaldehyde in the small intestine (μM)   
 
Amount cinnamaldehyde metabolized in small intestine to GSH conjugation by GSTs (AMSiAGGST, μmol) 
is described by a two substrate ping-pong model:  
dAMSiHGGST/dt = 
Vsmax, Si_GST * CVSi * CSicGSH / 
 (Km,Si_GST_G*CVSi + Km,Si_GST*CSicGSH + CSicGSH*CVSi )      --------------- eq.10  
where 
Vsmax, Si_GST Scaled Vmax for enzymatic conjugation of cinnamalcdehyde  in the small intestine 
(μmol/h) 
CSicGSH Concentration of GSH in the small intestine cytosol (μmol/kg)  
Km, Si_GST  Km toward cinnamaldehyde for enzymatic conjugation of cinnamaldehyde in the small 
intestine (μM)  
Km, Si_ GST _G Km toward GSH for enzymatic conjugation of cinnamaldehyde in the small intestine (μM) 
  
Amount cinnamaldehyde chemically bound in small intestine to GSH (AMSiAGchem, μmol) is described as 
following: 
dAMLAGchem/dt =  kGSH*CVSi*CGSHSiC*VSi   --------------- eq.11 
where   
kGSH  Second order rate constant of aldehyde binding to GSH (/μmol/h)   
VSi Volume of the small intestine (kg)  
 
Amount cinnamaldehyde protein adducts in small intestine (AMSiAP, μmol) is described as following: 
dAMSiAP/dt =  kGSH*CSiL*CPROSi*VSi   --------------- eq.12 
where   
CPROSi Concentration of protein reaction sites in the small intestine (μmol/kg liver) 
Amount of GSH present in small intestine cytosol (AMGSHSiC, μmol) is described in the same way as in 
the liver:   
dAMGSHSiC = GSYNSi *VSi*0.9- (eq.10 + eq. 11 + kGLOS_Si*AMGSHSiC)  ---------- eq. 13 
Init AMGSHSiC = InitGSHSi *VSi*0.9  
CGSHSiC = AMSicGSH/VSi   
where   
GSYNSi  Rate of GSH synthesis in small intestine (μmol/h)   
kGLOS_Si  First-order rate of GSH turnover in small intestine (/h)   
InitGSHSi  Initial concentration of GSH in small intestine (μmol/kg small intestine)   
  
As was the case in the liver, the value zero was used as the amount of GSH in the small  intestine cytosol 
when eq.13 gave negative values.   
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(5) Venous blood and arterial blood 
Concentration of cinnamaldehyde in venous blood (CV) and in arterial blood (CA, both in μmol/L) was 
described as follows:   
dAV/dt = QF*CVF + (QL+QSi)*CVL + QR*CVR + QS*CVS - QC*CV   
CV = AV/(VA+VV)   
CV = CA   
where  
AV  Amount of cinnamaldehyde in venous blood (μmol)  
QF  Blood flow into fat (L/h)   
CVF  Concentration of cinnamaldehyde in venous blood leaving fat (μmol/L)   
QR  Blood flow into richly perfused tissue (L/h)   
CVR  Concentration of cinnamaldehyde in venous blood leaving richly perfused tissue  (μmol/L)   
QS  Blood flow into slowly perfused tissue (L/h)   
CVS  Concentration of aldehyde in venous blood leaving slowly perfused tissue (μmol/L)  
 
 
Cinnamyl alcohol PBK/D submodel equations 
 
(1) Slowly perfused tissue, richly perfused tissue and fat   
Amount cinnamyl alcohol in slowly perfused tissue, richly perfused tissue or fat compartment was 
described as follows:    
dAohTi/dt = QTi*(CohA-CVohTi)   
CohTi = AohTi/VTi   
CohVTi = CohTi/PohTi    
where  
AohTi  Amount of cinnamyl alcohol in a tissue (μmol)  
CohA  Concentration of cinnamyl alcohol in arterial blood perfusing a tissue (μmol/L)   
CohVTi  Concentration of cinnamyl alcohol in venous blood leaving a tissue (μmol/L)   
CohTi  Concentration of cinnamyl alcohol in a tissue (μmol/kg)  
PohTi Tissue/blood partition coefficient of cinnamyl alcohol 
  
(3) Liver   
Amount cinnamyl alcohol in the liver (AohL, μmol) is described as follows:    
dAohL/dt  = QL*CohA +QSi*CohVSi - (QL+QSi) *CohVL + eq.2 - eq.14 
CohL = AohL/VL   
CohVL = CohL/PohL    
where  
QL  Blood flow into the liver (L/h)   
QSi  Blood flow into the small intestine (L/h)   
CohVSi  Concentration of cinnamyl alcohol in venous blood leaving the small intestine  (μmol/L)   
CohVL  Concentration of cinnamyl alcohol in venous blood leaving the liver (μmol/L)   
CohL  Concentration of cinnamyl alcohol in the liver (μmol/L)   
PohL  Liver/blood partition coefficient of cinnamyl alcohol  
 
Amount cinnamyl alcohol oxidized to cinnamaldehyde enzymatically in the liver (AohMLCA, μmol) is 
described to follow Michaelis-Menten equation:   
dAohMLCA/dt = Vsmax, L_OH * CVL / (Km,L_OH + CVL)     -------------- eq. 14   
where 
Vsmax,L_OH  Scaled Vmax for enzymatic oxidation of cinnamyl alcohol in the liver (μmol/h)   
Km, L_OH  Km for enzymatic oxidation of  cinnamyl alcohol in the liver (μM)   
 
(4) Small intestine   
Amount cinnamyl alcohol in small intestine tissue, (AohSi, μmol) is described as follows:    
dAohSi/dt = QSi*(CohA -CohVSi) + eq.9 – eq.15   
CohSi = AohSi/VSi  
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where   
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(4) Small intestine   
Amount cinnamyl alcohol in small intestine tissue, (AohSi, μmol) is described as follows:    
dAohSi/dt = QSi*(CohA -CohVSi) + eq.9 – eq.15   
CohSi = AohSi/VSi  
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CohVSi = CohSi/PohSi  
where   
CohSi  Concentration of cinnamyl alcohol in the small intestine (μmol/L)   
PohSi  Small intestine/blood partition coefficient of cinnamyl alcohol 
  
Amount cinnamyl alcohol enzymatically oxidized to cinnamaldehyde (AohMSiCA, μmol) in the  small 
intestine is described by Michaelis-Menten equation:   
dAohMSiCA/dt = Vsmax,Si_OH*CohVSi/(Km, Si_OH + CohVSi)   --------------- eq.15    
where    
Vsmax,Si_OH  Scaled Vmax for enzymatic oxidation of cinnamyl alcohol in the small intestine  (μmol/h)   
Km,Si_OH  Km for enzymatic oxidation of cinnamyl alcohol in the small intestine (μM) 
  
(5) Venous blood and arterial blood   
Concentration of cinnamyl alcohol in venous blood (CohV) and in arterial blood (CohA, both in μmol/L) 
was described as follows:   
dAohV/dt = QF*CohVF + (QL+QSi)*CohVL + QR*CohVR + QS*CohVS - QC*CohV   
CohV = AohV/(VA+VV)   
CohV = CohA   
where  
AohV  Amount of cinnamyl alcohol in venous blood (μmol)  
CohVF  Concentration of cinnamyl alcohol in venous blood leaving fat (μmol/L)   
CohVR  Concentration of cinnamyl alcohol in venous blood leaving richly perfused tissue  
(μmol/L)   
CohVS  Concentration of cinnamyl alcohol in venous blood leaving slowly perfused tissue (μmol/L)  
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This thesis aimed at examining dose-dependent detoxification and DNA adduct formation of DNA 
reactive α,β-unsaturated aldehydes using physiologically based in silico modelling, in order to 
safety assessment of these aldehydes used as food flavouring agents. In this chapter, the results of 
the thesis will be first summarized, followed by a general discussion including future perspectives 
for important aspects raised in the course of study.  At the end of this chapter, an overall 
conclusion will be provided. 
 
6.1 Summary of the results 
 
α,β-Unsaturated aldehydes are widely distributed in the environment, and the diet is one of the 
major exposure routes for humans. Various α,β-unsaturated aldehydes are present in fruits, 
vegetables, spices, or processed products containing these items as natural constituents [1]. Many 
of the aldehydes have a unique odour representing the smell of the commodities, and for this 
reason the aldehydes are often used as added food flavouring agents. Because of the 
α,β-unsaturated aldehyde moiety the β carbon in the molecule becomes electron deficient and the 
aldehydes react with electron rich molecules including DNA via Michael addition [2]. The 
formation of DNA adducts raises a concern for genotoxicity, while the formation of DNA adducts 
may not be significant at low doses relevant for dietary exposure in vivo because of adequate 
detoxification. The thesis therefore aimed at determining dose-dependent detoxification and DNA 
adduct formation of food-borne α,β-unsaturated aldehydes by using a physiologically based in 
silico modelling approach in order to contribute to the safety assessment of these aldehydes used 
as food flavourings.  
Physiologically based kinetic/dynamic (PBK/D) models were developed to simulate 
ADME (absorption, distribution, metabolism and excretion)(i.e. kinetics) as well as DNA adduct 
formation by the aldehydes (i.e. dynamics). In Chapter 2 and 3, rat and human PBK/D models 
were developed for the compound trans-2-hexenal, a model dietary α,β-unsaturated aldehyde used 
to investigate dose-dependent detoxification and DNA adduct formation, and to examine 
interspecies differences. The kinetic parameters for detoxification were collected by performing in 
vitro incubations using relevant rat or human tissue fractions. The PBK/D models revealed that at 
the estimated daily intake (EDI) i.e. 0.04 mg/kg bw, trans-2-hexenal is detoxified predominantly 
via GST-mediated conjugation with GSH in rat, while the reduction to 2-hexen-1-ol was the major 
pathway in human. Despite this interspecies difference in the detoxification, interspecies 
differences in the maximum DNA adduct levels in the liver were predicted to be limited. At the 
EDI, DNA adduct formation was predicted to be 0.01 adducts/108 nt in rat and 0.008 adducts/108 
nt in human. These levels were 3 orders of magnitude lower than the natural background levels of 
structurally similar exocyclic 1,N2-propanodeoxyguanosine adducts present in disease free human 
liver (i.e. 6.8–110 adducts/108 nt) [3, 4]. 
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The human PBK/D model was subsequently used to examine the impact of interindividual 
variation in trans-2-hexenal detoxification on DNA adduct formation in a human population. The 
parameters for detoxification were measured for 11 individuals to define the variation in aldehyde 
oxidation, reduction and conjugation with GSH and subsequently to simulate the distribution of 
DNA adduct formation in the population as a whole by performing Monte Carlo simulations. At 
the EDI, the maximum amount of DNA adducts in the liver was predicted to be 0.007 adducts/108 
nt for the 50th percentile and 0.039 adducts/108 nt for the most sensitive persons (the 99th 
percentile). At a high intake level of 0.178 mg/kg bw (the 95th percentile of the dietary intake), 
DNA adduct formation was predicted to be 0.18 adducts/108 nt for the 99th percentile. These 
values were all well below the natural background levels of structurally similar exocyclic 
1,N2-propanodeoxyguanosine adducts present in disease free human liver (i.e. 6.8–110 
adducts/108 nt) [3, 4]. Based on these results, it was concluded that trans-2-hexenal in the diet 
may not significantly increase the DNA adduct levels in the liver compared to the background in 
both rats and humans including the most sensitive persons.  
The objective of Chapter 4 was to extend the rat PBK/D model developed for 
trans-2-hexenal to other α,β-unsaturated aldehydes that may be used as food flavourings, to 
examine DNA adduct formation at low doses relevant for human dietary exposure and to facilitate 
group evaluation. Considering the large number of the aldehydes of interest, the efficiency to 
collect chemical specific detoxification parameters was increased by applying a QSAR 
(quantitative structure-activity relationship) approach. Eighteen acyclic α,β-unsaturated aldehyde 
flavouring agents without 2- or 3-alkylation, and with no more than one conjugated double bond 
were selected as model compounds. Six of these 18 aldehydes were selected as the training set to 
define QSAR models to estimate kinetic parameters for detoxification of the other 12 aldehydes in 
the test set. Among the 18 aldehydes, 2-propenal (acrolein) was predicted to induce the highest 
number of DNA adducts in rat liver due to the lowest efficiency for oxidation and conjugation 
with GSH. The maximum DNA adduct formation by the 18 aldehydes was between 10-10– 10-2 
adducts/108 nt at their respective EDI as food flavourings. These levels are at least two orders of 
magnitude lower than the natural background levels of structurally similar DNA adducts (i.e. 6.8–
110 adducts/108 nt). Based on these outcomes it was concluded that the DNA adduct formation by 
all 18 aldehydes when used as flavourings is negligible.  
Unlike many α,β-unsaturated aldehydes for which in vivo data on genotoxicity and 
carcinogenicity are absent, cinnamaldehyde has been tested not to be genotoxic or carcinogenic in 
vivo [5]. The aim of Chapter 5 was to examine DNA adduct formation by cinnamaldehyde using 
physiologically based kinetic/dynamic (PBK/D) modelling, and to compare these DNA adduct 
levels to those predicted for the 18 other food-borne α,β-unsaturated aldehydes in Chapter 4 for 
read-across. The cinnamaldehyde PBK/D models were developed based on kinetic parameters 
obtained by performing in vitro incubations with relevant tissue fractions. The model performance 
was evaluated, revealing that the kinetics of cinnamaldehyde such as time-dependent 
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differences in the maximum DNA adduct levels in the liver were predicted to be limited. At the 
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The human PBK/D model was subsequently used to examine the impact of interindividual 
variation in trans-2-hexenal detoxification on DNA adduct formation in a human population. The 
parameters for detoxification were measured for 11 individuals to define the variation in aldehyde 
oxidation, reduction and conjugation with GSH and subsequently to simulate the distribution of 
DNA adduct formation in the population as a whole by performing Monte Carlo simulations. At 
the EDI, the maximum amount of DNA adducts in the liver was predicted to be 0.007 adducts/108 
nt for the 50th percentile and 0.039 adducts/108 nt for the most sensitive persons (the 99th 
percentile). At a high intake level of 0.178 mg/kg bw (the 95th percentile of the dietary intake), 
DNA adduct formation was predicted to be 0.18 adducts/108 nt for the 99th percentile. These 
values were all well below the natural background levels of structurally similar exocyclic 
1,N2-propanodeoxyguanosine adducts present in disease free human liver (i.e. 6.8–110 
adducts/108 nt) [3, 4]. Based on these results, it was concluded that trans-2-hexenal in the diet 
may not significantly increase the DNA adduct levels in the liver compared to the background in 
both rats and humans including the most sensitive persons.  
The objective of Chapter 4 was to extend the rat PBK/D model developed for 
trans-2-hexenal to other α,β-unsaturated aldehydes that may be used as food flavourings, to 
examine DNA adduct formation at low doses relevant for human dietary exposure and to facilitate 
group evaluation. Considering the large number of the aldehydes of interest, the efficiency to 
collect chemical specific detoxification parameters was increased by applying a QSAR 
(quantitative structure-activity relationship) approach. Eighteen acyclic α,β-unsaturated aldehyde 
flavouring agents without 2- or 3-alkylation, and with no more than one conjugated double bond 
were selected as model compounds. Six of these 18 aldehydes were selected as the training set to 
define QSAR models to estimate kinetic parameters for detoxification of the other 12 aldehydes in 
the test set. Among the 18 aldehydes, 2-propenal (acrolein) was predicted to induce the highest 
number of DNA adducts in rat liver due to the lowest efficiency for oxidation and conjugation 
with GSH. The maximum DNA adduct formation by the 18 aldehydes was between 10-10– 10-2 
adducts/108 nt at their respective EDI as food flavourings. These levels are at least two orders of 
magnitude lower than the natural background levels of structurally similar DNA adducts (i.e. 6.8–
110 adducts/108 nt). Based on these outcomes it was concluded that the DNA adduct formation by 
all 18 aldehydes when used as flavourings is negligible.  
Unlike many α,β-unsaturated aldehydes for which in vivo data on genotoxicity and 
carcinogenicity are absent, cinnamaldehyde has been tested not to be genotoxic or carcinogenic in 
vivo [5]. The aim of Chapter 5 was to examine DNA adduct formation by cinnamaldehyde using 
physiologically based kinetic/dynamic (PBK/D) modelling, and to compare these DNA adduct 
levels to those predicted for the 18 other food-borne α,β-unsaturated aldehydes in Chapter 4 for 
read-across. The cinnamaldehyde PBK/D models were developed based on kinetic parameters 
obtained by performing in vitro incubations with relevant tissue fractions. The model performance 
was evaluated, revealing that the kinetics of cinnamaldehyde such as time-dependent 
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cinnamaldehyde blood concentrations observed in vivo [6, 7] were overall adequately predicted. 
The PBK/D models revealed DNA adduct formation due to oral exposure to cinnamaldehyde in 
human to be lower than in rat because of efficient oxidation. In rats, cinnamaldehyde was shown 
to induce higher DNA adducts per exposure dose than 6 out of the 18 food borne acyclic 
α,β-unsaturated aldehydes, indicating these 6 aldehydes may also test negative for genotoxicity 
and carcinogenicity at high dose levels. At the highest cinnamaldehyde dose that was tested 
negative for carcinogenicity in vivo and tested negative, the model predicted formation of 79 
DNA adducts/108 nt in rat. This value is at least three orders of magnitude higher than the PBK/D 
model based predictions of DNA adduct formation by the 18 other food-borne aldehydes at their 
respective EDI. These results corroborate the conclusion obtained in Chapter 4 that for all these 
18 α,β-unsaturated aldehydes DNA adduct formation at doses relevant for human dietary exposure 
does not raise a safety concern. This chapter furthermore illustrates that physiologically based in 
silico modelling facilitates a science-based comparison and read-across on the possible risks 
posed by food-borne DNA reactive agents.  
 
6.2 General discussion and future perspective 
 
The results of the present thesis can be discussed in a wider perspective also focussing on what 
would be topics of interest to include and consider in future studies. The topics that are relevant to 
discuss in some more detail in this respect include: 
- performance and need for further refinement of the PBK/D models,  
- aldehyde toxicity and DNA adduct formation in the gastrointestinal (GI) tract,  
- application of the integrated QSAR-PBK/D modelling to a wider range of α,β-unsaturated 
aldehydes,  
- implication of the results obtained in this thesis for safety assessment, and   
- future possibilities of PBK/D modelling for genotoxic agents in general. 
 
Performance and need for further refinement of the PBK/D models  
In order to draw conclusions that are relevant for in vivo situation from PBK/D model outcomes, 
it is important to ensure that the PBK/D models adequately simulate the behaviour of the 
compounds of interest in vivo. For this reason evaluation of a PBK/D model by comparing 
predictions with in vivo data is a crucial step in the model development to determine whether 
major determinants and/or process that are essential for describing the system behaviour have 
been adequately identified and characterized [8]. In this section the overview of the PBK/D model 
performance developed in this thesis is presented, as well as discussions on uncertainties that may 
have been present in the PBK/D models developed in this thesis.   
The performance of the rat PBK/D models was evaluated by comparing the predictions on 
DNA adduct formation with in vivo data in Chapter 2 and 4. The predicted values for 
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trans-2-hexenal matched well with the data reported by Schuler and Eder [9], with a maximum 
difference of 4-fold. The overestimation in the DNA adduct formation was remarkable when the 
predictions were compared with the data reported by Stout et al [10]: the maximum difference 
reached 9,717-fold in Chapter 4. DNA adduct formation was overestimated up to 947-fold also for 
2-butenal (crotonaldehyde) in Chapter 4 compared to the data reported by Budiawan and Eder 
[11]. The overestimation in the DNA adduct levels compared to certain in vivo studies [11, 12] 
may be attributed to the feeding status of the animals used in the in vivo studies. The assumption 
of the PBK/D models was the complete absorption of administered aldehyde at once. The rats 
used in the study by Stout et al. [12] were not fasted before the dosing, indicating that a part of the 
aldehydes may have reacted with thiol or other reactive protein residues of the food matrix thus 
being excreted in faeces without being absorbed. The binding of α,β-unsaturated aldehydes with 
food residues present in the GI lumen is supported by the fact that 15 to 28% of acrolein was 
excreted in faeces in Sprague-Dawley rats upon oral exposure to 2.5 to 15 mg acrolein/kg bw 
[13]. It should be furthermore noted that a part of the aldehydes may not have been absorbed due 
to severe damage to the mucosal tissue of the GI tract caused by extremely high concentration of 
trans-2-hexenal or crotonaldehyde reaching their LD50 (780 mg/kg bw for trans-2-hexenal and 
206 mg/kg bw for 2-butenal) [12].  
The performance of the cinnamaldehyde PBK/D model was thoroughly examined in 
Chapter 5. The predicted time-dependent cinnamaldehyde concentrations in blood were compared 
with data obtained from rats exposed to cinnamaldehyde via gavage or intravenous (iv) injection. 
The predicted values were within 10-fold of the in vivo data, except for the peak concentrations 
(Cmax) that occurred immediately after the dosing. The overestimation in Cmax was bigger upon 
oral administration than after iv injection, reaching up to 48–fold and 545-fold compared to the 
data reported by Yuan et al. [6] and Zhao et al. [7] respectively. The tendency to overestimate the 
Cmax especially upon oral exposure implies that the description of cinnamaldehyde oral 
administration could be improved. This may be done taking some of the following considerations 
into account. 
In all the PBK/D models developed in this thesis, the aldehyde uptake in the small intestine 
was described to follow a first-order reaction: 
dAGI/dt =-Ka*AGI   
where AGI is the amount of aldehyde remaining in GI cavity (μmol) and Ka is the first-order rate 
constant (/h). The value of Ka was set to be 5 (/h) regardless of the aldehyde studied, representing 
a swift absorption of the compound. In practice, however, the absorption may already occur 
before the aldehyde reaches the small intestine upon gavage. Frederick et al. [14] developed a 
PBK model for ethyl acrylate, an α,β-unsaturated ester (Figure 6.1). In this model the absorption 
is described to occur already in the forestomach, glandular stomach, duodenum and finally in the 
small intestine assuming gavage administration. The gut lumen was divided into two phases: 
vehicle (i.e. oil phase) and lumen contents (i.e.aqueous gel of food matter). The ester was 
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before the aldehyde reaches the small intestine upon gavage. Frederick et al. [14] developed a 
PBK model for ethyl acrylate, an α,β-unsaturated ester (Figure 6.1). In this model the absorption 
is described to occur already in the forestomach, glandular stomach, duodenum and finally in the 
small intestine assuming gavage administration. The gut lumen was divided into two phases: 
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described to be transported from the vehicle to the lumen contents before the absorption to the gut 
wall. The effect of inclusion of such an oral dosing model on the predicted cinnamaldehyde blood 
concentrations and subsequent DNA adduct formation can be evaluated by including these 
equations in the PBK/D model for cinnamaldehyde in rat developed in Chapter 5. The schematic 
diagram of this oral dosing model is presented in Figure 6.1, and the model equations and the 
parameters used in the model are attached at the end of this chapter as supplementary information. 
The parameters to describe the transportations from vehicle to lumen contents (KGUT) and from 
lumen contents to gut walls (KAB) may vary for each chemical. The parameters defined for ethyl 
acrylate by Frederick et al. [14] are applied in this chapter to obtain an idea about whether the 
inclusion of such an oral dosing model could improve the cinnamaldehyde PBK/D model 
performance.  
 
 
Figure 6.1 The schematic diagram of the oral dosing model derived from Frederick et al. [14]. The 
arrows represent the movement of an aldehyde. 
 
Figure 6.2 shows the predicted cinnamaldehyde levels in blood upon oral administration 
of 250 or 500 mg cinnamaldehyde/kg bw in rats. These figures demonstrate that the prediction 
(solid lines) matches better with the observed data (circles) if the oral dosing model is included. 
The overestimations in the Cmax of up to 17-fold and 450-fold compared to the data obtained by 
Yuan et al. [6] and Zhao et al [7], respectively, were lowered to 6-fold and 48-fold with the 
inclusion. In addition, the inclusion of the oral dosing model also improved the prediction on Tmax, 
the timing when Cmax occurs. The Tmax was between 0.3-2.0 hours at 250 mg/kg bw and 2.0-3.9 
hours at 500 mg/kg bw in vivo [6, 7]. The predicted Tmax was 0.01 hour (36 second) after the 
gavage without the oral dosing model, and the inclusion of the oral dosing model delayed this 
timing to 0.9 hour at 250 mg/kg bw and 1.3 hour at 500 mg/kg bw. While the inclusion of the oral 
administration model improves the model performance on cinnamaldehyde kinetics, its influence 
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on the predictions on DNA adduct formation seems to be limited. The inclusion altered the 
predicted values for DNA adduct formation by cinnamaldehyde from 0.065 to 0.085 adducts/108 
nt at its EDI and from 79 to 76 adducts/108 nt at 200 mg/kg bw, indicating the conclusions 
obtained in Chapter 5, stating that DNA adduct formation by the 18 α,β-unsaturated aldehydes at 
doses relevant for human dietary exposure does not raise a safety concern, will not be influenced.  
 
Figure 6.2 Performance of the rat cinnamaldehyde PBK/D model developed in Chapter 5 without 
(two figures on the left) or with (two figures on the right) the oral dosing model. The solid lines 
represent the predicted cinnamaldehyde levels in blood in rats upon oral administration of 250 or 
500 mg cinnamaldehyde/kg bw. The circles represent the in vivo data reported by Yuan et al. [15] 
(closed circles) or by Zhao et al. [7] (open circles).  
 
In order to see whether the description of the aldehyde uptake caused the remarkable 
overestimation in DNA adduct formation by trans-2-hexenal or 2-butenal (crotonaldehyde) in 
Chapter 2 and 4 as described above, the influence of the inclusion of the oral dosing model on 
DNA adduct level predictions for trans-2-hexenal was also examined (Table 6.1). The predicted 
DNA adduct formation is still 155 and 2,030-fold higher compared to the in vivo data reported by 
Stout et al. [12] or by Budiawan et al. [11], respectively, while the model performance is further 
improved deviating only up to 2.6-fold when the DNA adduct levels are compared with the data 
reported by Schuler and Eder [9]. This further supports that the remarkable overestimation in 
DNA adduct formation is possibly due to the differences in the experimental design of the three in 
vivo studies [9, 11, 12] such as the animal fasting status discussed already above.  
Altogether, the inclusion of the oral dosing model is recommended where the 
time-dependent kinetics of the α,β-unsaturated aldehydes are the model outcomes of interest, 
however, the inclusion may not be necessary to predict DNA adduct formation in the liver because 
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described to be transported from the vehicle to the lumen contents before the absorption to the gut 
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parameters used in the model are attached at the end of this chapter as supplementary information. 
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lumen contents to gut walls (KAB) may vary for each chemical. The parameters defined for ethyl 
acrylate by Frederick et al. [14] are applied in this chapter to obtain an idea about whether the 
inclusion of such an oral dosing model could improve the cinnamaldehyde PBK/D model 
performance.  
 
 
Figure 6.1 The schematic diagram of the oral dosing model derived from Frederick et al. [14]. The 
arrows represent the movement of an aldehyde. 
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hours at 500 mg/kg bw in vivo [6, 7]. The predicted Tmax was 0.01 hour (36 second) after the 
gavage without the oral dosing model, and the inclusion of the oral dosing model delayed this 
timing to 0.9 hour at 250 mg/kg bw and 1.3 hour at 500 mg/kg bw. While the inclusion of the oral 
administration model improves the model performance on cinnamaldehyde kinetics, its influence 
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doses relevant for human dietary exposure does not raise a safety concern, will not be influenced.  
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500 mg cinnamaldehyde/kg bw. The circles represent the in vivo data reported by Yuan et al. [15] 
(closed circles) or by Zhao et al. [7] (open circles).  
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improved deviating only up to 2.6-fold when the DNA adduct levels are compared with the data 
reported by Schuler and Eder [9]. This further supports that the remarkable overestimation in 
DNA adduct formation is possibly due to the differences in the experimental design of the three in 
vivo studies [9, 11, 12] such as the animal fasting status discussed already above.  
Altogether, the inclusion of the oral dosing model is recommended where the 
time-dependent kinetics of the α,β-unsaturated aldehydes are the model outcomes of interest, 
however, the inclusion may not be necessary to predict DNA adduct formation in the liver because 
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of the limited influence of the submodel. The oral dosing model, if it would be included, could be 
refined to a further extent to describe especially the transportation from vehicle to gut contents 
and the absorption of the chemical of interest in each compartment, which may vary depending on 
the compound.  
 
Table 6.1 Comparison of the PBK/D model predicted DNA adduct levels with in vivo data. 
 
In vivo 
reference 
Compound 
Dose and time 
of the 
measurement 
Observed 
values 
Predicted values 
(Prediction/ in vivo data) 
without the oral 
dosing model 
with the oral dosing 
model 
Budiawan 
and Eder 
[11] 
2-butenal 
(crotonalde
hyde) 
200 or 300 
mg/kg bw, 20h 
2.9 and 3.4 
adducts/108 nt 
1240 and 3220 
adducts/108 nt 
(428 and 946-fold) 
437 and 739 
adducts/108 nt 
(151 and 217-fold) 
Stout et al. 
[12] 
trans-2- 
hexenal 
200 or 500 
mg/kg bw, 24 h 
0.2 and 0.099 
adducts/108 nt 
94 and 962 
adducts/108 nt 
(470 and 9717-fold) 
65 and 195  
adducts/108 nt 
(325 and 1970-fold) 
Schuler and 
Eder [9] 
trans-2- 
hexenal 
200 or 500 
mg/kg bw, 48 h 
16 and 179 
adducts/108 nt 
61 and 625 
adducts/108 nt 
(3.8 and 3.5-fold) 
42 and 127  
adducts/108 nt 
(2.6 and 0.7-fold) 
 
In addition to uncertainties in the PBK/D model descriptions on the aldehyde apsorption, 
there may be some uncertainties related to the parameters that were incorporated in the models. 
The half-life of DNA adducts (T1/2) that represented the DNA repair efficiency is one of such 
parameters. In this thesis a half-life of 38.5 hours was applied for all compounds to describe the 
elimination of DNA adducts due to DNA repair. The value was derived from an in vivo study 
using male F344 rats [9], where the reduction in DNA adducts of trans-2-hexenal in the liver was 
followed after the dosing. However the elimination kinetics may vary depending on the 
compound. A shorter half-life of less than 3 hours has been observed for 4-hydroxy-2-nonenal in 
vitro [16], and moreover DNA repair kinetics may be biphasic consisting of a shorter half-life, 
reported to be as short as 15 min, which then slows down to a half-life of 48 hours [17, 18]. Such 
biphasic kinetics in DNA repair or chemical dependent variation in DNA adduct half-lives is not 
accounted for in this thesis. The parameter for DNA repair for each aldehyde could potentially be 
derived in vitro by incubating plasmid DNA substrates containing DNA adducts of interest in 
cell-free extracts of, for instance human cells that possess NER (nucleotide excision repair) 
mechanism, and by measuring the time-dependent elimination of the DNA adducts  [16]. 
 
Aldehyde toxicity and DNA adduct formation in the GI tract  
With the PBK/D models that were evaluated to be adequate, dose-dependent DNA adduct 
formation by different food-borne α,β-unsaturated aldehydes was predicted in the liver. The liver 
was selected as the organ of interest because several in vivo studies have reported DNA adduct 
formation in this organ [9, 11, 12]. These in vivo data were considered to be more reliable to 
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evaluate the PBK/D model performance than data in the first contact organs because no corrosion 
has been observed in liver due to the exposure to the aldehydes [12]. Also, the natural background 
levels of structurally similar DNA adducts are available for liver [3, 4], which were included in 
this thesis as reference values for evaluation of the significance of the DNA adduct levels formed 
by dietary aldehydes.  
It should be noted, however, that the concentrations of the aldehydes may be higher in the 
organs that have a direct contact with the aldehydes following oral intake such as the stomach. In 
rats, the most pronounced toxicity has been observed in forestomach upon single oral exposure to 
extremely high doses of aldehydes. Stout et al. [12], for example histologically analysed the 
toxicity of trans-2-hexenal in the first contact organs following single administration of 50, 200 or 
500 mg/kg  trans-2-hexenal by oral gavage. Necroulcerative lesions accompanied by 
inflammation were predominant in the forestomach. The damage to the glandular stomach was 
clearly present but minor compared to the forestomach, and there were no significant lesions 
observed in the livers. Schuler and Eder [9] measured the DNA adducts formed by 
trans-2-hexenal in different organs using a 32P post-labelling technique. The highest amount was 
observed in the forestomach, followed by the liver at 200 and 500 mg trans-2-hexenal/kg bw. The 
DNA adduct levels in colon and duodenum were lower than in the liver. These results suggest that 
in rats upon gavage administration of an extremely high dose of trans-2-hexenal reaching its LD50 
(780 mg/kg bw for male rats), the toxicity is most pronounced in the forestomach. 
Long-term carcinogenicity studies have suggested forestomach or blood cells to be 
affected in rats by different α,β-unsaturated aldehydes. Occurrence of neoplasms in the 
forestomach increased due to the aldehyde exposure in a sub-chronic study for 2-propenal 
(acrolein) [19] and in a 2-year feeding study for trans,trans-2,4-hexadienal [20]. In these rodent 
studies 2-propenal was dissolved in 0.5% methylcellulose and administered by gavage for 14 
weeks and trans,trans-2,4-hexadienal was dissolved in corn oil and deposited to the forestomach 
directly using a tube. In both studies an increase in hyperplasia was observed only in the 
forestomach and not in the glandular stomach or the liver. In 2-year studies for cinnamaldehyde 
and citral, the aldehydes were microencapsulated and provided in the feed [5, 21]. The 
microencapsulation was applied in these studies to prevent the spontaneous evaporation or 
oxidation of the aldehydes. Development of neoplasms was not observed in any of the organs in 
the study for cinnamaldehyde. Higher numbers of malignant lymphomas were observed in female 
rats receiving citral, which may have been related to exposure to citral [21]. The inconsistency in 
the experimental designs of the animal studies on aldehyde administration, such as dosing method 
(gavage or mixed in feed), form of aldehydes (with or without microencapsulation) and vehicle 
solution (corn oil, water or methylcellulose), makes the interpretation of the study outcomes 
problematic. Considering no toxicity was observed in forestomach when cinnamaldehyde and 
citral were encapsulated and mixed in feed, it may be concluded that the carcinogenicity observed 
in the forestomach for 2-propenal and trans,trans-2,4-hexadienal may have been caused by 
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of the limited influence of the submodel. The oral dosing model, if it would be included, could be 
refined to a further extent to describe especially the transportation from vehicle to gut contents 
and the absorption of the chemical of interest in each compartment, which may vary depending on 
the compound.  
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there may be some uncertainties related to the parameters that were incorporated in the models. 
The half-life of DNA adducts (T1/2) that represented the DNA repair efficiency is one of such 
parameters. In this thesis a half-life of 38.5 hours was applied for all compounds to describe the 
elimination of DNA adducts due to DNA repair. The value was derived from an in vivo study 
using male F344 rats [9], where the reduction in DNA adducts of trans-2-hexenal in the liver was 
followed after the dosing. However the elimination kinetics may vary depending on the 
compound. A shorter half-life of less than 3 hours has been observed for 4-hydroxy-2-nonenal in 
vitro [16], and moreover DNA repair kinetics may be biphasic consisting of a shorter half-life, 
reported to be as short as 15 min, which then slows down to a half-life of 48 hours [17, 18]. Such 
biphasic kinetics in DNA repair or chemical dependent variation in DNA adduct half-lives is not 
accounted for in this thesis. The parameter for DNA repair for each aldehyde could potentially be 
derived in vitro by incubating plasmid DNA substrates containing DNA adducts of interest in 
cell-free extracts of, for instance human cells that possess NER (nucleotide excision repair) 
mechanism, and by measuring the time-dependent elimination of the DNA adducts  [16]. 
 
Aldehyde toxicity and DNA adduct formation in the GI tract  
With the PBK/D models that were evaluated to be adequate, dose-dependent DNA adduct 
formation by different food-borne α,β-unsaturated aldehydes was predicted in the liver. The liver 
was selected as the organ of interest because several in vivo studies have reported DNA adduct 
formation in this organ [9, 11, 12]. These in vivo data were considered to be more reliable to 
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evaluate the PBK/D model performance than data in the first contact organs because no corrosion 
has been observed in liver due to the exposure to the aldehydes [12]. Also, the natural background 
levels of structurally similar DNA adducts are available for liver [3, 4], which were included in 
this thesis as reference values for evaluation of the significance of the DNA adduct levels formed 
by dietary aldehydes.  
It should be noted, however, that the concentrations of the aldehydes may be higher in the 
organs that have a direct contact with the aldehydes following oral intake such as the stomach. In 
rats, the most pronounced toxicity has been observed in forestomach upon single oral exposure to 
extremely high doses of aldehydes. Stout et al. [12], for example histologically analysed the 
toxicity of trans-2-hexenal in the first contact organs following single administration of 50, 200 or 
500 mg/kg  trans-2-hexenal by oral gavage. Necroulcerative lesions accompanied by 
inflammation were predominant in the forestomach. The damage to the glandular stomach was 
clearly present but minor compared to the forestomach, and there were no significant lesions 
observed in the livers. Schuler and Eder [9] measured the DNA adducts formed by 
trans-2-hexenal in different organs using a 32P post-labelling technique. The highest amount was 
observed in the forestomach, followed by the liver at 200 and 500 mg trans-2-hexenal/kg bw. The 
DNA adduct levels in colon and duodenum were lower than in the liver. These results suggest that 
in rats upon gavage administration of an extremely high dose of trans-2-hexenal reaching its LD50 
(780 mg/kg bw for male rats), the toxicity is most pronounced in the forestomach. 
Long-term carcinogenicity studies have suggested forestomach or blood cells to be 
affected in rats by different α,β-unsaturated aldehydes. Occurrence of neoplasms in the 
forestomach increased due to the aldehyde exposure in a sub-chronic study for 2-propenal 
(acrolein) [19] and in a 2-year feeding study for trans,trans-2,4-hexadienal [20]. In these rodent 
studies 2-propenal was dissolved in 0.5% methylcellulose and administered by gavage for 14 
weeks and trans,trans-2,4-hexadienal was dissolved in corn oil and deposited to the forestomach 
directly using a tube. In both studies an increase in hyperplasia was observed only in the 
forestomach and not in the glandular stomach or the liver. In 2-year studies for cinnamaldehyde 
and citral, the aldehydes were microencapsulated and provided in the feed [5, 21]. The 
microencapsulation was applied in these studies to prevent the spontaneous evaporation or 
oxidation of the aldehydes. Development of neoplasms was not observed in any of the organs in 
the study for cinnamaldehyde. Higher numbers of malignant lymphomas were observed in female 
rats receiving citral, which may have been related to exposure to citral [21]. The inconsistency in 
the experimental designs of the animal studies on aldehyde administration, such as dosing method 
(gavage or mixed in feed), form of aldehydes (with or without microencapsulation) and vehicle 
solution (corn oil, water or methylcellulose), makes the interpretation of the study outcomes 
problematic. Considering no toxicity was observed in forestomach when cinnamaldehyde and 
citral were encapsulated and mixed in feed, it may be concluded that the carcinogenicity observed 
in the forestomach for 2-propenal and trans,trans-2,4-hexadienal may have been caused by 
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extremely high concentrations of aldehyde directly deposited in the first contact organ, the 
forestomach in case of rats, as the results of local tissue irritation [22] as also pointed out by 
JECFA in their evaluation report for 2,4-hexadienal [23]. If this is the case, the toxicity observed 
in the forestomach in such animal studies does not represent the toxicity in humans because 
exposure of the forestomach is irrelevant for the human exposure situation with respect to 
exposure levels as well as organ.  
Although the forestomach is not a relevant target organ in human, overall GI organs 
including the stomach and small intestine may be the target for toxicity in human. It is therefore 
still of interest to examine what DNA adduct levels could be expected in the rat GI tract. In order 
to investigate the DNA adduct formation in these organs, the theoretical distribution of the 
aldehydes in the GI tract can be simulated using the oral dosing model described in the previous 
section. According to the rat trans-2-hexenal PBK/D model coupled with the oral dosing model, 
trans-2-hexenal concentrations are the highest in the glandular stomach, followed by in the 
forestomach, duodenum, small intestine and then in the liver. The AUCs (areas under the curve) 
obtained from the time-dependent trans-2-hexenal concentration change in the GI organs are 
summarized in Table 6.2. The AUCs in the glandular stomach are in general three orders of 
magnitude higher than in the liver. At 0.04 mg/kg bw, the EDI of trans-2-hexenal, the AUC in the 
glandular stomach (1.6 μM•h) was 533-fold higher than in the liver (0.003 μM•h). Based on these 
AUCs, DNA adduct formed in the glandular stomach can be estimated to be 0.53 adduct/108 nt 
from the predicted DNA adduct amount in the liver (0.001 adduct/108 nt) at this level of exposure, 
assuming a linear relationship between AUC in an organ and DNA adduct levels formed. 
Assuming the natural background levels of structurally similar DNA adducts in the glandular 
stomach is the same as in the liver (6.8-110 adducts/108 nt) [3, 4], the DNA adduct formation in 
the glandular stomach due to trans-2-hexenal in the diet is an order of magnitude lower and 
therefore may still be negligible. Furthermore, it should be noted that the oral administration 
model used in this chapter does not include aldehyde metabolism in the forestomach, glandular 
stomach and duodenum, which may further reduce the aldehyde levels in the GI tract if included. 
To further determine the aldehyde distribution and DNA adduct formation in the GI tract, it is 
recommended to obtain parameters to describe metabolism and transportation of specific 
aldehydes of interest in the GI organst to refine the oral dosing model.  
 
Table 6.2 AUC values (μM • h) of trans-2-hexenal predicted by the rat trans-2-hexenal PBK/D 
model coupled with the oral dosing model 
 
Dose 
 (mg/kg bw) 
Forestomach 
Glandular 
stomach 
Duodenum 
Small 
intestine 
Liver 
0.04 0.78 1.6 0.07 0.009 0.003 
500  4325 16021 1653 583 81 
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Application of the integrated QSAR-PBK/D modelling to a wider range of α,β-unsaturated 
aldehydes  
This thesis demonstrated that the integrated QSAR-PBK/D modelling approach remarkably 
accelerated group evaluation of structurally similar aldehydes. In Chapter 4, QSAR models were 
developed for kinetic parameters based on the experimentally derived kinetic data on 6 
compounds to predict the kinetic parameters for 12 other compounds, meaning the time and 
labour required to collect those chemical specific parameters were reduced to one third to 
develop PBK/D models for 18 compounds. The PBK/D models were shown to contribute to the 
safety evaluation of this large group of aldehydes by providing insights in the amount of DNA 
adducts formed at low doses relevant for dietary exposure, without performing animal 
experiments. Furthermore, the PBK/D models developed for the 18 aldehydes enabled to rank 
the compounds depending on their dose-dependent DNA adduct formation. This provides useful 
information to select aldehydes that represent the worst case within the group. Selecting such 
representative compounds contributes to a reduction, replacement, and refinement (3R) of 
animal studies because in vivo studies may not need to be performed for all compounds within a 
group but only for the worst case analogue to conclude on the safety of the group of structurally 
similar chemicals. Taking a group evaluation strategy, EFSA selected trans-2-hexenal, 2-octenal 
and trans-2-cis-6-nonadienal as representatives of the acyclic α,β-unsaturated aldehydes without 
2- or 3-alkylation, and with no more than one conjugated double bonds for the further 
genotoxicity and carcinogenicity testing. The selection was based on chain length, lipophilicity 
and the results of an unpublished (Q)SAR [24], but the consideration on the detoxification 
kinetics seems to be lacking in the selection process. The PBK/D modelling approach applied in 
this thesis indicated that 2-propenal would represent the worst case in the group. This result 
illustrates the importance to take not only the reactivity with DNA but also overall kinetics of 
the compounds into account when a group evaluation strategy is applied for DNA reactive 
compounds.  
The structures of dietary α,β-unsaturated aldehydes vary more than the variation between 
the 18 aldehydes that were examined in this thesis as presented in Table 1.1 in Chapter 1. To 
reach conclusions on a larger group of compounds than the 18 aldehydes, the integrated 
QSAR-PBK/D modelling approach is recommended to be applied to other dietary 
α,β-unsaturated aldehydes that were not examined in this thesis. To this end, an applicability 
domain first needs to be defined, and a sufficient number of aldehydes should be selected for a 
training set to develop statistically significant and robust QSAR models to define biochemical 
parameters such as Km and Vmax for the metabolism by performing in vitro experiments [25]. 
The PBK/D models developed based on QSAR estimated parameters will facilitate to select a 
compound in a subgroup or a subgroup from the entire group of α,β-unsaturated aldehydes used 
as food flavourings that represents the worst case analogue, taking crucial information such as 
detoxification efficiencies, reactivity with DNA and exposure levels into account. 
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extremely high concentrations of aldehyde directly deposited in the first contact organ, the 
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JECFA in their evaluation report for 2,4-hexadienal [23]. If this is the case, the toxicity observed 
in the forestomach in such animal studies does not represent the toxicity in humans because 
exposure of the forestomach is irrelevant for the human exposure situation with respect to 
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Although the forestomach is not a relevant target organ in human, overall GI organs 
including the stomach and small intestine may be the target for toxicity in human. It is therefore 
still of interest to examine what DNA adduct levels could be expected in the rat GI tract. In order 
to investigate the DNA adduct formation in these organs, the theoretical distribution of the 
aldehydes in the GI tract can be simulated using the oral dosing model described in the previous 
section. According to the rat trans-2-hexenal PBK/D model coupled with the oral dosing model, 
trans-2-hexenal concentrations are the highest in the glandular stomach, followed by in the 
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obtained from the time-dependent trans-2-hexenal concentration change in the GI organs are 
summarized in Table 6.2. The AUCs in the glandular stomach are in general three orders of 
magnitude higher than in the liver. At 0.04 mg/kg bw, the EDI of trans-2-hexenal, the AUC in the 
glandular stomach (1.6 μM•h) was 533-fold higher than in the liver (0.003 μM•h). Based on these 
AUCs, DNA adduct formed in the glandular stomach can be estimated to be 0.53 adduct/108 nt 
from the predicted DNA adduct amount in the liver (0.001 adduct/108 nt) at this level of exposure, 
assuming a linear relationship between AUC in an organ and DNA adduct levels formed. 
Assuming the natural background levels of structurally similar DNA adducts in the glandular 
stomach is the same as in the liver (6.8-110 adducts/108 nt) [3, 4], the DNA adduct formation in 
the glandular stomach due to trans-2-hexenal in the diet is an order of magnitude lower and 
therefore may still be negligible. Furthermore, it should be noted that the oral administration 
model used in this chapter does not include aldehyde metabolism in the forestomach, glandular 
stomach and duodenum, which may further reduce the aldehyde levels in the GI tract if included. 
To further determine the aldehyde distribution and DNA adduct formation in the GI tract, it is 
recommended to obtain parameters to describe metabolism and transportation of specific 
aldehydes of interest in the GI organst to refine the oral dosing model.  
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developed for kinetic parameters based on the experimentally derived kinetic data on 6 
compounds to predict the kinetic parameters for 12 other compounds, meaning the time and 
labour required to collect those chemical specific parameters were reduced to one third to 
develop PBK/D models for 18 compounds. The PBK/D models were shown to contribute to the 
safety evaluation of this large group of aldehydes by providing insights in the amount of DNA 
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In the following text several molecular descriptors that may be considered to model aldehyde 
metabolism or reactivity with DNA are discussed, since they provide possible parameters to be 
used for QSARs in future studies. For the chemical reaction of the aldehydes with DNA or with 
GSH, the important determinants to be considered are the energy value of the lowest unoccupied 
molecular orbital (ELUMO) and the LUMO density at the reaction site within the molecule based 
on the frontier molecular orbital theory [26]. ELUMO parameterizes the ability of an electrophilic 
compound to accept electrons. A molecule with a low ELUMO value tends to show a high 
reactivity with electron rich molecules. Increasing LUMO density at the reaction atom makes it 
easier for the electrophilic site of the molecule, the β carbon in the case of α,β-unsaturated 
aldehydes, to accept electrons from a donor. The hard and soft acid and base (HSAB) theory has 
also been used to profile the reactivity of the aldehydes with nucleophilic substances [27]. Based 
on the HSAB theory, hard electrophiles react with hard nucleophiles i.e. DNA rather than soft 
nucleophiles i.e. GSH, protein. Hardness of a molecule (η) can be calculated from the energy 
levels of LUMO and HOMO (highest occupied molecular orbit) (η = [ELUMO-EHOMO]/2). The 
HSAB parameters are related to the ease with which electron redistribution occurs during the 
formation of covalent adducts, which in turn, is related to the rate of the adduct forming 
reaction. The molecular electrophilicity index (ω) is another comprehensive measure of 
electrophilicity, which is calculated from ELUMO and EHOMO (ω= 
[EHOMO
2+2EHOMOELUMO+ELUMO
2]/[4(ELUMO-EHOMO)]).  
The values of these descriptors of some aldehydes are listed in Table 6.3 together with the 
second-order rate constants with DNA (kDNA) or with GSH (kGSH) when available. The kDNA 
obtained in in vitro studies decreased in the following order: trans-2-hexenal (1.6×10
-7 /μM/h, 
Chapter 1) > 2,4-hexadienal (7.6×10-8 /μM/h, MSc thesis of Y. Wulansary) > cinnamaldehyde 
(1.6×10-8 /μM/h, Chapter 5). The order cannot be explained by ELUMO,  ω or by η, but may be 
explained by the higher LUMO density at the β carbon of trans-2-hexenal compared to that of 
2,4-hexadienal or cinnamaldehyde. Nevertheless, the number of the compounds is too small to 
determine what is the most important determinant to quantitatively describe the reactivity of the 
aldehydes with DNA, but the increased tendency with increased LUMO density on the β carbon 
suggests that this LUMO density could be one of the important molecular descriptors to be 
considered when QSARs are made for kDNA. The experimentally derived kGSH decreased in the 
following order: 2,4-hexadienal (2.3×10-3/μM/h, MSc thesis of Y. Wulansary) > cinnamaldehyde 
(6.6 ×10-4/μM/h, Chapter 4) > trans-2-hexenal (5.8 ×10-4 /μM/h, Chapter 1), which could not be 
explained by any of the parameters listed in Table 6.3. Again the number of compounds to be 
compared should be increased to draw any conclusions, but it may be already considered that 
other descriptors than those listed in Table 6.3, such as steric hindrance [28] may be important 
determinants for aldehyde reactivity with GSH.  
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Table 6.3 The molecular descriptors of α,β-unsaturated aldehydes from different subgroups.  
 
Compound Structure 
ELUMO
a,b 
(eV) 
LUMO 
density 
at C-βb 
ωb,c 
(eV) 
Ηb,d 
(eV) 
kDNA 
(/μM/h) 
kGSH 
(/μM/h) 
trans-2-hexenal 
 
-0.17 0.40 2.7 5.1 1.6×10-7 5.8 ×10-4 
trans, trans- 
2,4-hexadienal  
-0.66 0.25 2.9 4.4 7.6×10-8 2.3×10-3 
trans, trans- 
2-ethyl-2-hexen
al  
-0.13 0.39 2.6 4.9 NAd NA 
trans, trans 
-3-ethyl-2-hexe
nal 
 
-0.13 0.39 2.6 4.9 NA NA 
citral 
 
-0.17 0.39 2.5 4.7 NA NA 
cinnamaldehyde 
 
-0.83 0.20 3.1 4.3 1.6×10-8 6.6 ×10-4 
aenergy value of LUMO. bELUMO and EHOMO were obtained using MOPAC Interface version 13.0 
run on ChemBio 3D Ultra version 13.0.0.3015 (both PerkinElmer, Massachusetts). 
celectrophilicity index. dhardness. enot available 
 
For enzyme-mediated detoxification of α,β-unsaturated aldehydes, this thesis revealed that 
within the acyclic α,β-unsaturated aldehydes without 2- or 3-alkylation, and with no more than 
one conjugated double bond, increasing bulkiness of the molecule decreases Km of 
ALDH-mediated oxidation. Also, the increased bulkiness was shown to increase the 
GST-mediated conjugation efficiencies with GSH. These findings are in agreement with the 
findings reported in literature. A decrease in Km was observed with increasing chain length for 
ALDH-mediated oxidation of 2-alkenals in human cells [29], and an increased specificity constant 
(kcat/Km) was reported for mammalian cytosolic GST with increasing hydrophobicity of 
4-hydroxy-2-alkenals [30]. More data on a wider variety of α,β-unsaturated aldehydes are 
required to establish quantitative relationships between the structures and  kinetic parameters for 
metabolism such as Vmax and Km.   
 
Implication for safety assessment 
For the safety assessment on the use of α,β-unsaturated aldehydes as food flavourings, JECFA 
applied the TTC (toxicological threshold of concern) approach and the exposure resulting from 
the level of use as flavouring for each aldehyde [23, 31, 32]. When the exposure level of an 
aldehyde was above the TTC, which was the case for cinnamaldehyde, in vivo carcinogenicity test 
results were examined [32] to conclude on its safety in use. The Expert Panel of FEMA has 
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For enzyme-mediated detoxification of α,β-unsaturated aldehydes, this thesis revealed that 
within the acyclic α,β-unsaturated aldehydes without 2- or 3-alkylation, and with no more than 
one conjugated double bond, increasing bulkiness of the molecule decreases Km of 
ALDH-mediated oxidation. Also, the increased bulkiness was shown to increase the 
GST-mediated conjugation efficiencies with GSH. These findings are in agreement with the 
findings reported in literature. A decrease in Km was observed with increasing chain length for 
ALDH-mediated oxidation of 2-alkenals in human cells [29], and an increased specificity constant 
(kcat/Km) was reported for mammalian cytosolic GST with increasing hydrophobicity of 
4-hydroxy-2-alkenals [30]. More data on a wider variety of α,β-unsaturated aldehydes are 
required to establish quantitative relationships between the structures and  kinetic parameters for 
metabolism such as Vmax and Km.   
 
Implication for safety assessment 
For the safety assessment on the use of α,β-unsaturated aldehydes as food flavourings, JECFA 
applied the TTC (toxicological threshold of concern) approach and the exposure resulting from 
the level of use as flavouring for each aldehyde [23, 31, 32]. When the exposure level of an 
aldehyde was above the TTC, which was the case for cinnamaldehyde, in vivo carcinogenicity test 
results were examined [32] to conclude on its safety in use. The Expert Panel of FEMA has 
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referred to the low amount of use of the aldehydes as food flavouring agents when affirming their 
GRAS (generally recognized as safe) status, using the same TTC approach as applied by JECFA 
[33, 34].  In the EU, because of the absence of a safe level of exposure, genotoxic compounds 
are not allowed to be intentionally added to foods. Compounds for which positive in vitro 
genotoxicity data exist, which is the case for α,β-unsaturated aldehydes, require follow up in vivo 
studies to exclude the concern about genotoxicity and carcinogenicity. With the implementation of 
the EU regulation for food flavouring agents (Regulation (EU) No. 872/2012) the use of most of 
α,β-unsaturated aldehydes and their related compounds have been suspended since the 
enforcement of the regulation in 2013. 
This inconsistency in the safety evaluation by JECFA and FEMA on one hand and EFSA 
on the other highlights the urgent need for better safety assessment methods, to allow harmonized 
and ideally quantitative evaluation of the safety and/or risks connected to exposure to low levels 
of genotoxic compounds. This thesis presented the use of physiologically based in silico 
modelling as a powerful and useful tool to contribute to the safety evaluation of food-borne DNA 
reactive agents. Using PBK/D models detoxification and DNA adduct formation were simulated 
for a number of aldehydes at low exposure doses, at which levels an increase in DNA adducts 
above background levels cannot be easily detected in in vivo experimental studies. In order to 
examine whether the predicted increase in DNA adduct levels due to exposure to the 
α,β-unsaturated aldehydes in the diet is significant, reference values are needed. In Chapter 2, 3 
and 4, the predicted adduct levels were compared with the natural background levels of 
structurally similar exocyclic 1,N2-propanodeoxyguanine adducts (Figure 6.3 B and C for the 
structures). The structurally similar exocyclic 1,N2-propanodeoxyguanine adducts are present in 
the liver as background in disease-free human livers because some α,β-unsaturated aldehydes 
such as 2-butenal (crotonaldehyde) and malondialdehyde are formed endogenously due to lipid 
peroxidation in vivo. The natural background level of exocyclic 1,N2-propanodeoxyguanine 
adducts has been determined to be 6.8-110 adducts/108 nt based on two studies where the DNA 
adduct levels of 2-butenal and malondialdehyde were examined in human livers [3, 4].  In 
Chapter 5, the formation of DNA adducts by cinnamaldehyde used as a food flavour agent was 
used for a comparison, because cinnamaldehyde is known not to be genotoxic or carcinogenic in 
vivo despite the fact that it induces formation of exocyclic 1,N2-propanodeoxyguanine adducts in 
vitro [35]. The structure of the DNA adducts formed by cinnamaldehyde is presented in Figure 
6.3D. 
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Figure 6.3 The structures of exocyclic 1,N2-propanodeoxyguanosine adducts formed by 
trans-2-hexenal (A), 2-butenal (crotonaldehyde) (B), malondialdehyde (C), cinnamaldehyde (D) 
or by 2-propenal (acrolein) (E and F).  
 
The dose-dependent DNA adduct formation defined for the 18 aldehydes in this thesis 
provides a good starting point for read-across between the structurally related α,β-unsaturated 
aldehydes. The DNA adducts, namely exocyclic 1,N2-propanodeoxyguanine adducts formed by  
α,β-unsaturated aldehydes disrupt base pairing within duplex DNA, which may result in mutations 
[36].  It is important to be aware that the comparison of the DNA adduct levels is based on the 
assumption that each adduct has similar mutagenic and carcinogenic potency, while mutation 
potencies may not be the same for all the aldehydes. For example, γ-HOPdG, an exocyclic 
1,N2-propanodeoxyguanine adduct of 2-propenal (acrolein) (Figure 6.3E) induced ≤ 1% G to T 
and G to A base substitutions in HeLa and xeroderma pigmentosum complementation group A 
cells, whereas the α-HOPdG adduct, the regioisomeric guanine adduct of 2-propenal (Figure 6.3F) 
induced 10% base substitutions, primarily G to T transversions [36]. The aldehydes with longer 
chain length than 2-propenal are known to form γ-propanoguanine adducts [37] and therefore the 
high mutation potency as reported for the α-HOPdG adducts of 2-propenal is not expected. 
Nevertheless it is still recommended to determine the mutation frequency for each dietary as well 
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as endogenous aldehyde to allow for an even better safety assessment based on comparison of the 
DNA adduct levels induced by the α,β-unsaturated aldehydes and background DNA adduct levels. 
The PBK/D model based predictions on dose-dependent DNA adduct formation 
elucidated that 2-propenal would be the most reactive aldehyde of the 18 aldehydes studied in 
DNA adduct formation (Chapter 4). If an in vivo study would still be performed despite the 
negligible levels of DNA adducts predicted to be formed for the 18 aldehydes at their EDIs, 
2-propenal is recommended to be selected to represent the worst case in this group of acyclic 
α,β-unsaturated aldehydes. 2-Propenal could be seen as a compound of the highest concern also 
because of the increased mutation potency of the α-HOPdG adducts, which can be formed by 
2-propenal but not by the other aldehydes as described in the previous paragraph. Considering the 
low LD50 (26 mg/kg bw) and high volatility (269 Torr) of 2-propenal, administration of high doses 
of pure 2-propenal by gavage is not practical but the aldehyde needs to be microencapsulated and 
mixed in feed to achieve a stable long-term feeding without resulting in high mortality [22]. 
Further PBK/D studies are needed to examine to what extent 2-propenal also represents a worst 
case for other dietary α,β-unsaturated in other subgroups including for example 2- or 3- alkylated 
aldehydes, 2,4-dienals and cyclic aldehydes. 
 
Future possibilities of PBK/D modelling for genotoxic agents in general 
The ultimate goal of physiologically based in silico models developed for DNA reactive 
compounds is not limited to predicting DNA adduct formation but to predict further steps in the 
development of tumours. A tumour development is a multi-step process, which is often described 
to be divided into three phases: initiation, promotion, and the final stage progression. The first 
steps are reversible thus the formation of DNA adduct does not per se cause a tumour. A useful 
strategy to model chemical induced carcinogenicity would be to construct mathematical equations 
based on multistage carcinogenesis models reported by Luebeck et al.[38], as previously 
suggested by Punt et al. [39] and Paini [40]. Luebeck et al. described that a four-stage model that 
they could predict the epidemiological data on the age-specific incidence of colorectal cancers 
among the US population. The four-stage model consisted of two rare mutations in adenomatous 
polyposis coli (APC) genes, followed by high-frequency events in the conversion of a normal cell 
into an initiated cell that expands clonally to give rise to an adenomatous polyp, and subsequently 
by a transition of a preinitiated stem cell into an initiated cell capable of clonal expansion. To use 
this multi-stage model it is crucial to parameterize the frequency of the first two rare mutations for 
each chemical. The parameterisation could be achieved in vitro by exposing human cell lines to a 
chemical with or without bioactivation to quantify the mutation frequency in the APC genes 
including P53 and K-ras.  
 
  
General discussion 
 
175 
 
6.3 Conclusions 
 
This thesis presented an alternative approach for the current methods relying on animal 
experiments for the safety evaluation of genotoxic compounds using α,β-unsaturated aldehydes as 
model compounds. Physiologically based in silico models were developed for 18 α,β-unsaturated 
aldehydes to define dose-dependent detoxification of these aldehydes and to obtain insights in 
DNA adduct formation at low doses relevant to human dietary exposure to these compounds. 
DNA adduct formation by the 18 aldehydes was negligible at their estimated levels of use as food 
flavourings compared to the natural background levels of structurally similar exocyclic 
1,N2-propanodeoxyguanosine adducts present in disease free human liver. The same conclusion 
for the 18 aldehydes was obtained by comparing the DNA adduct levels with that of 
cinnamaldehyde that is known to test negative for genotoxic and carcinogenic in vivo even at high 
dose levels. Overall, the results indicated that the DNA adduct formation by the 18 
α,β-unsaturated aldehydes as food flavourings are negligible and do not raise a safety concern at 
their levels of intake resulting from their use as food flavourings. 
In addition, this thesis illustrated that physiologically based in silico models provide a 
very useful and powerful tool to facilitate a group evaluation and read-across for food-borne DNA 
reactive agents. The application of QSAR models to predict kinetic parameters to build PBK/D 
models strongly accelerated the development of the PBK/D models of the group of 18 
compounds. PBK/D models furthermore enabled comparison of DNA adduct formation by the 18 
aldehydes for which in vivo data are limited or even absent, with data on DNA adduct formation 
for a structurally related compound, cinnamaldehyde, which is known not to be genotoxic or 
carcinogenic in vivo. Altogether this thesis presented physiologically based in silico modelling as 
an approach to test relevance of positive in vitro genotoxicity results by DNA reactive compounds 
in vivo without using animal experiments.   
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low LD50 (26 mg/kg bw) and high volatility (269 Torr) of 2-propenal, administration of high doses 
of pure 2-propenal by gavage is not practical but the aldehyde needs to be microencapsulated and 
mixed in feed to achieve a stable long-term feeding without resulting in high mortality [22]. 
Further PBK/D studies are needed to examine to what extent 2-propenal also represents a worst 
case for other dietary α,β-unsaturated in other subgroups including for example 2- or 3- alkylated 
aldehydes, 2,4-dienals and cyclic aldehydes. 
 
Future possibilities of PBK/D modelling for genotoxic agents in general 
The ultimate goal of physiologically based in silico models developed for DNA reactive 
compounds is not limited to predicting DNA adduct formation but to predict further steps in the 
development of tumours. A tumour development is a multi-step process, which is often described 
to be divided into three phases: initiation, promotion, and the final stage progression. The first 
steps are reversible thus the formation of DNA adduct does not per se cause a tumour. A useful 
strategy to model chemical induced carcinogenicity would be to construct mathematical equations 
based on multistage carcinogenesis models reported by Luebeck et al.[38], as previously 
suggested by Punt et al. [39] and Paini [40]. Luebeck et al. described that a four-stage model that 
they could predict the epidemiological data on the age-specific incidence of colorectal cancers 
among the US population. The four-stage model consisted of two rare mutations in adenomatous 
polyposis coli (APC) genes, followed by high-frequency events in the conversion of a normal cell 
into an initiated cell that expands clonally to give rise to an adenomatous polyp, and subsequently 
by a transition of a preinitiated stem cell into an initiated cell capable of clonal expansion. To use 
this multi-stage model it is crucial to parameterize the frequency of the first two rare mutations for 
each chemical. The parameterisation could be achieved in vitro by exposing human cell lines to a 
chemical with or without bioactivation to quantify the mutation frequency in the APC genes 
including P53 and K-ras.  
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6.3 Conclusions 
 
This thesis presented an alternative approach for the current methods relying on animal 
experiments for the safety evaluation of genotoxic compounds using α,β-unsaturated aldehydes as 
model compounds. Physiologically based in silico models were developed for 18 α,β-unsaturated 
aldehydes to define dose-dependent detoxification of these aldehydes and to obtain insights in 
DNA adduct formation at low doses relevant to human dietary exposure to these compounds. 
DNA adduct formation by the 18 aldehydes was negligible at their estimated levels of use as food 
flavourings compared to the natural background levels of structurally similar exocyclic 
1,N2-propanodeoxyguanosine adducts present in disease free human liver. The same conclusion 
for the 18 aldehydes was obtained by comparing the DNA adduct levels with that of 
cinnamaldehyde that is known to test negative for genotoxic and carcinogenic in vivo even at high 
dose levels. Overall, the results indicated that the DNA adduct formation by the 18 
α,β-unsaturated aldehydes as food flavourings are negligible and do not raise a safety concern at 
their levels of intake resulting from their use as food flavourings. 
In addition, this thesis illustrated that physiologically based in silico models provide a 
very useful and powerful tool to facilitate a group evaluation and read-across for food-borne DNA 
reactive agents. The application of QSAR models to predict kinetic parameters to build PBK/D 
models strongly accelerated the development of the PBK/D models of the group of 18 
compounds. PBK/D models furthermore enabled comparison of DNA adduct formation by the 18 
aldehydes for which in vivo data are limited or even absent, with data on DNA adduct formation 
for a structurally related compound, cinnamaldehyde, which is known not to be genotoxic or 
carcinogenic in vivo. Altogether this thesis presented physiologically based in silico modelling as 
an approach to test relevance of positive in vitro genotoxicity results by DNA reactive compounds 
in vivo without using animal experiments.   
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SUPPORTING INFORMATION 
 
Supporting information 6.1. Physiological and biochemical parameters used in the oral dosing 
model 
 Description Value Reference 
Blood flow to tissue (fraction of the cardiac output, %)   
 QFSc (forestomach) 0.3 [14] 
 QGSc (glandular stomach) 1.0 [14] 
 QDUOc (duodenum) 1.6 [14] 
 QSIc (small intestine) 11.8 [41] 
Volume (fraction to the body weight, %)   
 VFSc (forestomach) 1.6 [14] 
 VGSc (glandular stomach) 0.47 [14] 
 VDUOc (duodenum) 0.34 [14] 
 VSIc (small intestine) 1.2 [41] 
Transportation rate of the gut contents down the gastric tract 
(/h) 
  
 KTR1 (forestomach to glandular 
stomach) 
0.7 [42] 
 KTR2 (glandular stomach to duodenum) 0.7 [42] 
 KTR3 (duodenum to small intestine) 7 [42] 
Transfer rate from vehicle to the lumen contents (KGUT, /h) and from lumen contents to the gut 
wall (KAB, /h) 
Exposure dose of 50 mg/kg bw or lower   
 KGUT1 (forestomach) 0.35 [14] 
 KGUT2 (glandular stomach) 9 [14] 
 KGUT3 (duodenum) 10 [14] 
 KGUT4 (small intestine) 10 [14] 
 KAB1 (forestomach) 0.35 [14] 
 KAB2 (glandular stomach) 9 [14] 
 KAB3 (duodenum) 10 [14] 
 KAB4 (small intestine) 10 [14] 
Exposure dose higher than 50 mg/kg bw  
 KGUT1  (forestomach) 0.20 [14] 
 KGUT2 (glandular stomach) 2.50 [14] 
 KGUT3 (duodenum) 5.00 [14] 
 KGUT4 (small intestine) 10 [14] 
 KAB1 (forestomach) 0.20 [14] 
 KAB2 (glandular stomach) 2.50 [14] 
 KAB3 (duodenum) 5.00 [14] 
 KAB4 (small intestine) 10 [14] 
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Supporting information 6.2. Equations for the oral dosing model made based on the study by 
Frederiek et al. [14] 
 
(1) forestomach compartment 
dAOFS/dt = -AOFS*(KGUT1+KTR1)  
Init AOFS = dose 
where 
AOFS Amount aldehyde in vehicle oil in the forestomach (μmol) 
 
dALFS/dt = AOFS*KGUT1 - ALFS*(KTR1+KAB1) 
where 
ALFS  amount aldehyde in the lumen contents in the forestomach (μmol) 
KGUT1 transfer rate of the aldehyde from vehicles to the lumen contents (/h) 
KTR1 transportation rate of the gut contents from forestomach to glandular stomach (/h) 
KAB1 transfer rate of the aldehyde from the lumen contents to the gut wall (/h) 
 
dAFS/dt = ALFS*KAB1 - QFS*CVFS 
CFS = AFS/VFS 
CVFS = CFS/PRALD 
where  
AFS  amount aldehyde in the forestomach (μmol) 
QFS blood flow into the forestomach (L/h) 
CVFS concentration of aldehyde in venous blood leaving the forestomach (μmol/L) 
CFS concentration of aldehyde in the forestomach (μmol/L) 
VFS volume of the forestomach (kg) 
PRALD tissue/blood partition coefficient of aldehyde  
 
(2) glandular stomach compartment  
dAOGS/dt = AOFS*KTR1 - AOGS*(KGUT2+KTR2)  
where 
AOGS amount aldehyde in vehicle in the glandular stomach (μmol) 
KGUT2 transfer rate of the aldehyde from vehicles to the lumen contents (/h) 
KTR2  transportation rate of the gut contents from glandular stomach to duodenum (/h) 
 
dALGS/dt = AOGS*KGUT2 +ALFS* KTR1 - ALGS*(KTR2+KAB2) 
where 
ALGS amount aldehyde in the lumen contents in the glandular stomach (μmol) 
KAB2 transfer rate of the aldehyde from the lumen contents to the gut wall (/h) 
 
dAGS/dt = ALGS*KAB2 - QGS*CVGS 
CGS = AGS/VGS 
CVGS = CGS/PRALD 
where 
AGS amount aldehyde in the glandular stomach (μmol) 
QGS blood flow into the glandular stomach (L/h) 
CVGS concentration of aldehyde in venous blood leaving the glandular stomach (μmol/L) 
CGS concentration of aldehyde in the glandular stomach (μmol/L) 
VGS volume of the glandular stomach (kg) 
 
(3) Duodenum compartment 
       dAODUO/dt = AOGS*KTR2 - AODUO*(KGUT3+KTR3)  
where 
AODUO amount aldehyde in vehicle in the duodenum (μmol) 
KGUT3 transfer rate of the aldehyde from vehicles to the lumen contents (/h) 
KTR3 transportation rate of the gut contents from duodenum to small intestine (/h) 
 
32620 Reiko Kiwamoto.indd   178 17-03-15   15:36
6General discussion
179
General discussion 
 
178 
 
SUPPORTING INFORMATION 
 
Supporting information 6.1. Physiological and biochemical parameters used in the oral dosing 
model 
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where 
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KGUT2 transfer rate of the aldehyde from vehicles to the lumen contents (/h) 
KTR2  transportation rate of the gut contents from glandular stomach to duodenum (/h) 
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where 
ALGS amount aldehyde in the lumen contents in the glandular stomach (μmol) 
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CVGS = CGS/PRALD 
where 
AGS amount aldehyde in the glandular stomach (μmol) 
QGS blood flow into the glandular stomach (L/h) 
CVGS concentration of aldehyde in venous blood leaving the glandular stomach (μmol/L) 
CGS concentration of aldehyde in the glandular stomach (μmol/L) 
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(3) Duodenum compartment 
       dAODUO/dt = AOGS*KTR2 - AODUO*(KGUT3+KTR3)  
where 
AODUO amount aldehyde in vehicle in the duodenum (μmol) 
KGUT3 transfer rate of the aldehyde from vehicles to the lumen contents (/h) 
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       dALDUO/dt = AODUO*KGUT3 +ALGS*KTR3 - ALDUO*(KTR3+KAB3) 
where 
ALDUO amount aldehyde in the lumen contents in the duodenum (μmol) 
KAB3 transfer rate of the aldehyde from the lumen contents to the gut wall (/h) 
 
dADUO/dt = ALDUO*KAB3 - QDUO*CVDUO 
CDUO = ADUO/VDUO 
CVDUO = CDUO/PRALD 
where 
ADUO  amount of aldehyde in the duodenum (μmol) 
QDUO blood flow into the duodenum (L/h) 
CVDUO concentration of aldehyde in venous blood leaving the duodenum (μmol/L) 
CDUO concentration of aldehyde in the duodenum (μmol/L) 
VDUO volume of the duodenum (kg) 
 
(4) small intestine compartment 
dAOSI/dt = AODUO*KTR3 - AOSI*KGUT4  
where 
AOSI amount of aldehyde in vehicle in the small intestine (μmol) 
KGUT4 transfer rate of the aldehyde from vehicles to the lumen contents (/h) 
 
dALSI/dt = AOSI*KGUT4 +ALDUO*KTR3 - ALSI*KAB4 
where 
ALSI Amount aldehyde in the lumen contents in the small intestine (μmol) 
KAB4 transfer rate of the aldehyde from the lumen contents to the gut wall (/h) 
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Various α,β-unsaturated aldehydes are present in fruits, vegetables, spices, or processed products 
containing these items as natural constituents [1] or as added food flavouring agents. Because of 
the α,β-unsaturated aldehyde moiety the β carbon in the molecule becomes electron deficient and 
the aldehydes react with electron rich molecules including DNA via Michael addition [2]. The 
formation of DNA adducts raises a concern for genotoxicity, although formation of DNA adducts 
may not be significant at low doses relevant for dietary exposure in vivo because of adequate 
detoxification. The thesis therefore aimed at determining dose-dependent detoxification and DNA 
adduct formation of food-borne α,β-unsaturated aldehydes by using a physiologically based in 
silico modelling approach in order to contribute to the safety assessment of these aldehydes used 
as food flavourings.  
Chapter 1 of this thesis introduced occurrence, metabolism, genotoxicity and 
carcinogenicity, and regulatory status of dietary α,β-unsaturated aldehydes as the basic 
background information of the compounds. Also, the uncertainty in the evaluation of genotoxicity 
at low exposure doses, a challenge for the safety evaluation of these flavouring compounds, the 
use of PBK/D (physiologically based kinetic/dynamic) models for DNA reactive compounds, and 
the aim and overall objectives of the thesis were described. 
In Chapter 2 and 3, rat and human PBK/D models were developed for the model 
compound trans-2-hexenal. The kinetic parameters for detoxification were collected by 
performing in vitro incubations using relevant tissue fractions. The PBK/D models revealed that at 
the estimated daily intake (EDI) i.e. 0.04 mg/kg bw, trans-2-hexenal is detoxified predominantly 
via GST-mediated conjugation with GSH in rats, while the reduction to trans-2-hexen-1-ol was 
the major pathway in humans. Interspecies differences in the maximum DNA adduct levels in the 
liver were predicted to be limited. At the EDI, DNA adduct formation was 0.01 and 0.008 
adducts/108 nt in rat and human, respectively. These levels were 3 orders of magnitude lower than 
the natural background levels of structurally similar exocyclic 1,N2-propanodeoxyguanosine 
adducts present in disease free human liver (i.e. 6.8–110 adducts/108 nt) [3, 4]. In Chapter 3, the 
human PBK/D model was subsequently used to examine the impact of interindividual variation in 
trans-2-hexenal detoxification on DNA adduct formation in the human population. The 
parameters for detoxification were measured for 11 individuals to define the variation in the 
parameters and subsequently the distribution of DNA adduct formation in the population was 
simulated by Monte Carlo simulations. At a high intake level of 0.178 mg/kg bw (95th percentile 
of the dietary intake), DNA adduct formation was predicted to be 0.18 adducts/108 nt for the 99th 
percentile of the population. This value was well below the natural background levels of 
structurally similar exocyclic 1,N2-propanodeoxyguanosine adducts (6.8–110 adducts/108 nt) [3, 
4]. Based on these results, it was concluded that trans-2-hexenal in the diet may not significantly 
increase the DNA adduct levels in the liver in rats, or in humans including the most sensitive 
persons.  
The objective of Chapter 4 was to extend the rat PBK/D model for trans-2-hexenal to 
 
 
other α,β-unsaturated aldehydes that may be used as food flavourings and to facilitate a group 
evaluation. Considering the large number of the aldehydes of interest, a QSAR (quantitative 
structure-activity relationship) approach was applied to collect chemical specific detoxification 
parameters. Eighteen acyclic α,β-unsaturated aldehyde flavouring agents without 2- or 
3-alkylation, and with no more than one conjugated double bond were selected as the aldehydes of 
interest. Six of the 18 aldehydes were selected as the training set to define QSAR models to 
estimate the kinetic parameters for detoxification of the other 12 aldehydes in the test set. Among 
the 18 aldehydes, 2-propenal (acrolein) was predicted to induce the highest number of DNA 
adducts in rat liver due to the lowest catalytic efficiency for oxidation and conjugation with GSH. 
DNA adduct formation by the 18 aldehydes was predicted to be between 10-10– 10-2 adducts/108 nt 
at their respective EDI as food flavourings. These levels are at least two orders of magnitude 
lower than the natural background levels of structurally similar DNA adducts (i.e. 6.8–110 
adducts/108 nt). Based on these outcomes it was concluded that the DNA adduct formation by all 
18 aldehydes when used as flavourings is negligible.  
Unlike many α,β-unsaturated aldehydes for which in vivo data on genotoxicity and 
carcinogenicity are absent, cinnamaldehyde has been shown not to be genotoxic and to test 
negative in a long term carcinogenicity study in vivo [5]. The aim of Chapter 5 was to examine 
DNA adduct formation by cinnamaldehyde and to compare these DNA adduct levels to those 
predicted for the 18 aldehydes in Chapter 4. The cinnamaldehyde PBK/D models revealed that in 
rats, cinnamaldehyde was shown to induce higher DNA adducts per exposure dose than 6 out of 
the 18 food borne acyclic α,β-unsaturated aldehydes, indicating these 6 aldehydes may also test 
negative for genotoxicity and carcinogenicity at high dose levels. At the highest cinnamaldehyde 
dose that tested negative for genotoxicity and carcinogenicity in vivo, the model predicted a 
formation of 79 DNA adducts/108 nt in rat. This value is at least three orders of magnitude higher 
than the predicted DNA adduct formation by all 18 other food-borne aldehydes at their respective 
EDI. These results corroborate the conclusion obtained in Chapter 4 that for all 18 α,β-unsaturated 
aldehydes DNA adduct formation at doses relevant for human dietary exposure does not raise a 
safety concern.   
Chapter 6 of the thesis presented general discussions and future perspectives on different 
topics raised based on the results obtained in this thesis. For instance, a consideration was given 
on possible aldehyde toxicity in the GI tract where concentrations of aldehydes may become 
higher than in the liver. An oral dosing model that has been developed to describe kinetics of an 
α,β-unsaturated ester ethyl acrylate in the GI tract [6] was added to the rat trans-2-hexenal PBK/D 
models developed in this thesis. The results obtained from this tentative model indicated that 
trans-2-hexenal concentrations may be higher especially in the glandular stomach than in the 
liver, but DNA adduct formation in the GI organs would still not be of concern assuming the 
background levels of structurally similar DNA adducts in these organs to be comparable to the 
liver. Chapter 6 further presented general discussions and future perspectives on the performance 
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Various α,β-unsaturated aldehydes are present in fruits, vegetables, spices, or processed products 
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the aldehydes react with electron rich molecules including DNA via Michael addition [2]. The 
formation of DNA adducts raises a concern for genotoxicity, although formation of DNA adducts 
may not be significant at low doses relevant for dietary exposure in vivo because of adequate 
detoxification. The thesis therefore aimed at determining dose-dependent detoxification and DNA 
adduct formation of food-borne α,β-unsaturated aldehydes by using a physiologically based in 
silico modelling approach in order to contribute to the safety assessment of these aldehydes used 
as food flavourings.  
Chapter 1 of this thesis introduced occurrence, metabolism, genotoxicity and 
carcinogenicity, and regulatory status of dietary α,β-unsaturated aldehydes as the basic 
background information of the compounds. Also, the uncertainty in the evaluation of genotoxicity 
at low exposure doses, a challenge for the safety evaluation of these flavouring compounds, the 
use of PBK/D (physiologically based kinetic/dynamic) models for DNA reactive compounds, and 
the aim and overall objectives of the thesis were described. 
In Chapter 2 and 3, rat and human PBK/D models were developed for the model 
compound trans-2-hexenal. The kinetic parameters for detoxification were collected by 
performing in vitro incubations using relevant tissue fractions. The PBK/D models revealed that at 
the estimated daily intake (EDI) i.e. 0.04 mg/kg bw, trans-2-hexenal is detoxified predominantly 
via GST-mediated conjugation with GSH in rats, while the reduction to trans-2-hexen-1-ol was 
the major pathway in humans. Interspecies differences in the maximum DNA adduct levels in the 
liver were predicted to be limited. At the EDI, DNA adduct formation was 0.01 and 0.008 
adducts/108 nt in rat and human, respectively. These levels were 3 orders of magnitude lower than 
the natural background levels of structurally similar exocyclic 1,N2-propanodeoxyguanosine 
adducts present in disease free human liver (i.e. 6.8–110 adducts/108 nt) [3, 4]. In Chapter 3, the 
human PBK/D model was subsequently used to examine the impact of interindividual variation in 
trans-2-hexenal detoxification on DNA adduct formation in the human population. The 
parameters for detoxification were measured for 11 individuals to define the variation in the 
parameters and subsequently the distribution of DNA adduct formation in the population was 
simulated by Monte Carlo simulations. At a high intake level of 0.178 mg/kg bw (95th percentile 
of the dietary intake), DNA adduct formation was predicted to be 0.18 adducts/108 nt for the 99th 
percentile of the population. This value was well below the natural background levels of 
structurally similar exocyclic 1,N2-propanodeoxyguanosine adducts (6.8–110 adducts/108 nt) [3, 
4]. Based on these results, it was concluded that trans-2-hexenal in the diet may not significantly 
increase the DNA adduct levels in the liver in rats, or in humans including the most sensitive 
persons.  
The objective of Chapter 4 was to extend the rat PBK/D model for trans-2-hexenal to 
 
 
other α,β-unsaturated aldehydes that may be used as food flavourings and to facilitate a group 
evaluation. Considering the large number of the aldehydes of interest, a QSAR (quantitative 
structure-activity relationship) approach was applied to collect chemical specific detoxification 
parameters. Eighteen acyclic α,β-unsaturated aldehyde flavouring agents without 2- or 
3-alkylation, and with no more than one conjugated double bond were selected as the aldehydes of 
interest. Six of the 18 aldehydes were selected as the training set to define QSAR models to 
estimate the kinetic parameters for detoxification of the other 12 aldehydes in the test set. Among 
the 18 aldehydes, 2-propenal (acrolein) was predicted to induce the highest number of DNA 
adducts in rat liver due to the lowest catalytic efficiency for oxidation and conjugation with GSH. 
DNA adduct formation by the 18 aldehydes was predicted to be between 10-10– 10-2 adducts/108 nt 
at their respective EDI as food flavourings. These levels are at least two orders of magnitude 
lower than the natural background levels of structurally similar DNA adducts (i.e. 6.8–110 
adducts/108 nt). Based on these outcomes it was concluded that the DNA adduct formation by all 
18 aldehydes when used as flavourings is negligible.  
Unlike many α,β-unsaturated aldehydes for which in vivo data on genotoxicity and 
carcinogenicity are absent, cinnamaldehyde has been shown not to be genotoxic and to test 
negative in a long term carcinogenicity study in vivo [5]. The aim of Chapter 5 was to examine 
DNA adduct formation by cinnamaldehyde and to compare these DNA adduct levels to those 
predicted for the 18 aldehydes in Chapter 4. The cinnamaldehyde PBK/D models revealed that in 
rats, cinnamaldehyde was shown to induce higher DNA adducts per exposure dose than 6 out of 
the 18 food borne acyclic α,β-unsaturated aldehydes, indicating these 6 aldehydes may also test 
negative for genotoxicity and carcinogenicity at high dose levels. At the highest cinnamaldehyde 
dose that tested negative for genotoxicity and carcinogenicity in vivo, the model predicted a 
formation of 79 DNA adducts/108 nt in rat. This value is at least three orders of magnitude higher 
than the predicted DNA adduct formation by all 18 other food-borne aldehydes at their respective 
EDI. These results corroborate the conclusion obtained in Chapter 4 that for all 18 α,β-unsaturated 
aldehydes DNA adduct formation at doses relevant for human dietary exposure does not raise a 
safety concern.   
Chapter 6 of the thesis presented general discussions and future perspectives on different 
topics raised based on the results obtained in this thesis. For instance, a consideration was given 
on possible aldehyde toxicity in the GI tract where concentrations of aldehydes may become 
higher than in the liver. An oral dosing model that has been developed to describe kinetics of an 
α,β-unsaturated ester ethyl acrylate in the GI tract [6] was added to the rat trans-2-hexenal PBK/D 
models developed in this thesis. The results obtained from this tentative model indicated that 
trans-2-hexenal concentrations may be higher especially in the glandular stomach than in the 
liver, but DNA adduct formation in the GI organs would still not be of concern assuming the 
background levels of structurally similar DNA adducts in these organs to be comparable to the 
liver. Chapter 6 further presented general discussions and future perspectives on the performance 
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of the PBK/D models developed in this thesis and how it could be improved, on the application of 
the integrated QSAR-PBK/D modelling to the other food-borne α,β-unsaturated aldehydes and 
important molecular determinants to be considered for the QSAR development, on implication of 
the results obtained in this thesis for the safety evaluation of the use of α,β-unsaturated aldehydes 
as added food flavourings, and on PBK/D modelling for genotoxic agents in general.      
In conclusion, this thesis presented an alternative approach for the current methods relying 
on animal experiments for the safety evaluation of genotoxic compounds, focussing on 
α,β-unsaturated aldehydes. Physiologically based in silico models were developed for 18 
α,β-unsaturated aldehydes, and the model outcomes indicated that the DNA adduct formation by 
the 18 α,β-unsaturated aldehydes as food flavourings is negligible and does not raise a safety 
concern at their levels of intake resulting from their use as food flavourings. Higher levels of 
exposure is not likely to occur due to the self-limiting use of flavouring agents, with higher 
exposure leading to off-flavours. In addition, this thesis illustrated that physiologically based in 
silico models provide a very useful and powerful tool to facilitate a group evaluation and 
read-across for food-borne DNA reactive agents. The application of QSAR models strongly 
accelerated the development of the PBK/D models of the group of 18 compounds. PBK/D models 
developed for the group of compounds supported read-across from an aldehyde which is known 
not to be genotoxic or carcinogenic in vivo to other aldehydes, by allowing comparison of 
dose-dependent DNA adduct formations. Altogether this thesis presented physiologically based in 
silico modelling as an approach to test relevance of positive in vitro genotoxicity results by DNA 
reactive compounds in vivo without using animal experiments.  
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Samenvatting 
 
Verschillende α,β-onverzadigde aldehydes zijn van nature aanwezig in fruit, groenten, kruiden of 
als toegevoegde smaakstoffen in bewerkte producten. α,β-Onverzadigde aldehydes kunnen door 
hun structuur reageren met elektronenrijke moleculen, zoals eiwitten en DNA, volgens een 
Michael-additie. Door deze reactiviteit is er zorg dat deze stoffen in vivo genotoxisch zijn, ook al 
is de vorming van DNA adducten mogelijk minimaal bij lage doses via de voeding door 
voldoende detoxificatie. Om meer inzicht te krijgen in de relevantie van DNA adductvorming bij 
lage doseringen en om bij te dragen aan de risico-evaluatie van deze stoffen in de voeding, richtte 
dit proefschrift zich op het onderzoeken van dosis-afhankelijke detoxificatie en DNA 
adductvorming van α,β-onverzadigde aldehydes met behulp van fysiologisch gebaseerde in silico 
modellen. 
Hoofdstuk 1 van dit proefschrift introduceerde het voorkomen van α,β-onverzadigde 
aldehydes in de voeding, het metabolisme, de genotoxiciteit en carcinogeniciteit en de stand van 
zaken met betrekking tot regelgeving als basis achtergrondinformatie van de stoffen. Ook werden 
onzekerheden in de evaluatie van genotoxiciteit bij lage doseringen, de uitdagingen in de 
veiligheidsevaluatie van deze smaakstoffen, het gebruik van PBK/D (fysiologische gebaseerde 
kinetische/dynamische) modellen voor DNA-reactieve stoffen en het globale doel van het 
proefschrift beschreven. 
In Hoofdstuk 2 en 3 werden PBK/D modellen voor de rat en de mens ontwikkeld voor de 
modelstof trans-2-hexenal. De kinetische parameters voor detoxificatie werden verzameld door in 
vitro incubaties uit te voeren met weefselfracties die betrokken zijn bij het metabolisme. De 
PBK/D modellen lieten zien dat bij een geschatte dagelijkse inname (i.e. EDI) van 0,04 mg/kg 
lichaamsgewicht, GST-gemedieerde conjugatie met glutathion (GSH) de belangrijkste metabole 
route was in ratten, terwijl reductie naar trans-2-hexen-1-ol de voornaamste route was in de mens. 
Ondanks deze verschillen in metabolisme waren de onderlinge verschillen tussen ratten en 
mensen wat betreft de maximum DNA adductniveaus in de lever beperkt. DNA adductvorming 
was 0,01 adducten/108 nt in de rat en 0,008 adducten/108 nt in de mens bij de EDI. Deze niveaus 
waren 3 ordes van grootte lager dan de natuurlijk achtergrondniveaus van structureel gelijke 
exocyclische 1,N2-propanodeoxyguanosine adducten die aanwezig zijn in ziektevrije humane 
levers (i.e. 6,8-110 adducten/ 108 nt). In hoofdstuk 3 is het humane PBK/D model 
achtereenvolgens ook gebruikt om de invloed te onderzoeken van interindividuele variatie in 
trans-2-hexenal detoxificatie op DNA adductvorming in de menselijke populatie. De parameters 
voor detoxificatie van 11 individuen werden gemeten om de variatie in de parameters te bepalen. 
Vervolgens werd de distributie van DNA adductvorming in de populatie nagebootst door Monte 
Carlo simulaties. Bij een hoog innameniveau van 0,178 mg/kg lichaamsgewicht (95e percentiel 
van de dieetinname) zou de DNA adductvorming 0,18 adducten/108 nt zijn voor het 99e percentiel 
van de populatie. Deze waarde ligt ver beneden de natuurlijk achtergrondniveaus van structurele 
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gelijke exocyclische 1,N2-propanodeoxyguanosine adducten (6,8-110 adducten/108 nt). Gebaseerd 
op deze resultaten werd geconcludeerd dat trans-2-hexenal in voeding DNA adductniveaus niet 
aanzienlijk verhoogt in de lever van de rat of de mens, inclusief de meest gevoelige personen. 
Het doel van Hoofdstuk 4 was het PBK/D model voor trans-2-hexenal in de rat uit te 
breiden naar andere α,β-onverzadigde aldehydes die gebruikt worden als smaakstoffen in voeding. 
Om PBK/D modellen te kunnen maken voor een grote groep stoffen is gebruik gemaakt van 
zogenaamde QSARs (kwantitatieve structuur-activiteitsrelaties) om de parameters voor 
detoxificatie te verzamelen. Achttien acyclische α,β-onverzadigde aldehyde smaakstoffen zonder 
2- of 3-alkylatie en met niet meer dan één samengestelde dubbel-bond werden geselecteerd als de 
meest relevante aldehydes. Zes van de 18 aldehydes werden geselecteerd als de proefset (training 
set) om QSAR modellen te definiëren die de kinetische parameters voor detoxificatie van de 
andere 12 aldehydes in de proefset (test set) schatten. Van de 18 aldehydes zou 2-propenal 
(arcolein) het hoogste aantal DNA adducten in de rattenlever induceren. Dit werd veroorzaakt 
door de laagste catalytische efficiency voor oxidatie en GSH conjugatie. DNA adductvorming 
door de 18 aldehydes was tussen de 10-10 en 10-2  adducten/108 nt bij de respectievelijke EDI als 
smaakstoffen. Deze niveaus zijn ten minste twee ordes van grootte lager dan de natuurlijke 
achtergrondniveaus van structureel gelijke DNA adducten (i.e. 6,8-110 adducten/108 nt). Op basis 
van deze uitkomsten werd geconcludeerd dat de DNA adductvorming door alle 18 aldehydes, bij 
gebruik als smaakstoffen, te verwaarlozen is. 
In tegenstelling tot de meeste α,β-onverzadigde aldehydes waarvoor in vivo 
genotoxiciteits- en carcinogeniciteitsdata ontbreken, zijn deze data wel aanwezig voor 
cinnamaldehyde. Deze stof blijkt niet genotoxisch te zijn en is negatief getest in een langlopende 
carcinogeniticteitsstudie. Het doel van Hoofdstuk 5 was de DNA adductvorming door 
cinnamaldehyde te onderzoeken en de verkregen DNA adductniveaus te vergelijken met de 
niveaus die voorspeld werden voor de 18 aldehydes in hoofdstuk 4. Uit deze vergelijking kwam 
naar voren dat cinnamaldehyde in ratten meer DNA adducten induceerde per blootstellingsdosis 
dan 6 van de 18 acyclische α,β-onverzadigde aldehydes, wat indiceert dat deze 6 aldehydes 
waarschijnlijk eveneens negatief zullen zijn voor genotoxiciteit en carcinogeniciteit bij hoge 
doseringen. Bij de hoogste cinnamaldehydedosis die negatief was voor genotoxiciteit en 
carcinogeniciteit in vivo, voorspelde het model een vorming van 29 DNA adducten/108 nt in de 
rat. Deze waarde is minstens drie ordes van grootte hoger dan de voorspelde DNA adductvorming 
door alle 18 andere voedselgedragen aldehydes bij hun respectievelijke EDI. Deze resultaten 
bevestigen de conclusie die in hoofdstuk 4 is verkregen dat voor alle 18 α,β-onverzadigde 
aldehydes DNA adductvorming, bij de voor menselijk voeding relevante doseringen, geen reden 
tot zorg geven. 
Hoofdstuk 6 van dit proefschrift presenteerde de algemene discussies en 
toekomstperspectieven over verschillende behandelde thema´s gebaseerd op de in dit proefschrift 
verkregen resultaten. Zo is bijvoorbeeld een afweging gemaakt over mogelijke aldehyde toxiciteit 
 
 
in het maag-darmstelsel waar concentraties van aldehydes hoger kunnen worden dan in de lever. 
Een oraal doseringsmodel dat is ontwikkeld om de kinetiek te beschrijven van een 
α,β-onverzadigde ester ethyl acrylaat in het maag-darmstelsel werd toegevoegd aan het 
trans-2-hexenal PBK/D model in de rat dat in dit proefschrift is ontwikkeld. De verkregen 
resultaten uit dit proefmodel toonden aan dat trans-2-hexenal concentraties vooral in de 
glandulaire maag mogelijk hoger zijn dan in de lever, maar dat DNA adductvorming in de 
gastro-intestinale organen nog steeds geen reden tot zorg zouden zijn, er van uitgaand dat de 
achtergrondniveaus van structureel gelijke endogene DNA adducten in deze organen vergelijkbaar 
zijn met de lever. Hoofdstuk 6 biedt verder algemene discussies en toekomstperspectieven ten 
aanzien van het resultaat van de PBK/D modellen die in dit proefschrift zijn ontwikkeld en hoe 
dat resultaat nog verbeterd zou kunnen worden, over de toepassing van de geïntegreerde 
QSAR-PBK/D modelling op de andere α,β-onverzadigde aldehydes die gebruikt worden in de 
voeding en belangrijke moleculaire determinanten die werden overwogen voor QSAR 
ontwikkeling, over de implicatie van de verkregen resultaten in dit proefschrift voor de 
veiligheidsevaluatie van α,β-onverzadigde aldehydes die als smaakstoffen aan voedsel worden 
toegevoegde, en over het gebruik van PBK/D modelling voor genotoxische stoffen in het 
algemeen. 
Concluderend heeft dit proefschrift een alternatieve benadering voor de huidige methodes 
voor veiligheidsevaluatie van genotoxische stoffen gepresenteerd, die niet steunt op dierproeven. 
Voor 18 α,β-onverzadigde aldehydes zijn PBK/D modellen ontwikkeld en de modeluitkomsten 
toonden aan dat de DNA adductvorming door de 18 α,β-onverzadigde aldehydes te verwaarlozen 
is en geen reden tot zorg zijn voor de veiligheid bij innameniveaus kenmerkend voor gebruik als 
voedselsmaakstoffen. Hogere blootstellingsniveaus liggen niet voor de hand gezien het 
zelfbeperkend gebruik van smaakstoffen, waarbij hogere blootstelling leidt tot een onaangename 
smaak. Bovendien illustreerde dit proefschrift dat PBK/D modellen voorzien in een zeer nuttig en 
krachtig instrument om een groepsevaluatie te faciliteren and read-across voor DNA- reactieve 
stoffen uit te voeren. De toepassing van QSAR modellen versnelde de ontwikkeling van de 
PBK/D modellen voor de groep van 18 stoffen. De PBK/D modellen ondersteunden read-across 
van een aldehyde waarvan bekend is dat deze in vivo niet genotoxisch of carcinogeen is naar de 
andere aldehydes, door vergelijking van dosisafhankelijke DNA adductvorming. Alles bijeen 
genomen presenteerde dit proefschrift PBK/D modelling als een benadering om de in vivo 
relevantie van positieve in vitro genotoxiciteitsresultaten bij DNA-reactieve stoffen te 
onderzoeken zonder dierproeven te gebruiken. 
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